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Zusammenfassung
Ziel dieser Arbeit war die Entwicklung kontrollierter Wirkstofffreisetzungssysteme
für die Anwendung im Rahmen der modernen Wundbehandlung. Im modernen
Wundmanagement werden feucht-warme Wundheilungsbedingungen als optimal be-
schrieben. Dies wird durch die Verwendung geeigneter Wundauflagen sichergestellt,
welche z.B. aus Hydrogelen oder Polyurethanschäumen bestehen. Durch den Einsatz
geeigneter Wirkstoffe kann die Wundheilung weiter verstärkt werden, wobei solche
Wirkstoffe jedoch während der gesamten Anwendungsdauer der Wundauflage in ei-
nem bestimmten Konzentrationsbereich vorliegen müssen.
In dieser Arbeit wurden kontrollierte Wirkstofffreisetzungssysteme entwickelt, um
eine möglichst lange Versorgung der Wunde mit dem Wirkstoff zu gewährleisten; es
wurden zwei Ansätze verfolgt. Der erste Ansatz besteht in der Entwicklung eines
kontrollierten Wirkstofffreisetzungssystems, welches in eine auf Polyurethanschaum
basierenden Wundauflage eingearbeitet werden kann (Kap. 3 und 5). Im zweiten
Ansatz war das Ziel, ein wasserbasiertes System zu entwickeln (Kap. 7), welches vor
der Anwendung der Wundauflage direkt auf die Wunde appliziert werden kann. Der
Schwerpunkt lag auf dem ersten Ansatz; hier wurde zusätzlich die Finite-Elemente-
Methode zu einer näheren Charakterisierung des Systems verwendet (Kap. 6 und 4).
Als Wirkstoff wurde aus zweierlei Gründen die semi-essentielle Aminosäure L-Arginin
gewählt. Zum einen ist der Konzentrationsbereich, in dem L-Arginin eine positive
Wirkung zeigt, relativ groß, und zum anderen ist bekannt, dass aus einer zu geringen
L-Arginin-Konzentration eine verminderte Wundheilung resultiert. Dies lässt sich
damit erklären, dass L-Arginin auf zwei Wegen Einfluss auf die Wundheilung nimmt.
Genauer gesagt, dominiert zu Beginn die Degradation durch Stickstoffmonoxid-
Synthase, welche L-Arginin zu Stickstoffmonoxid abbaut, wobei dieses Radikal zum
Beispiel mittels einer verstärkten Vasodilation die Wundheilung positiv beeinflusst.
Im späteren Verlauf der Wundheilung wird L-Arginin hauptsächlich durch L-Arginase
zu Citrullin abgebaut und in weiteren Schritten zu Prolin und Polyaminen. Wobei
Prolin als Substrat in der Collagen-Synthese benötigt wird und Polyamine in der
Zellproliferation beteiligt sind. Beide Prozesse sind essentiell für die Wundheilung.
Wie bereits erwähnt, wurde zunächst ein System entwickelt, welches in eine auf Po-
lyurethanschaum basierende Wundauflage eingearbeitet werden kann. Hierzu wur-
den Silikonmikropartikel entwickelt, welche kristallines L-Arginin enthalten (Kap. 3,
S. 63). Die nahezu lineare Freisetzung erfolgt hier über mehrere Tage hinweg. Hier-
mit wurden beide Ziele bezüglich des Freisetzungsverhaltens erreicht: Einerseits war
eine Freisetzungsdauer von mindestens zwei bis drei Tagen erwünscht, andererseits
ergab sich eine relativ lineare Freisetzung. Zusätzlich wurde die Freisetzungskinetik
in Abhängigkeit der Partikelgröße, des L-Arginin-Gehalts, des pH-Werts und anderer
Parameter untersucht. Das Ziel hierbei war, die optimalen Parameter zum Einsatz
in der Wundauflage zu bestimmen. Desweiteren wurde untersucht und gezeigt, dass
die Partikel für verschiedenste Wunden geeignet sind. So ist zum Beispiel der pH-
Wert von Wunden individuell und wurde deshalb in den experimentellen Arbeiten
berücksichtigt.
Zusätzlich zeigten Proliferations- und Toxizitätszellversuche mit in der Wundhei-
lung beteiligten Zelltypen (Endothelzellen, Keratinozyten und Fibroblasten), dass
die Partikel keine Cytotoxizität zeigen und sie zudem das Zellwachstum fördern.
Insgesamt ergab sich also, dass die entwickelten Silikonmikropartikel sehr gut für
den Einsatz in modernen Wundauflagen geeignet sind.
Der nächste Schritt bestand darin, die Partikel in Polyurethanschaum einzuarbeiten
(Kap. 5, S. 133). Vorab wurde bestätigt, dass L-Arginin, welches direkt in den Po-
lyurethanschaum eingearbeitet wurde, ohne Verzögerung freigesetzt wird. Anschlie-
ßend wurden Freisetzungsversuche aus Polyurethanschäumen durchgeführt, welche
mit den zuvor entwickelten Silikonpartikeln beladen waren. Hierbei wurde ein soge-
nannter Burst-Release gefunden, also eine unkontrollierte Freisetzung einer größeren
Wirkstoffmenge direkt zu Beginn der Freisetzungszeit. Dies ist ein Unterschied zum
Freisetzungsprofil direkt aus Silikonpartikeln, welcher auf die Einarbeitung der Par-
tikel in den Polyurethanschaum zurückgeführt werden kann. Genauer gesagt, wird
bei der Herstellung von Mikropartikel-enthaltenen Polyurethanschäumen in einer
wässrigen Dispersion gearbeitet, so dass bei diesem Prozess bereits L-Arginin aus
den Partikeln freigesetzt wird, welches dann frei im Polyurethanschaum vorliegt und
so für den Burst-Release sorgt. Bei genauerer Betrachtung ist dies für die Anwen-
dung positiv zu werten, da zu Beginn der Behandlung mit der Wundauflage zuerst
ein gewisses Konzentrationsniveau in der Wunde erreicht werden muss.
Um den Lymphfluss, welcher in Wunden herrscht, während der Freisetzungsversuche
nachzuahmen, wurde eine Diffusionszelle entwickelt (Kap. 5). Es zeigte sich, dass un-
ter diesen Bedingungen die L-Arginin-Konzentration über etwa drei Tage hinweg im
gewünschten Konzentrationsbereich bleibt. Diese Ergebnisse zeigen, dass sich solch
ii www.bth.rwth-aachen.de
ein mit wirkstoffhaltigen Silikonmikropartikel beladener Polyurethanschaum gut als
Wundauflage eignet.
Ein weiterer Bestandteil dieser Arbeit war die Anwendung der Finite-Elemente-
Methode. Hierbei wurde die Freisetzung einerseits aus der Wundauflage in der Dif-
fusionszelle (Kap. 6) und andererseits aus Silikonmikropartikeln (Kap. 4) simuliert.
Die experimentellen Ergebnisse aus Kapitel 5, die mit der Diffusionszelle erzielt wur-
den, konnten erfolgreich simuliert werden (Kap. 6, S. 157). Zudem konnten Konzen-
trationsprofile der Wunde ausgegeben werden, welche im Experiment nicht zugäng-
lich sind. Da die hohe Qualität der Implementierung durch die Übereinstimmung
mit den experimentellen Daten gezeigt wurde, konnten im Folgenden zahlreiche Pa-
rameter variiert werden und so ihr Einfluss auf die Freisetzung untersucht werden.
So wurden die Flussrate, die Dicke der Wundauflage, die Tiefe der Wunde und vie-
le andere Parameter variiert, die in der Praxis nur mit großem Aufwand geändert
werden können. Da der Einfluss der verschiedenen Parameter auf die Konzentration
in der Wunde bestimmt wurde, kann nun die Wundauflage weiter optimiert werden.
Somit hat solch eine Simulation einen hohen Stellenwert in der Optimierung einer
wirkstoffhaltigen Wundauflage.
Die Freisetzung aus Silikon-Mikropartikeln, welche in Kapitel 3 experimentell näher
untersucht wurde, wurde unter der Annahme programmiert (Kap. 4), dass der für
die Freisetzung entscheidende Prozess entweder allein auf Wirkstoffdiffusion oder
sowohl auf Wirkstoffdiffusion als auch auf der Quellung mit Wasser beruht. Hierbei
wurde für die Diffusion von drei verschiedenen Annahmen ausgegangen. Im ers-
ten Fall wurde angenommen, dass der Wirkstoff in der Silikonmatrix sehr langsam
mit einem bestimmten, zeitlich konstanten Diffusionskoeffizienten diffundiert, der
im gesamten Partikel konstant ist. Zweitens wurde eine Abhängigkeit des Diffusi-
onskoeffizienten von der bereits freigesetzten Wirkstoffmenge implementiert, so dass
der Diffusionskoeffizient zeitlich und örtlich abhängig verschiedene Werte annimmt.
Dieser Ansatz wurde auf Basis des Freisetzungsmechanismus gewählt. In der drit-
ten Näherung wird davon ausgegangen, dass es zwei Wirkstoffarten gibt, eine frei
in Poren diffundierende und eine in der Silikonmatrix vorliegen und damit nur sehr
langsam diffundierende. Hier wurden also zwei verschiedene Diffusionskoeffizienten
verwendet und der Anteil des frei diffundierenden Wirkstoffs wurde anhand der
bereits freigesetzten Menge in der entsprechenden Schale, also des entsprechenden
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finiten Elements, in jeder Iteration neu berechnet.
Zusätzlich wurde für die Quellungskinetik die Wasseraufnahme in Silikonzylinder
mittels bildgebender NMR untersucht, wobei eine scharfe Front gefunden wurde,
durch die die Silikonmatrix in zwei klar abgetrennte Bereiche unterteilt wird, näm-
lich einen gequollenen und einen unberührten Bereich. Es konnte eine Gleichung
für die Quellungskinetik aufgestellt werden. In der Simulation wurde nun mittels
dieser Gleichung bestimmt, ob in der jeweiligen Iteration Diffusion im jeweils be-
trachteten finiten Element stattfinden darf oder nicht.
Die Freisetzungsprofile konnten relativ gut simuliert werden, jedoch konnte in der
Simulation keine zeitlich lineare Freisetzung erzielt werden. Insgesamt ist der Frei-
setzungsprozess aus Silikonmikropartikeln also so komplex, dass es nicht möglich ist,
die Freisetzung mit einem Modell, welches auf den gewählten Annahmen beruht, ge-
nau zu simulieren.
Nichtsdestotrotz konnten einige Ergebnisse aus der Simulierung erzielt werden. Ers-
tens zeigte sich, dass die Quellung und damit die Diffusion von Wasser einen ent-
scheidenden Einfluss auf die Freisetzung nimmt. Zweitens ergaben sich für den Dif-
fusionskoeffizienten in der Silikonmatrix sehr geringe Werte, tatsächlich wurde ein
Wert von etwa 10−16 m2/s festgestellt, im Vergleich hierzu beträgt der Diffusionsko-
effizient von L-Arginin in Wasser 6.1 · 10−10 m2/s. Auch bei Annahme von teilweise
freier Diffusion durch Poren ist der Wert auf etwa 10−15 m2/s reduziert. Drittens
zeigten die simulierten Konzentrationsprofile, dass innerhalb des betrachteten Frei-
setzungszeitraums von 24 h nur die äußersten Schichten der Partikel an der Frei-
setzung beteiligt sind, was die Bedeutung der Wasseraufnahme, welche etwa analog
verläuft, für den Freisetzungsprozess betont.
Zusätzlich sollte ein System hergestellt und auf seine Eignung untersucht werden,
welches als wässrige Lösung vor Auflegen einer Wundauflage verwendet werden könn-
te und L-Arginin kontrolliert freisetzt. Hierzu wurden mehrschichtige Polymersome
mit eingekapselten L-Arginin entwickelt und auf ihr Freisetzungsverhalten hin un-
tersucht (Kap. 7, S. 213). Durch die zahlreichen Schichten des Vesikels soll eine
kontrollierte Freisetzung bewirkt werden. Tatsächlich konnte mit dem verwendeten
System eine Freisetzung über einige Stunden hinweg erzielt werden, was jedoch deut-
lich kürzer als bei Silikonmikropartikeln ist. Dennoch ist diese Freisetzungsdauer ein
guter Ansatzpunkt zur weiteren Optimierung des Systems, zum Beispiel durch Mo-
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difikation des verwendeten Polymers.
Im letzten Kapitel (Kap. 8, S. 245) dieser Dissertation wird die Theorie von NMR-
Diffusionsmessungen erläutert. Zusätzlich werden die Möglichkeiten dieser Methode
in Hinsicht auf ihren Einsatz bei der Charakterisierung von uni- als auch von multi-
lamellaren Vesikeln näher beschrieben. In der Tat können Vesikel mit Hilfe von NMR
auf ihre Größe und ihre Porengröße hin untersucht werden. Desweiteren kann die
Permeabilität der Vesikelmembranen für verschiedenste Moleküle untersucht werden,
was einen wesentlichen Punkt zu ihrer Anwendung als Wirkstofffreisetzungssysteme
darstellt. Gegebenenfalls kann die Freisetzungsrate und die Dicke der Schichten (bei
vielschichtigen Vesikeln) bestimmt werden.
Wird diese Methode verwendet, müssen jedoch zahlreiche experimentelle Aspekte
berücksichtigt werden, damit die Methode genaue Werte gibt. Diese Thematik wird
ebenfalls diskutiert.
Keywords:
kontrollierte Wirkstofffreisetzung, L-Arginin, Wundheilung, Silikonmikropartikel, Wund-
auflage, Polyurethanschaum, Finite-Elemente-Methode, Diffusionszelle, mehrschich-
tige Vesikel, Polymersome, PFG-NMR
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Abstract
This work concerns the development of controlled drug delivery systems, for the
application in modern wound management. Indeed, it is preferable to have moist-
warm wound healing conditions, which can be achieved by special wound coverings,
consisting of hydrogels, polyurethane foams, or the like. Further improvement of
wound healing can be attained by appropiate drugs, where such drugs have to be
present within a drug-specific concentration range. In this work, controlled drug re-
lease systems were developed, in order to ensure a drug supply of the wound, as long
as possible. For this, two approaches are traced. First, a controlled drug delivery
system was developed to be embedded into a polyurethane based wound covering
(chapter 3 and 5). Second, the aim was to develop and investigate an aqueous sys-
tem (chapter 7), which can be applied directly to the wound, prior to using a wound
covering. Where, the focus was on the first approach. Accordingly, this system was
further characterized, using the finite element method (chapter 6 and 4).
The semi-essential amino acid L-arginine was chosen as wound healing drug. This
is reasoned by two aspects. Firstly, there is a hugh concentration range, where
L-arginine acts well and do not show side effects. Secondly, it is well known that
disturbed wound healing results from a too low L-arginine concentration. Latter is
based on the effect of L-arginine in the wound healing process: In the beginning,
degradation by nitrogen monoxide synthase dominates, where the product, namely
nitrogen monoxide, is a radical with versatile influence on the wound healing, e.g. by
enhancement of vasodilation. Later, there is degradation by L-arginase to citrulline
and further to proline and polyamines. Where, proline acts as substrate in the col-
lagen synthesis and polyamines are involved in cell proliferation, both is essential
for wound healing.
As already mentioned, the first aim was to develop a system, which can be incor-
porated into a polyurethane based wound covering. For this purpose, silicone mi-
croparticles were developed, containing crystalline L-arginine (chapter 3, page 63).
In detail, it was desired to get a relatively linear release over at least two or three
days. And indeed, the silicone microparticles provide both, an almost linear release
and a release over several days. Furthermore, the release kinetics was further investi-
gated, in dependence of the particle size, the L-arginine content in the particles, the
pH value of the release medium and some other parameter. In doing so, the optimal
parameter for application in a wound covering could be determined, additionally, it
could be shown that the particles are appropiate for different wounds, which differ
e.g. in their pH value.
Moreover, proliferation and toxicity cell experiments were performed, using cell types
which are involved in wound healing, namely endothelial cells, keratinozytes, and
fibroblasts. The results were positive: the particles show no cytotoxicity, addition-
ally, they support cell proliferation; therefore, they are proved to be well-suited for
their desired application in modern wound coverings.
The next step was the incorporation of the particles into the foam (chapter 5,
page 133). Prior to this, it was confirmed that L-arginine is released without any
delay, after incorporation into the foam, without an additional matrix like silicone.
Then, release experiments with polyurethane foams containing the developed silicone
microparticles were performed and compared with the release profiles of L-arginine
out of silicone microparticles, in order to investigate the effect of the incorpora-
tion process on the release. Actually, there is a difference: The release out of the
foam loaded with silicone microparticles, shows a burst release, i.e. a non-controlled
release in the very beginning of the release period. However, the burst release is
only small and can be attributed to the incorporation process of the particles into
the foam, since the foam preparation is based on an aqueous dispersion. Hence, L-
arginine release starts during this process, and in the finished foam, a small amount
of the L-arginine occurs freely, which is set free, in the burst release. On further
reflection, this is welcome, because a certain concentration has to be yield, in the
beginning of the wound covering supply.
A further step was the consideration of the influence of the lymph fluid flow on the
drug concentration, in wounds. Thus, a diffusion cell was developed (chapter 5),
which simulated the lymph fluid flow. Also, under these conditions, the L-arginine
concentration is within the desired concentration range, over about three days.
Another part of this thesis is the utilization of the finite element method. Here, on
the one hand, the release out of the wound covering in the diffusion cell (chapter 6)
and on the other hand, out of silicone microparticles (chapter 4) were modelled.
The experimental results of chapter 5, obtained with the diffusion cell, could be
simulated successfully (chapter 6, page 157). Additionally, concentration profiles of
the drug in the wound could be yield, which are not available, in practice. Since
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the high quality of the implementation could be proved by the conformity with the
experimental data, the influence of several parameter could be investigated. In de-
tail, the flow rate, the thickness of the wound covering, the deepness of the wound
and many other parameter were varied, where these parameter can be changed only
with great effort, in practice. Basing on the knowledge of the parameter effect, the
wound covering can be further optimized, which emphasises the important role of
such a modelling for the optimization of a drug-containing wound covering.
The release out of the microparticles, experimentally investigated in chapter 3, was
programmed in two ways, for finite element simulation (chapter 4, page 93): Either
the release is assumed to be based on drug diffusion, or it is assumed to be based
on both, drug diffusion and swelling with water. Where, three different approaches
were set, for diffusion. Firstly, there is a small diffusion coefficient, constant over
time and over the whole particle. Secondly, the diffusion coefficient is set to be
dependent on the drug amount which has already been released, resulting in a time
dependent and local different diffusion coefficient. Thirdly, it is proceeded on the
assumption that it can be differentiated between two drug species, one embedded in
the silicone matrix and another diffusing freely through pores. Accordingly, there
are two different diffusion coefficient, where the former is constant, and the latter
depends on the amount of already released drug in the considered shell.
Additionally, swelling kinetics of water into silicone cylinder was investigated by
NMR imaging; here, a sharp border between the swollen and the inner part was
found. Due to this, an equation for the progress of the water front was set up. In
case of drug diffusion and swelling, this equation was used to determine if the diffu-
sion is allowed in the considered finite element, in every iteration of the simulation.
The drug release profiles could be simulated relatively well, but instead of linear
release, a dependence of the square root of the time was found. Accordingly, the
release process from silicone microparticles is very complex. Thus, on the chosen
suppositions, it is not possible to simulate the release, exactly.
Nevertheless, there are some results obtained by simulation. Firstly, both, swelling
and diffusion, are important processes in the release mechanism. Secondly, the ob-
tained diffusion coefficients are very small. In fact, a diffusion coefficient of about
10−16 m2/s was determined, which is quite small regarding to the value for L-arginine
in water (6.1 · 10−10 m2/s). Even under assumption of partly free diffusion through
pores, the diffusion coefficient is just as high as about 10−15 m2/s. Thirdly, it could
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be shown that only the outer shells of the silicone microparticles take part in the
release process (in the first 24 hours), in conformity with the water uptake. This
emphasises the importance of the silicone swelling by water regarding the release
process.
In addition, an aqueous controlled L-arginine delivery system should be prepared,
and investigated regarding to its suitability in regards to the usage, prior to sup-
plying a wound covering. For this purpose, multilayered polymersomes with en-
capsulated L-arginine were developed, and their release behaviour was investigated
(chapter 7, page 213). Due to plenty of vesicle's layers, a controlled release shall be
achieved. In fact, the developed system provides a release over a few hours, i.e. less
than for the silicone microparticles. Anyhow, it is a good starting point for further
optimization, e.g. by modification of the used polymer.
The last chapter (chapter 8, page 245) deals with NMR diffusion experiments. After
description of the theory, the possibilities regarding to the characterization of uni-
as well as multilayered vesicles are presented. In fact, the vesicle size and the pore
size can be determined by such measurements. Furthermore, the permeability of
vesicle membranes can be investigated for different molecules, which is an essential
point for the application as drug delivery system. In some cases, the drug release
rate, and the thickness of the layers (for multilayered vesicles) can be determined.
But using this method, several experimental aspects have to be considered, in order
to get trustworthy values, this is also discussed, detailed.
Keywords:
controlled drug delivery, L-arginine, wound healing, silicone microparticles, wound
covering, polyurethane foam, finite element method, diffusion cell, multilayered vesi-
cles, polymersomes, PFG-NMR
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Chapter 1
Introduction
1.1 Concept
About 25 % of stationary treatments in hospitals are caused by bad wound healing[1],
resulting in an important research area for improved wound coverings. Especially,
decubitus ulcers  also called pressure ulcers or bedsore  are chronic lesions. In fact,
this is the best known example for chronic wounds, they occur often for bed-ridden
patients, caused by long-lasting pressure of the bones against the skin, combined
with other factors as humidity, shearing forces and temperature.
Nevertheless, in modern wound management, demands on wound coverings are
made, which go beyond the scope of just covering the wound, for both acute and
chronic wounds[2]. In fact, optimal wound healing conditions in terms of temper-
ature, pH value, moisture and the like should be achieved by wound coverings. In
Germany, nowadays, there are coverings available which support these conditions[3].
For example, they consist of polyurethane foam, hydrocolloids or hydrogels[4]. In
this work, polyurethane foam was preferred as the wound covering to be loaded
with a wound healing drug. This is due to its high capacity to absorb wound fluid,
additionally, it fits well and flexibly to the wound.
However, additional to the wound covering, salves are often applied in order to sup-
ply different kinds of drug; as consequence, the oxygen supply is reduced strongly,
resulting in a degraded wound healing environment. In fact, oxygen is essential for
wound healing[5]. Thus, it is preferable to either add drugs directly to the wound in
a way which does not reduce oxygen supply or to embed wound healing supporting
drugs directly in wound coverings; both options were considered, in this work.
1
Concept
Nowadays, there already exist some wound coverings, impregnated or saturated
by drugs, which act antiseptically like polyhexanide, antibacterially like silver and
honey, or odour-neutralising like activated carbon. Furthermore, there are wound
dressings consisting of collagen or hyaluronic acid, both act specifically in the healing
process and can be used for particular wounds[3]. Moreover, there are patents[68]
on wound coverings, impregnated with wound-healing supporting or antiseptically
acting (and more) drugs.
But drug impregnating or saturation results usually in a burst release, meaning that
in the very beginning almost the whole drug amount is released at once. In order to
support wound healing over time, it is necessary to release a drug continuously over
at least several days. In fact, one patent states that the used superabsorber controlls
the release[6]. Except for this, and the patent[9] originated in this dissertation, at
the present day, there is no wound covering releasing a water soluble drug in this
way.
This leads to another important research area, namely controlled drug delivery sys-
tems [1014]. In fact, it is desirable that the drug is within a certain concentration
range, the so-called therapeutic window[10]. Beneath this window, the drug is non-
effective, whereas, it acts toxically and side effects arise, above the therapeutic
window. This is based on Paracelsus' famous statement, that every drug above
a certain concentration is toxic or sententiously the dose makes the poison ('All
Ding' sind Gift und nichts ohn' Gift; allein die Dosis macht, das ein Ding kein Gift
ist.' )[15, 16].
However, for this purpose, controlled drug release systems are invented, because the
release is retarded in order to do not reach a toxic concentration. Such controlled
drug release systems have to be adapted to the drug properties and to a certain aim
system for every kind of application: Releasing hydrophobic drugs, they have to be
embedded in hydrophilic carriers in many cases, in order to enable intake within
gastro-intestinal tract or within circulatory system. Whereas, water soluble drugs
are often too well and fast soluble, desiring systems, which retard the release.
In practice, the release can be controlled by encapsulating or by embedding the drug
into a matrix or the like. Where the release systems can be divided on the basis of
their release mechanism[17, 18]. There are diffusion, erosion, and swelling controlled
systems. This means that the drug is released in a controlled way, where the kinetics
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are determined by drug diffusion, matrix erosion or matrix swelling.
For drug release systems, there are plenty of theroretical models, which are devel-
oped either to better understand the release, or to be able to prepare or optimize
controlled drug delivery systems, based on theoretical considerations. In this work,
the finite element method[19, 20] is used for both, getting a further insight in the re-
lease mechanism, and for optimization suggestions in the development of the wound
covering. In fact, the finite element method is a numerical method used for solving
differential equations. Where, the basic principle of FEM is a separation of the
considered system into any number of finite small elements, with side conditions;
this results in equations which can be solved for every single element.
This method has been used a few times, in the field of drug release. For example,
the release from different kinds of drug delivery systems was investigated, namely
from matrix systems[2125], from microspheres[26], from biodegradable drug de-
livery system[27, 28], from cellulose-based pharmaceutical devices[29], and more
specialised, from coronary drug-eluting stents[30], and from a finite drug reservoir
into the skin[31].
L-Arginine is the wound healing supporting drug to be used in this work, it belongs
to the class of nitrogen monoxide (NO) donors. Where, NO itself plays a signif-
icant role in wound healing process, due to its supporting of vasodilation, and of
the unspecific immune defence[1, 3234]. But as radical, it has a very short life-
time[35], therefore, it has to be generated in situ. Anyway, the role of L-arginine in
wound healing process is much more essential. In concurrence to NO production,
there is L-arginine degradation to L-ornithine, which is a precursor for proline and
polyamine[1, 32]. Proline acts as substrate in collagene synthesis[36] and polyamine
is involved in cell proliferation[37], thus, also this L-arginine degradation supports
wound healing.
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Contents of this Thesis
1.2 Contents of this Thesis
This thesis concerns L-arginine delivery systems for application in modern wound
management. Both, a system for inclusion in wound coverings, and a system for
usage during application of a wound covering, have been considered.
Chapter 2 'State of the Art' (page 11) gives an overview about wound coverings,
wound healing, controlled drug delivery systems, the role of L-arginine in wound
healing, drug release kinetics, the finite element method, and about the use of vesi-
cles as drug delivery systems.
Chapter 3 'Silicone Microparticles as Controlled L-Arginine Delivery System' (page
63) deals with the development and characterization of silicone microparticles as con-
trolled drug delivery system for L-arginine. The release kinetics are investigated in
dependence of the pH value, the particle size, the drug loading and the like. Addi-
tionally, these particles were evaluated by cell culture experiments.
Chapter 4 'Finite Element Method: L-Arginine Release Modeling from Silicone
Microparticles' (page 93) discusses the possibilities of finite element method for the
calculation of the release behaviour of L-arginine out of silicone microparticles. Here,
either diffusion according to Fick's law, or diffusion as well as swelling kinetics are
considered, where different approaches for the diffusion coefficient were used. For
the swelling kinetics, data obtained by NMR imaging of silicone cylinders were used.
Chapter 5 'Release of L-Arginine from Polyurethane Foams' (page 133) presents
the results of L-arginine release from polyurethane foams, where L-arginine is either
embedded directly in the PU foam, or it is encapsulated in silicone microparticles
(described in chapter 3), which are incorporated into the foam. Moreover, a new
diffusion cell was developed, in order to simulate wound fluid flow, and it was used
for further investigation of L-arginine release from latter polyurethane foam.
Chapter 6 'Finite Element Method: Drug Release Modeling Using a Diffusion Cell'
(page 157) further investigates the drug release properties of the polymer foam with
embedded L-arginine containing silicone microparticles within the diffusion cell. The
experimental results (from chapter 5) could be simulated successfully. Thus, this
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model could be used to obtain information, which is hard-to-reach by experimental
work. For example, concentration profiles in the wound are presented, and the effect
of different parameter, like the thickness of the wound covering, the deepness of the
wound, the flow rate and more, were varied. Where, the results can be used for
further optimisation of the wound covering.
Chapter 7 'Polyglycidol Based Polymersomes as L-Arginine Drug Delivery System'
(page 213) investigates the self-assembled morphologies of a polyglycidol-based am-
phiphilic block copolymer, in an aqueous L-arginine derivatives solution, with or
without addition of fluorescence dyes. Basing on this, multilayered polymersomes
with encapsulated L-arginine derivatives were prepared, and the release behaviour
of L-arginine was investigated. Finally, the use of such vesicles as drug delivery
systems is discussed, on the basis of the results obtained in release experiments.
Chapter 8 'Pulsed-Field Gradient Diffusion NMR Measurements: Characterization
of Vesicles' (page 245) describes the theory of NMR diffusion experiments. Further-
more, it gives an overview on the field of application of such experiments, in the
characterization of vesicles. For example, it presents the determination of the vesicle
and the pore size, of the amount of entrapped molecules, the permeability, and the
like. Moreover, the aspects, to be considered in practice, are summarized.
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Chapter 2
State of the Art
2.1 Wound Management and Wound Coverings
In modern wound management, demands on wound coverings are made much be-
yond the scope of just covering the wound[1]. For example, for almost 50 years, the
principle of moist wound healing is known[2], which is combined with special require-
ments in temperature, pH value, moisture and the like for optimal wound healing.
But for a long time, little attention has been paid to patients's view or more pre-
cisely on wound related trauma and pain, exudate management and malodour[3, 4].
Altogether, one can state that an ideal wound covering should fulfil several condi-
tions. Firstly, there are essential properties: wound coverings should be self-adhesive
and easily removable, non-toxic and non-irritant, and long-term applicable; there
should be no release of non-biodegradable substances into the wound. Additionally,
they should form a water-resistant seal to peri-wound skin and an effective bacterial
barrier. Besides optimal hydration of wound and the surrounding skin, optimal tem-
perature and pH should also be provided. Furthermore, wound-related pain should
be as minimal as possible[4]. But there are also other desirable properties like an-
timicrobial and wound cleaning activity; in addition, odour should be absorbed, and
related to this, proteolytic enzyms may be removed or inactivated.
Most requirements are self-explanatory. In general, wound covering should not dis-
turb wound healing by foreign matter, they rather should protect the wound without
interacting too less or too much. Due to the requirement of long-term application
duration, nursing costs are reduced, the healing process is not disturbed frequently,
and pain, related to dressing removal, is reduced. Since pain results in delayed
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healing[46], pain mimimizing is an important point. Moreover, decreased quality
of life results in delayed healing[4, 7, 8].
Further to this, excudate management is another key aspect. Excess of excudate
may lead to maceration whereas drying out of the wound can lead to cell and tis-
sue death[9]. Especially excudate from chronic wounds impairs wound healing[3],
this is probably caused by a decay of tissue matrix components due to high lev-
els of proteases[10]. Furthermore, failure in excudate management leads to leakage
or malodour, which in turn affects health economics[11] and leads to distress in
patients[7, 12].
Conformable wound coverings reduce non-contact areas, where micro-organisms may
proliferate[13]. Ease of use is related to nursing time on the one side and on the
other side to trauma and pain. Pain decreases the quality of life, resulting in a
delayed healing[4, 7, 8], as already mentioned above.
However, different wounds demand different wound coverings, a short introduction
in which covering should be used for which wound can be found elsewhere[1, 14],
e.g. dry wounds should be nursed by hydrocolloids, whereas foams should be used
in case of excuding wounds[15].
2.1.1 Historical Development of Wound Coverings
History of wound treatment started a very long time ago, in fact, 4000 years ago
but most developments were reached within last 50 years[1, 16]. In the beginning,
cotton compresses were used. In 1962, Winter found that moist wound milieu results
in better wound healing and less pronounced scars[2]. In this context, polymer gels
(glycol methacrylate) were introduced in the early 60s, followed by hydrocolloids
in the late 70s  available in sheet, fibrous, paste and powder forms, nowadays .
Furthermore, alginate-based wound coverings were launched in the 70s. Foam-based
wound coverings were even introduced earlier; they were developed as improvement
for films, which have limited absorbency. Foams are based on polyurethanes or sili-
cone.
All in all, in Germany nowadays, there are more than 500 wound coverings com-
mercially available, they are described in a database[14]; in fact, beside conventional
wound coverings like gauze and non-woven fabric compresses, there are a lot of mois-
ture supplying, so-called hydroactive, antibacterial and odour absorbing coverings
readily available. Indeed, hydroactive are such wound coverings generating an op-
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timal moist-warm wound healing environment by absorption and accumulation of
wound fluid, without drying out the wound. As mentioned above, they are based
on alginate, collagen, hydrophilic polyurethane or other.
In fig. 2.1, global market in 2008 of five common moist wound coverings is shown.
Figure 2.1: Global market of moist wound dressings (2008): There is a wound
covering market for alginates, films, foams, hydrocolloids and hydrogels of 3 billion
US dollar altogether; foams and hydrocolloids have the highest percentage. (Values
are taken from a MedMarket Diligence's Report (Report #S247).)
Foams and hydrocolloids have the biggest share of the market[17], each of them
have almost 1 billion US dollars i.e. about 35 % of the global market of the five
hydroactive wound coverings. Taking other modern wound healing-related thera-
peutics, like growth factor and physical therapy, into account, the whole market of
advanced wound-related products has a value of approximately 5 billion US dollars
(2008)[17]. Additionally, there is global market of about 10 billion US dollars of
conventional wound products[17]. It is estimated that with strong market growth,
one may rightly assume values of 16 billion US dollars for advanced wound prod-
ucts and 12 billion US dollars for conventional wound products; the part of above
mentioned five hydroactive wound coverings, is estimated to more than 6 billion US
dollars in 2017[17].
2.2 Controlled Drug Delivery Systems
As Paracelsus once famously stated, every drug above a certain concentration is
toxic, or sententiously, the dose makes the poison ('All Ding' sind Gift und nichts
ohn' Gift; allein die Dosis macht, das ein Ding kein Gift ist.' )[18, 19]. But a drug
can only take affect if the amount is high enough. Thus, for medicine, there is a
problem that the concentration has to be high enough, but also low enough, so that
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it acts in the desired way, without being toxic. The drug and application specific
concentration range between minimal effective concentration and minimal toxic con-
centration is called therapeutic window[20], as shown as coloured area, in fig. 2.2.
When applying conventional release systems, a typical release parabola (for a plot
Figure 2.2: Therapeutic window: Conventional and ideal drug release.
The coloured area shows the therapeutic window: Above this, the concentration is
toxic, beneath it, the drug is without any effect. When applying a conventional
release system at time zero, the drug concentration in the considered region (e.g.
in a certain organ) increases with the time, reaches its maximum and decreases
(presented as dotted line). Where, the concentration passes the ineffective region,
the therapeutic window, and maybe also the toxic region, depending on the given
drug amount. Whereas, the dashed line represents the ideal concentration course,
which can be approximated by the controlled drug release systems. (modified from
[20])
of released drug amount in dependence of the time) is generated, as can be seen
in fig. 2.2. More specifically, it is very similar to a parabola, but the concentration
increases just slowly, in the very beginning, and also in the end, the concentration
decreases only slowly. In fig. 2.2, it can be seen that drug concentration is too low
in the beginning (it is beneath the therapeutic window), then the optimal region 
the therapeutic window  is paced until the concentration is toxic, i.e. above the
therapeutic window. After reaching the top of the peak, drug concentration de-
creases; this is due to removal and degradation processes, which decreases the drug
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concentration into the desired concentration range, and further into the effectless re-
gion. Of course, the top of the peak also could be beneath or within the therapeutic
window. But it is not optimal because on the one hand, most side effects are caused
by concentrations above the therapeutic window, and on the other hand, there is no
effect beneath the therapeutic window, nevertheless, such a course is not satisfying,
independent on the values of the maximal concentration and its time point.
There are two possibilities to prevent a toxic affect as well as non-effective concentra-
tions: (1) Lower drug amounts per application could be chosen combined with a lot
of additional administration, in the optimal case, this would result in a sinuous line
within the therapeutic window. But it is very difficult for patients to manage taking
medicine with a short regular distance of time. (2) Controlled drug delivery systems
are the other possibility. Here, drug release is controlled in a way that there is a
continous drug release over a long period of time. An additional advantage of this
system is that the drug's potency also stretches over otherwise inaccessible regions:
for example, tumours could be cured by drug 5-fluorouracil (5-FU) embedded in a
triblock copolymer matrix (PCL6-b-PEO90-b-PCL6), which is not possible without
the matrix[21].
Such controlled release systems can be applied in medicine, nursing and cosmetics.
Where, controlled drug release systems have to be adapted to drug properties and
to the desired system for every kind of application: When releasing hydrophobic
drugs, they have to be embedded in hydrophilic carriers in many cases, in order to
enable intake within gastro-intestinal tract or within circulatory system. Whereas,
water soluble drugs are often too readily soluble, desiring systems retarding release.
In the research area of controlled drug release, there are specialised approaches, e.g.
targeted drug release, here, the drug is released at a specific target (e.g. a tumuor).
The most simpliest way for drug targeting is by means of the size[22], because small
particles are distributed within the body in dependence on their size, as given in
tab. 2.1.
Furthermore, one can differentiate between actively and passively controlled releases[23].
One could also add a third group  active self programmed systems  being the aim
for the next generation of controlled drug release systems. In fact, such systems
should be developed, whose release is determined by biological stimuli e.g. sugar
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Table 2.1: Particle size and respective biodistribution in organs and tissue.
The simpliest way of drug targeting is by the size of the drug containing particles.
Here, it is presented, where particles, with a certain size, are accumulated. (accord-
ing to [22], modified)
Size Organ, Tissue
> 10 µm localized activity
5 - 10 µm captured in lung capillary blood vessels
< 5 µm captured by phagocyte system
1 - 3 µm spleen
0.1 - 1 µm liver
< 0.1 µm bone marrow
concentration in the blood, in the case of diabetes treatment. Nevertheless, active
control is found in electric systems[2427], which can be implanted and controlled
externally, and in other systems which can be controlled magnetically[28] or by
ultrasonics[29]. There are also biologically controlled systems being passively con-
trolled e.g. by pH value[30, 31] or by temperature[32].
Another kind of targeted controlled drug release system is applied as wound cover-
ings. That means that the drug is released externally to the body, then, it diffuses
and streams, through the destroyed skin of the wound, into the body, directly to the
target, i.e. the wound. About 25 % of stationary treatment in hospital is caused by
bad wound healing[33] resulting in an important research area for improved wound
coverings.
Nowadays, there are different dosage forms like tablets, capsules, pellets, patches
and microparticles. Usually, controlled release systems consist of a matrix because
it is relatively easy and cheap manufacturable. There are hydrophobic (e.g. wax,
PE, PP, ethyl cellulose) and hydrophilic (e.g. hydroxy-, hydroxypropyl-, sodium
carboxy-, methylcellulose, (meth)acrylate, alginate, sceroglucan) matrices.
Mathematical methods for calculating time-dependent drug concentration can be
used in order to determine the details of a release system. There are many different
mathematical models used in considering just one certain parameter, furthermore,
physical data like diffusion coefficients are needed.
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2.2.1 Historical Review of Polymer Therapeutics Develop-
ment
In 1920, the origin of polymer science was engendered by an article[34] of Hermann
Staudinger, leading to his consideration as the father of polymer science. There-
fore, the nobel prize[35, 36] in chemistry was awarded to him 'for his discoveries
in the field of macromolecular chemistry' in 1953. In the 60s, block copolymers at-
tracted attention[37], and in the 80s, Ringsdorf group suggested the idea to use block
copolymers for development of drug delivery systems[3840], which caused a growing
interest, which was visible in the number of articles on drug release combined with
polymers, shown in fig. 2.3. Interest grew (see fig. 2.3) due to the introduction of
Figure 2.3: Trend of research in drug delivery or drug release combined
with polymers or block copolymers. Here, whole bars represent published
articles dealing with drug delivery or drug release in conjunction with polymers,
whereas, the dark coloured part of the bars represent published articles dealing with
drug delivery or drug release in conjunction with block copolymers. And the Inlet
shows latter mentioned articles, i.e. the dark coloured part of the bars. (Values were
obtained in September 2011 using SciFinder Scholar software (American Chemical
Society); it was searched for (drug delivery OR drug release) and refined either for
polymers or for block copolymers.)
amphiphilic block copolymer micelles as drug delivery systems, in 1996/97[40]; un-
der certain conditions concerning temperature, solvent, pH value or concentration,
amphiphilic block copolymers self arrange to structures of different morphologies,
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e.g. micelles, vesicles, tubes. Micelles were introduced as drug delivery system for
hydrophobic drugs, several years ago, in order to channel them into hydrophilic bod-
ies; they have many advantages: they are (1) easily producible, and (2) applicable
for many drugs, they can be used for (3) targeting, (4) their release properties can
be adjusted by changing kind or composition of used polymers or by micelle size.
Furthermore, they show (5) simple uptake of hydrophobic drugs without chemical
derivatization, (6) relatively high drug loading capacity, (7) controlled release be-
haviour, and (8) negligible influence of drug's chemistry.
Since the science of drug delivery systems is based on polymer science, it is reason-
able that it is a young science, one could say that its origin was in the 70s. First
polymer therapeutica reached clinical phase, in the 70s/80s[41].
In this context, discovery of enhanced permeability and retention (EPR) effect by
Maeda and Matsuma, being a kind of passive drug targeting, was an important
step[4244], in 1986. They found that macromolecules prefer to accumulate in tu-
mours, which was explained[43, 45] by (1) hypervascularization of tumours, (2)
microvascular hyperpermeability of tumours[4648], (3) much less pronounced re-
moval of macromolecules via capillaries compared to other tissues, and (4) impaired
lymphatic drainage of macromolecules in tumour tissue[37, 49]. Second is suggested
to be caused by overexpression of the vascular permeability factor (VPF)/vascular
endothelial growth factor (VEGF)[50, 51], and secretion of other factors such as the
basic fibroblast growth factor (bFGF)[52], the peptide bradykinin, nitric oxide and
peroxynitrate in tumor tissues[53, 54].
Meanwhile, it was found that also biocompatible carriers like polymers, liposomes
and polymer micelles show EPR effect[55, 56] as well as was found that this effect
occurs in other diseased sites[37, 57] than tumours, too. In fact, EPR effect was also
found after a balloon injury in the rat carotid artery, in the area of an experimental
myocardial infarction, and in the choroidal neovascularization sites in rat models[37];
this offers also new approaches in the treatment of very few other diseases.
2.3 L-Arginine as Wound Healing Supporting Drug
L-arginine (Arg) belongs to the charged basic amino acids, its structure is shown
in fig. 2.4. Arg has a very strong basic guanidino group having an acid constant of
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Figure 2.4: pH-dependent structure of L-arginine.
The structure of Arg and its charge is pH-dependent; the protonation steps have fol-
lowing values of acid constants: pKCOOHa = 2.0, pK
NH2
a = 9.0, and pK
gua
a = 12.5[58].
The isoelectric point is 10.75[58].
pKguaa = 12.5 (amino group pK
NH2
a = 9.0, carboxyl group pK
COOH
a = 2.0). Like all
other amino acids, Arg is an ampholyte, thus, the charge of Arg is pH-dependent,
where, its isoelectric point is 10.75[58, 59] at 25 oC (11.55 at 0 oC[58] and 11.2 at
20 oC[60]). The isoelectric point (pI) can be calculated as arithmetic average from
pKa values of amino and carboxyl group as pI =
pKguaa +pK
NH2
a
2
. In the physiological
environment, Arg supports substrate binding for many enzyms by fixation of neg-
atively charged groups (e.g. phosphate or carboxy groups)[61]. Arg is the amino
acid which has the highest nitrogen amount, stating a significant role in nitrogen
balance.
In a healthy adult, Arg can be built in amounts high enough, by the body itself,
but under certain conditions like disease or growth, additional Arg is needed, and
therefore, Arg is called semi-essential[61]. In the body, Arg can be synthesised from
L-citrulline, which takes place during the urea cycle primarily in the kidneys[62].
And it is mainly degraded in the body within the urea cycle in the liver[63], gen-
erating L-ornithine. The intracellular Arg concentration is between 100 µM and
800 µM [6466], which is tuned by the intracellular metabolism or by Arg transport
from the cell environment through a cation amino acid transporter called y+.
The task of Arg is not limited to its functions as important amino acid, moreover it
plays a central role in wound healing. In fact, Arg deficiency results in wound healing
failure[67]. Furthermore, it was found that Arg supplementation promotes wound
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healing[68], it stimulates immune response by increased T lymphocytes function
[69], and it supports a positive nitrogen footprint[70]. Additionally, Arg stimulates
microvascular blood flow[71].
Moreover, Arg belongs to the class of NO donors. NO itself has a lot of other
physiological activities[33, 72], more so, it plays a significant role in wound healing
process[33, 73]. NO as a radical is relatively transient, hence, it has to be generated
in situ. For all these processes, it is important to know that both Arg degradation
reactions occur in wound tissue[62, 74].
As demonstrated in fig. 2.5, Arg supports wound healing by its intracellular enzy-
matic degradation on two different ways, competing against each other. In the early
Figure 2.5: Role of L-arginine during wound healing process.
Concerning wound healing, different processes are shown, in which Arg is involved.
In fact, Arg is degraded by both enzymes, arginase and NOS, either to proline and
polyamine, or to NO. All of them play an important role in wound healing. Addi-
tionally, it can be seen whether processes take place intracellularly, or extracellularly.
(according to Witte, Barbul[33], modified)
wound healing phase, Arg is primarily degraded by so-called NO synthase (NOS),
which synthesises NO within L-citrulline NO cycle. As already described, NO plays
an important role in wound healing. Despite others, it reacts in versatile ways, e.g.
in vasodilation, and in unspecific immune defence; both of them are essential during
wound healing.
Later, degradation by arginase in urea cycle to L-ornithine dominates. It is sup-
posed that later suppression of the NO path, combined with arginase metabolism,
supports macrophage function in wounds[73]. As can be seen in fig. 2.5, in presence
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of arginase, Arg reacts to L-ornithine and further to proline, and polyamines; these
products contribute to collagen synthesis and cell proliferation, and thus, to wound
healing.
2.3.1 Wound Healing: Arg Degradation by NOS
There are different isoforms of NOS[75, 76]: induced NOS (iNOS or NOS-2) and
two types of constitutive NOS, namely neuronal (nNOS or NOS-1) and endothelial
NOS (eNOS or NOS-3). Since constitutive NOS is always available by definition,
it has to be regulated strictly, whereas iNOS is only available in small amounts,
but can be expressed in large amounts, therefore, activity of iNOS is hardly regu-
lated, resulting in a fast, strong and long-lasting NO synthesis, after activation by
transcription factors (namely endotoxines or proinflammentory cytokines). Hence,
it is understandable that iNOS can produce 1000 times higher NO amounts than
constitutive eNOS. Such high concentrations are cytotoxic and serve in immune de-
fence. But activation of iNOS can be down-regulated by the concurrence reaction
of arginase. After being activated by 4-6 hours calcium dependent induction, iNOS
produces NO over hours or days without any further activation.
iNOS and nNOS are soluble and are predominantly found in cytosol, while eNOS is
membrane associated. As their names imply, eNOS is mainly found in endothelial
cells, nNOS in neurons and iNOS in diseased tissue, where, latter is exprimed due
to pathologic stimuli in macrophages, astrocytes, Kupffer cells, endothelial cells,
chondrocytes and other[77].
In fact, iNOS produces NO in micro molar amounts[78, 79]1. Indeed, such small
amounts operate toxically, for example, resulting in autoinhibition of key enzyms of
mitochondrial respiratory chain or within Krebs cycle, whereas, nNOS and eNOS
just produce NO in pico molar amounts[80], and even under medical stimulation,
just in nano molar amounts[81].
In wound healing, iNOS is the crucial enzyme form[62]. Its major sources are
macrophages, but also fibroblasts, endothelial cells and keratinocytes[62]. In fact,
the function of NO differs depending on the origin: For example, NO produced by
1In constrast, other literature[80] states nano molar amounts instead of micro molar amounts.
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macrophages acts cytostatic to bacteria, fibroblasts' NO supports collagen synthesis,
and endothelial cells' NO is involved in angiogenese. iNOS is stimulated by a set of
cytokines, which inhibit Arg degradation by arginase.
Exact regulation of iNOS activity is very complex. Since the Michaelis-Menten con-
stant, KM , has a value of KM = 1−10 µM , which is relatively small in comparision
to Arg concentration in the cells (100−800 µM), the reaction should take place un-
der substrate saturation. This follows from saturation function of Michaelis-Menten
enzyms[82, 83]
v =
vmax · [S]
KM + [S]
⇒ v(KM[S]) = vmax · [S]
KM + [S]︸ ︷︷ ︸
≈[S]
≈ vmax (2.1)
where, v is reaction velocity, vmax maximal reaction velocity, and [S] substrate con-
centration (here, Arg concentration).
As shown in fig. 2.6, in L-citrulline NO cycle, Arg is first degraded to L-NG-hydroxy
arginine, this is why NOS is also called oxidative L-arginine deiminase (OAD). Then,
Figure 2.6: Arg degradation by NOS.
Arg is degraded by NOS to L-NG-hydroxy arginine, which is further degraded to L-
citrulline and NO. Both steps need activation by NADPH, additional oxygen is also
needed. The degradation product, NO, plays an important role in wound healing,
and in many other processes. (according to [61, 63, 84])
it further reacts to L-citrulline and NO, both under oxygen and NADPH consump-
tion. NO contributes much to wound healing, as described in the next section.
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2.3.2 Nitrogen Monoxide
Nitrogen monoxide (NO) is a short living, lipophilic, free diffusing gaseous radical,
having a relatively low water solubility[72, 85]. In the extracellular environment,
NO reacts with water and oxygen to form nitrite (NO−2 ) and nitrate (NO
−
3 ), ac-
cordingly, NO has a short half-life period of 5-10 s[63]. Because of its short living
time, NO has to be produced locally, in order to be used as a drug. As long as in
the end of the 19th century, NO donors  e.g. nitroglycerin for treatment of angina
pectoris or hypertony  were used as medicine without knowing the active drug nor
the mechanism of action.
In 1980, Furchgott and Ignarro started to clear the mechanism up. They found that
a diffusible vasodilator is produced by endothel (which are the cells covering blood
vessels from the interior  particulars[86]) this results in the former name endothe-
lium derived relaxing factor (EDRF). But the real drug, namely NO, was identified
19 years later by Ignarro[87].
'For their discoveries concerning nitric oxide as a signalling molecule in the car-
diovascular system', Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad were
awarded in nobel prize in physiology or medicine in 1998. In detail, Murad pos-
tulated a new concept for signalling in biological systems, indeed he came up with
the idea that NO and other nitrogen-containing molecules move through cell mem-
branes and regulate the function of other cells. Some years later, in 1980, Furchgott
discovered the EDRF effect. And in 1986 Ignarro found out that EDRF is, in fact,
NO, thus he could prove that Murad's postulation was correct.
After having been published, physiological effects of NO were further investigated
and a lot of other processes have been found where NO plays a significant role.
For example, NO acts in unspecific immune defence, neurodegenerativ deseases, ar-
teriosklerosis, sepsis, and in diabetes. Additionally, NO regulates blood pressure
and action of the bowels because of its relaxating effect on smooth muscle cells,
furthermore, it has neurotransmitter functions and it inhibits thrombocyte aggre-
gation, and it takes part in cell-mediated immune response[72]. For wound healing,
especially, NO's effect on vasodilation, and unspecific immune defence is important.
In 1992, the respected journal Science declared nitric oxide as its 'molecule of the
year'[88].
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2.3.3 Wound Healing: Arg Degradation by Arginase within
the Urea Cycle
There are two different forms of arginase: arginase I ist the cytosolic 'hepatic' iso-
form, which is also present in wound-derived fibroblasts[62], and arginase II, the
mitochondrial extrahepatic isoform exists in many cell types. It is unclear which
Figure 2.7: Arg degradation within urea cycle.
The urea cycle consists of several steps, where most of them occur in the cytosol,
except of the reaction of L-ornithine to L-citrulline, taking place in the mitochon-
drium. In wound healing, Arg degradation by arginase to L-ornithine, and further
to L-citrulline, is important, which is part of the urea cycle. (according to [61])
isoform acts in wound healing[62]. However, arginase exists extracellularly in high
concentrations in wounds; there is debate about whether it is provided by living
macrophages[89] or it is set free exclusively by necrotic macrophages[89]. As well as
iNOS, arginase is stimulated by a set of cytokines, e.g. by growth factor-β, which
inhibits iNOS[62].
Arginase, consisting of three tetrameres[90, 91], degrades Arg within urea cycle to
urea and L-ornithine, which is partially further degraded to L-citrulline (and fur-
ther to glutamate[61]), as can be seen in fig. 2.7. L-Ornithine is a precursor of
proline (fig. 2.8) and polyamines[33, 73], which results in wound healing as proline
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Figure 2.8: Arg degradation to proline by arginase.
Arg is degraded by arginase to L-ornithine, which is further degraded to proline via
several intermediates. (according to [61])
acts as the substrate in collagen synthesis[92], and polyamine is involved in cell
proliferation[93]. Actually, when cellular polyamine synthesis is inhibited, cell pro-
liferation is strongly reduced, or even stopped.
In the context of tissue injury, need of proline in tissue increases since new collagen
has to be produced to close the wound[74]. Indeed, in rats a strongly enhanced
arginase expression in wound fibroblasts compared with usual fibroblasts has been
verified[94].
Altogether, it can be stated that Arg plays an essential role in wound healing, both,
in the beginning during high NO synthesis, and later during arginase metabolism.
Thus, it is desirable to provide the wound tissue with Arg amounts high enough,
during the whole wound healing process.
2.3.4 Wound Healing: Progression of Cell Types
During unimpaired wound healing, there is a characteristic progression of relative
numbers of certain cell types[84] and of concentrations of substances involved in
the healing process, as presented in fig. 2.9. In fact, relative cell numbers of two
cell types involved in the healing process, are shown. Macrophages participate in
unspecific defense, therefore, they can be found frequently during the inflammation
phase, in the beginning of the wound healing process. Whereas, fibroblasts synthe-
sise collagen and extracellular matrix, which is part of the proliferation phase, the
second wound healing phase; thus, the maximal number of fibroblasts can be found
during proliferation.
Arg degradation by NOS dominates in the first days, thereafter, Arg is mainly de-
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Figure 2.9: Wound healing: Temporal progression of Arg, L-ornithine, L-
citrulline, NO, macrophages, and fibroblasts. (according to [33, 73], modified;
in detail, the data of NO and of the cells are taken from [33], and the origin of the
other data are in [73].)
In unimpaired wound healing, a typical progress of cell types which are involved
in the wound healing process, and of substances like Arg, NO, L-ornithine, and L-
citrulline can be found. During the first phase, namely inflammation, L-citrulline,
Arg, NO and macrophages have their most frequent occurence. In fact, Arg degra-
dation by NOS to L-citrulline and NO dominates, in the early wound healing phase.
The time points of their maximal concentrations are shifted to each other, this
is probably caused by the fact, that the data of both curves have different ori-
gins, therefore, the temporal progressions of wound healing do not coincide exactly.
Macrophages are involved in non-specific defense, which is important during in-
flammation, in particular. Whereas, fibroblasts take part in the collagen synthesis
and are therefore essential during proliferation, maximal fibroblast cell number can
be found in the mid of the second phase, namely proliferation. Furthermore, in
this stage, Arg is mainly degraded by L-arginase to L-ornithine, whose maximal
concentration can be found during the proliferation and regeneration phase. Dur-
ing regeneration, the last phase of wound healing, the relative cell numbers and
concentrations of all cell types and substances decrease to their typical values of
non-destroyed tissue.
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graded by arginase. Where, the products of former reaction are L-citrulline and
NO, whose maximal concentrations can be found during inflammation. Contrary
to expectations, these two maxima do not arise at the same time point, which is
probably caused by the different origins of the data. Later, there is an enhanced
concentration of L-ornithine, which can be attributed to high L-arginase activity[73].
Ornithine is a substrate for the formation of proline and polyamines. Furthermore,
it reacts to citrulline, within the urea cycle, which is probably the reason for the
slight recovery of the citrulline concentration, during proliferation. In the last phase
of wound healing, regeneration, the amounts of all involved substances and cells
regress to their typical values of non-destroyed tissue.
However, the wound healing process is much more complex than described by fig-
ure 2.9, because the kind of Arg degradation path is determined by the concentration
of certain substrates, and by the amount of certain single cell types. For exam-
ple, L-hydroxy arginine, and the end product nitrite strongly inhibit degradation
by L-arginase[33], furthermore, distinct cytokines either prefer or inhibit different
degradation processes.
2.4 Kinetics
Based on Langer and Peppas[95, 96], drug release systems can be classified by their
rate-limiting step. In accordance with this, such systems are differentiated between
diffusion, erosion and swelling controlling, as demonstrated in chart 2.10. Here,
diffusion controlled systems can be further divided into reservoir and matrix based
systems, which follows either Fick's first or second law or it follows neither Fick's
law and is treated by Higuchi model[97]. Models for erosion controlled systems are
either empiric or mechanistic methods, where one divides between surface and bulk
erosion[98]. Moreover, swelling controlled systems, which are either oral matrix-
based or cross-linked swelling controlled systems, can be arranged somewhere be-
tween two extreme cases, named case I and case II[97]. More detailed information
is given in following sections.
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Figure 2.10: Kinetics: classification of drug delivery systems. Drug delivery
systems can be divided into several subgroups, on the basis of their release kinetics.
In the following sections, the chart is explained, in detail. (according to the text of
[97])
2.4.1 Diffusion Controlled Systems
Reservoir Systems
Reservoir systems like micro or macro capsules, membranes (mainly transdermal
systems), and hollow fibers are usually diffusion controlled. Here, the drug is en-
capsulated in a polymer, which does not degrade, during release time. The release
mechanism is based on drug diffusion through the polymer, and proceeds according
to Fick's law:
JA = −DAB dcA
dz
. (2.2)
with the flow JA of drug molecules, drug's diffusion constant DAB, and the gradient
dcA
dz
of the drug concentration along z. The release rate can be adjusted by physical
parameter, like geometry of the body and polymer membrane thickness.
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Matrix Systems
In matrix based systems, drugs are dissolved or disperged directly in a matrix.
Meaning, that these systems can be differentiated by drug loading concentration
(c0): either c0 is smaller or higher than saturation concentration (cs) of the drug in
the matrix.
For a dissolved drug system, c0 < cs applies. Under the assumption of an one-
dimensional release, second Fick's law can be applied, where, the system's geometry
is essential, having been investigated by Baker and Lonsdale[99]. For example,
equation for disk like system is given as
dcA
dt
= DAB
d2cA
dz2
for disk like systems (2.3)
with the concentration cA of drug A, the time t, the diffusion lenght z, and the
diffusion coefficient DAB of drug A in matrix B.
In the case of non-bioerodible microparticles, Siepmann et al.[100, 101] suggested
two models. Both of these assume a three step release: firstly, the drug diffuses
from the inner part of the microparticle to its surface, in the second step, drug
molecules diffuse through an unmoved liquid boundary layer and finally into the
release environment. Here, convection is neglected. For spherical particles, second
Fick's law is given by
∂c
∂t
= D ·
(
∂2c
∂r2
+
2
r
∂c
∂r
)
for spherical systems. (2.4)
Where, the drug concentration (c) in the polymer matrix is dependent on the time
(t) and the position (r) (c → f(t, r)); D is the diffusion coefficient of the drug in
the matrix.
The first model supposes that the diffusion rate within the matrix is as high as
outside of the matrix. Additionally, there is an equilibrium condition between drug
concentration at the surface, and in the environment. Whereas, the other model
assumes that the mass transfer resistance around the particle can be neglected com-
pared to mass transfer resistance in the particle, resulting in an infinite mass transfer
coefficient in the layer directly around the particle.
There are different models for dispersed drug systems with c0 > cs. Despite its
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simplification, the Higuchi model is very common[102]. In 1961, Higuchi supposed
a quadratic time-dependence of released drug amount (Mt). However, to be applied
correctly, systems have to fulfil some conditions:
1. Initial drug concentration in the matrix is much higher than its solubility
(c0  cs).
2. Matrix swelling is neglectable.
3. Ideal sink conditions are given during whole release duration.
4. Edge effects are neglectable.
This model was generalised later, as can be found in literature[103, 104]. Ad-
ditionally, there are a wide range of other models, which have been reviewed in
literature[97].
2.4.2 Erosion Controlled Systems
Models for erosion controlled systems are usually very complicated, this can be
attributed to the inclusion of mechanisms like erosion, which are connected with
chemical processes, and are much more sophisticated than mechanisms like diffu-
sion or swelling, which are connected with physical processes. The erosion mecha-
nism starts by water absorption of the polymer. In most cases, hydrolysis follows;
monomer or oligomere products can influence physical parameter like pH value in
the micro environment, which in turn influences erosion, for example by auto catal-
ysis. Furthermore, both drug molecules and erosion products diffuses out of the
matrix leaving pores.
One differentiate between surface erosion and bulk erosion, its difference is demon-
strated in fig. 2.11. In the case of a higher water diffusion rate compared to a
polymer erosion rate, the entire matrix is eroded uniformly, this is known as 'bulk
erosion'. Whereas, surface erosion starts at the surface, the deeper layer are affected
only after erosion of surrounding layers, because water diffusion into the matrix is
slower than erosion.
There are two different approaches, namely empirical and mechanistic models. Em-
pirical models suppose a single zero order kinetic process, which is meaningless
regarding to mechanism. Whereas, mechanistic models are based on specific physic-
ochemical phenomena like diffusion induced mass transfer or chemical reactions[98].
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(a) bulk erosion
(b) surface erosion
Figure 2.11: Sketch of bulk and surface erosion.
There are two types of erosion: (a) The system erodes regularly over its whole bulk,
resulting in an decreasing density and a steady size, or (b) the system erodes only on
its surface, thus, it gets smaller over time, without any change in density. (according
to [97])
Empirical Models
Empirical methods like those developed by Hopfenberg[105] and Cooney[106], sup-
pose a heterogeneous zero order erosion process (surface erosion) with a constant
verlocity. In detail, Hopfenberg's model assumes that the whole process is of zero
order, as a consequence of which, it can only be applied for surface eroding systems
having a rate-determining step of zero order. It results in the following general
equation[105]
Mt
M∞
= 1−
(
1− k0t
c0a
)n
(2.5)
with the released amount Mt or M∞, at time t or infinity, the velocity constant k0,
the uniform initial drug concentration in the matrix c0, the radius a of spherical or
cylindrical particle or layer thickness 2a, and with the geometry dependent exponent
n (sphere n = 3, cylinder n = 2, disk n = 1).
The latter model describes a non-porous, homogeneous system with surface erosion.
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Here, a molecule dissolves from the surface and diffuses further afar in a way that
the velocity of the drug release is proportional to the time dependent surface size.
For a cylindrical system, the following equation[106] holds
f =
(D0 − 2Kt)2 + 2 (D0 − 2Kt) (L0 − 2Kt)
D20 − 2D0L0
(2.6)
with the initial cylinder lenght L0, the initial diameter D0, and a constant K. It
can be differentiated between constant release, for disk like cylinders with L0
D0
< 1,
and the release rate for rodlike cylinders with L0
D0
> 1, which converges to zero, at
the process end.
Mechanistic Models
Monte Carlo based models are appropiate for surface eroding systems, where erosion
is considered as a random process. Göpferich[107] developed methods for both,
surface and bulk eroding systems, based on the Monte Carlo and diffusion theory
with regard to properties like crystallinity and porosity. Further analytical methods
are reviewed in the literature[97].
2.4.3 Swelling Controlled Systems
There is non-Fickean or anomalous diffusion in swelling controlled systems. Where,
the deviation from Fick's law is caused by the velocity, with which the polymer struc-
ture changes, in order to absorb solvent molecules. Alfrey et al.[108] distinguish two
extreme cases, namely, case I and case II transport. The former are diffusion con-
trolled systems, which means that release is dependent upon molecular diffusion
along a chemical potential, where the mobility of solvent molecules is smaller than
the segment relaxation rate. In drug delivery, the solvent is water, i.e. release is
controlled by hydrophilic swelling. In contrast, case II transport occurs in devices
that are swelling controlled, and anomalous transport has intermediate character-
istics. This relaxational release is connected with stresses and state-transition in
hydrophilic polymers during swelling.
Swelling controlled release systems can be classified into oral matrix-based drug
delivery systems and cross-linked swelling controlled delivery systems[97]. Usually
these systems are stored dryly. For a water soluble polymer, contact with moisture
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effects a fast glass transition and add-on solvation. However, in cross-linked sys-
tems, the swelling equilibrium occurs, once the network cannot be stretched apart.
Release occurs in swelled regions. Diffusion results because of a relaxation of the
macromolecular chains, taking the polymer from a glassy to a rubbery state. This
dynamic swelling of the glassy polymer is generally the release control mechanism.
2.5 Finite Element Method
The finite element method (FEM) is based on applied mathematics, physics and
engineering. FEM research has mainly been performed in engineering, especially
Turner as well as Argyris and Kelsey promoted FEM. The term 'finite element
method' was introduced by Clough in 1960[109]. In fact, the basic principle of FEM
is a separation of a considered system into any number of finite small elements, here,
side conditions exist for every element. Meaning, there are equations which can be
solved for every single element.
FEM is a modern method, which was mainly developed over the past 50 years.
However, its origin was during the 19th century, when Karl Schellbach solved a
minimal surface problem[110], in a very similar way as FEM. Further work was then
performed by Kirsch and Rayleigh[111113]. Nevertheless, FEM's real origin was
introduced by Boeing, in order to optimize wings[114], in 1956. In this case, they
needed a method applicable for a high degree of freedom. Furthermore, a strong
basis was laid by much improvements in computer capability, later.
FEM is a numerical method used for solving of differential equations. This method
results in an approximate function to the exact solution of the differential equation;
where, approximation can be improved by enhancing the degrees of freedom, and
thereby, by an enhanced computing time.
Nowadays, FEM is the most common algorithm for the calculation of complex
structures in mechanical and apparatus engineering, architecture, automotive and
aerospace engineering. In principal, FEM can be used everywhere, where physi-
cal phenomena can be described by place- and time-dependent partial differential
equations; some typical examples are given in table 2.2. For example, during new
product development in the automobile industry, it is used to optimize parameters,
topology or shape. In chemistry, it can be used e.g. for calculation of diffusion,
anodic oxide formation and corrosion of valve metals aluminium and tantalum.
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Table 2.2: Areas of FEM application.
equilibrium
electrostatics rigidity, displacement, stress, deformation
design optimization parameter, form, topology
stability problems collapse load, buckling load
stationary heat conduction temperature field
diffusion equation
instationary heat conduction heating, temperature field, heat flow field,
pressure, velocity
acoustics sound distribution
fracture mechanics crack propagation
diffusion soakage flow
equations of motion
elastodynamics vibration, resonant frequency, fatigue
crash behaviour deformation, acceleration
technical fluid dynamics aeroelasticity
The basic principle of FEM is  as already mentioned  a separation of the con-
sidered system into any number of finite small elements, with side conditions, this
results in equations, which can be solved for every single element.
In the case of diffusion, first Fick's law[115]
J = −D δc
δx
(2.7)
has to be solved. This can also be expressed as
dn
Adt
= −Ddc
dx
(2.8)
⇔ dn
dt
= −D · Adc
dx
(2.9)
(2.10)
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with the diffusion flux (J), which measures the amount of substance (n) flowing
through a small area (A), during a small time interval (dt); with the diffusion co-
efficient (D), the concentration (c), and the position (x). When applied to finite
elements, it follows:
∆n
∆t
= −D · A∆c
∆x
(2.11)
⇔ ∆n = −D · A ·∆t∆c
∆x
. (2.12)
(2.13)
When all finite elements have the same volume, the equation simplifies for a finite
element (FE) with f neighbours to
∆n = −D · A ·∆t∆n
′/V (FE)
∆x
(2.14)
= −D ·∆t
V (FE)
· A∆n
′
∆x
(2.15)
⇔ n(FE)t+∆t = n(FE)t −
f∑
i=1
(
D ·∆t
V (FE)
· Ain
(FE)
t − n(i)t
∆x
)
(2.16)
= n
(FE)
t −
D ·∆t
V (FE)∆x
f∑
i=1
(
Ai · (n(FE)t − n(i)t )
)
(2.17)
(2.18)
and if these elements are cubic with an edge length of l, the following is true
∆x = l (2.19)
A(FE) = l2 (2.20)
V (FE) = l3 (2.21)
(2.22)
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and thus,
n
(FE)
t+∆t = n
(FE)
t −
D ·∆t
l3 · l
6∑
i=1
(
l2 · (n(FE)t − n(i)t )
)
(2.23)
= n
(FE)
t −
D ·∆t
l2
6∑
i=1
(
(n
(FE)
t − n(i)t )
)
(2.24)
(2.25)
This equation can be solved easily and iteratively, the exact solution is approxi-
mated.
In medicine meanwhile, it is possible to achieve a very high degree of accuracy in
model development and interactive simulation for the bones, backbone, liver and
heart. In this context, the advantages of this method are that (1) the structures, to
be calculated, have to be limited hardly, (2) equations are build relatively simply,
and (3) occuring system matrices have good numerical properties, and thus, can be
calculated efficiently.
In the field of drug release research, FEM has already been used a few times to model
and calculate drug release, to optimize devices or to model the release environment.
In the case of drug administration to the eye, on the one side drug distribution in
the posterior human eye[116], and on the other side pharmacokinetics in the eye,
after drug administration by intravitreal injection and implant for the treatment of
retinal disease were investigated[117].
Drug release from different kinds of drug delivery systems was investigated, namely
from matrix systems[118122], from deformed coating films[123], from a single sphere,
a monolayer, and multiple layers of microspheres[124], from biodegradable dense
collagen matrices [125], from biodegradable implantable micro-porous drug delivery
system[126], from hydroxypropyl methyl cellulose-based pharmaceutical devices[127],
and more specialised , from oral targeted drug delivery systems[128], from porous
bone grafts[129, 130], from coronary drug-eluting stents[131], and from a finite drug
reservoir into the skin[132].
Additionally, FEM was used to investigate drug release related properties, like drug
distribution in the inner ear[133], in the stratum corneum[134, 135], into the paren-
chyma[136], within the vessel wall in the context with stents[137], and during a trans-
dermal drug delivery process[138]. In addition, uptake of systemically-administered
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antibody by a tumor[139] was modelled, as well as the dynamic behavior of an
eroding polyelectrolyte gel[140]. It was also used for the design optimization of
tablets[141] and stents[131].
For actively controlled drug delivery systems; design of valves[142], of microdia-
phragms[143, 144], and of a micromachined pump[27] were optimized using FEM
as well as design of microneedles[145] and of a miniature ultrasonic probe for cell
penetration[146]. Furthermore, for such systems magnetic force control[28], elec-
tric field distributions[25], electrokinetic transport mechanics[26] and convective
diffusion-dissolution process connected with automated multisample flow-through
system[147] were studied.
One divides into the Lagrange and the Eulerian approach; the former is also called
substantive, here the material volume, corresponding to an element, is constant,
whereas, in Euler or spatial approach, elements are spatially fixed.
2.6 Polymersomes
Polymersomes are a special kind of vesicles. Vesicles, in turn, are three-dimensional
structures, build up by amphiphilic molecules. In the middle of such a structure,
there is a void, usually filled with water; it is bounded by a hydrophilic-hydrophobic-
Figure 2.12: Sketch of an unilamellar vesicle. Vesicles are usually shown in a
spherical shape, where the `shell' consists of bilayer forming amphiphiles. In case
of polymersomes, the amphiphiles are polymers. The inner hydrophobic layer is
illustrated darker than the hydrophilic layers. The void is filled with water, and
optionally with hydrophilic drug molecules (illustrated by the small balls).
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hydrophilic bilayer, which is formed by amphiphilic molecules, as illustrated in
fig. 2.6. Depending on the kind of these amphiphilic molecules, they are called
liposomes, polymersomes, peptosomes and the like[148]. Liposomes are the first
kind of known vesicles, they are known for a very long time, whereas, polymersomes
were firstly described in 1995[149, 150], therefore, the term 'liposome' is often used
simultaneously to the term 'vesicle' (in this work, the term 'liposomes' is only used
for vesicles consisting of lipids). The term 'polymersomes ' for vesicles made from
block copolymers was coined in 1999[151].
2.6.1 Vesicle Preparation
There are versatile methods to prepare vesicles. Where, most of the methods have
been used for both, liposomes[152160] and polymersomes[151, 161169]. It can be
differentiated between methods without[151, 161, 170172] and with usage of or-
ganic solvents[149, 150, 168, 173177]. Additionally, in aqueous medium, one can
further divide between mechanical and non-mechanical methods.
For the use in biological systems, it is preferable to avoid organic solvents. In the fol-
lowing, some examples of creating vesicles, mechanically, without an organic solvent,
are given. For example, the film hydration method is comprised of two steps: Firstly,
a film consisting of amphiphilic molecules is created. After the solvent is evaporated
completely, water is added under applying mechanical energy (e.g. stirring), here
the temperature has to be chosen above the phase transition temperature[178]. The
electroformation method is similar, but here, the film is exposed to alternating volt-
age instead of stirring. It is also possible to use ultrasound in order to build vesicles.
Formed vesicles can be further processed mechanically by extrusion; here, the vesi-
cle dispersion is pressed through a non-interacting membrane with defined pores for
several times; due to high shear forces, this results in smaller and more uni-sized
vesicles.
There are also further non-mechanical methods without organic solvents. For ex-
ample, in the surfactant removal method, an aqueous buffer solution is added to the
amphiphilic film having a high content of surfactants, this causes vesicle formation,
where the surfactant molecules are incorporated. In order to get surfactant-free
vesicles, the surfactant can be removed by dialysis[157], by hollow fibres[179], by
tangential filtration [180], by BioBeads[181] or by simple dilution[182]. Addition-
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ally, vesicles can be prepared by the freeze-thaw and the pH method.
Using organic solvents, vesicles can be prepared by solvent removal from an oil-
in-water (o/w) or from a water-in-oil-in-water (w/o/w) emulsion. Furthermore,
vesicles can be created by increasing the water content in an organic amphiphile
solution[183]. Moreover, using the direct injection method, an organic solution of
amphiphiles is injected into water above the Krafft point, which is that temperature
at the intercept point of the solubility and the critical micell concentration curve;
here, the vesicle concentration may be enhanced by ultrafiltration. Additionally, a
special case is printing of vesicles[184].
However, it is not possible to create vesicles from every amphiphilic molecule. For
example, it was found that copolymers with long block lengths, rather build vesicles
than ones with short block lengths[173]. Diblock copolymers with a long soluble and
a short unsoluble block, usually form spherical micelles, since here, the curvature is
energetically more favourable[185]. In case of shorter soluble blocks than unsoluble
blocks, cylindric or donut shapes are built[183]; in case of an even shorter soluble
block length, vesicles are formed. It was supposed that it is not possible to form
vesicles by polydispersed blocks, but it was proved otherwise[174]. There have al-
ready been found a lot of polymers which spontaneously form vesicles[149, 186].
Indeed, for vesicle formation, different polymer types have been used; namely, lin-
ear diblock or triblock copolymers or even multiblock copolymers[174], but also
comb copolymers[187, 188] with a hydrophilic backbone block and hydrophobic comb
branches, and dendronized block copolymers[189] with a hydrophilic dendrimer por-
tion are used. In the case of triblock copolymers, the membrane is either a mono-
layer that mimics a bilayer, where the triblock copolymers lie straight through the
bilayer[175], or the triblock copolymer molecules are bent in such a way that the
two hydrophilic blocks face to one of the bilayer sides.
2.6.2 Application of Vesicles
The application of vesicles is versatile. For example, vesicles are promising for
biomedical applications as 'artificial cells' or as 'mimicking cell membranes'. Further-
more, it is possible to create nanocapsules from spontaneously formed vesicles[175,
Mona Wambach, RWTH Aachen 39
Polymersomes
185]. Moreover, polymersomes can be used as nanoreactors, which may contain ac-
tive enzymes, thus, the enzymes are protected, and by proteins in the polymersome
membrane, substrates can be provided to the enzymes[190, 191]. Additionally, vesi-
cles can be used as controlled drug delivery systems[192], as described later, more
precisely. In the context of application, the vesicle stability is an important point
to be considered.
2.6.3 Stabilization of Vesicles
Polymersomes exhibit an increased stability and reduced permeability compared to
liposomes, while having many of the same properties as natural liposomes. Since
polymers usually have a low entropy of mixing, the disassembly of the bilayer, and
thus of the whole vesicle, is hindered. This causes an enhanced stability, and a higher
selectivity for dissolution of hydrophobic molecules, which plays an important role
for polymersomes used as drug delivery systems.
Further advantages of using synthetic polymers is the possibility to control perme-
ability, release rates, stability and other properties of polymersomes, by manipulat-
ing the characteristics of the membrane.
Relevant to biomedical applications, the instability of self-assembled polymersomes
is problematic; especially, their blood circulation time is very short. In order to
avoid this, their antigenity should be low; this can be achieved by a hydrophilic
non-active surface, which cannot be recognized by living systems. This avoids up-
take by phagocytosis or by the reticulo-endothelial system, which recognizes foreign
bodies and transports them to the liver or to the kidneys.
In this context, stealth vesicles play an important role, which are nearly invisible to
the immune system[193]; actually, these are PEG coated vesicles, where the coating
results in longer circulation times, because vesicles are camouflaged to the immune
system like stealth bomber to the radar. Therefore, vesicles containing PEG blocks
are called stealth vesicles. Indeed, PEG block copolymer vesicles are found not until
after 15 - 20 h in the liver, and in the kidneys. Next to PEG, also a few other
polymers were found to form stealth vesicles[194]. However, PEG blocks have even
more advantages; they are water soluble, chemical stable under physiological envi-
ronment, and they show low bounding affinity towards proteins.
There are also other possibilities to enhance the stability. For example, this can
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be achieved by 'surface grafting' of hydrophilic polymers[185, 195], by polymerisa-
tion of reactive lipid molecules in the vesicle membrane[195], or by formation of a
nano or micro sized spherical shell[175, 185]. For the latter, three methods have
already been published. Firstly, the vesicles can be stabilised mechanically by the
swelling of the vesicle membrane with hydrophobic monomers, which are polymerised
subsequently[196200], in order to build 'hollow spheres'. Secondly, poly electrolytes
can be deposited by the 'layer-by-layer deposition' method, on the surface of charged
nanoparticles[201]. Thirdly, amphiphilic diblock copolymers can be self-assembled
to micells, followed by selective cross-linking of the hydrophobic shell, and by the
final degradation of the hydrophobic core[202].
Further important point in the context of stability, is the storage stability; here,
among others, it is important to remove all of the residual organic solvent because
this causes membrane liquefaction especially in water-chloroform systems[168].
In the case of a biomedical application, another interesting point referring to vesicle
stability might be considered, namely, the usage of biodegradable vesicles. Here,
PDLLA can be used, which is degraded completely after 12 - 16 months[203], and
thus is removed from the body, after some time.
2.6.4 Vesicles as Drug Delivery Systems
Vesicles can be used for drug release, here two types are characteristic, namely trig-
gered release, and diffusional release. In the latter case, the drugs are released, due
to drug permeation through the bilayer, following Fick's law. It results in a release
rate of τ−1 = 3P
2lRV
(with the permeation coefficient P , the bilayer thickness l, and
the vesicle radius RV ). This implies the possibility to influence the release rate by
modification of the vesicle size or of the membrane thickness, where both are con-
trolled by the block length and the vesicle preparation method. Here, it should be
mentioned that permeation through polymeric bilayers takes longer than through
lipid bilayers, due to their higher thickness; in fact, polymeric bilayers are about
5 - 20 nm thick, whereas, lipid bilayers have a thickness of just 3 - 5 nm.
In 2008, eleven therapeutic and diagnostic agents in liposomal dosage form were
approved[204], and the number has been increased until today[205]. Although, unil-
amellar as well as multilayered liposomes are well-known[205, 206], polymersomes
are hardly investigated, especially in the context of drug delivery. In the following,
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examples of studies on the drug release properties of unilamellar polymersomes are
given. Most of them are triggered release systems. Examples for drug release from
multilayered polymersomes could not be found in literature.
In contrast, for triggered release, the drug is released completely under certain con-
ditions, due to spontaneous structural rearrangement. More precisely, there are two
different release mechanisms; in fact, the release can be triggered by changes in local
environment or by external stimuli[207]. Local influences are, for example, changes
of the pH value or of the salt concentration[22]. Latter specifically applies to polyion
complex vesicles.
Former can be used for cytosol as release target, for example. The pH dependence
can be achieved by using amine based copolymers, having a pH-dependent water
solubility, which is determined by the pKa value: protonated, they act as cationic
polyelectrolytes, whereas, unprotonated amine based copolymers are relatively hy-
drophobic. For example, pH triggered release of a dye was realised, using poly(2-
vinylpyridine) (P2VP) based copolymer vesicles (despite its high Tg value), here,
the morphological change happens at a pH value of about 5[208]. More common,
poly(tertiary amine methacrylates) polymers with a low Tg value are used[209], their
pKa value is about 7.3.
Moreover, hydrolytically cross-linkable monomers can be statistically added to the
vesicle membrane, resulting in tough vesicles with tuneable permeability[166]. Nev-
ertheless, for biological applications, pH responsive vesicles based on poly(2-(meth-
acryloyloxy)ethyl phosphorylcholine) (PDPA) (pKa ≈ 6.3), and biomimetic hy-
drophilic poly(2-(diisopropylamino)ethyl methacrylate) (PMPC) were developed[210]:
these highly biocompatible PMPC-PDPA vesicles can be used in in vitro delivery[211,
212]; after the rapid endocytosis of these vesicles, the hydrophobic PDPA chains are
protonated, due to locally low pH values (pH 5-6) within the endocytic organelle,
which results in vesicle destruction, and in the release of the loaded DNA. In this
context, high transfection efficiencies were found, using human skin fibroblasts[212].
Depending on the application, intracellular or extracellular drug release is required,
which can be achieved by oxidation responsive vesicles[207]. For example, redox
active vesicles could be prepared by insertion of electro active ferrocen residues into
the hydrophilic corona[213]. Furthermore, there are also polymersomes, which can
be used for the targeted release within the cells; where the targeting is based on
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disulfid bounds, which are stable in oxidising extracellular environment, whereas,
they are cracked intracellular[214]. Such redox active vesicles could be used for
targeted drug delivery to inflamed tissue. For example, a dye releasing vesicle con-
sisting of poly(ethylene glycol)-disulfid-poly(propylene sulfide) (PEG-SS-PPS), has
already been tested successfully[214]. On the contrary, extracellular release can be
achieved by encapsulation of glucose oxidase or katalase. This enzymatically con-
trolled vesicle destruction is a special case of triggered release, where it has to be
considered whether a specific or unspecific decomposition is desired. The former
enzyme encapsulation is used in case of diabetis. Due to intravesicular enzymatic
oxidation of β-D-glucose to glucolacton, H2O2 is formed, which destabilises the vesi-
cle, resulting in insulin release[215].
In constrast to triggering by changes in the local environment, the release can be
triggered by external stimuli like heat or light[207]. For former, poly(N-isopropyl-
acrylamide) (PNIPAM) is often used[216], because its lower critical solution temper-
ature (LCST ≈ 32oC) is close to physiological temperature, additionally, its solution
point is relatively sharp. Vesicles consisting of hydrophobic PNIPAM, and a cross-
linkable hydrophilic corona block are also stable beneath LCST, which results in a
temperature dependent membrane permeability[217, 218]. In the case of light driven
release, the cis-trans isomerisation of azobenzene based diblock copolymers can be
used for formation of vesicles[219], which can be destroyed and rebuild by irradia-
tion.
There are some model systems to investigate the suitability of vesicles as drug de-
livery system. On the one side, release systems for hydrophobic drugs like Rho-
damine B[185], and fluorescent zinc compounds[177] were tested, and on the other
side, both, hydrophobic Nile Red, and either hydrophilic calcein[220] or hydrophilic
fluoresceinamin[168], were embedded. In this context, an additional mechanism,
called flip-flop mechanism[221], was found. Here, the vesicle forming amphiphiles
flip through the membrane and may take drug molecules with them.
However, it is not that easy to distinguish micells, unilamellar and multilayered
vesicles. Therefore, some of the above described systems, declared to be vesicular,
might be micells or multilayered vesicles instead.
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Chapter 3
Silicone Microparticles as Controlled
L-Arginine Delivery System
Abstract
This chapter describes the development of a controlled drug delivery system for ap-
plication in wound healing. For this purpose, silicone microparticles with embedded
L-arginine monohydrochloride (Arg-HCl) were designed. L-arginine (Arg) is known
to be a very versatile drug, which also plays a significant role in wound healing; even
so, it has not been used in everyday wound management, yet.
Particles with different Arg-HCl contents were prepared by a modified solvent-
evaporation method, and their release behaviour was studied in dependence of the
particle size, as well as of the Arg-HCl content in the particles. It was found that the
release is almost linear for the first 24 hours and persists over more than five days;
the total release period is dependent on size. Furthermore, the release is dependent
on the particles' size: the smaller the particles, the faster is the release. Moreover,
the released Arg concentration is higher for particles having a higher Arg content,
whereas, the percental release is independent of the drug content.
In addition, the pH value of the release medium was varied, in further release exper-
iments, using the above mentioned particle parameter variations; and for particles
with a content of 10 wt%, release experiments for both Arg-HCl, and Arg loaded
particles were performed. It was found that the release is pH dependent (the lowest
release was found for pH 7.4), and that the release is faster for Arg-HCl containing
particles, compared to Arg loaded particles.
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Supplementary cell experiments were done. Firstly, the effect of different Arg con-
centrations on three different cell types  endothelial cells, fibroblasts and ker-
atinocytes  were tested in order to determine an optimal Arg concentration range;
afterwards, cell experiments were carried out successfully, using Arg free cell medium
and addition of Arg-HCl loaded silicone particles; the particles show no cytotoxic-
ity, moreover, they actually support cell proliferation, in case of all three cell types
which have been investigated. In detail, growth of fibroblasts and endothelial cells
is almost tripled, and growth of keratinocytes is even enhanced by a factor of about
6, compared to the control. Considering all results, one can state that silicone
microparticles are promising new drug delivery systems for embedding in wound
coverings.
3.1 Introduction
In medicine, high costs result from badly-healing and chronic wounds. This situa-
tion can be improved by using wound healing supportive drugs. Such a powerful and
interesting drug is nitrogen monoxide (NO), which affects vasodilation, non-specific
immune defense, regulation of blood vessel tonus, inhibition and reversal of platelet
aggregation [1], and even more. All of these effects result in an improvement in
wound healing.
There already exist NO releasing systems[24]: for example, three different systems
with covalently linked diazeniumdiolated (N2O
−
2 ) alkyl amines were developed, here
each N2O
−
2 group is able to release two NO molecules; NO releasing silicone rubber
coatings were developed in order to minimize the thrombogenic nature of catheters,
tubings and similar medical devices[2]. Other systems  polymer films containing
silica particles [3] and polyurethanes [4], respectively  show a NO release over about
one day. Furthermore, a wound dressing consisting of a linear polyethyleneimine/NO
adduct was prepared and tested in rats[5], the half life was about 9 hours.
Nevertheless, NO is a radical with a very short lifetime, thus, it is better to form it
in-situ. There is only one natural way of producing NO in the human body, in fact,
it is the degradation of L-arginine (Arg) by NO synthase (NOS). There are different
isoforms of NOS and one of them, induced NOS (iNOS), only exists in wounds and
it is that one which produces the highest amount of NO.
Actually, Arg plays a decisive role in the natural wound healing process. There
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are two competitive ways of Arg degradation taking part in wound healing[6]. In
the early phase of wound healing, degradation by iNOS to NO dominates. As al-
ready mentioned, NO has a lot of wound healing supporting properties. After a few
days, Arg is mainly degraded by L-arginase, which occurs in high concentrations
in wounds, within the urea cycle. The resulting L-ornithine is further degraded to
proline and polyamines[7]. Actually, proline is a substrate in the collagene synthe-
sis, whereas, polyamines are involved in cell proliferation. Thus, latter degradation
is supposed to improve wound healing. Additionally, later suppression of degrada-
tion by NOS combined with L-arginase metabolism probably assists the function of
macrophages within wounds[6].
Oral administration of Arg has already been tested successfully[8]. Nevertheless,
targeted release is generally much better because it avoids or minimizes side effects,
what is more, the local concentration can be adjusted more easily. Furthermore,
targeting is very easy for this application by just embedding a controlled drug deliv-
ery system in a wound covering. This targeting can also be achieved by the usage of
ointments, but there is a hugh disadvantage, namely the reduction of oxygen supply.
Since oxygen is an essential factor in wound healing[9], it is preferable to develop a
controlled drug delivery system embedded in a wound covering which is not reducing
the oxygen supply.
An important point to make is the pH value: The investigation of the pH value of
chronic and acute wounds shows that the pH value of both  cronic and acute 
wounds is in the range of 5.45 and 8.65 (found in a study with 39 chronic and 12
acute patients)[10].
Since wound healing is a very complex process, an optimal pH value or range cannot
be stated. For some purposes, an acidic pH value of 4 - 5 is preferred in contrast to
other wounds with a vantaged alkaline pH value of 8; e.g. the most efficient inhi-
bition of colonisation of microorganism is at a pH value of 4 - 5, while the optimal
pH environment for microorganism is neutral[1113]. But on the opposite side, the
reason for a bacteriostatic or even bacteriolytic effect caused by using biochirurgy,
i.e. therapy with maggots, could be the pH shift towards alkaline pH values[14, 15].
However, chronic wounds are often alkaline because of formation of necrosis, whereas,
physiological acidosis occurs within the normal healing process, which is effected by
(1) the formation of organic acids and carbon dioxide (CO2)  its enrichment is
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caused by stasis ; by (2) the anaerobic glycolysis, followed by an increasing lactose
production, especially during collagen synthesis; and by (3) the formation of pus.
Indeed, a therapeutic induced decreasing of the pH value causes a progression of the
wound healing[16, 17], which is probably dependent on the Bohr effect resulting in
a higher availability of oxygen [16, 18]. (The Bohr effect describes the hemoglobin's
affinity to oxygen in dependency of the pH value and the CO2 concentration. De-
creasing of the pH value  or increasing of the CO2 concentration, which is followed
by a decreased pH value  decreases the affinity to oxygen, i.e. increases the release
of oxygen.) Thus, there are so many parallel processes that one cannot determine
one optimal pH value for all wounds, this is followed by the necessarity of an indi-
vidual therapy for all patients.
Nevertheless, as long as the effects of decreasing or increasing the pH value is not
fully understood, the pH value of wound coverings should be within the pH range of
typical wounds, i.e. pH 5.5 - 8.5[10], even so, there are well founded facts advising
the usage of lower pH values described above, so that the pH value of the wound
covering should be rather within the range of 5.5 - 7. Taking this into account, in
this work, pH neutral L-arginine monohydrochloride (Arg-HCl) was chosen as drug
instead of alkaline Arg, whose isoelectric point is at pH 10.8[19, 20].
In this work, polydimethylsiloxane (PDMS) was chosen to build the matrix of the mi-
croparticle delivery system because it has a great versatility, furthermore, it is com-
mon and etablished for medical purposes[2124]. In fact, there already exist plenty
of PDMS drug delivery systems for hydrophobic drugs  like dexamethason[25],
sulphanilamide[26], prednisolone[27, 28], and timolol[29] , a few systems for hy-
drophilic drugs  clonidine hydrochloride[30], potassium dichromate[31] and glucose
for the use in biotechnology based therapies[32] , but also a system for gaseous
drugs, namely for nitrogen monoxide (NO)[2].
In pure PDMS, water uptake occurs only with an amount of approximately 0.07 wt%[33],
but the water uptake increases by adding fillers[34]. Since the release is widely in-
fluenced by the osmotic pressure, which is caused by hydrophilic molecules within
the silicone matrix; especially, the release of hydrophobic drugs can be optimized by
addition of hydrophilic additives. For example, this was tested for the release of the
model drug sulphanilamide by addition of sodium chloride[26] and for the release of
the steroide prednisolone by addition of sodium chloride, glycerol, ethylene glycol
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and PEG, respectively[27].
On one hand, a pH-independent release rate can be achieved by using buffer molecules
as di- or trisodium phosphate[29], on the other, a gastrointestinal prednisolon de-
livery system was developed[35], whose pH-controlled release could be ensured with
the assistence of a pH-sensitive hydrogel.
Nevertheless, hydrophilic Arg is not soluble in highly hydrophobic PDMS, thus, the
crystalline drug has to be dispersed in the matrix. However, silicone microparticles
with different contents of Arg-HCl (or Arg) were prepared by a modified solvent-
evaporation method. The release of Arg was determined by comparing different
particles' diameter, different contents of Arg and comparing the difference in the
release behaviour of Arg and Arg-HCl loaded particles, respectively. Since the pH
value differs from patient to patient and also during the healing process, drug release
experiments were carried out using different pH values of the release medium.
Human fibroblasts, keratinozytes, and rat aorta endothelial cells were chosen for
cell experiments because of their role in wound healing; first of all, in wound heal-
ing, cells have to be reformed  mainly fibroblasts, keratinozytes and endothelial
cells ; moreover, above mentioned iNOS is mainly expressed by macrophages but
also by the above mentioned three cell types: It was found that fibroblast NO sup-
ports the synthesis of collagen, endothelial NO plays a role in angionesis, whereas,
macrophagic NO affects cytostatically against bacteria[8].
3.2 Experimental
3.2.1 Materials
A silicone kit, named Sylgard R© 184, and the catalyst 'Syl-Off R© 4000' were purchased
from Dow Corning, Arg from BASF, whereas, Arg-HCl, chloroform (p.a.), methanol
(p.a.), fuming hydrochloric acid, Pluronic R© F127, PBS foil pouches, sodium azide,
and sodium dihydrogen phosphate were bought from Sigma. Cell culture dishes
were purchased from Greiner (Frickenhausen, Germany). Serum-free keratinocyte
medium was acquired from Gibco Life Technologies (Eggenstein, Germany), RPMI
1640 from PAA Laboratories (Linz, Austria), anti-CD31 magnetic beads from Dynal
(ASA, Oslo, Norway), M200 medium and serum supplements from Cascade Biologics
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(Portland, OR, USA) All other chemicals and media used for cell culture experiments
were purchased from Sigma (Deisenhofen, Germany).
3.2.2 Instruments
Quantitative Arg analyses for the release experiments were performed with high
performance liquid chromatography (HPLC). The HPLC 'Agilent 1100 Series' is
equipped with an autosampler and fluorescence detector 'Agilent 1200 Series' using
an Eclipse Plus C18 column.
In a few cases, instead of HPLC, Amino acid analyser "Alpha Plus" from Pharma-
cia/LKB (Freiburg) was used for quantitative Arg analyses; buffer solution used in
the physiological program was lithium-citrate.
For the preparation of the particles, a 1 L reactor 'HWS Borosilicatglas 3.3 DN 100
1' with a four propellic stirrer  purchased from hws Mainz  was used.
Drug release experiments were carried out in an incubator 'Heidolph Inkubator 1000'
combined with 'Heidolph Unimax 1010'. SEM pictures were created by Hitachi S-
3000N REM, the samples had been sputtered for 2 min using Sputter Coater S150B
Edwards.
For the analysis of cell culture experiments, a CytoFluor Multi-Well Plate Reader
Series 4000 (PerSeptive Biosystems, Framingham, MA) and a fluorescence micro-
scope from Zeiss were used.
3.2.3 HPLC
Quantitative analyses were performed using the HPLC method described in ap-
pendix A on page 275.
3.2.4 Milling of Arg-HCl and Arg
For the preparation of small Arg and Arg-HCl crystals, a vibratory micro mill /
vibratory sieve shaker (Spartan, produced by Fritsch GmbH, Idar-Oberstein) was
used. Firstly, Arg or Arg-HCl was milled with the help of mortar and grinding ball
made of steel (Fritsch GmbH, Idar-Oberstein). Then, it was fractionated by stainless
steel sieves (mesh widths of 20 µm, 50 µm, and 100 µm) and rubber balls as sieve
aid (Fritsch GmbH, Idar-Oberstein). For inclusion into the silicone microparticles,
the size fraction of 20 µm− 50 µm was used.
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3.2.5 Preparation of Arg-HCl or Arg loaded Silicone Mi-
croparticles
Silicone microparticles were prepared by using a modified solvent-evaporation method,
described in detail in literature[36]; nevertheless, the parameter used in [36] were
adapted, as follows. In summary, a mixture of 300 mL 13.3 wt% aqueous Pluronic R©
solution and 700 mL methanol was used as aqueous phase. This mixture was satu-
rated with Arg-HCl in order to avoid a high loss of Arg-HCl from the particles.
Furthermore, a certain amount of small Arg-HCl or Arg crystals (20 µm ≤  ≤
50 µm) were dispersed homogeneously in 8.54 g component A of Sylgard R© 184 and
0.34 g catalysator; the used Arg-HCl amount, with respect to the silicone matrix,
was 5 wt%, 10 wt%, 15 wt%, or 20 wt%, Arg (not Arg-HCl) loaded silicone particles
have an Arg amount of 10 wt% (and the particles' label is 10 R). Then, air bubbles
were removed by using ultrasound and evacuation. Afterwards, 0.85 g component B
of Sylgard R© 184 and 3.125 mL chloroform were added, the dispersion was stirred
carefully and was added slowly to the reactor, which contains the aqueous phase
(25 oC, 350 rpm), with the help of a syringe with a 15 G cannula, within 6 - 10 min.
The content of the reactor was stirred for two hours (300 rpm), then, the temperature
was increased to 50oC for 30 min. After cooling to room temperature, particles were
separated into three fractions ( ≤ 300µm, 300µm ≤  ≤ 850µm, and  ≥ 850µm)
by metal sieves. Finally, they were dried over night at 50oC (optionally under vac-
uum). Particles were labeled for the release experiments with the theoretical Arg
content and the size. The theoretical Arg content (wt0) was calculated by
wt0 =
m(drug) ·M(Arg)/M(drug)
m(drug) +m(PDMS)
(3.1)
with the mass m(drug) of the drug - Arg or Arg-HCl -, the mass m(PDMS) of
component A plus component B of Sylgard R© 184, and the molecular weight of the
drug M(drug), and of Arg M(Arg). In the case of Arg loading, the content is labeled
as 10 R (R - 1-letter nomination of Arg), whereas, it is labeled e.g. as 10 % for Arg-
HCl loaded particles. Particles having a diameter of 300 − 850 µm are labeled with
k and particles > 850µm are labeled with g. This nomenclature is also presented
later, in table 3.1 (page 74).
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3.2.6 Drug Release Experiments
Drug release experiments were carried out under sink conditions, over 24 hours, and
over more than one week, respectively; in the former case, eleven samples (50 µL)
were taken over 24 hours with increasing time distance, whereas samples (100 µL)
were taken every 24 hours, over at least 7 days, in the latter case. Phospate buffer
solutions (0.01 M) with four different pH values, namely 8.0, 7.4, 5.8 and 4.1, were
used. Every data point of the graphics is the mean value of five parallel experiments.
Since silicone particles are strongly hydrophobic, the contact between particles and
buffer solution had to be enforced by using syringes as experiment containers, under
exclusion of air.
A certain amount of silicone microparticles were weighed in a syringe. Buffer solu-
tion was then added, air bubbles were eliminated, and the locked syringe was put
in an incubator (37oC, 150 Hz). For taking a release sample, a small volume VPr
was removed out of the syringe after strongly shaking (in order to eleminate con-
centration gradients). Optionally, the same volume of buffer solution was added to
the syringe.
Quantitative analyses of the samples were performed by HPLC. The concentrations
plotted in the graphics (cn(Arg)  the Arg concentration at the time of the nth
sample taking) were calculated by using the following equation
cn(Arg) =
[
cHPLCn · Vn +
n−1∑
i=1
(
cHPLCi · V Pri
)]
/V0 (3.2)
with the Arg concentration cHPLCn of the nth sample determined by HPLC, the
volume Vn of release medium in the release container before the nth sample taking,
with the volume V Pri of the nth sample and with the initial release volume V0. In
the case of a release experiment with refilling of the release medium, Vn = V0 is
valid, and with a constant sample volume (V Pr =! V Pri = const), the equation can
be simplified to
cn(Arg) = c
HPLC
n +
V Pr
V0
·
n−1∑
i=1
cHPLCi , (3.3)
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whereas, in the case of an experiment without refilling and constant sample volumes
V Pri = const, Vn = V0 is valid, and the equation can be simplified to
cn(Arg) = c
HPLC
n ·
V0 − (n− 1) · V Pr
V0
+
V Pr
V0
·
n−1∑
i=1
cHPLCi . (3.4)
The standard error σn to the arithmetic mean value cn(Arg) of the five parallel
experimental determined concentrations cni(Arg) (with i = 1, 2, · · · p) was calculated
via
σn =
1
p
·
√√√√ p∑
i=1
(cn(Arg)− cni(Arg))2. (3.5)
Cumulative weight percent (w in wt%) plotted in figure 3.2(b) is calculated by the
equation
wn =
cn · V0 ·M
wreal0 ·mSP
(3.6)
with the molecular weight M of the drug, the (real) initial Arg mass content wreal0
of the used silicone particles (determined as described below and listed in table 3.1),
and with the mass mSP of silicone particles used in the release experiment.
3.2.7 Drug Content Determination in the Silicone Micropar-
ticles
Since a small amount of drug gets lost during preparation, it is necessary to deter-
mine the total drug content in the silicone particles. For this purpose, 3 mL HCl
(5.7 M) were added to 100 mg silicone particles, afterwards, the glass phial was
closed by melting. After heating (110 oC) for 24 hours, the phial was opened and
the acid was completely removed using a rotary evaporator.
A certain amount of water was added to dissolve the drug; whereupon the concen-
tration was determined either by HPLC or by amino acid analysis. Nevertheless, it
can be supposed that the real drug content is higher because the particles cannot
be disturbed completely by acidic total hydrolysis. To quantify this problem, the
particles were cryo milled before acidic total hydrolysis, in that cases, where there
were enough particles left for cryo milling, after performing the release experiments.
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3.2.8 Cell Culture Experiments
Cell extraction (from respective tissue) and subculturing was followed by prolifera-
tion and cytotoxity assays. Afterwards, the growth rates and viability were deter-
mined. Finally, apoptotic and necrotic cells were detected.
In detail, rat aorta endothelial cells were isolated by outgrowth from rat aortic
rings, and characterized as described in [37]; whereas, primary cultures of human
keratinocytes and fibroblasts were derived from breast reduction material and also
from foreskin material, as described in [38]. The cells were grown under standard cul-
ture conditions: Keratinocytes were maintained in serum-free keratinocyte medium
supplemented with penicillin-streptomycin (0.8 vol%), whereas, primary human fi-
broblasts were cultured in RPMI 1640 supplemented with 10 % fetal calf serum
(FCS), apart from that under the same conditions. Endothelial cells were incubated
in RPMI 1640 with 20 % FCS and 100 µg/mL endothelial cell growth supplement
in a humidified incubator, at 37oC in a 95 % air / 5 % CO2 atmosphere. The cells
were passaged every 4-5 days. All further experiments were carried out with cells
from passages 2-8.
Proliferation assays were performed with 2 ·104 fibroblasts, whereas, 2 ·105 cells were
used for cytotoxicity assays; the cells were seeded in 6-well tissue culture plates in a
humidified incubator at 37 oC in RPMI 1640/10 % FCS  where applicable, under
addition of either Arg-HCl loaded silicone particles (theoretical Arg content of 10 %
and a diameter of 300 − 850 µm) or the respective additives obtaining indicated
concentrations . At indicated time points, growth rates and viability, apoptotic
and necrotic cell death were assessed.
The growth rates and viability were considered by determination of the cell num-
ber via the use of Alamar Blue[39], in detail, cell cultures have been incubated for
90 min with Alamar Blue (1:10 dilution) in growth medium, then the plates were
incubated for 1 h at 37 oC under 5 % CO2. Since fluorescence intensity is sensitive
to temperature, the plates have been allowed to equilibrate to room temperature
for approximately 30 min prior to reading the fluorescence at λex = 530 nm and
λem = 590 nm and a gain of 40. Afterwards, the plates were returned to the incu-
bator, until the next time point.
At different time points of cell incubation, apoptotic or necrotic cells were detected
after staining. After washing with PBS, the cells have been stained with Hoechst
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dye H33342 (8 µg/mL) and/or propidium iodide (0.5 µg/mL) for 5 min, afterwards,
either nuclei or necrotic cells were visualized by using a fluorescence microscope.
In each sample, a minimum of 400 cells were counted, however, condensed or frag-
mented nuclei as well as necrotic cells were expressed as percentage of total cells.
3.3 Results and Discussion
Firstly, silicone microparticles were prepared with different loadings of Arg-HCl or
Arg; they were characterized. Then, drug release was investigated for the different
silicone microparticles. Furthermore, release experiments in phosphate buffer solu-
tions with different pH values were performed. Lastly, cell culture experiments 
using fibroblasts, endothelial cells, and keratinocytes  were done.
3.3.1 Preparation of the Silicone Microparticles
Silicone microparticles containing Arg-HCl and Arg, respectively, could be prepared
by the modified solvent-evaporation method described above. The theoretical Arg
(a) comprehensive view (b) surface
Figure 3.1: SEM pictures of an Arg-HCl loaded silicone particle with a
theoretical content of 15 wt% Arg. (a) Prepared silicone microparticles are
perfectly spherically symmetrical, (b) their surface is rough.
mass content of the Arg-HCl loaded particles is 5 wt%, 10 wt%, 15 wt%, and 20 wt%;
Arg loaded particles have a theoretical Arg mass content of 10 wt% (denoted as
10 R). The obtained particles are separated into three size fractions, but for further
drug release experiments only two size fractions were used; in fact, the ones having
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Table 3.1: Nomination and Arg content of silicone microparticles. In this
table, the nomination of silicone microparticles, which were used in the drug release
experiments, is given, combined with their Arg content, and their size.
sample particle included theoretical experimental
name diameter drug Arg content
 wtheo0 wreal0
particles used for 24 h drug release experiments
5 % k 300 - 850 µm Arg-HCl 5 % 5.04 %
5 % g > 850 µm Arg-HCl 5 % 3.7 %
10 % k 300 - 850 µm Arg-HCl 10 % 9.34 %
10 % g > 850 µm Arg-HCl 10 % 6.1 %
15 % k 300 - 850 µm Arg-HCl 15 % 9.9 %
15 % g > 850 µm Arg-HCl 15 % 10.2 %
particles used for > 7 d drug release experiments
5 % k 300 - 850 µm Arg-HCl 5 % 4.4 %
10 % k 300 - 850 µm Arg-HCl 10 % 6.5 %
10 % g > 850 µm Arg-HCl 10 % 6.9 %
15 % k 300 - 850 µm Arg-HCl 15 % 13.1 %
15 % g > 850 µm Arg-HCl 15 % 12.9 %
20 % k 300 - 850 µm Arg-HCl 20 % 10.3 %
20 % g > 850 µm Arg-HCl 20 % 15.1 %
10 R k 300 - 850 µm Arg 10 % 5.1 %
10 R g > 850 µm Arg 10 % 8.0 %
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a diameter of 300 − 850 µm are nominated as 'k', and particles with a diameter of
≥ 850 µm are nominated as 'g'.
As can be seen in figure 3.1(a), the obtained particles are spherically symmetrical.
Because of the included drug crystals, the particle surface is not smooth, as can be
seen in figure (3.1(b)) produced by scanning electron microscopy (SEM).
3.3.2 Drug Release Experiments
Drug release experiments were performed over 24 h, and over one week. For this,
two size fractions of the silicone particles, five different Arg contents and four dif-
ferent release media (phosphate buffer solution with pH values of 4.1, 5.8, 7.4, and
8.0) were used; particles' labelling is given in table 3.1.
The release mechanism has already been investigated. It was found that after con-
tact between a particle and the aqueous phase, the hydrophilic molecules, which
are embedded in the particle, cause an osmotic pressure. This pressure is strong
enough to draw water molecules into the matrix[4044], resulting in tunnels, which
are broken into the particle[30, 36, 45].
After that, the release mechanism is determined by diffusion, both, in and out of the
particles. Indeed, also the diffusion into the particles affects the release[30], which is
probably caused by the influence of the medium ions on the pH value. Nevertheless,
when water molecules reach a drug crystal, drug molecules dissolve and can diffuse
through the tunnels out of the particle. That in turn, entails a very strong con-
centration gradient (decreasing from the surface of the drug crystal till somewhere
in the outer aqueous phase). This results in a dependence on the drug's solubility,
which was also found in this section.
Results of 24 hours release experiments are plotted in figure 3.2 in two different
ways, namely, the concentration profile (see fig. 3.2(a)), and the percental release
(see fig. 3.2(b)); i.e. either the cumulative concentration, or the cumulative weight
percent is plotted against the release time. The advantages of the first way is obvi-
ous  namely, the progress of the concentration, of the release and the release rate,
respectively, can be seen easily , in contrast, the advantage of the second way is
that the release from silicone particles with different drug contents can be compared
more easily, e.g. regarding the release mechanism.
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(a) Concentration profile
(b) Percental release
Figure 3.2: Release of L-arginine from Arg-HCl loaded silicone micropar-
ticles over 24 hours, in PBS buffer solution (pH 7.4). For the release exper-
iments (50 mg particles in 10 mL PBS), different particles were used: firstly, two
different diameters were used, namely 350−850 µm (k), and > 850 µm (g); secondly,
the theoretical L-Arg content was varied, namely 5 wt%, 10 wt%, and 15 wt%. The
results were plotted in two different ways, in fact, as (a) cumulative concentration,
and as (b) cumulative percental release profile. It can be seen that the release from
smaller particles is much faster; furthermore, the concentrations for particles having
a higher Arg content are higher. Using the plot of cumulative weight percent, it can
be seen that the release profiles for particles, which have the same size, differ only
slightly from each other. The inlet is a sketch of the release profiles' shape.
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In fig. 3.2, it can be seen that after a small burst release, the release is almost lin-
ear, over the whole duration of the experiment. Furthermore, release from smaller
particles (k) is faster than from larger particles (g). In fig. 3.2(b), it can be seen
that there is almost no difference of the release profile within the groups of particles
with the same size range, considering the percental plot.
In conclusion, the percental release is dependent on the size of the particles, and not
on the drug content (at least for a content of 5 % till 15 %). The dependence on
the size is based on the different surface-to-volume ratio: The lower the particle's
diameter (), i.e. the higher the surface-to-volume ratio, the better the contact is
between the particles and the release medium, followed by a higher release; mean-
ing that with increasing diameter, the released amount of drug  concentration or
weight percent  at time t is decreased (( ↑↓ wt), and ( ↑↓ ct)).
As already mentioned, release from silicone particles starts immediately after con-
tact with an aqueous phase, as can be seen in figure 3.2; furthermore, the release is
almost linear within the first 24 hours; afterwards, the release rate decreases rather
abruptly (see figure 3.3), depending on the considered particles. On closer consid-
eration, a typical shape of the release profile can be found, as plotted in the inlet of
fig. 3.2(b). In fact, there is a small burst release, afterwards, (I) the concentration
increases linearly, but only with a very small release rate. (II) Then, there is a linear
release, which (III) slows down after more than one day, as can be seen in fig. 3.3.
The first linear part (I) of the release profile is probably caused by diffusional re-
lease through the silicone matrix in the outer shell of the silicone microparticle.
After some time, (II) tunnels are broken into the matrix, due to osmotic forces, here
the release rate is higher. Then, (III) it slows down, since resources of the releasable
drug are almost depleted.
The release duration depends mainly on the size of the particles (see figure 3.3):
In fact, the release from larger particles persists longer, e.g. the release from the
particles `20 % - k - pH 7.4'1 lasts over about two days, whereas, the release from
the larger particles `20 % - g - pH 7.4' persists over at least four days.
Acting on two assumptions, the direct consequence of the faster release from smaller
particles, in the beginning, is a longer release duration from larger particles than
from small particles. Where, first assumption is that, after an infinite time period,
1'20 % - k - pH 7.4'  a theoretical content of 20 % Arg, k: 300 - 850 µm, release medium:
phosphate buffer solution with a pH value of 7.4
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Figure 3.3: Release of L-arginine from Arg-HCl loaded silicone micropar-
ticles over nine days, in PBS buffer solution (pH 7.4). For the release
experiments (50 mg particles in 6 mL PBS), different particles were used: firstly,
two different diameters were used, namely 350 − 850 µm (k), and > 850 µm (g);
secondly, the theoretical L-Arg content was varied, namely 5 wt%, 10 wt%, 15 wt%,
and 20 wt%, additionally, particles loaded with 10 wt% Arg (not Arg-HCl) were
used (named as `10 R'). It can be seen that the relase from smaller particles is much
faster; furthermore, the concentrations for particles having a higher Arg content are
higher. It is important to note that the release for `10 R' is smaller than for `10 %'.
the released drug amount is independent on the size; and second assumption is that
the drug content of both size fractions is equal. Additionally, the (time-dependent)
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concentration of released Arg is higher for particles with a higher total drug amount
(w0 ↑↑ ct) (figure 3.2(a), 3.3), which is quite clear.
Nevertheless, this kind of release mechanism is followed by the fact that particles
with a drug content higher than a certain value show a different release behaviour.
For such a high content, the osmotic pressure is so high that particles 'explode',
and consequently, the drug is released much faster, which can be seen in fig. 3.3, in
case of the particles with a theoretical content of 20 wt%. In the SEM picture 3.4,
Figure 3.4: SEM picture of an Arg-HCl loaded silicone particle, after a
drug release experiment. In the SEM picture, it can be seen that for particles
with a very high content, the osmotic pressure might be that high that the particles
'explode', and craters are formed. Here, an Arg-HCl loaded silicone particle with a
theoretical content of 15 wt% Arg, is shown; usually, the effect of crater formation
can just be found, for contents of 20 wt% and higher.
a silicone microparticle with a high Arg content, after a drug release experiment,
can be seen; such a crater, caused by local small 'explosions', was found once for a
content of 15 wt% Arg, usually, higher loadings are needed for such a process.
Comparing figures 3.2(a) and 3.3, different values for the release after 24 hours and
1 day, respectively, can be observed. For example, in case of '5 % k - pH 7.4', the
values c(24 h) = 167 µmol/L in the 24 h experiment, and c(1 d) = 225 µmol/L in
the one week experiment were found.
This apparent contradiction has two reasons: Firstly, the used particles for the 24
hour experiments had a slightly different content of Arg-HCl (as given in tab. 3.1).
The second reason is that the movement of the release media is not ensured, because
of the enforced usage of syringes as release experiment containers, and because of
the enforced eliminating of air bubbles. During the 24 hour experiments, the media
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were shaken several times, whereas, there was only one sample taken during the
first day of the long-term experiments, i.e. only one shaking, thus, there are small
differences in the released drug amount.
Considering the above mentioned values for '5 % k - pH 7.4', the values have to be
compared to the real Arg contents, which are given in tab 3.1. Thus, first experimen-
tal differences can be eliminated by considering the quotient (167 µmol/5,04 wt%)
(225 µmol/4,4 wt%)
= 1.1;
that means there is just a small difference left.
3.3.3 pH-Dependent Release Experiments
Since the pH value plays an important role in the wound healing process, the release
Figure 3.5: Release of L-arginine from Arg-HCl loaded silicone micropar-
ticles over one week, for different pH values. For the release experiments
(50 mg particles in 6 mL PBS), Arg-HCl loaded particles with an Arg content of
10 wt% were used; their size is either 350 − 850 µm (k), or > 850 µm (g). The
pH value of the medium was varied, in order to investigate the pH dependence of
the release behaviour. It can be seen that the relase from smaller particles is much
faster; furthermore, the release for pH 8.0 results in the concentrations, which are
higher than for pH 7.4, but lower than for pH 5.8, and pH 4.1 (the latter ones have
similar concentrations).
was determined, using release media with different pH values. As can be seen in
figure 3.5, the strongest release can be found for pH 5.8 and pH 4.1, the release rate
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has the smallest value for pH 7.4, and the release at pH 8.0 lies inbetween.
The results show no clear tendency, because there are two interfering trends: On the
one hand, alkaline pH values induce swelling of silicone, which is followed by a higher
release rate for alkaline pH values ((pH > 7) ↑↑ ct). On the other hand, the higher
the pH value of the used buffer solution, the lower is the concentration of released Arg
(pH ↑↓ ct), which is a consequence of the release mechanism. As already explained
at the beginning of this section, there is a very strong concentration gradient, which
decreases from the surface of the drug crystal (embedded in the silicone particle)
till somewhere in the outer aqueous phase. This results in a dependence on the
drug's solubility; and in fact, the solubility of Arg is highly pH-dependent. The
isoelectric point of Arg is alkaline (pH 10.8[19, 20]), thus, the solubility increases
with a decreasing pH value (considering the pH range lower than 11.2); therefore,
the release also increases with a decreasing pH value.
Another consequence of the described dependency on the drug's solubility is shown
in figure 3.6. Here, the release of Arg from Arg-HCl loaded and Arg loaded silicone
particles having equal theoretical Arg contents is compared. It can be seen that the
release of Arg loaded particles is much lower than the release of Arg-HCl loaded
particles, which follows the same explanation as the pH dependence: Arg is less
soluble than Arg-HCl.
3.3.4 Cell Culture Experiments
In order to determine the effect of Arg-HCl loaded silicone particles (namely '10 % k')
on endothelial cells, fibroblasts, and keratinocytes, cell culture experiments were per-
formed in an Arg free medium, either under addition of Arg solutions with different
concentrations, or of silicone microparticles containing Arg-HCl.
Nevertheless, first of all, toxicity tests with endothelial cells were performed sucess-
fully, as described above. However, toxicity tests with non post-treated silicone mi-
croparticles show that there are still cytotoxic, non-cross-linked silicone oligomeres
in the particles. Thus, silicone microparticles were post-treated by extraction with
n-pentane or by applying a vacuum for 12 to 24 hours at 50 oC. Further toxicity
tests (data not shown) confirmed that all volatile, cytotoxic, non-cross-linked silicone
oligomeres could be removed by both kinds of post-treatment. Since both methods
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Figure 3.6: Comparison of the release behaviour from silicone particles,
either loaded with L-arginine, or L-arginine hydrochloride, for different
pH values. The release behaviour of Arg from silicone microparticles loaded with
Arg-HCl (solid lines) and Arg (dashed lines), respectively is compared, using dif-
ferent pH values of the release buffer solution. For the release experiments (50 mg
particles in 6 mL PBS), different particles with an Arg content of 10 wt% were used:
firstly, two different diameters were used, namely 350− 850 µm (k), and > 850 µm
(g); secondly, either Arg ('10 R') or Arg-HCl ('10 %') are loaded. It can be seen that
the release from smaller particles is much faster; furthermore, for each pH value, the
release from Arg-HCl loaded particles is higher than from Arg loaded particles.
works well, using a vacuum dryer was chosen for further experiments, because of the
simplicity of its usage.
In order to determine the optimal Arg concentration range for further application
in wound healing, cell culture experiments were performed using different Arg con-
centrations. Arg concentrations higher than 3 mmol/L are followed by an osmotic
pressure causing cell death (datas not shown). Thus, the upper limit of the thera-
peutic window is set equal to 3 mmol/L.
In figure 3.7, the growth curves using different Arg concentrations are shown, for
the three different cell types used in this work. The progress of the growth curves of
fibroblasts and keratinocytes are almost identical, especially after 6 days culturing,
as can be seen in figure 3.7; in the first days, the relative keratinocyte numbers for
82 www.bth.rwth-aachen.de
Silicone Microparticles as Controlled L-Arginine Delivery System
(a) Fibroblasts (b) Keratinocytes
(c) Endothelial cells
Figure 3.7: Growth curves of fibroblasts, keratinocytes, and endothelial
cells in dependence of different L-arginine concentrations The aim of this
experiment was to determine the optimal Arg concentration range, for fibroblasts,
keratinocytes, and endothelial cells. Therefore, growth curves of these cells were
determined using different Arg concentrations, which are denoted as follows: 0 (◦),
10 (N), 30 (4), 100 (), 300 (), 1000 µM (•). It can be seen, that the higher
the concentration, the better the cells grow. In principle, the progress of the curves
is very similar for the three cell types, although, the relative cell numbers, in case
of endothelial cells, are much smaller than for the other cell types. The strength
of the growth enhancing effect by increasing the Arg concentration decreases, with
increasing Arg concentrations, due to this, the optimal concentration range was set
to be 100 - 300 µ mol/L, nevertheless, even the highest concentration, namely 1000 µ
mol/L does not reach the upper limit of the therapeutic window.
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the different Arg concentrations are more spread than the relative fibroblast num-
bers.
In comparison, the relative endothelial cell numbers are smaller, but apart from
that, the qualitative progress of the growth curves is very similar to the curves of
fibroblasts and keratinocytes.
Considering the Arg concentrations (0, 10, 30, 100, 300 and 1000 µmol/L), it can be
seen in figure 3.7 that the higher the concentration, the more increases the relative
cell number. Furthermore, the higher the concentration the less is this effect, espe-
cially, the effect of increasing the concentration from 300 µmol/L to 1000 µmol/L is
little, additionally, concentrations lower than 100 µmol/L do not show such a great
effect; thus, 100 - 300 µmol/L was set as optimal range of Arg concentrations.
Finally, cell experiments with silicone particles were carried out, taking the three
different cell types (fibroblasts, keratinocytes and endothelial cells). The mass of
silicone particles per cell experiment was calculated arbitrarily from drug release
experiments, without consideration to the differences in the performance of both ex-
periments; i.e. the effect of the release medium was neglected (e.g. in literature[30]
it is described that the release from silicone matrix is faster in PBS than in normal
saline). Due to the experimental problem of taking such small amounts of silicone
microparticles per well for the cell culture experiments, the amounts of silicone mi-
croparticles contains errors.
This variation in the amount of silicone microparticles results in spreaded growth
curves; they are plotted together as area, as can be seen in figure 3.8, the arith-
metic mean values are plotted as line. In general, the relative cell number is much
higher in experiments using silicone microparticles containing Arg-HCl than in the
control (without Arg), regardless of the cell type. Indeed, under addition of sili-
cone microparticles, the relative cell number is enhanced by the factor of about 6
for keratinocytes, and by the factor of about 3 for fibroblasts and endothelial cells,
compared to the control.
The effect of the silicone microparticles on keratinocytes is more significant than
for fibroblasts and endothelial cells: Already on the second day, the cell number is
clearly different to the control (fibroblasts: 4th day, endothelial cells: 3rd day), on
the fifth day, the number is twice than the control (fibroblasts: 6th day, endothelial
cells: 8th day), and in the end of the experiment after 11 days, the cell number is
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(a) Fibroblasts
(b) Keratinocytes (c) Endothelial cells
Figure 3.8: Growth curves of three different cell types, under addition of
Arg-HCl containing silicone microparticles. The cell growth with or without
addition of Arg-HCl loaded silicone microparticles (having a theoretical Arg content
of 10 % and a diameter of 300− 850 µm), respectively, were compared. The mean
value of the experiments is given as a curve enclosed by a marked area including all
growth curves. There were 16 fibroblast culture experiments including 4 controls
done, whereas in the case of keratinocytes and endothelial cells, 24 experiments
including 6 controls were performed. The amount of silicone particles were 23 mg -
45 mg per well, i.e. per 6 mL cell medium. It can be seen that, due to the addition of
Arg-HCl containing silicone microparticles, the growth of fibroblasts, keratinocytes,
and endothelial cells is strongly increased, in regards to the control without Arg
addition.
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4.6 times higher than the control (fibroblasts: 4.3 times after 13 days, endothelial
cells: 2.6 times after 9 days).
However, also the relative cell number in the control experiment is slightly increas-
ing, which is due to the fact that these cells are able to produce small amounts of
Arg themselves (Arg is a semi-essentiell amino acid). Nevertheless, the cell culture
experiments with silicone microparticles show that growth of the three cell types is
much improved, in reference to the control.
Altogether, cell culture experiments with human fibroblasts, keratinozytes, and en-
dothelial cells show that cell proliferation is promoted by Arg solutions, and by
silicone particles containing Arg-HCl. Furthermore, it was found that the optimal
range of Arg concentration is approximately 100 - 300 µM, even so, only at con-
centrations as high as 3 mM, the osmotic pressure is too high for living cells. This
results in a therapeutic window of 100 µmol til 3 mmol/L. And, as could be shown,
it is possible to choose an initial weight of silicone particles to reach the just men-
tioned concentrations and/or the physiological concentrations (e.g. the intracellular
Arg concentration is 100 - 800 µM[46]).
3.4 Conclusions
In summary, silicone microparticles with different contents of L-arginine hydrochlo-
ride (Arg-HCl) and L-arginine (Arg), respectively, can be prepared. These particles
are spherically symmetrical. Furthermore, they are appropriate to the inclusion in
wound coverings.
More so, the release of Arg-HCl from silicone microparticles persists over several
days (dependent on the size and the content); within the first day, the release is
almost linear. Due to the different volume-to-surface ratio, the percental release is
dependent on the silicone particle's diameter  that means the higher the diameter,
the lower is the percental release  but it is not dependent on the content of the drug;
former is followed by a decreasing concentration release with increasing diameter.
And of course, the concentration progress is dependent on the drug content of the
particles  the higher the drug content, the higher is the release .
Additionally, the effect of using Arg instead of Arg-HCl was investigated: There is
a higher release rate from Arg-HCl loaded particles than from Arg loaded particles,
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this is easily explained by the strongly pH-dependent solubility of Arg and Arg-HCl,
which is also the reason for the slower Arg release, in a medium with a pH value of
7.4, compared to the release in pH 4.1 and pH 5.8 (being almost equal); for a release
medium with a pH value of 8.0, the release rate is higher than for pH 7.4, which
is caused by pH-dependent properties of the silicone matrix. This pH-dependent
release behaviour has to be considered for the application in wound management
because of the wide range of pH values in wounds.
Moreover, cell culture experiments with human fibroblasts, keratinozytes and en-
dothelial cells showed that cell proliferation is promoted by silicone particles con-
taining Arg-HCl. Furthermore, it was found that the optimal range of Arg concen-
tration is approximately 100 - 300 µM even so, only at concentrations as high as 3
mM, the osmotic pressure is too high for living cells. And, as can be seen in the
graphics, it is possible to choose an initial weight of silicone particles to reach the
just mentioned concentrations. All in all, Arg-HCl loaded silicone microparticles are
a promising drug delivery system for the application in wound coverings.
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Chapter 4
Finite Element Method: Modeling of
L-Arginine Release from Silicone
Microparticles
Abstract
In chapter 3, silicone microparticles were developed as controlled drug delivery sys-
tems for Arg, where the release kinetics were determined. Whereas in this chapter,
the release kinetics are investigated theoretically. Therefore, a model based on finite
element method was constructed; in fact, a silicone microparticle was segmentated
into several shells having the same thickness. The release was determined by calcu-
lating the diffusion of the drug from shell to shell. Actually, the value of the diffusion
coefficient is guessed in different ways. It is either estimated to be constant over
time and over the shells, or to be dependent on the already released drug amount
in the considered shell, or it is assumed that the drug molecules can be separated
into two species, a slow and a faster diffusing.
A further variation of the model includes the water uptake kinetics. Herefore, NMR
imaging experiments were performed in order to investigate the water uptake of sil-
icone cylinders. It was found that there is a sharp border between the swollen and
the non-swollen part of the silicone matrix. On that account, it is easy to determine
the water uptake kinetics. In detail, water uptake starts after about 3 h, here the
water uptake is relatively fast with about 14 µm/h; after about 24 h, it slows down.
Despite the sophisticated variation of the diffusion implementation, the conformity
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of the simulated data to the experimental results of chapter 3 is just restricted
good. Indeed, the shape of the simulated curves are mainly proportional to the
square root of the time, whereas the experimental curves are proportional to the
time. This causes to believe that there is another important step in the release
mechanism, next to diffusion and swelling, which both turned out to be essential for
the release.
However, the FEM simulation showed that the diffusion coefficient is reduced strongly,
by a factor of about 10−8 regarding to that one in water, even for the differentiation
between free and matrix-bound water, the diffusion coefficient of the free molecules
is reduced by a factor of about 10−6. Furthermore, it was found that in the first
24 h, only the outer part of the particle is involved in the release process.
The programmed code can be found in the appendix B.1 on page 279.
4.1 Introduction
In the beginning, hydrophobic matrices like silicone were only used for hydrophobic
drugs. In the 1980s, a release mechanism, different from molecular diffusion through
the polymer, was described, resulting in suitability of materials like PDMS as matrix
for controlled hydrophilic drug delivery systems. This release mechanism is based
on water uptake due to osmotic pressure, which is caused by hydrophilic molecules
located in the hydrophobic silicone matrix[14].
In fact, in pure PDMS, water uptake occurs only with an amount of approximately
0.07 wt%[5], but water uptake increases by adding fillers[6], which is an essential
point for drug release out of the silicone matrix. The effect of water-soluble additives
on the release of hydrophobic drugs from matrices, based on hydrophobic polymers,
has already been investigated[14, 717]. It was found that the osmotic force of the
additives affects, how well they accelerate drug release[8]; additionally, there is an
influence of their aggregate state[8], and also of their affinity to the drug[9].
Further observation were performed by DSC; in fact, there are two different phases:
in the first phase, the molecules located next to the formed cracks are released
diffusion-controlled, whereas, in the second phase, residual molecules are released
dissolution-diffusion-controlled[1, 9].
Additionally, it was microscopically observed that there is crack formation around
94 www.bth.rwth-aachen.de
Finite Element Method: L-Arginine Release Modeling from Silicone Microparticles
small, water soluble salt crystals embedded in the PDMS matrix, during water
absorption into hydrophobic polymers, by means of osmosis[18]. Basing on this ob-
servation, it was stated that for a salt content, high enough, there is a progression
from a dispersion of discrete particles to a dispersion of growing cavities and cracks,
further to a network of water filled cracks and cavities, which promotes as basis for
drug release.
A theory states that the release mechanism from silicone microparticles is initiated
by diffusion of water vapor[19, 20]; at the interface between the drug particle and
the polymer, the water phase is separated, causing dissolution of a part of the drug
crystal, resulting in a water activity gradient between the drug crystal and the ex-
ternal medium. Consequently, water is drawn to the drug particle, and it swells till
an equilibrium between swelling and elastic nature of the polymer, surrounding the
drug, is reached.
Stretching of elastomer releases energy in the form of chain extension, bond stretch-
ing or bond bending. In the case of bond breaking, i.e. crack formation, or in case
of a viscoelastic flow, there is further energy release. In the end, there is also an
equilibrium of osmotic pressure, and the resisting pressure of the elastomere.
Due to crack formation, the content of the drug particle is connected to the pore
network, and thus, the drug is connected to the surface of the release system. Such
a process follows layer-by-layer manner through the whole system[21, 22]. Hence,
three zones can be found in the release system, namely, (1) an outer, transparent
layer, where drug is released completely, (2) a middle layer, where drug particles are
swollen, and (3) an inner dry white layer. Due to this release mechanism, it follows
that spherical as well as slab-like systems cannot release in zero order[23], expect
of a radial non-homogeous drug distribution (higher drug amount in the inner layer
than in the outer layer)[21, 23].
There are also other osmotic-driven release systems based on silicone elastomeres or
on ethylene vinylacetat copolymers, being summarised in a review about controlled
release from hydrophobic matrices[7]. Here, pores are formed due to osmotically
active additives or water soluble drugs (exceeding the percolation threshold). In
principle, release is proportional to square root of time, but by variation of formu-
lation variables, kinetics can be changed to obtain release of pseudo-zero order.
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Zero-order release was found only for a few PDMS or ethylene-vinyl acetate (EVAc)
based monolithic systems with osmotically active drug salts[2427]. Here, the main
release factor is osmotically penetration of water into the cracked drug particles,
followed by a pumping of saturated drug solution through the network of cracked
drug particles into the environment. No bulk swelling of these matrices has been
reported.
Pseudo-zero-order release (with an intial burst release) was found for the release of
clonidine hydrochloride from PDMS monolithic disk-like or cylindrical matrices[27].
In contrast to the former release system, another mechanism is assumed: Due to the
swelling, the polymer permeability increases, which is connected to polymer crack-
ing, that in turn, induces polymer swelling, which is essential for release. Further
investigation[27] showed that kinetics are dependent on a proper balance between
crack formation support, and crack resisting factors, which causes an appropiate
crack formation over time, within the whole matrix volume.
There are different approaches to model release from silicone or similar release sys-
tems. For example, osmotic driven release fo solid drug particles from a rubbery
cylindrical polymer matrix can be described by a mathematical model[28], which is
based on capsule swelling and spontaneous rupturing proceeding in a serial manner
through the device, from the surface to the centre. Furthermore, this modell is
created for a volumetric loading of the active agent in the polymer matrix which is
beneath the percolation threshold[29]; where, for most geometries, a value of about
0.33 applies[30]. Several examples can be found in literature, namely, examples for
constant osmotic-driven release[2, 7, 21, 29, 3135], for release mechanism[21, 22],
for rodlike zero-order systems following layer-by-layer mechanism[29, 31, 35], for
spherically[23] or for rodlike[29] geometries.
FEM has also been used in the field of drug release research, to model and calcu-
late drug release, to optimize devices[3645] or to model release environment and
other drug release related properties[4657]. Drug release from different kinds of
drug delivery systems was investigated, namely from matrix systems[5862], from
deformed coating films[63], from a single sphere, a monolayer, and multiple layers of
microspheres[64], from biodegradable dense collagen matrices [65], from a biodegrad-
able implantable micro-porous drug delivery system[66], from hydroxypropyl methyl
cellulose-based pharmaceutical devices[67], and more specialised, from oral targeted
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drug delivery systems[68], from porous bone grafts[69][70], from coronary drug-
eluting stents[57], and from a finite drug reservoir into the skin[71].
However, the release mechanism of a hydrophilic drug out of silicone microparticles
 to be simulated in this chapter  is very complex, and probably consists of five
processes: Firstly, water molecules enter the silicone matrix. Secondly, the drug
crystals are (partially) dissolved by the water. Thirdly, the particle is eroded in a
way that channels are broken into the silicone. Fourthly, drug solution is released
through the arised pores. And simultaneously to these steps, the fifth process is a
very slow permeation of the drug solution through the silicone matrix.
The first process (water penetration) might be the most important one because it
induces most of the other steps. Here, the flow is determined by the permeability
coefficient, the surface area and the water concentration gradient. Furthermore, it
is influenced by the concentration of the drug crystals, their sizes and their osmotic
force. As already mentioned above, Schirrer et al. stated that water penetrates the
silicone as water vapor[20]. This would occur faster than with liquid water. After
contact with water, the drug crystals start to be dissolved. Where, the dissolving
process' velocity is affected by the crystal size (and the crystal size distribution), by
the drug's solubility and its enthalpy change of solution.
Another essential step is the crack formation, which is influenced by the degree of
cross-linking of the silicone matrix (because covalent bonds have to be destroyed for
this) and hereby by the resisting pressure of the elastomere. The degree of crack
formation is given by the equilibrium of latter and of the osmotic pressure of the
drug molecules. The major release part is the flow through these arised pores. In
fact, the drug is released at least as fast as determined by its diffusion coefficient in
water. The fifth process, the permeation of the drug solution through the matrix,
probably plays a minor part of the release process.
The above described mechanism is very complex and dependent on plenty of pa-
rameters resulting in the need of a very complicated model, but the aim of this
work was to establish a relatively simple model. Thus, in this chapter, FEM is used
to simulate the release of a hydrophilic drug out of a silicone microparticle, in the
following way. Different cases were implemented: In the first three cases, the drug
diffusion is simulated by a diffusion coefficient, which is either constant or dependent
on the already released amount of drug. Latter is connected to crack formation. In
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one case, two different diffusion coefficients are used, one for the relatively free drug
molecules in the cracks, and one for diffusion through the silicone matrix. The other
three cases are implemented analogously to the former ones, but under considera-
tion of the matrix swelling by water. In detail, NMR imaging was used to determine
the time-dependent water uptake of the drug loaded silicone. The resulting water
uptake kinetics are used for FEM simulation. In fact, the FEM diffusion step is only
allowed, when the matrix is swollen in the considered finite element.
4.2 Experimental
4.2.1 Materials
A silicone kit, named Sylgard R© 184, and the catalysator 'Syl-Off R© 4000' were pur-
chased from Dow Corning. All other chemicals were purchased from Sigma.
4.2.2 Instruments
NMR imaging was performed at Bruker AV 300, using the software paravision. And
for programming, the software 'Borland Delphi Enterprise, Version 6.0' from Bor-
land Software Corporation was used.
4.2.3 Preparation of the Silicone Cylinders
Silicone cylinders for NMR measurements were prepared, as similar as possible com-
pared to the silicone microparticles' preparation. Just an additional container is
needed to yield the cylindric geometry.
In detail, a mixture of 300 mL 13.3 wt% aqueous Pluronic R© solution, and 700 mL
methanol is used as aqueous phase. This mixture is saturated with Arg-HCl in order
to avoid a high loss of Arg-HCl from the silicone matrix.
Furthermore, a certain amount of small Arg-HCl crystals (20 µm ≤  ≤ 50 µm)
was dispersed homogeneously, in 8.54 g component A of Sylgard R© 184, and 0.34 g
catalysator; the used Arg-HCl amount is 10 wt%, with respect to the silicone matrix.
Then, air bubbles were removed by using ultrasound, and evacuation. Afterwards,
0.85 g component B of Sylgard R© 184 and 3.125 mL chloroform were added, the
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dispersion was stirred carefully, and it was drawn up into disposable pipettes. This
step had to be performed carefully, since the educt mixture is extremely viscous and
it is difficult to avoid arising of air bubbles. The filled pipettes were put into the
reactor, containing the aqueous phase (25 oC, 350 rpm).
The content of the reactor was stirred for two hours (300 rpm), inbetween it was
tested, whether the silicone was cured enough to be stable in its shape. When this
was the case, silicone was cut out of the pipette, and it was put back into the re-
actor, for the remaining time period. After stirring for two hours, the temperature
was enhanced to 50oC for 30 min. After cooling to room temperature, the cylinders
were dried with filter paper. Finally, they were dried over night at 50oC (optionally
under vacuum).
4.2.4 Finite Element Simulation
Finite element method (FEM) was used to simulate the release of Arg out of a sili-
cone microparticle. Firstly, the system, which is modelled, is described. Thereafter,
the simplification, which are made for simulation, are specified. Furthermore, the
structure chart outline of the program is presented. And finally, the used equations
are derivated.
Description of the System to be Modelled
The silicone microparticles  which were developed and further investigated, in chap-
ter 3  are perfectly, spherically symmetrical. They consist of silicone, an elastomeric
polymer; Arg-HCl crystals are embedded homogenouesly. Here, Arg is used as drug,
it is hydrophilic.
Moreover, the release mechanism has already been investigated, detailed. It was
found that, after contact between a particle and the aqueous phase, the hydrophilic
molecules  which are embedded in the particle  cause an osmotic pressure, which
is that strong that tunnels are broken into the particle[30, 36, 45].
After that, the release mechanism is determined by diffusion, both, in and out of the
particles. Indeed, also the diffusion into the particles affects the release[30], which is
probably caused by the influence of the medium ions on the pH value. Nevertheless,
when water molecules reach a drug crystal, drug molecules dissolve and can diffuse
through the tunnels out of the particle. That in turn, entails a very strong con-
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centration gradient (decreasing from the surface of the drug crystal till somewhere
in the outer aqueous phase). This results in a dependence on the drug's solubility,
which was also found in chapter 3.
Summing up, the release out of a spherically symmetrical silicone microparticle starts
by the uptake of water, due to osmosis. This is followed by crack formation. When
water molecules reach a drug crystal, the drug can be dissolved gradually, where
solved drug molecules diffuse out of the particle through the cracks. Subsequently,
deeper layers are reached.
Description of the FEM Model
For FEM simulation, following assumptions are made. First of all, it is assumed
that the drug is distributed homogeneously in the whole matrix; i.e. in the model,
there are no drug crystals. Additionally, there are two different approaches; on the
one hand, the concentration is set constant over the particle, on the other hand, a
concentration gradient starting with the highest concentration in the particle center
is assumed. Furthermore, the release mechanism is assumed to be just based on the
drug diffusion out of the particle, later on, also swelling is considered in terms of a
time function revealed by NMR experiments.
For diffusion, different approaches are used. Either a constant diffusion coefficient is
chosen, or it is set dependent on the ratio of the current concentration to the initial
concentration of the considered shell, or two different species  a relatively fast, and
a slowly diffusing species  are assumed. Furthermore, based on the NMR experi-
ments, the influence of swelling is introduced in that way that (fast) diffusion is only
allowed, after a certain time period in relation to the performed NMR experiments.
The particle is segmentated into N spherical shells, as shown in fig. 4.1. The thick-
ness of the shells, namely ∆x, is kept constant. Therefore, the radius, the volume
and the area of each shell differ from each other, in fact, for the ith shell, the outer
radius ri of the shell is given by
ri = i ·∆x, (4.1)
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Figure 4.1: Segmentation of the silicone microparticle for FEM. For FEM,
the system has to be divided into sections. In detail, the ball-shaped silicone mi-
croparticle is divided into N spherical shells, between which the diffusion takes place.
in this figure, the assigment of the surface areas for A1, AN−1, and AN are given;
furthermore, the radius and the thickness of the layers (∆x) are illustrated.
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and the volume follows
Vi =
4
3
pi
(
r3i − r3i−1
)
(4.2)
=
4
3
pi ·∆x3 (i3 − (i− 1)3) , (4.3)
furthermore, the outer area of the spherical shell 'i' is calculated by
Ai = 4pir
2
i (4.4)
= 4pi ·∆x2 · i2. (4.5)
Additionally, the initial amount of substance in the shell i, can be determined by
n
(0)
i =
w ·mSP
MArg︸ ︷︷ ︸
Arg amount in the whole particle
· Vi
VSP
(4.6)
=
w · ρSP
MArg
· Vi. (4.7)
Here, the percental drug content w in the particle, the mass of the silicone particle
mSP , its volume VSP , its density ρSP , and the molar mass of the drug MArg are
used.
Structure Chart Outline of the Program
As can be seen in figure 4.2, the first step is the declaration, and the initialisation
of all variables. Then, values of certain parameters are read (e.g. the number of
iterations, and the kind of calculation of the diffusion coefficient), and others are
calculated (e.g. r(i), V(i), A(i)). Secondly, the process started by choosing the inital
values for the 'old' amount of substance nold(i), for each shell i; that is, in this case,
the initial amount of substance, and in general (i.e. in the following loop), it is that
amount of substance of the prior iteration, which is used to calculate the current
amount of substance of the considered iteration.
The main part follows, it is a for-loop over the experimental time (t), in intervals
of ∆t. The loop can be divided into several steps: Firstly, the diffusion coefficient
for each shell is calculated, depending on the chosen case. The next step is the
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Figure 4.2: Outline of the scheme of the drug release simulation out of
a silicone microparticle. The case-dependent calculations cover the calculation
of the diffusion coefficients D(i), and where necessary, also the calculation of the
amounts of substance which are slowly (nPDMS(i)) or faster (nfree(i)) diffusing, and
of the diffusion coefficient of the second drug species. The detailed description of
the flow chart can be found in the text.
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determination of the diffusion, i.e. the calculation of the current amount of substance
for each shell. This is followed by the calculation of the released amount of substance.
Finally, the amount of released substance is plotted, e.g. for every hour, in a plot on
the surface of the program. After that, the next iteration of the for-loop starts. In
the following subsections, the choice of the diffusion coefficient, and the calculation
of the diffusion are presented, more precisely.
Setting of the Diffusion Coefficient
As already mentioned above, in this simulation, several different settings for the
diffusion coefficient are implemented. In the first case, the diffusion coefficient is set
to a constant value (Dti = F · D), which is equal in all shells. Where, the value is
determined in a way that the simulated released concentration after 24 h equals the
experimental one.
In the second case, it is assumed that the diffusion coefficient of each shell is de-
pendent on the ratio of the current amount of substance in the shell, to its initial
amount. This is consistent to the release mechanism, because the drug molecules
will only diffuse out of the particle if there already exist tunnels, in the particle. It
is estimated that the diffusion coefficient increases linearly with decreasing ratio of
the current amount of substance to the initial value. Here, the diffusion coefficient
D(i) of the shell i at the time point (t+ ∆t) is calculated by
D
(t+∆t)
i = D · F ·
(
1− n
(t)
i
n
(0)
i
)
(4.8)
with the diffusion coefficient D of the drug in water, and the reducing factor F .
The third case is based on the assumption that one can divide between two drug
spezies  the free one, and the in the silicone matrix embedded drug , thus one set
two different amounts of substance
n
(t)
free(i) := n
(t−∆t)
i ·
(
1− n
(t−∆t)
i
n
(0)
i
)
(4.9)
n
(t)
matrix(i) := n
(t−∆t)
i − n(t−∆t)free (i) (4.10)
=
(
n
(t−∆t)
i
)2
n
(0)
i
(4.11)
104 www.bth.rwth-aachen.de
Finite Element Method: L-Arginine Release Modeling from Silicone Microparticles
where the free species belongs to nfree and to the diffusion coefficient Ffree ·D, and
the embedded species to nmatrix and Fmatrix ·D.
The further three cases are based on the results of NMR measurements. Here, the
time-dependent water uptake of cylinders, which consist of the same material as the
modelled particles, is investigated. It is assumed that the diffusion is stronger, after
water uptake, in the considered shell.
In fact, in the 4th case, there is only diffusion in the swollen shells. And in the 5th
case, diffusion takes place with Ffree ·D in the swollen shells, and with Fmatrix ·D
in the other shells. Whereas in the 6th case, the diffusion in the swollen shells is
determined by
Dfree(i) = Ffree ·D ·
(
1− n
(t)
i
n
(0)
i
)
(4.12)
where the value is corrected to the diffusion coefficient of the others shells, i.e.
Dmatrix(i) = Fmatrix ·D, if the value of Dfree(i) is smaller.
Diffusion Equations
It is assumed that the diffusion follows the first Fick's law
J = −D δc
δx
. (4.13)
It states that the flow (J) of the molecules through an area unit, per time unit can
be calculated by the diffusion coefficient D, and by the infinitesimal concentration
gradient δc along the infinitesimal distance δx. As already mentioned in chapter
2.5, for finite elements follows
∆n
∆t
= −D · A∆c
∆x
(4.14)
∆n = −D · A ·∆t∆c
∆x
. (4.15)
In this chapter, this equation is applied to a spherical system, which has already
been further declared above (see page 100). Here, the sphere has a radius of R,
it is seperated into N = R
∆x
spherical shells, which are indexed by i; this leads for
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∀i = 2, 3, . . . , N − 1 to
n
(t+∆t)
i = n
(t)
i −D ·
∆t
∆x
·
(
Ai−1 ·
(
c
(t)
i − c(t)i−1
)
+ Ai ·
(
c
(t)
i − c(t)i+1
))
(4.16)
= n
(t)
i −D ·
∆t
∆x
·
(
Ai−1 ·
(
n
(t)
i
Vi
− n
(t)
i−1
Vi−1
)
+ Ai ·
(
n
(t)
i
Vi
− n
(t)
i+1
Vi+1
))
, (4.17)
and for i = 1 to
n
(t+∆t)
1 = n
t
1 −D ·
∆t
∆x
·
(
A1 ·
(
c
(t)
1 − c(t)2
))
(4.18)
= n
(t)
1 −D ·
∆t
∆x
· A1 ·
(
n
(t)
1
V1
− n
(t)
2
V2
)
, (4.19)
and  under assumption of ideal sink conditions, i.e. neglectable concentration
outside the particle  for i = N to
n
(t+∆t)
N = n
(t)
N −
D ·∆t
∆x
·
AN−1 · (c(t)N − c(t)N−1)+ AN · (c(t)N − c(medium)︸ ︷︷ ︸
→0
)
 (4.20)
= n
(t)
N −D ·
∆t
∆x
·
(
AN−1 ·
(
n
(t)
N
VN
− n
(t)
N−1
VN−1
)
+ AN · n
(t)
N
VN
)
. (4.21)
All these equations are used in the simulation, to determine the diffusion of molecules
between two contiguous finite elements.
Concentration Gradient within the Silicone Microparticle
As further variation, a concentration gradient within the silicone microparticle was
included. This is based on the consideration that there is a loss of drug content
during the preparation process of the particles, in fact, the theoretical drug content
(Gtheo) is higher than the experimental content (G). Thus in a further attempt, a lin-
ear concentration gradient in the particle is assumed with the highest concentration
in the center of the particle, here the concentration shall be equal to the concentra-
tion determined by the theoretical drug content Gtheo. Thus, the concentration at
the distance x from the center is given by
c(x) = a · x+Gtheo · ρ(SP )
M
(4.22)
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where ρ(SP ) is the density of the silicone particle (SP), and M the molar mass
of the drug. Additionally, there is a constant a which is still to be determined, as
follows:
R∫
0
(c(x) · A(x)) dx != nges (4.23)
with the particle radius R, the spherical area A(x) with the distance x from the
center, and the whole amount of substance nges in the particle, given by
A(x) = 4pix2 (4.24)
nges = G · ρ(SP )
M
· 4
3
piR3 (4.25)
From the latter three equations, it follows
R∫
0
(c(x) · A(x)) dx = 4
3
piR3 ·
(
3a
4
·R +Gtheo · ρ(SP )
M
)
!
= G · ρ(SP )
M
· 4
3
piR3
(4.26)
⇒ a = ρ(SP )
M
· 4
3
G−Gtheo
R
(4.27)
⇒ c(x) = ρ(SP )
M
· 4
3
G−Gtheo
R
· x+Gtheo · ρ(SP )
M
(4.28)
Next, the amount of substance in the shell i can be calculated by
n(i) =
i·R
N∫
(i−1)·R
N
(c(x) · A(x)) dx (4.29)
=
4
3
pi · ρ(SP )
M
·
[
G−Gtheo
R
· x4 +Gtheox3
]i·R
N
(i−1)·R
N
(4.30)
=
4
3
pi
(
R
N
)3
· ρ(SP )
M
·
(
G−Gtheo
N
· (i4 − (i− 1)4) +Gtheo(i3 − (i− 1)3)
)
(4.31)
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In order to confirm this, following calculation was performed
N∑
i=1
n(i)
!
= nges (4.32)
N∑
i=1
n(i) =
4
3
pi
(
R
N
)3
· ρ(SP )
M
·
(
G−Gtheo
N
· (
N∑
i=1
i4 −
N∑
i=1
(i− 1)4) +Gtheo(
N∑
i=1
i3 −
N∑
i=1
(i− 1)3)
)
(4.33)
=
4
3
pi
(
R
N
)3
· ρ(SP )
M
·
(
G−Gtheo
N
· (
N∑
i=1
i4 −
N−1∑
i=0
i4) +Gtheo(
N∑
i=1
i3 −
N−1∑
i=0
i3)
)
(4.34)
=
4
3
pi
(
R
N
)3
· ρ(SP )
M
·
(
G−Gtheo
N
·N4 +GtheoN3
)
(4.35)
= G · ρ(SP )
M
· 4
3
piR3 (4.36)
= nges (4.37)
From this, the concentration in the shell i can be calculated by dividing by the
shell's volumen V (i):
c(i) =
n(i)
V (i)
(4.38)
=
4
3
pi
(
R
N
)3 · ρ(SP )
M
· (G−Gtheo
N
· (i4 − (i− 1)4) +Gtheo(i3 − (i− 1)3)
)
4
3
pi
(
R
N
)3 · (i3 − (i− 1)3) (4.39)
=
ρ(SP )
M
·
(
G−Gtheo
N
· i
4 − (i− 1)4
i3 − (i− 1)3 +Gtheo
)
(4.40)
Choice of the Parameter
In FEM, parameter values have to be chosen carefully, otherwise, absolutely wrong,
or inconstant curves are yield, which may differ from the basic curve. Therefore, it
is assigned to call for positive concentrations, in all cases. Since the concentration
gradient has the highest possible value for the border between the furthest layer
of the particle and the outer medium, at the first FEM iteration, just eq. 4.21 is
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required; thus, the initial molar amount of the outer layer is used:
n
(∆t)
N = n
(0)
N −D ·
∆t
∆x
·
AN−1 ·
(
n
(0)
N
VN
− n
(0)
N−1
VN−1
)
︸ ︷︷ ︸
=0
+AN · n
(0)
N
VN
 (4.41)
= n
(0)
N
(
1−D · ∆t
∆x
· AN
VN
)
(4.42)
= n
(0)
N
(
1−D · ∆t
∆x
· 4pi · (∆x)
2 ·N2
4
3
pi · (∆x)3 (N3 − (N − 1)3)
)
(4.43)
= n
(0)
N
(
1−D · ∆t
(∆x)2
· 3 ·N
2
N3 − (N − 1)3
)
. (4.44)
For the latter conversions, firstly, the fact is used that, there is no concentration
gradient in the particle, in the very beginning; secondly, the equations for the volume
(eq. 4.3), and for the area (eq. 4.5) of the shell are used. Above expression is set
greater than zero, as follows
n
(∆t)
N
!≥ 0 (4.45)
⇔ n(0)N
(
1−D · ∆t
(∆x)2
· 3 ·N
2
N3 − (N − 1)3
)
!≥ 0 (4.46)
⇔ D · ∆t
(∆x)2
· 3 ·N
2
N3 − (N − 1)3
!≤ 1 (4.47)
⇔ D · ∆t
R2
· 3 ·N
4
N3 − (N − 1)3
!≤ 1 (4.48)
for large N⇒ D ·∆t ·N
2
R2
!
< 1. (4.49)
In the very last conversion, following approximation for large N, is used
3 ·N4
N3 − (N − 1)3 =
3 ·N4
3N2 − 3N + 1 ∧ limN→∞(3N
2 − 3N + 1) = 3N2 (4.50)
⇒ 3 ·N
4
N3 − (N − 1)3 = N
2 for large N. (4.51)
This approximation is followed by an error of just about 100/N %; i.e. for N = 100,
the error of ∆t's limit is 1.0 %; for N = 200, the error is 0.5 %, and so forth.
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However, for large N, there is following limit for ∆t
∆t
!
<
R2
D ·N2 . (4.52)
That means that the limit of ∆t is proportional to the squared radius of the particle,
and it is inversely proportional to the diffusion coefficient, and to the squared number
of layers of the particle.
4.3 Results and Discussion
In the following, the results of FEM simulation based on diffusion are presented and
discussed. Afterwards, the water uptake kinetics was investigated by NMR imaging.
The result was used for FEM simulation, based on diffusion and water uptake, in the
following section. Finally, the influence of an inital concentration gradient within the
silicone microparticle (as might exist due to the preparation process, as previously
discussed) was studied, for all the six contructed cases of section 4.3.1 and 4.3.3.
4.3.1 Simulated Release based on Diffusion
As already described above (in section 4.2.4 on page 104), three different cases
are assumed. Firstly, a simple diffusion-controlled system is considered. Here, the
drug`s diffusion coefficient determined in water is decreased by a factor, because the
diffusion of the drug is much lower in the PDMS matrix than in water. Such a factor
is called reducing factor, in the following.
The second model is that the diffusion coefficient in a certain shell is dependent on
the drug amount which has already been released. This is based on the fact that
there is as much more water in the shell, the more drug is released. In detail here,
the diffusion coefficient D(i) of the shell i at the time point (t+ ∆t) is calculated by
D(t+∆t)(i) = D · F ·
(
1− n
(t)(i)
n0(i)
)
(4.53)
with the diffusion coefficient D of the drug in water, and the reducing factor F .
The third approach is similar to the second, here it is assumed that there are two
drug species  the free drug within the broken tunnels, and the drug embedded in
the PDMS matrix, which can hardly diffuse. Thus, there are two different diffusion
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Figure 4.3: Simulation of drug release, based on diffusion, from a silicone
microparticle. All the three cases, considered in this section, are plotted together
with the experimental release profile. The simulated curves resemble each other
strongly. It can be seen that the release curve is simulated relatively well, although,
the shape of the release profile is more linearly, in case of the experimental work.
(Inlet) In case 3, there are different possibilities of choosing the reducing factors
F(PDMS) and F(free). For a hugh difference of both values, the curve is not smooth,
which is caused by the setting of the free amount of substance, furthermore, here
the initial slope is somewhat higher.
coefficients, and the drug amount is divided into two parts, calculated by
n
(t+∆t)
free (i) = n
(t)(i) ·
(
1− n
(t)(i)
n0(i)
)
↔ Dfree(i) (4.54)
n
(t+∆t)
PDMS(i) = n
(t)(i)− n(t+∆t)free (i) ↔ DPDMS(i) (4.55)
The factor reducing the in-water diffusion coefficient, is fitted in that way that
the value, after a release period of 24 hours, is equal to the experimental found
value. For the first two cases, following values are found F (case 1) = 8.5 · 10−7 and
F (case 2) = 1.35 · 10−6, where the second value is higher because it is reduced by(
1− n(i)
n0(i)
)
regarding to the first approach.
For the third case, different combinations of the both reducing factors can be deter-
mined, examples are plotted in fig. 4.3(Inlet). Here, it can be seen that the initial
slope is higher for a higher difference of both values, furthermore, it can be seen that
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the curves are not smooth for such high differences, which is caused by the setting
of nfree(i). However, the values FPDMS = 5 · 10−8 and Ffree = 2.4 · 10−6 are chosen.
In fig. 4.3, the simulated curves of the three considered cases are shown, it can be
seen that all of them resemble each other, the first and the second case are almost
equal, whereas the curve of the third case has a lower slope in the beginning. More-
Figure 4.4: Square root proportionality of the simulated curves. The simu-
lated curves of three different cases (described in the text) are plotted against the
square root of the time. The differences between case 1 and 2 are very small, there-
fore, they can only be distinguished from each other, under magnification; the same
applies for case 4 and 5. It can be seen that the curves of case 1, 2, and 3 are
proportional to the square root of the time, with neglectible deviations. For case
4, 5, and 6, the curves are not proportional to the square root of the time, in the
beginning; later on, they are relatively proportional. For comparision, there is also
a linear trend line for case 2.
over, the simulated values are more or less proportional to the square root of the
time, as can be seen in fig. 4.4; whereas, the experimental curve is almost linear re-
garding the release time, after the burst release. Furthermore, the simulated curves
resemble the experimental curve relatively well (fig. 4.3), especially the burst release
in the first few minutes is simulated well, but after that, the simulated concentration
are higher than the experimental ones. Both has its origin in the proportionality to
the square root of the time combined with the setting of the diffusion coefficients in
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(c) Concentration profile of Case 3
Figure 4.5: Temporal progress of the concentration profiles. For the three
different cases ((a) case 1, (b) case 2, and (c) case 3), the concentration profiles at
certain time points are plotted. On z-axis, the concentration regarding the initial
concentration c0 is plotted. Since only the outer 100 at most (of the 1000 shells) are
affected, the abscissa is only plotted from shell 900 to shell 1000. It can be seen that
in course of the time, the concentration profiles flatten more and more. However,
the shape of the profile depends on the considered case; regarding from shell 900 to
shell 1000, the concentration decreases slowly and then more and more strongly, for
case 1 (a), whereas in case 2 (b), the concentration decrease is almost linear, and in
case 3 (c), the shape of the concentration profile is similar to an S-shape.
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a way that the released concentration after 24 hours fits to the experimental values.
However, the deviation of the simulated data to the experimental data are relatively
small.
Despite the similarity of the simulated curves, the shape of the concentration pro-
files within the particle differentiate from each other significantly, as can be seen in
fig. 4.5. However, within the first 24 h, drug is only released out of the outer layers of
the particle, in all simulations. In the first case (fig. 4.5(a)), about one-tenth of the
particle thickness is affected by the release. Here, the concentration decreases slowly
and then more and more strongly, till the outest shell, where the concentration is
very low. The concentration profile of the second case is similar, but here less shells
are involved in drug release and the concentration decrease, from the inner to the
outer shells, is relatively linear. In the third case, almost the same number of shells,
as in case 2, are affected, but the profil is S-shaped.
4.3.2 NMR Measurements
By NMR imaging, time-dependent cross-sections at different heights of a silicone
cylinder, loaded with Arg-HCl, are measured in order to investigate the water up-
take kinetics. As can be seen in fig. 4.6, immediately after filling the NMR tube
(containing the silicone cylinder) with water, the signal of the cylinder is more or
less homogeneously (see fig. 4.6(a)). In fact, in the very beginning, no outer layer is
visible, but after a few hours, an outer layer, which is brighter than the cylinder's
inner part, arises. This layer represents that part of the silicone cylinder, where
water is taken up. For example, this brigther layer can be seen in fig. 4.6(b) show-
ing a cross-section after 8 hours. The thickness of that layer, where water is taken
up, increases in course of the time (see fig. 4.6(c) - 4.6(f)). Firstly, the thickness
increases strongly, then, it increases almost linearly, and finally, water uptake slows
down, after about four days.
It is interesting that there is a definite border between the non-swollen and the
swollen layer. This underlines the suitability of using FEM (with spherical shells
as finite elements) for simulating the release behaviour from silicone microparticles,
because these NMR images show a process in a serial manner, which gives rise to the
assumption that the whole release process follows such a serial manner. In addition,
very bright, very small areas can be seen in the outer layer, which are probably holes
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(a) after 0 h (b) after 8 h
(c) after 20 h (d) after 40 h
(e) after 80 h (f) after 144 h
Figure 4.6: Time-dependent NMR images of a silicone cylinder loaded
with Arg-HCl. There are cross-sections at different heights of an Arg-HCl loaded
silicone cylinder, in a water filled NMR tube. The images are measured every hour,
here are images presented at the chosen time points (a) 0 h, (b) 8 h, (c) 20 h, (d)
40 h, (e) 80 h, and (f) 144 h, after filling the tube with water. One pixel has a size
of about (60 µm)2, therefore single Arg-HCl crystals cannot be resolved.
The very bright circle represents a cross section of the NMR tube, in fact, the
brightness is caused by the water resonance; the black area on the left hand side is
an air bubble, and the circle in the middle is a cross section of the silicone cylinder.
It can be seen that the outer bright layer of the silicone cylinder gets thicker in the
course of time, where this layer represents the swollen part of the silicone cylinder.
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filled with water; on closer examination, these holes are filled immediately (on the
time scale of the measurements, i.e. in hours) with the swelling of that part of the
matrix, but these areas getting brighter with time. This gives rise to the assump-
tion that there are air bubbles in the matrix (see subsection 4.2.3), either empty
or filled with a small amount of drug. Furthermore, for the outer layer next to the
outer air bubble, it can be seen that after about 40 h, bright areas arise next to the
cylinder. These areas are water drops, which cover the silicone cylinder because of
the enhanced hydrophilicity caused by the water uptake.
The progress of the broadening of the outer layer is determined in dependence of the
time, which is plotted in fig. 4.7. Since a water uptake kinetics function is needed for
Figure 4.7: Time-dependent thickness of the outer layer of the silicone
cylinder. The thickness of that layer, where water is taken up, increases in course of
the time. Where, the values are determined at different places, and are represented
by different symbols, whose arithmetic mean values are shown as large squares.
And the black line is the trend line, whose function (together with the regression
coefficient) is written down in the graphic, and also in the text. In fact, it is
determined in order to be used in FEM simulation. In this chapter, only 24 hours
are considered, in simulation; the trend line of the 120 hours period also fits very
well for this time period, as can be seen in the Inlet.
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FEM simulation, the determined points are fitted to yield following fitting function
f(t) = −1 · 10−5µm
h4
· t4 + 0.0035µm
h3
· t3− 0.3723µm
h2
· t2 + 19.888µm
h
· t− 24.815µm
(4.56)
In the context that the fitting function is just calculated for the usage in FEM
simulation, it is irrelevant that f(t = 0) is negative. Indeed, in FEM simulation, it
is only ask whether the layer is swollen or not.
4.3.3 Simulated Release in Relation to the NMR Results
In the last section (section 4.3.2), the water uptake into the PDMS matrix with
embedded Arg-HCl is investigated in dependence on the time, the resulting time-
dependent thickness of the swollen layer is used in further simulation. In the fol-
lowing three cases (named case 4, 5, and 6), the diffusion is dependent on this
time-function. Firstly, it is set that diffusion is only allowed in that shells which
are swollen. In case 5, additionally to this diffusion, there is slow diffusion in the
non-swollen shells. And case 6 differs from case 5 in that way that the diffusion co-
efficients of the swollen shells are dependent on the drug amount which has already
been released.
As in the section 4.3.1, the reducing factors are chosen in a way that the value of the
released concentration after 24 h is equal to the experimental data. For the case 4,
a reducing factor of F = 9 · 10−7 was determined; this is somewhat higher than the
value for the first case in the second last section, that means that the time function
is limiting the release in this assumption only slightly.
For case 5 and 6, two reducing factors have to be determined, in fig. 4.8(a) and in
fig. 4.8(b), different choices are presented. For the 5th case, there is no difference
noticeable. Whereas in the 6th case, there are slight distinctions, in fact, the smaller
the difference between the two reducing factors, the higher is the concentration in
the beginning and the less distinct is the step. Following values are chosen for the
reducing factors: for the 5th case, Ffree = 9 · 10−7, and FPDMS = 5 · 10−8; and in
case 6, Ffree = 1.45 · 10−6, and FPDMS = 1 · 10−11. All the values of the reducing
factors are summed up, in table 4.1. Since the time function gives a limitation in
case 4-6, it can be expected that the factors are higher than in comparable cases.
Case 4 is equal to case 1, except for the time function; as given in table 4.1, the
value of case 4 is just slightly higher than the value of case 1, meaning that the
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(a) Case 5: different combinations of the re-
ducing factors F(PDMS) and F(free).
(b) Case 6: different combinations of the re-
ducing factors F(PDMS) and F(free).
(c) Case 4  6
Figure 4.8: Simulation of drug release from a silicone microparticle, based
on diffusion and swelling. The simulated curves of three different cases concern-
ing swelling (described in the text), based on NMR results, are plotted together with
the experimental values. First of all, different combinations of the reducing factors
F(PDMS) and F(free) are plotted, for case 5 (a), and case 6 (b). For case 5 (a), no
significant difference between the combinations can be seen, whereas, the curve differ
somewhat, in the first 2 h of the release period, for case 6 (b). In subfig. (c), it can
be seen that there is only little difference between the three cases, especially, case 4
and 5 resemble each other strongly, the difference can only be seen in magnification
(Inlet). In difference to case 1, 2, and 3 (fig. 4.3), there is a step in the beginning.
Thus, the simulation is improved by the swelling function, at least for the release in
the first two hours, after that, the shape of the release curve is proportional to the
square root of the time, in constrast to the experimental curve.
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Table 4.1: Reducing factors for the cases 1  6. In this table, the values
of the reducing factors are given. These factors are determined in that way that
the simulated concentration, after 24 h releasing period, equals the experimental
determined concentration. In case 1, 2, and 4, there is only one reducing factor,
whereas, there are two factors for the other cases because of the differentiation into
a slowly and a faster diffusing drug species.
case # reducing factors F
(Ffree) (FPDMS)
1 8.5 · 10−7
2 1.35 · 10−6
3 2.4 · 10−6 5 · 10−8
4 9 · 10−7
5 9 · 10−7 5 · 10−8
6 1.45 · 10−6 5 · 10−8
time function confines the diffusion marginally. In case 5, there is slow diffusion in
addition to the faster diffusion of case 4; the value of Ffree in case 5 is equal to the
reducing factor in case 4, thus, there is almost no influence of this slow diffusion on
the release. Case 6 is comparable to case 2, here the factor is somewhat higher than
in the latter case, as expected.
The simulated curves, which can be seen in fig. 4.8, are alike each other, there is just
a slight difference, especially in the very beginning. However, these curves simulate
the experimental data better than the three cases of the second last section. Here,
the step in the beginning is simulated well, i.e. the small burst release followed by
a short time period with just a slight concentration enhancement. The simulated
burst release is marked less than in the experimental data, this is probably caused
by drug crystals directly at the surface of the silicone microparticles in the experi-
ment, as discussed in chapter 3. After the burst release, in simulation, there is no
release for one hour, in case 4 and 5, and just a small concentration enhancement,
in case 6; after that, the release is rather proportional to the square root of the time
(see fig. 4.4), nonetheless, the data fit better to the experimental curve than the
simulated results of the second last section.
As in the second last section (4.3.1), also here, the concentration profiles has dif-
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ferent shapes, as can be seen in fig. 4.9. Indeed, the profiles of case 4 and 5, look
very similar to case 1; whereas, the profiles of case 6, resemble case 2. However, in
all three cases, there is one difference to the profiles of the comparable cases of the
second last section, indeed, in the first hours, the limitations of the time function
can be seen, less shells are affected than in case 1 and 2. This again shows that
there is not a strong influence, resulting from the time function.
4.3.4 Simulated Release Starting with a Concentration Gra-
dient within the Particle
During preparation of the silicone microparticles, a drug-saturated water-methanol
mixture is used. However, it is not possible to saturate it perfectly, since the particle
formation is disturbed if there is any solid material in, furthermore, in the end,
the temperature is increased, this is followed by a higher saturation concentration.
As a consequence, the experimental drug amount found in the silicone particles
is lower than the theoretical amount. Anyway, it can be assumed that there is a
concentration gradient.
In the following, it is assumed that the concentration gradient is linear starting with
the maximal concentration in the center of the particle, here the concentration is
set to a concentration corresponding to the theoretical drug amount. Thus, the
concentration in each shell is calculated to be
n(i) =
4
3
pi
(
R
N
)3
· ρ(SP )
M
·
(
G−Gtheo
N
· (i4 − (i− 1)4) +Gtheo(i3 − (i− 1)3)
)
(4.57)
The concentrations c(i), and the amounts of substance n(i), in case of a constant
concentration or a concentration gradient, are plotted in fig. 4.10. It can be seen
that there is a relatively big change in the amount of substance in the outer shells,
but apart from that, there is just a small difference in the amount of substance,
having a concentration gradient or not.
Again, the reducing factors are set in order to achieve the same concentration af-
ter 24 h, as in the experiment, the values are given in table 4.2. The values of F
or Ffree are enhanced by a factor of 1.37 ± 0.05 compared to the reducing factors
in table 4.1, where the factors for a constant concentration over the whole silicone
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(a) Concentration profile of Case 4
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(b) Concentration profile of Case 5
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(c) Concentration profile of Case 6
Figure 4.9: Concentration profiles within the particle. The concentration
profiles of case 4, and 5, resemble the profile of case 1, which is caused by the
similarity of the kind of diffusion; in fact, in case 4, and 5, the swelling function is
considered, as in case 6, whose concentration profile is similar to the one of case 2.
In comparision to the profiles of case 1, 2, and 3 (see fig. 4.5), it can be seen that
there is only little influence of the swelling function on the profiles.
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Figure 4.10: The initial amount of substance, and the concentration de-
pendent on the shells, in case of an inital constant concentration or a
concentration gradient. The molar amounts of substance n(i) [bright squares],
and the concentrations c(i) [dark triangles] are plotted against the shell i, for both
cases: with [filled symbols] or without [non-filled symbols] a concentration gradient.
The values of n(i) are calculated by eq. 4.7 for a constant concentration, and by
eq. 4.57 with a concentration gradient. And the concentration c(i) was calculated
by c(i) = n(i)/V (i). It can be seen that the amount of substance in the outer shells
is higher for a particle without a concentration gradient, for the rest there is no
great difference between the two cases.
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Table 4.2: Reducing factors for the cases 1  6, for particles with a con-
centration gradient. In this table, the values of the reducing factors are given.
These factors are determined in that way that the simulated concentration after
24 h releasing period equals the experimental determined concentration. In case 1,
2, and 4, there is only one reducing factor, whereas, there are two factors for the
other cases because of the differentiation into a slowly and a faster diffusing drug
species.
case # reducing factors F
(Ffree) (FPDMS)
1 1.15 · 10−6
2 1.85 · 10−6
3 3.4 · 10−6 5 · 10−8
4 1.2 · 10−6
5 1.2 · 10−6 5 · 10−8
6 1.95 · 10−6 5 · 10−8
microparticle are given. This can be explained by the competition of two effects,
the stronger effect is based on the lower concentration in the outer shells in case of
a concentration gradient, this is followed by a need of a higher diffusion coefficient,
whereas, the weaker effect causes a smaller diffusion coefficient, in fact, here is a
concentration gradient over the whole particle and thus, there is diffusion in the
whole particle in contrast to a particle with a constant concentration.
However, the resulting curves are plotted in fig. 4.11, it can be seen that there is al-
most no difference regarding to the simulated release profiles (fig. 4.3 and fig. 4.8(c))
out of particle with a constant concentration. In the graphic of different choices of
the two reducing factors for case 3, 5, and 6 (graphics not shown), there is no signif-
icant difference except that the curves for case 5 do not lay over each other, instead
they resemble the graphics of case 6.
Furthermore, the concentration profiles of the release simulation out of the parti-
cle with a concentration gradient (graphics not shown) resemble the concentration
profiles without the concentration gradient; they only differ in the number of shells
which are involved in the release process, in fact there are up to 20 more shells
involved.
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Figure 4.11: Simulation of drug release, based on diffusion and swelling,
from a silicone microparticle with an Arg concentration gradient. The
simulated curves of all the different cases (described in the text), based on NMR
results concerning swelling, are plotted together with the experimental values. There
is no significant difference to the simulated curves for a particle without an initial
concentration gradient.
4.4 Conclusions
By NMR imaging, it is possible to trace the water uptake of a silicone cylinder. It is
found that the volume enhancement, due to swelling, is negligible. Furthermore, a
time function for swelling could be set easily, since there is a sharp border between
the swollen and the non-swollen part of the matrix.
In FEM simulations, there are almost no differences between the different ap-
proaches, which has been set up, furthermore, there is almost no influence of starting
with a constant concentration or a concentration gradient over the whole particle.
But introducing the time function, determined by NMR, the simulated release curves
show a step, which is also visible in the experimental curve. This gives evidence of
the importance of the water uptake to the release kinetics.
However, the release curve can be simulated relatively well, except that the simu-
lated data show a proportionality to the square root of the time over the whole or
a part of the considered time period, in contrast to the experimental data. As a
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consequence, one can state that diffusion (together with the water uptake) plays an
important role in the drug release process, but there is also an additional process.
In addition, time-dependent concentration profiles could be simulated. It is found
that only the outer layers are involved in the release process (over 24 h). In the
FEM model, it is assumed that the drug is distributed homogenously over the whole
particle, but in the experiment, there are drug crystals in the silicone microparti-
cles, this gives rise to the assumption that probably not all of the drug is released.
Thus, the concentration profiles in the experiment are probably somewhat flatter
than the simulated ones. However, it can be stated that also in the experiment the
drug molecules in the inner shells of the particle are not involved in the drug release
process, in the first 24 h.
4.5 Outlook
The release of Arg could be further investigated by repeating the NMR imaging
experiments, but in D2O, not in H2O. In the performed imaging experiments, water
filled pores were found, after many hours. Indeed, they can be originated from
air bubbles in the silicone matrix or by drug crystal agglomeration. In D2O, it is
probably possible to differentiate between these two assumptions. Furthermore, it
might be possible to investigate the release of Arg.
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Chapter 5
Release of L-Arginine from
Polyurethane Foams
Abstract
In modern wound management, polyurethane (PU) foams are well etablished as
wound coverings. In order to further improve wound healing supporting properties
of such a wound covering, the aim of this chapter consists of two parts: Firstly, the
release of L-arginine (Arg) as a wound healing supporting drug out of a PU foam is
characterized. Secondly, this system is optimized in terms of enhancing the release
duration by using controlled Arg delivery systems. In fact, a release duration of
several days is desired.
It was found that Arg release, directly out of a PU foam, is completed within some
minutes, which does not meet the requirements in terms of a long release duration.
Thus, silicone microparticles containing Arg (detailed described in chapter 3) were
embedded in PU foam, thereby, the release duration could be elongated to several
days, which was found by drug release experiments. However, such experiments are
far different to conditions found in wounds. Hence, a new diffusion cell was devel-
oped, which mimics fluid flow in wounds.
Additionally, a release experiment in this diffusion cell was performed. Here, it was
desired to have concentrations within the therapeutic window as long as possible.
It was found that drug concentration is within the desired concentration range for
about three days.
Thus, release experiments show that PU foams with embedded silicone micropar-
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ticles containing Arg are well suitable for promoting wound healing, by means of
releasing a wound healing supporting drug over several days even under wound fluid
flux simulating conditions.
5.1 Introduction
Modern wound management states that optimal wound healing conditions are moist
and warm[1], furthermore, oxygen supply is essential[2]. Actually, history of wound
treatment started almost 4000 years ago, but most developments were reached within
the last 50 years[1, 3]. In 1962, Winter found that moist wound milieu results in
better wound healing and less pronounced scars[4]. In order to achieve these condi-
tions, a lot of wound coverings have been developed until today and are commercial
available.
All in all, in Germany nowadays, there are more than 500 wound coverings commer-
cially available, they are well described in a database[5]. In fact, besides conventional
wound coverings like cellulose-based, silk, gauze, and non-woven fabric compresses,
there are a lot of moisture supplying, so-called hydroactive, antibacterial and odour
absorbing coverings available. Where hydroactive are such wound coverings gener-
ating an optimal moist-warm wound healing environment by absorption and accu-
mulation of wound fluid, without drying out the wound. For example, such wound
coverings are based on alginate, collagen, polyurethane foams with wide or narrow
pores, hydogels, and hydrocolloids[1]. Conventional wound coverings just protect
wounds mechanically, whereas, advanced dressings also support wound healing.
However, for a long time, focus has been set on mechanical wound protection, and
later, on wound healing (temperature, moisture); little attention has been paid to
patients's view, or more precisely, on wound related trauma and pain, exudate man-
agement, and malodour[6, 7]. All in all, quality of wound coverings are related to
(1) wound healing, (2) in-use characteristics, and (3) patient-centered outcomes, as
described in the following, in detail.
The first aspect, namely wound healing (1) can be evaluated by time needed for com-
plete healing, percentage of reduction in wound size, proportion of wound healed,
wound condition and the need for wound cleaning. Properties during use (2) are
related to wear time, total number of dressings used for a wound, time required to
134 www.bth.rwth-aachen.de
Release of L-Arginine from Polyurethane Foams
change dressings, ease of application and removal, absorbency, leakage, and con-
formability. Further important points for patients (3) are wound odour, trauma,
pain at dressing removal, and general comfort/sense of well-being. Since pain is
related to delayed healing period[79], pain mimimizing is an important point.
Almost all above mentioned characteristics interact with each other, especially, sec-
ond and third point are closely connected. In detail, excess of excudate may lead to
maceration, whereas, drying out of the wound could lead to cell and tissue death[10].
Especially, excudate from chronic wounds impairs wound healing[6], this is probably
caused by a decay of tissue matrix components due to high levels of proteases[11].
Furthermore, failure in excudate management leads to leakage or malodour, which
in turn, affects health economics by increased nursing time[12] and leads to distress
to patients[13, 14]. Excudate management (i.e. absorption and retaining) influences
wear time. Where increased wear time is followed by fewer dressing changes, de-
creased procedure-related pain and reduced wound care costs in relation to nursing
time and improved healing rates[15]. It acts similarly as ease of use, which is related
to nursing time on the one side and to trauma and pain on the other side. Pain
itself decreases quality of life resulting in a delayed healing[7, 14, 16]. In addition,
conformable wound coverings reduce non-contact areas, where micro-organisms may
proliferate[17].
The two most important hydroactive wound coverings  namely polymeric foams
and hydrocolloid dressings  are compared[10] on the basis of several studies. In
total, both show statistically identical good results in many aspect. But, there is
one advantage of hydrocolloids over foam dressings, in contrast to several points
where foams outperform hydrocolloids, as described in the following.
In detail, foam-based wound coverings show advantages towards hydrocolloids in
wound healing, and in the easiness of application resulting in less nursing time;
furthermore, there is no occurence of maceration and bleeding, and no excess of
granulation tissue, moreover, overgranulated wounds can be treated by foams to
reduce height of granulation tissue. Whereas, hydrocolloids show an advantageous
behaviour in wound dehydration, and there is no occurence of dressing adhesion to
the wound surface. But, some hydrocolloid dressings interact with excudate form-
ing liquefied material leading to malodour, furthermore, this material resembles pus,
leading to distress to patients[13, 14].
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In 2008, the global market of common hydroactive wound coverings (foams, hydro-
colloids, films, alginates, and hydrogels) was about 3 billion US dollars[18], where
foams and hydrocolloids have the biggest share, each of them have approximately
35 % of above mentioned global market, i.e. almost 1 billion US dollars. It is
estimated that with strong market increases, e.g. one can assume market shares
of foams and hydrocolloids to be about 2.8 and 1.5 billion US dollars in 2017,
respectively[18]. Indeed, foam dressings are one of the fastest growing segments in
the advanced wound care market[1922], in contrast to hydrocolloids having a mod-
erate market growth rate.
However, different wounds demand different wound coverings, a short introduction
in chosing an appropiate covering for which wound can be found elsewhere[1, 5], e.g.
dry wounds should be nursed by hydrocolloids, whereas, foams should be used in
case of excuding wounds[23].
For this study, PU foams with small pores were chosen as wound covering. For
example, these hydroactive dressings are used for decubitus and other bad healing
wounds; by using PU foams, such wounds can be conditioned (i.e. applying of a
granulation supporting stimulus) since PU foam can soak up great amounts of wound
fluid and necrotic tissue. Another advantage of PU foams (as well as of alginates)
is its gaspermeability[1, 24]. In fact, hydrocolloids and hydrogels are usually non
gaspermeable due to occlusive effect, but, for some wounds, it is stated that a lack
of oxygen stimulates vascularisation[25, 26].
What is more, wound healing can be further promoted by using wound healing sup-
porting drugs. However, the usage of ointments could be counterproductive because
of the inhibition of oxygen supply resulting in declined wound healing. Thus, it
should be preferred to embed wound healing supporting drugs directly in wound
coverings without reduction of oxygen permeability or to apply drugs to wounds
prior usage of a wound covering.
There are a few drug containing dressings available; for example, wound coverings
containing hyaluronic acid support angionesis and collagen synthesis; but available
drug loaded wound coverings are usually just drug impregnated resulting in a non-
controlled drug delivery[27].
Controlled release systems are preferable because, here, the drug can be provided
over a long time period, whereas, in non-controlled release systems, the drug is set
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free completely, at once, after applying the wound covering to the wound. Such a
release control can be achieved, for example, by embedding the drug into a matrix
which retards the release. In detail, more controlled drug delivery systems are de-
scribed in chapter 2.2 (page 13).
An example of a wound healing supporting drug is L-arginine (Arg). Indeed, Arg
deficiency results in wound healing failure[67]. Furthermore, it was found that Arg
supplementation promotes wound healing[68]. Thus, in this thesis, Arg is used as a
wound healing supporting drug to be released in a controlled manner.
In detail, Arg supports wound healing by its intracellular enzymatic degradation in
two different ways competing against each other, as already discussed in section 2.3.1
considering fig. 2.5. In the early wound healing phase, Arg is primarily degraded by
so-called NO synthase (NOS), which synthesises NO within L-citrulline NO cycle.
Where, NO is a versatile acting drug, for example, NO acts in unspecific immun
defence[72].
Later, degradation by arginase dominates. Arginase exists in high concentrations in
wounds[89]; it degrades Arg within urea cycle to urea and L-ornithine, which is par-
tially further degraded to L-citrulline (further to glutamate[61]), as already said in
section 2.3.1 (see fig. 2.7). L-Ornithine is a precursor of proline and polyamines[33,
73], which results in wound healing since proline acts as substrate in collagen
synthesis[92] and polyamine is involved in cell proliferation[93] (fig. 2.8). Actually,
when cellular polyamine synthesis is inhibited, cell proliferation is strongly reduced
or even stopped. In the context of tissue injury, need for proline in tissue increases,
since new collagen has to be produced to close the wound[74].
Coming back to drug containing wound coverings, they should be investigated in
respect to release behaviour, this can be done in a conventional manner or under
simulation of wound conditions. For the latter case one could choose a Franz cell[28]
but such a cell is optimized to model transdermal delivery as principally all model
cells. Nonetheless, a modified Franz diffusion cell was used to investigate the release
of silver ions out of wound coverings[29]; this cell was rather/initially developed
with the objective of sampling automation[30]. However, such a modified diffusion
flow-through cell might be used for modeling the effect of very deep wounds. But,
in order to simulate wound fluid flow in flat wounds, a different diffusion cell was
developed, and was used in this work.
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5.2 Experimental
5.2.1 Materials
Aqueous PU dispersion (named 9-WAS) was produced and contributed by Bayer
Material Science. A silicone kit, named Sylgard R© 184, and the catalysator 'Syl-
Off R© 4000' were purchased from Dow Corning, Arg from BASF, whereas, all other
chemicals were purchased from Sigma.
5.2.2 Instruments
Quantitative Arg analyses for the release experiments were performed with high
performance liquid chromatography (HPLC). The HPLC 'Agilent 1100 Series' is
equipped with an autosampler and fluorescence detector 'Agilent 1200 Series' using
an Eclipse Plus C18 column.
Drug release experiments were carried out in an incubator 'Heidolph Inkubator 1000'
combined with 'Heidolph Unimax 1010'. SEM pictures were created by Hitachi S-
3000N REM, for this purpose, some samples have been sputtered for 2 min using
Sputter Coater S150B Edwards.
Polymer foams were prepared using a 3Mix hand mixer equipped with beaters man-
ufactured by Krups.
The diffusion cell was prepared by photopolymer jetting technology, using the 3-
dimensional printer `Eden350' from Objet Ldt. As Material `FullCure720' was used.
5.2.3 HPLC
Quantitative analyses were performed using the HPLC method described in ap-
pendix A on page 275.
5.2.4 Preparation of Arg Loaded Silicone Microparticles
Silicone microparticles were prepared with a modified solvent-evaporation method,
as described in chapter 3, on page 69. In summary, small Arg-HCl crystals (20 µm ≤
 ≤ 50 µm) were dispersed homogeneously in a mixture of component A of Sylgard R©
184, and the catalysator; after the addition of component B of Sylgard R© 184 and
a small volumen of chloroform, this viscous dispersion was added slowly to the
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reactor, which contains an Arg-HCl saturated aqueous phase, with the help of a
syringe combined with a 15 G cannula. The content of the reactor was stirred until
silicone was cured significantly. After size fractionating, particles were heated over
night at 50oC under vacuum in a vacuum dryer for complete cure.
5.2.5 Preparation of Loaded Polyurethane Foams
PU foams were prepared in the following way: 100 g polyurethane dispersion hav-
ing a solid content of FK = 50 − 60 wt%, Arg-HCl solution and 30 wt% aqueous
Pluronic R© PE 6800 solution were mixed for 4 min using a 3Mix stirrer. The amount
of Pluronic R© solution was chosen in a way that the mass of solid Pluronic R© is 5 %
of solids content of the dispersion (mPluronic(aq) =
0.05·(FK·m(Disp))
0.3
). Afterwards, large
air bubbles are removed by beating the beaker on the bench. Then, the foam is
squeegeed (4 mm) on coated paper. Finally, the foam is put into the dryer at 100 oC
for 45 min. Due to this kind of preparation, it is assumed that the whole drug
amount is included into the PU foam, in case of Arg or Arg-HCl loaded PU foams.
In the case of including Arg or Arg-HCl, the first step is to add aqueous Arg or Arg-
HCl solution to the PU dispersion prior to addition of Pluronic R© solution. Whereas,
in the case of embedded silicone particles, the first step is to mix for a short period
of time silicone particles with PU dispersion, afterwards Pluronic R© solution is added
and the above described procedere is going on.
5.2.6 Drug Release Experiments
For release experiments, PU foam was cut into 4 cm x 4 cm squares. After putting
them into release containers with a diameter of about 5.65 cm, 10 mL or 20 mL PBS
(pH 7.4) were added, and the experiment container were given into an incubator
(37oC, 200 rpm). At certain time points, samples were taken (200 µL) and analysed
by HPLC, PBS was refilled (200 µL).
5.2.7 Drug Release Experiments Using a Diffusion Cell
In collaboration with C. Suschek and M. Helmedag, the diffusion cell was created,
in order to determine the release under simulated wound fluid flow. Such a cell
consists of two parts (see figure 5.1): Buffer solution can flow through small chan-
nels distributing fluid over the whole cell width into the lower part  which can be
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filled with a drug-less foam  such as lymph flow. At the end of the cell, fluid is
collected and flows out of the cell. Due to the complicated structure of the lower
part, diffusion cell was created by photopolymer jetting technology.
In the cover of this cell, there is a cavity to be filled with the wound covering. Since
the used PU foam is strongly hydrophilic, fluid is drawn into the wound covering;
this induces release of Arg. Arg molecules diffuse to the lower part of the diffusion
cell, where they are carried out by the buffer solution flow, Arg containing buffer
solution is collected and can be quantified.
The release experiment was performed at room temperature. At t0 = 0 h, the cham-
ber was filled with PBS, at once. Afterwards, PBS was pumped into the chamber,
using a syringe pump. Samples were collected at the end of the diffusion cell and
were analyzed.
Flow rate was chosen on the basis of lymph flow in wounds: According to literature[31,
32], there is a lymph flow of 1.2 g/cm2/d; with an area of 5 cm x 5 cm, and a density
of lymph fluid of 1.14 g/cm3, it results in a flow rate of 1.10 mL/h for the described
diffusion cell.
5.3 Results and Discussion
Firstly, PU foams with Arg, Arg-HCl, or without any drug were prepared; after
that, release behaviour was investigated. The second step was to embedd Arg-loaded
silicone microparticles into the PU foam; subsequently, release behaviour was also
investigated for this system. Finally, release behaviour using a diffusion cell was
determined for PU foams with embedded Arg-HCl loaded silicone microparticles.
5.3.1 Preparation of Drug Loaded PU Foams
PU foams with and without Arg/Arg-HCl could be prepared, using above described
method (page 139). The pore sizes of PU foam were investigated, using SEM pictures
and NMR. Using SEM pictures, it was found that the pores have an average size of
approximately 700 µm; results of NMR experiments (according to NMR experiments
described in chapter 8) could not be used because pores are too large and too leaky,
additionally, a further problem might be a non-constant relaxation time (this kind
of problem is discussed in chapter 8), resulting in a dubious value of 110 µm.
140 www.bth.rwth-aachen.de
Release of L-Arginine from Polyurethane Foams
5.3.2 Release from Arg-HCl loaded PU foams
Firstly, release behaviour (without a diffusion cell) from PU foams loaded with Arg-
HCl was investigated. For this, foams loaded with different amounts of Arg-HCl
were prepared (namely, with Arg amounts of 0.03 wt%, 0.05 wt%, 0.08 wt%, and
0.26 wt%). Cumulative release profiles were plotted, namely the amount of released
drug concerning the total drug amount was plotted against the release time, as
shown in fig. 5.2.
There is a burst release over about 10 min; after 15 min, there is almost no release
anymore (fig. 5.2). That means that there is no release barrier; release is only de-
termined by diffusion of Arg-HCl out of the foam. Furthermore, in this percentage
plot, it can be seen that there is no difference between release profiles of PU foams
loaded with different amounts of Arg-HCl (0.03 wt% - 0.28 wt%).
Additionally, another approach was tested: the idea was that Arg might be embed-
ded better or different than before, when Arg is added during preparation of PU
dispersion, instead of addition during PU foam preparation. PU foam was prepared
using the Arg containing dispersion as usual, but without addition of Arg-HCl solu-
tion. A release experiment was performed; results are shown in fig 5.3. The release
profile resembles the ones discussed before (see fig. 5.2), here, release is even faster.
Thus, it is necessary to embed a controlled Arg delivery system into the PU foams
(as described in the next section), otherwise, there is no chance to control the Arg
release.
5.3.3 PU Foams with Embedded Silicone Microparticles
In order to improve the release behaviour of PU foams, Arg containing silicone
microparticles were included during PU foam preparation. Such PU foams could
be prepared using the method described above. Indeed, it was possible to load PU
foams with up to 3.4 wt% silicone particles, where a higher amount was not checked.
Regarding the volume, a content of 3.4 wt% silicone microparticles in PU foam
is relatively small, it is less than 2.5 vol%; thus, combined with the experimental
handling, it can be expected that much higher loadings are possible, which simplifies
the development of an appropiate wound covering.
Silicone microparticles embedded in the PU foam are covered with a thin PU film,
as can be seen in SEM pictures fig. 5.4(b). The effect of this covering film on release
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Figure 5.1: Construction of the diffusion cell, used in this chapter. The
diffusion cell consists of two parts. In the cover, there is a cavity, where the wound
covering, to be investigated, is put in. The lower part of the cell has an inlet and
an outlet. Buffer solution is pumped into the diffusion cell, and is distributed over
the whole width of the cell, by small channels, into the cavity of the lower part of
the cell. The cavity is filled by a very hydrophilic foam in order to fix the wound
covering to its place. Buffer solution is collected by a pyramidal-like part prior to
the outlet, then it flows out of the outlet, and is collected for analyses. For a more
detailed illustration of the diffusion cell, see figure 6.1.
Figure 5.2: Cumulative Arg release profile out of Arg-HCl loaded PU
foams. Presented is the percentage of the released Arg relating to Arg used during
PU foam preparation; this percental amount is plotted against the time. The re-
lease is completed within some minutes, one could say that the whole release profile
consists of a burst release. Furthermore, progress of the release curve is independent
on the amount of PU foam's drug loading.
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Figure 5.3: Cumulative release profile of Arg out of a PU foam which was
prepared from an Arg containing PU dispersion. In this case, Arg was added
during preparation process of the PU dispersion, not during PU foam preparation.
Presented is the percentage of the released Arg, relating to Arg used during PU
foam preparation. Here, release is completed within some minutes. (In this case,
quantitative analysis was performed using amino acid analysis instead of HPLC.)
(a) Overview (b) Magnification
Figure 5.4: Scanning electron microscope images of a PU foam with embed-
ded silicone microparticles. The foam structure, with different magnifications
(a,b), is presented. In the center of fig. (a), a silicone microparticle can be seen. In
fact, it is covered by a thin PU film.
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behaviour is considered later.
5.3.4 Release from PU Foams with Embedded Silicone Mi-
croparticles Loaded with Arg-HCl
Release behaviour of PU foams  loaded with Arg-HCl containing silicone micropar-
ticles  were investigated. There is a burst release on the first day (see fig. 5.5(a)),
here the release rate, in fact, 63 µmol/L/d, is much higher than in the following
days. This makes a sharp distinction from the release profiles of non-embedded sil-
icone microparticles (investigated in chapter 3, see fig. 3.2, page 76); this different
release behaviour is discussed in the next subsection (page 147). Release rate further
decreases, as can be seen in fig. 5.5; additionally, in fig. 5.6, values of release rate per
day are plotted against the time. Even so, there is still a significant release over the
considered time period of seven days, which implies a great advantage of PU foams
with embedded Arg-HCl loaded silicone microparticles over PU foams containing
non-encapsulated Arg-HCl.
In fig. 5.5(b), the results of two release experiments with altogether nine samples
are plotted: single release profiles from silicone microparticles embedded in PU foam
are shown as bright lines; the dark line connects arithmetic mean values of these
experiments, furthermore, the standard error is given. It can be seen that the bright
lines diversify comparatively strongly, this is caused by the fact that small PU foams
(4 cm x 4 cm) used for drug release experiments are not perfectly homogeneous; they
differ in their exact dimension, and in their weights, and thus, in the embedded Arg
amount. Hence, standard error was used instead of standard deviation, as already
mentioned.
In order to prove this assumption, a different plot was chosen (see fig. 5.7): Namely,
the concentration of released Arg-HCl concerning the initial weight of PU foams
was calculated. Here, the percental standard deviation decreases from values of
about 26 % to values of about 15 % (see tab. 5.1). Since standard deviation is still
relatively high, the plot (see fig. 5.7(b)) was changed again: namely, the released
amount of Arg after 5 days was set to equal 100 %. In fig. 5.7(c), it can be seen
that the nine lines hardly differ, meaning (1) that the silicone particles embedded
in the foam are not distributed absolutely homogeneously, and (2) that release be-
haviour of Arg out of the different PU foams do not differ from each other but in (1).
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(a) Cumulative release profile over 24 h
(b) Cumulative release profile over one week
Figure 5.5: Release behaviour of Arg from PU foams with embedded Arg-
HCl containing silicone microparticles. Connected squares represent the cu-
mulative release profile, obtained in a single release experiment. The bold line shows
the arithmetic mean values of the single experiments. (a) There is a burst release
in the first minutes; afterwards, concentration increases slowly, but continuously.
(b) However, the drug is released during the whole time period of the experiment,
namely, over a week. At the first day, release rate is much higher than afterwards,
but after the first day, release is almost linear. (Dashed line represents the non-
cumulative release profile.
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Table 5.1: Standard deviation and standard error for the release exper-
iments from PU foam with embedded silicone microparticles. Standard
deviation and standard error is considered for different plots of the release profile.
Values taken in the plots are in bold print. In the plot of the usual concentration
profile, standard error was used, the values of standard error and standard deviation
are given in the first column. The second column show the values for the release
profile per 1 g PU foam (standard deviation was used). In the third plot, Arg con-
centration after 5 days (c(5d)) was plotted including standard deviation, values of
standard error and standard deviation are given in the third column.
standard deviation
concentration plot per gram PU foam 100 %
!
= c(5d)
13.72 (22 %) 13.69 (18 %) 8.17 (13 %)
21.33 (27 %) 13.61 (14 %) 2.41 (3.2 %)
23.22 (26 %) 15.27 (14 %) 1.80 (2.1 %)
25.66 (26 %) 17.37 (15 %) 1.57 (1.7 %)
28.74 (28 %) 19.41 (16 %) 0.00 (0.0 %)
14.09 (14 %) 14.98 (11 %) 1.68 (1.5 %)
standard error
concentration plot per gram PU foam 100 %
!
= c(5d)
4.31 (6.8 %) 4.30 (5.7 %) 2.57 (4.2 %)
6.70 (8.4 %) 4.28 (4.5 %) 0.76 (1.0 %)
7.30 (8.2 %) 4.80 (4.5 %) 0.57 (0.7 %)
8.06 (8.3 %) 5.46 (4.7 %) 0.49 (0.5 %)
9.03 (8.7 %) 6.10 (4.9 %) 0.00 (0.0 %)
6.10 (6.1 %) 6.49 (4.8 %) 0.73 (0.7 %)
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Figure 5.6: Release rate per day of the release experiment from Arg out
of PU foam with embedded silicone microparticles loaded with Arg-HCl.
Release persists over at least 5 days. Release rate has the highest value at the first
day; afterwards, release rate is much lower, it decreases almost linearly. At the 5th
day, there is still a release rate of about 8 µmol/L/d.
Comparision of the Release from Silicone Microparticles and from Sili-
cone Microparticles Embedded in a PU Foam
The first expectation was that the release behaviour from silicone microparticles
does not change significantly, due to embedding into PU foams, but as already men-
tioned, this does not match. Indeed, release behaviour from silicone microparticles
embedded in PU foams is different in comparision to release directly out of silicone
microparticles (discussed in chapter 3). Striking differences in concentration profiles
of release experiments is the existence or non-existence of a burst release, which can
be explained by the PU foam preparation process. In fact, silicone microparticles are
exposed to an aqueous environment from mixing the components, till the end of the
drying process, which takes almost 1 h, resulting in Arg-HCl release. Moreover, PU
foam's drying process is performed using high temperatures, which further increases
the loss of Arg-HCl from the particles into the foam, due to kinetics.
Thus, in release experiments from PU foams with embedded silicone microparticles,
a concentration profile can be expected as follows: In the very beginning, there is a
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(a) Concentration profile: standard error is given.
(b) Concentration profile: concentration released per 1 g PU
foam; standard deviation is used.
(c) Concentration profile: concentration of the 5th day was
set to equal to 100 % (100 % != c(5d)); standard deviation is
used.
Figure 5.7: Release experiments of PU foams with embedded silicone mi-
croparticles containing Arg-HCl (pH 7.4): Different plots. Several parallel
experiments are presented, where the bold lines show the arithmetic mean values
of these curves; here, standard deviation or standard error is given. Firstly, (a) the
concentration of the released drug is plotted against the time; here, the standard
error is high. Since the error in sample cutting in combinition to non-perfect ho-
mogeneity of the foam, increases the standard error strongly, (b) the concentration,
normalized to 1 g PU foam, was plotted. It can be seen that the standard deviation
is much lower. (c) Plot was changed again; in fact, the concentration at the 5th day
was set to equal to 100 %. The standard deviation is very low. That means that
the silicone microparticles are not distributed perfectly within the PU foam.
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burst release; release kinetics is dominated by the release of that Arg-HCl released
during preparation process from the particles into the foam. This burst release
resembles that release out of Arg-HCl loaded PU foams (shown in fig. 5.2). There-
after, Arg-HCl just releases from silicone microparticles; that, in turn, resembles the
release behaviour from silicone microparticles (not embedded in PU foams) after
about one hour. Even so, it is not equal because (1) silicone has to swell again, but
there are already cracks due to the first swelling, (2) in the outer layer of the parti-
cles most of Arg-HCl has been released and, furthermore, (3) silicone particles are
covered by a PU film (SEM picture fig. 5.4(b)), which probably act as an additional
release barrier. However, such a burst release is advantageouse because, first of all,
in a wound, a certain concentration level has to be build up, in order to reach the
therapeutic window; this process is accelerated by an initial burst release.
5.3.5 Release Experiment in a Diffusion Cell
The next step was to simulate wound conditions during release experiments, in
Figure 5.8: Release experiment using a diffusion cell: Release of Arg out of
a PU foam with embedded silicone microparticles containing Arg-HCl.
The straight line represents the lower limit of the therapeutic window; its upper
limit (about 3000 µmol/L is not shown, since it is out of range. It can be seen that
Arg concentration reaches the therapeutic window after about 8 h, with a maximal
value of about 400 µmol, which is reached after about 1 d. Concentration is within
this desired range for almost 3 days; afterwards, concentration further decreases.
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terms of using a diffusion cell. Such a diffusion cell was developed, as demonstrated
in fig. 5.1. During experimentation, samples of buffer solution  coming out of the
diffusion cell  were collected over a certain time period, and were analyzed.
Resulting concentration profile is shown in fig. 5.8: concentration increases over one
day, and after about 7 hours Arg concentration is above 100 µmol/L  the concen-
tration set as the lower limit of the therapeutic window (as described in section 3.8,
on page 85). 24 hours after starting the experiment, concentration decreases; after
2.5 d, the concentration stays almost equal to 100 µmol/L till the end of the third
day. In the following days, the concentration further decreases slowly; at the end of
the experiment (7 d), the concentration shows a value of about 20 µmol/L.
This result shows that PU foams are appropiate for their intended purpose, even
under conditions mimicking wound conditions. The therapeutic window is reached
relatively fast. Additionally, the concentration is within the therapeutic window
during a long time period, and this time can be elongoated sufficiently. The lat-
ter statement is plausable due to two aspects: (1) As already explained, maximal
loading capacity of PU foam with silicone microparticles was not reached, to double
the amount of silicone microparticles results in about doubled the concentration of
the released drug because Arg's solubility in water is extremly high, so that sink
conditions are even fulfilled, using even more than 200 times the amount of silicone
microparticles. The latter value is true for pure water, thus the real value is smaller,
but sink conditions are surely fulfilled, using concentrations within the therapeutic
window of Arg. (2) Additionally, it is possible to enhance the Arg-HCl loading of the
silicone microparticles as investigated in chapter 3, here, release behaviour changes
but not significantly considering this experiment.
5.4 Conclusions
In summary, PU foams can be prepared either containing non-encapsulated Arg/Arg-
HCl or containing silicone microparticles loaded with Arg-HCl. This is an essential
requirement for the application of silicone microparticles in wound coverings, in or-
der to develop wound coverings which promote wound healing by drugs and do not
reduce oxygen supply.
Arg release, directly out of PU foams, shows a burst release and a release duration
of just about 15 min, and thus, does not meet the requirements. Therefore, silicone
150 www.bth.rwth-aachen.de
Release of L-Arginine from Polyurethane Foams
microparticles loaded with Arg-HCl were embedded in PU foams. Here, there is a
significant release rate till the end of the experiment i.e. during seven days.
Furthermore, a diffusion cell was designed; the intention was to be able to perform
release experiments under similar conditions to wound covering applications. It can
be shown that Arg content in PU foams can be selected so that Arg concentration is
within the therapeutic window (fig 2.2) for over three days. Moreover, it is possible
to increase the content of silicone microparticles in PU foams to enlarge the time
period of concentrations within the therapeutic window, as discussed before.
Altogether, Arg-HCl loaded silicone microparticles in combination with PU foams
are promising wound coverings for diseases like decubitus.
5.5 Outlook
A difference in the release behaviour out of silicone microparticles, embedded in
polyurethane foam, in respect to the release directly out of silicone microparticles
was found. In order to ascertain, whether this difference is originated by the foam
preparation process, silicone microparticles could be pretreated analogously to the
PU foam prepation method, i.e. by the addition of a certain amount of water and
heating, where the water amount should be chosen in a way that it is evaporated
completely, after heating. The release behaviour of such pretreated silicone mi-
croparticles can be compared to the release from silicone microparticles embedded
in PU foam in order to investigate the influence of PU film covering silicone mi-
croparticles in the latter system.
Additional release experiments could be performed, using the developed diffusion
cell, with following parameters: (1) higher content of silicone microparticles in PU
foam, (2) different temperatures (with respect to wound temperature), (3) open cell
because this simulates wound covering use even better because of water evaporation
through the wound covering. Furthermore, results should be compared to the Franz
cell in order of determining which cases the new diffusion cell is more suitable for.
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Chapter 6
Finite Element Method: Modeling of
Drug Release Using a Diffusion Cell
Based on a Common Release profile
Abstract
The finite element method (FEM) was used successfully to model the release be-
haviour from a wound covering using a diffusion cell; where, the diffusion cell sim-
ulates wound conditions. The simulation is based on a common release profile of
this drug loaded wound covering. Indeed, the wound covering used in this simula-
tion study, consists of PU foam, which is loaded with L-arginine (Arg) containing
silicone microparticles. In chapter 5, the release from such a wound covering was
investigated, without and with using a diffusion cell.
In addition, the influence of different parameter were investigated. It was found
that there is no significant influcence of initial loading of Arg containing silicone
microparticles on the concentration profile if normalized by the initial Arg loading.
Whereas, a significant influence was found for an inclusion of a diffusion barrier
between the wound covering and the lower volume, and for the following parameter:
temperature, flowrate, diffusion coefficient, the height of the diffusion cell, and the
thickness of the wound covering.
The programmed code can be found in the appendix B.2 on page 299.
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6.1 Introduction
In field of drug release research, FEM  a common method in engineering  has
already been used to model and calculate drug release[114], to optimize devices[15
26], or to model release environment[2729]. In this context, there are two interesting
publications, which do not refer wound coverings but release through the skin: In
fact, drug release from a finite drug reservoir into the skin was investigated[30], and
FEM was used to investigate drug release related properties, during a transdermal
drug delivery process[31].
To the knowledge of the author, FEM has not been used to model wound condi-
tions, yet. In literature, only following similar applications were found: Firstly,
FEM has been used several times to investigate wound contraction and closure[32
35], also in terms of mechanics[36, 37], in connection with mechanical stress induced
by suturing[38], and under application of vacuum-assisted therapy[39, 40]. Sec-
ondly, there are few publications investigating the interaction between mechanics
and wound healing; namely, two papers simulate the mechanical behaviour of hu-
man skin, forces and stresses during wound closure[36, 37], furthermore, two publica-
tions dealt with the influence of mechanical stress on corneal wound healing[41, 42].
Thirdly, cell movement[43], also in context to wound healing, was investigated.
Less noteworthy in this context are two publications: one dealing with wound
ballistics[44], and the other concerning bone remodeling after dental implant[45].
As already described in chapter 5, a diffusion cell was developed in order to inves-
tigate the release behaviour from wound coverings under similar conditions as in
wounds in terms of lymph flow. The aim of this chapter is to develop a program,
based on FEM, to model release under these conditions, based on common release
experiments, performed without such a cell.
The advantages of such a model are that (1) experimental parameters like diffusion
coefficient or size of the cell can be changed, without great effort, in the model;
whereas, it would be very time-consuming in the experimental work. In addition,
(2) parameters which cannot be changed in the experiment can be easily changed
in a model, after showing that the model works well for the performed experiment.
For example, the experimental diffusion cell has to have a relatively narrow outlet,
whereas, in the model, this can be skipped. Furthermore, (3) data like concentration
profiles within the wound, can be determined, which are not accessible, in practice.
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6.2 Experimental
In the following, the system to be modelled is described, then the model is specified.
Thereafter, more details are given, concerning the segmentation of the model, the
programmation, the used equations for diffusion and convection, and the parameter
limitations.
Henceforth, the upper drug loaded foam is the named wound covering, whereas,
the lower foam is just called foam. Both of them are segmentated into discrete
elements. These elements are often called finite elements; although, this is not the
correct nomination, it is also used here.
6.2.1 Instruments
For programming the software `Borland Delphi Enterprise, Version 6.0' from Bor-
land Software Corporation was used.
6.2.2 Description of the System to be Modelled
The release experiment in a diffusion cell, which is described in chapter 5 (see sec-
tion 5.3.5, e.g. fig. 5.8), should be modelled. There is a release from a wound
covering, which is a PU foam containing silicone microparticles. The silicone mi-
croparticles, in turn, are loaded with the used drug Arg-HCl, whose release was
determined.
The diffusion cell consists of two parts, as shown in fig. 6.1: The cover has a cavity,
where the wound covering is filled in. Also the lower part has a cavity, which is
larger than the other one; however, it is filled with a polymer foam, which is ex-
tremly hydrophilic, its destination is the fixation of the wound covering in its upper
cavity. Furthermore, the lower part has an inlet, and an outlet; the cavity is con-
nected to both. The release medium is pumped into the inlet, and it flows through
small tunnels to the cavity. Due to these tunnels, the fluid is distributed over the
whole width of the cavity. The oulet part is attached to the end of the cavity, it
tapers, more and more, till it ends, exterior of the diffusion cell, where the medium
is collected for further analyses.
The experiment starts with filling the diffusion cell with the fluid, at once. After
that, the fluid is pumped with a certain flow rate into the inlet; it flows through the
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Figure 6.1: Construction of the diffusion cell. The diffusion cell consists of
two parts: The cover has a cavity, where the wound covering is put in. Whereas,
the cavity of the lower part is filled with a hydrophilic foam, which fixes the wound
covering to its place. The latter cavity is connected to both, the inlet and the
outlet. There are small tunnels, which connect the inlet with the cavity, in order
to distribute the release medium over the whole width of the diffusion cell. On the
opposite side of the diffusion cell, the cross section is reduced in a pyrimidal shape,
till it ends in the outlet. The fluid is pumped into the inlet, passes the lower cavity,
filled with the hydrophilic foam, and leaves the diffusion through the outlet. Due to
the hydrophilicity of the wound covering and capillary action of its pores, the fluid
is also drawn into the upper part of the diffusion cell.
tunnels, then, through the cavity; here, the fluid is enriched by the drug, because the
drug is set free continously by the wound covering, and it diffuses also into the lower
part of the diffusion cell. Enriched fluid is collected at the outlet, and is analysed.
6.2.3 Description of the Model and its Assumptions
Only the important part of the above described system is used for the model. For
this, the first and the last part of the diffusion cell is cut, or in other words, only
that part is simulated, which contains the wound covering and everything beneath
it, which is shown in fig. 6.2. The cell is divided into identically dimensioned finite
elements, as shown in the bottom of fig. 6.2. Therefore, the cell is divided into Nv
elements in z-direction, i.e. the height, and into Nh elements in x-direction, i.e. the
flow direction; whereas, it is not divided in y-direction. The latter is not necessary,
because a homogenous turbulent flow is assumed, for simplicity. Thus, there are no
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Figure 6.2: Description of the segmentation process and of the simplifica-
tion of the diffusion cell, for FEM simulation. At the top of the picture, the
diffusion cell is shown, as it is used in the release experiment. The upper part, which
contains the wound covering, is coloured green, and the lower part of the diffusion
cell is coloured blue. For FEM simulation, the experimental construction was sim-
plified. For this, only a small part of the diffusion cell is chosen, where the cutting is
presented in red. The part of the diffusion cell to be modelled, is segmentated into
identically sized finite elements, as illustrated at the bottom of the picture. There
are Nv or Nh elements in z and x direction, respectively, whereas, the diffusion is
not divided into y direction. Furthermore, the flow direction of the release medium
is given.
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concentration differences in y-direction.
In order to model the release from the diffusion cell described in chapter 5, the
process was divided into three subprocesses, as can be seen in figure 6.3. Firstly,
diffusion between contiguous finite elements (fig. 6.3(a)) takes place. Thereafter,
there is convection caused by the flow through the lower part of the diffusion cell
(fig. 6.3(b)). And the final step is the drug release (i.e. concentration enhancement
by cFS), in the upper part of the diffusion cell, which is filled by the drug releasing
wound covering (fig. 6.3(c)).
Furthermore, the wound covering is considered as a homogenous volume, where,
the drug is increased over time; in the experiment, silicone microparticles are dis-
tributed, relatively homogenously in the PU foam, the drug is released out of the
silicone microparticles into the foam, and diffuses out of the foam.
The release kinetics of the drug in the wound covering, is fitted from other experi-
ments (see fig. 5.5(b), page 145). In these experiments, the release out of PU foams,
which are loaded with Arg-HCl containing silicone microparticles, is investigated.
For this, a piece of the foam is put into a container, which is filled with release
medium. Then, the container is put in an incubator, and it is `shaken' at 37 ◦C with
200 rpm. Sampling were performed by simply taking a certain volume of the release
medium next to the foam, as shown in fig. 6.4.
The difference of the concentration, determined in this experiment, to the concen-
tration enhancement in the wound covering in the diffusion cell, is that in the former
case, the concentration outside of the foam is determined, whereas, in the simula-
tion the concentration enhancement within the wound covering is needed. However,
there is just a small deviation, because the investigation of release from Arg-HCl
loaded PU foams showed that the release is completed within some minutes (see
fig. 5.2, page 142); at this point, it is notable that the experiment with the diffusion
cell takes several days.
A further experiment with an Arg-HCl loaded foam was performed, in order to de-
termine whether the diffusion out of the foam is that fast, as expected. Therefore,
the experiment was done in the same way, as described above, but the foam was
pressed prior to sample taking. The resulting concentrations (data not shown) were
compared to that without pressing; it was found that there is no difference. This
is an additional proof of the similarity of the experimentally determined concentra-
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(a) Diffusion (b) Convection
(c) Release of the wound covering
Figure 6.3: Subprocesses of finite element method. In the pictures a part
of the simulated diffusion cell is presented, the non-transparent finite elements are
chosen for consideration of the single steps. The simulation is divided into three
subprocesses. (a) There is diffusion between contiguos finite elements, due to con-
centration gradients, which is demonstrated for four finite elements, representative
for all other finite elements. (b) Next, convection takes place due to the flow through
the diffusion cell, but only in the lower part (blue coloured) of the diffusion cell. For
simplicity, turbulent flow is assumed. (c) In the upper part (green coloured) of the
diffusion cell, namely in the wound covering, the drug concentration is enhanced by
cwc due to controlled drug release in the wound covering, whereas, the concentration
is constant in the lower part, in this step. The value of cwc is equal for every finite
element, but it is dependent on the time, t, and on ∆t.
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Figure 6.4: Set up of the release experiment from Arg-HCl loaded PU
foams. A piece of the PU foam was arranged in a container, which is filled with the
release medium. The container is put into an incubator (37 ◦C, 200 rpm). Here, the
sample taking is presented; using an eppendorf pipette, the sample is taken, next to
the foam.
tions, and the ones needed for simulation.
In addition, there is a difference in the concentration within the wound covering
next to the particles, either with or without the diffusion cell, because the drug is
dissipated, in the diffusion cell, due to the flow, in contrast to the beaker experiment.
Thus, the concentration gradient at the outside of the silicone particles is slightly
different. However, this does not matter, due to the fact that sink conditions are
fulfilled, in both cases, because of the very high solubility of Arg-HCl.
In summary, the model system consists of two parts. The wound covering is the
upper part, here, drug is released in terms of concentration enhancement according
to former release experiments, where the release out of a PU foam with Arg-HCl
loaded silicone microparticles was determined in a simple experiment. In the lower
part, convection takes place, for this, a turbulent flow is used, due to simplicity. Ad-
ditionally, it is assumed that Arg diffusion takes place in both parts of the diffusion
cell, according to Fick's law.
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6.2.4 Segmentation of the System into Finite Elements
The considered system was divided into finite elements, all of the same volume, as
demonstrated in figure 6.5. The geometry of the whole simulated diffusion cell is
given by its height H, its length L, and its width B, as shown in figure 6.5(a); where,
H is divided into two parts, in fact, the wound covering has a hight of HPU , and
the release volume beneath it, has a height of (H − HPU). The simulated part of
the diffusion cell is segmentated into finite elements, having the dimensions of ∆x,
∆y = B, and ∆z in x, y, and z direction, respectively, as can be seen in figure 6.5(b).
Their areas are calculated as Ax = ∆y ·∆z, Ay = ∆x ·∆z, and Az = ∆x ·∆y.
In figure 6.5(a), it is demonstrated that the diffusion cell is divided into Nh elements
in the x direction, and into Nv elements in the z direction. Here, NPU elements
belong to the wound covering, they are indexed by (i,j) with i ∈ [Nv −NPU + 1, Nv]
and j ∈ [1, Nh], all other elements belong to the release volume.
6.2.5 Structure Chart Outline of the Program
The program was set up, as shown in flow chart 6.6. First of all, all variables are
declared and initialized. Then, the values of certain parameters are read, and others
are calculated (e.g. VFE = ∆x ·∆y ·∆z). Secondly, the process starts by choosing
the inital values for the `old' concentration, that is, in this case, the initial concen-
tration, and in general (i.e. in the following loop), it is that concentration of the
prior iteration, which is used to calculate the current concentration of the considered
iteration.
The main part follows, in fact, it is a for-loop over the experimental time (t), in
intervals of ∆t. The loop can be divided into several steps: (1) The concentra-
tion values of the prior iteration are transfered as to so-named old concentration
(c(t−∆t)i,j → c(old)(t)i,j ). Afterwards, (2) diffusion, (3) convection, and (4) drug concen-
tration enhancement due to release out of the wound covering is performed. Where,
the latter step only occurs in the upper part of the diffusion cell, whereas convection
takes only place within the lower part of the diffusion cell. Finally, the concentration
is plotted, for every hour, in a plot, on the software surface. After that, the next
iteration of the for-loop starts. In the following subsections, single steps are shown,
more precisely.
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(a) Segmentated diffusion cell
(b) A finite element of the upper and one of the lower part of the diffusion cell
Figure 6.5: Segmentation of the simulated diffusion cell into finite elements,
and definition of the used variables. (a) The whole diffusion cell is shown,
parameter H, L, and B are defined as geometry of the diffusion cell, additionally,
HPU gives the height of the wound covering. The diffusion cell is divided into Nv
or Nh elements in z and x direction, respectively. Furthermore, NPU is defined as
number of finite elements of the wound covering, in z direction. (b) Every finite
element, both, in the wound covering and in the release volume, have the same size,
it is given by ∆x, ∆y, and ∆z. Areas Ax, Ay, and Az in x, y and z direction,
respectively, are also defined.
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Figure 6.6: Outline of the scheme of the program. Description of the flow
chart can be found in the text of subsection 6.2.5.
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6.2.6 Diffusion
In the case of diffusion, first Fick's law
J = −D δc
δx
(6.1)
has to be solved. As already mentioned in chapter 2.5, for finite elements applies
∆n
∆t
= −D · A · ∆c
∆x
(6.2)
∆n = −D · A ·∆t · ∆c
∆x
(6.3)
For a system which is separated into cuboids, having all the same volume V , this
leads to
∆n = −D · Ai ·∆t · ∆n
V ·∆xi (6.4)
In the considered case of this chapter, the diffusion in the x and in z direction has
to be regarded, in each case of two contiguous finite elements. That means, if the
system is separated into Nv, Nb = 1, and Nh cells into the x, y and z direction,
respectively, following equation holds, considering an element (i,j) (∀ i ∈ [2, Nv− 1],
j ∈ [2, Nh − 1])
n
(t+∆t)
ij = n
(t)
ij −D ·∆t · Ax ·
n
(t)
i,j − n(t)i+1,j
V ·∆x −D ·∆t · Ax ·
n
(t)
i,j − n(t)i−1,j
V ·∆x
−D ·∆t · Az ·
n
(t)
i,j − n(t)i,j+1
V ·∆z −D ·∆t · Az ·
n
(t)
i,j − n(t)i,j−1
V ·∆z (6.5)
= n
(t)
ij −D ·∆t ·
(
2 · n(t)i,j − n(t)i+1,j − n(t)i−1,j
(∆x)2
+
2 · n(t)i,j − n(t)i,j+1 − n(t)i,j−1
(∆z)2
)
(6.6)
For the last step, the equations Ax = ∆y ·∆z, Az = ∆x ·∆y, and V = ∆x ·∆y ·∆z
are used.
In this program, it is calculated using concentrations instead of amounts of sub-
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stance. That means, following equation is used
c
(t+∆t)
ij = c
(t)
ij −D ·∆t ·
(
2 · c(t)i,j − c(t)i+1,j − c(t)i−1,j
(∆x)2
+
2 · c(t)i,j − c(t)i,j+1 − c(t)i,j−1
(∆z)2
)
(6.7)
which holds for all i ∈ [2, Nv − 1] and for all j ∈ [2, Nh − 1]. And for the other [i, j]
combinations, following equations hold
c
(t+∆t)
11 = c
(t)
11 −D ·∆t ·
(
c
(t)
1,1 − c(t)2,1
(∆x)2
+
c
(t)
1,1 − c(t)1,2
(∆z)2
)
(6.8)
c
(t+∆t)
Nv ,Nh
= c
(t)
Nv ,Nh
−D ·∆t ·
(
c
(t)
Nv ,Nh
− c(t)Nv−1,Nh
(∆x)2
+
c
(t)
Nv ,Nh
− c(t)Nv ,Nh−1
(∆z)2
)
(6.9)
c
(t+∆t)
1,Nh
= c
(t)
1,Nh
−D ·∆t ·
(
c
(t)
1,Nh
− c(t)2,Nh
(∆x)2
+
c
(t)
1,Nh
− c(t)1,Nh−1
(∆z)2
)
(6.10)
c
(t+∆t)
Nv ,1
= c
(t)
Nv ,1
−D ·∆t ·
(
c
(t)
Nv ,1
− c(t)Nv−1,1
(∆x)2
+
c
(t)
Nv ,1
− c(t)Nv ,2
(∆z)2
)
(6.11)
c
(t+∆t)
i,1 = c
(t)
i,1 −D ·∆t ·
(
2 · c(t)i,1 − c(t)i+1,1 − c(t)i−1,1
(∆x)2
+
c
(t)
i,1 − c(t)i,2
(∆z)2
)
∀ i ∈ [2, Nv − 1]
(6.12)
c
(t+∆t)
i,Nh
= c
(t)
i,Nh
−D ·∆t ·
(
2 · c(t)i,Nh − c
(t)
i+1,Nh
− c(t)i−1,Nh
(∆x)2
+
c
(t)
i,Nh
− c(t)i,Nh−1
(∆z)2
)
∀ i ∈ [2, Nv − 1]
(6.13)
c
(t+∆t)
Nv ,j
= c
(t)
Nv ,j
−D ·∆t
(
c
(t)
Nv ,j
− c(t)Nv−1,j
(∆x)2
+
2 · c(t)Nv ,j − c(t)Nv ,j+1 − c(t)Nv ,j−1
(∆z)2
)
∀ j ∈ [2, Nh − 1]
(6.14)
c
(t+∆t)
1,j = c
(t)
1,j −D ·∆t
(
c
(t)
1,j − c(t)2,j
(∆x)2
+
2 · c(t)1,j − c(t)1,j+1 − c(t)1,j−1
(∆z)2
)
∀ j ∈ [2, Nh − 1]
(6.15)
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Limits for Time Increment
If variables in finite element method are not chosen carefully, problems can arise;
therefore, the condition was set that the concentration has to have a positive sign:
ct+∆tij = c
t
ij −
D ·∆t
V
·

∆c1x︷ ︸︸ ︷
(c
(t)
i,j − c(t)i,j+1) +
∆c2x︷ ︸︸ ︷
(c
(t)
i,j − c(t)i,j−1)
∆x/Ax
+
∆c1z︷ ︸︸ ︷
(c
(t)
i,j − c(t)i+1,j) +
∆c2z︷ ︸︸ ︷
(c
(t)
i,j − c(t)i−1,j)
∆z/Az
 !≥ 0
(6.16)
= ctij −D ·∆t ·
(
∆c1x + ∆c
2
x
(∆x)2
+
∆c1z + ∆c
2
z
(∆z)2
)
!≥ 0 (6.17)
this also has to hold for one-dimensional diffusion, i.e. diffusion in the x, and in
the z directions are considered individually. The highest value of ∆c, which can be
reached in all different cases, is ∆c ≤ c0, where, c0 is the imaginary concentration
of the whole drug amount dissolved in the volume of the wound covering. This
Figure 6.7: Location of maximal concentration gradient. The highest possible
concentration gradient between two adjacent finite elements, can be found in the
case of non-controlled release. In detail, when starting the simulation (t = 0), the
concentration is either zero (in the release volume), or is equals c0 (in the wound
covering). Therefore the maximal concentration difference can be found at the
border between the wound covering and the release volume, where the concentration
gradient is ∆c = c0−0 = c0. Indeed, the diffusion between these two contiguos finite
elements is used, in order to determine the upper limit of the time difference between
two iterations.
maximal value can only be reached in case of a non-controlled release, in fact, only
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for that finite elements located directly at the border between the wound covering
and the lower foam (i.e. diffusion in z direction), as demonstrated in figure 6.7.
Therefore, it follows that following equations have to hold
ct+∆tij =
=c0︷︸︸︷
ctij −D ·∆t ·
(
c0
(∆z)2
)
!≥ 0 (6.18)
and
ct+∆tij =
=0︷︸︸︷
ctij −D ·∆t ·
( −c0
(∆z)2
)
!≥ 0 (6.19)
⇒ ct+∆tij =
c0 ·D ·∆t
(∆z)2
≥ 0 (6.20)
where the latter equation is always true, since c0, D, ∆t, ∆z are, greater than zero,
per definition.
Considering former equation, ∆z = H/Nv holds. And ∆t is chosen in a way that
convection is easier; i.e. every iteration, there should be a convection in the length
of one finite element, namely ∆x, this results in ∆t = ∆x·B·(H−HPU )
f
, initially. In
the case of finite element method, the parameter have to be chosen carefully, as
already mentioned (the steps must not be too large  i.e. the time difference ∆t
between two diffusion steps must not be too great), an additional parameter (Nt)
was introduced in the way that diffusion is calculated for time steps of ∆t/Nt so
that for ∆t following equation holds
∆t =
∆x ·B · (H −HPU)
f
/Nt (6.21)
with the flowrate, f , and Nt as the variable parameter, where width B and height H
gives the geometry of the diffusion cell, and HPU the height of the wound covering,
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i.e. in general fixed values. Applying eq. 6.21 to eq. 6.18, it follows that
ct+∆tij = c0 −D ·
L/Nh ·B · (H −HPU)
f
/Nt · c0
(H/Nv)2
!≥ 0 (6.22)
= c0 ·
(
1− D
f
· L ·B · (H −HPU)
H2
· (Nv)
2
Nt ·Nh
)
!≥ 0 (6.23)
⇒ 1 !≥ D
f
· L ·B · (H −HPU)
H2
· (Nv)
2
Nt ·Nh (6.24)
⇔ Nt ·Nh
(Nv)2
!≥ D
f
· L ·B · (H −HPU)
H2
(6.25)
hold. For Nb = 1, f = 1.1 mL/h, D = 6.1 · 10−10 m2/s, B = L = 5 cm, H = 1 cm,
and HPU = 0.5 cm, the former equation results in
Nt
!≥ D
f
· (H −HPU) · L ·B
H2
· (Nv)
2
Nh
≈ 0.25 · (Nv)
2
Nh
(6.26)
For example, in the case of Nv = Nh = 50, Nt has to be at least as high as Nt ≥ 13,
and for Nh = 40 and Nv = 30 at least Nt ≥ 6. That means that diffusion is
calculated every ∆t, whereas, convection is performed only every Nt ·∆t.
6.2.7 Convection
Due to the flow of the medium through the lower part of the diffusion cell, after
the time t = Nt ·∆t, convection takes place, in means of changing indices of finite
elements in the lower part, i.e.
ct+Nt·∆ti,j = c
t
i,j−1 ∀j 6= 1,∀i ∈ [1, Nv −NPU ] (6.27)
ct+Nt·∆ti,1 = 0. (6.28)
In this step, release out of the diffusion cell also takes place. Because of the equality
of the finite element volumes, the released concentration (cFS) for this step can be
calculated as an arithmetic mean, i.e.
ctFS =
1
Nv −NPU ·
Nv−NPU∑
i=1
cti,Nh . (6.29)
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6.2.8 Fitting of the Release out of the Wound Covering
The release from a PU foam without a diffusion cell (see chapter 5, figure 5.5 on
page 145) is fitted. Following conditions are set to the fitting function r(t):
(i) r(0) = 0
(ii) limt→∞(r(t)) = c0
(iii) dr(t)
dt
> 0 for all t ∈ R≥0
(iv) d
2r(t)
dt2
< 0 for all t ∈ R≥0
(v) continuous at every point of t ∈ R≥0.
Following continuous function
r(t) = 1− e−ni·t (6.30)
with ni > 0 holds
f(0) = 0 (6.31)
lim
t→∞
f(t) = 1 (6.32)
df(t)
dt
= ni · e−ni·t > 0 ∀t (6.33)
d2f(t)
dt2
= −n2i · e−ni·t < 0 ∀t (6.34)
Based upon this, one can state that all above mentioned conditions are hold for a
function like
f(t) =
c0
m∑
i=1
ai
·
m∑
i=1
(
ai · (1− e−ni·t)
)
(6.35)
with ai > 0 ∀i ∈ [1,m ∈ N+], and ni > 0 ∀i ∈ [1,m].
However, here, it shall be repeated that the usage of the fitting function r(t), in
FEM simulations of the diffusion cell, is an approximation. In fact, the reason for
the difference in the release behaviour has its origin in the experimental conditions:
in the common release experiment, the release medium is added, a sample is taken,
and the medium is refilled; this results in oscillating concentrations, whereas, the
concentration progress in the diffusion cell is continuous. For practical reasons,
wound coverings loaded with different amounts of silicone particles were used in both
kinds of experiments, and the maximal concentration reached in the experiment, was
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about four times higher in case of the diffusion cell (but only for a short time period).
Another difference is that in the common release experiment, the wound covering
is put into a container, which is shaken in an incubator at 37 oC, whereas, in the
diffusion cell, there is the flow in the lower part, which is simulated here, additionally,
this experiment was performed at room temperature. Anyway, another important
difference may be that the concentrations to be fitted, equal those, which have
already been released to the environment, whereas, the fitting function is used as
if the fitted concentrations have been found within the wound covering. The latter
difference has already been discussed, before (see section 6.2.3), and it came out
that it is negligible.
6.2.9 Implementation of the Outlet
Up until this point, the diffusion cell was considered as cuboid, which is divided into
an upper part containing the wound covering, and a lower part, where convection
takes place. In practice, this is not possible because the medium has to be collected
at the end of the diffusion cell, therefore, an outlet was designed. However, this has
Figure 6.8: Illustration of the outlet. The outlet consists of two parts: a pyri-
madal one and the last part of the outlet. Latter is divided into Noutlet finite el-
ements, which are strung together; in practice, this part was cylindric and not
cuboidal. The pyrimidal part consists of NPyr finite elements, which are strung
together; they have the same volumes but not the same geometry.
to be taken into account in order to proof the quality of the simulation, because the
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medium flows through the outlet, prior to be released out of the diffusion cell, which
delays the detected release.
The outlet consists of two different parts, both divided into finite elements. The first
part has somewhat a capped pyramidal geometry to collect the medium, coming from
the diffusion cell; the other part is a relatively narrow channel, where the medium
is let out. This is shown in figure 6.8.
In the experimental work, the outlet was designed slightly different. Firstly, the
last part of the outlet was cylindrical, not cuboidal, but this does not influence the
simulation, since the size of the squared area in the y,z plane in FEM simulation is
chosen equal to the size of the corresponding circular area in the experiment. The
length of this part is fixed to the length of the designed `real' diffusion cell's outlet.
The pyrimidal part also looks somewhat different but this difference is most likely
negligable.
The difficulty of the former part is the changing size of the area. Here, the length
∆xpyr of the finite elements is chosen dependent on their volume, otherwise, the
concentrations of the finite elements would be mixed up, in a convection step.
At xpyr = 0, the dimensions of the edges are equal to that of the lower part of the
diffusion cell, i.e. B = 5 cm, and H −HPU = 5 mm. And at the `highest point' of
the capped pyramide (xpyr(Npyr) = Hpyr = 8 mm), the cross section is square with
an edge lenght of Cpyr = 2.5 mm. With this, for the area Apyr(xpyr) of the cross
section at the height xpyr follows
Apyr(xpyr) =
(
B − B − Cpyr
Hpyr
· xpyr
)
·
(
(H −HPU)− (H −HPU)− Cpyr
Hpyr
· xpyr
)
(6.36)
=
((H −HPU)− Cpyr) · (B − Cpyr)
H2pyr
· x2pyr +B · (H −HPU)
− B · ((H −HPU)− Cpyr) + (H −HPU) · (B − Cpyr)
Hpyr
· xpyr (6.37)
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The volume of the pyramidal part can be calculated by integration
Vpyr =
Hpyr∫
0
Apyr(xpyr)dxpyr (6.38)
=
Hpyr
6
· (2 · (H −HPU) ·B + 2 · C2pyr − Cpyr · (H −HPU +B)) (6.39)
analogously, the volume V (i)pyr of the ith finite element can be calculated by
V (i)pyr =
xipyr∫
xi−1pyr
Apyr(xpyr) dxpyr (6.40)
for example, this yields for the first finite element to
V (1)pyr =
x
(1)
pyr∫
0
Apyr(xpyr) dxpyr (6.41)
=
((H −HPU)− Cpyr) · (B − Cpyr)
3 ·H3pyr
· (x(1)pyr)3 +B · (H −HPU) · x(1)pyr
− B · ((H −HPU)− Cpyr) + (H −HPU) · (B − Cpyr)
2 ·H2pyr
· (x(1)pyr)2 (6.42)
Together with the condition that all Npyr finite elements, the pyramidal part is
segmented in, has the same volume, i.e.
V (i)pyr =
Vpyr
Npyr
∀ i ∈ [1;Npyr] (6.43)
a cubic polynomial equation is obtained, which can be solved by Cardano's method,
and thus, the values of xipyr can be determined, subsequently.
A further important point is the convection. It is preferable to set the convection
in a way that the solution in the finite elements of the diffusion cell, which are
contiguous to the pyramidal part, is distributed into a certain number (Nconv) of
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finite elements of the pyramidal part. That means, following equation has to hold
Nconv · V jpyr =
Nv−NPU∑
i=1
VFE(1, i) for any j ∈ [1, Npyr] (6.44)
Nconv · Vpyr
Npyr
= B · (H −HPU) ·∆x = B · (H −HPU) · L
Nh
(6.45)
Using the above mentioned values, this results in following summation
Npyr
Nconv
= Nh ·Hpyr ·
2 · C2pyr + 2 · (H −HPU) ·B − Cpyr · ((H −HPU) +B)
6 ·B · (H −HPU) · L (6.46)
=
Nh
25
(6.47)
The value ofNh is determined in the experimental section (subsection 6.3.1, page 178);
with this, the ratio of Npyr and Nconv is given, and different combinations can be
chosen.
Since the intension of the outlet implementation is done to find out whether the
model simulates a proper release profile, which fits to the experimental results, the
outlet should be implemented as an approximation. Meaning that, there is only a
chain of finite elements (fig. 6.8), not a matrix as in the diffusion cell (fig. 6.5).
If the finite elements would be chosen in the way that convection changes the indices
of concentration only by one, there would arise problems in the diffusion process.
Therefore, these bigger' finite elements are divided into a chain of finite elements.
6.3 Results and Discussion
First of all, the limits for the number of finite elements were determined, in order to
get confidential simulation results. The next step was to get a proper implementa-
tion so that the simulated concentration profile fits well to the previously obtained
experimental data. Therefore, different fitting functions were tested and the diffu-
sion cell's outlet was implemented. Additionally, the progress of the concentration
profile within the diffusion cell at different heights, were presented and discussed.
Finally, the influence of different parameter on the release profile were investigated,
namely (1) the drug amount which is loaded by the wound covering, (2) the drug's
diffusion coefficient, and the temperature, (3) the flowrate, (4) the height of the
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diffusion cell, (5) wound covering's thickness, and (6) a diffusion barrier. For this,
the implementation of the diffusion cell's outlet was commented out, because the
outlet is needed for the experimental performance, but there is no counterpart in
a wound. In table 6.1, the values for the different parameter are listed, which are
used in the following sections.
6.3.1 Determination of the Limits for the Number of Finite
Elements
As already mentioned above, it is essential for the FEM to choose the values of
parameter carefully. In detail, that means, it is important to use values high enough
for the number of elements, and values small enough for the time difference between
two iterations. A limit for the parameter NT , determining the time difference, has
already been determined theoretically, in subsection 6.2.6. Since several parameter
are intended to be varied, NT was implemented higher than neccessary for the stan-
dard parameter setting, indeed, it was implemented as NT = 100 ·Nv. Actually, NT
is proportional to Nv
2
Nh
, but here, the problem arises that NT has to be an integer,
in implementation.
In order to find proper values for the number of elements Nh, and Nv, the simulated
data for different values were compared. Minimal values are found as the smallest
ones, for which the simulated data are still equal to that for a higher number of
elements.
As already explained in subsection 6.2.6, that system having the highest concentra-
tion differences should be considered for this, therefore, it was assumed that there is
no controlled release in the wound covering, instead the whole drug amount is free
(named case iii=1), in the volume of the wound covering.
Firstly, it was found that there is only a slight difference for Nh = 30, 40, 50, 75, and
100 (data not shown); in order to be on the safe side, the value was set to Nh = 100.
Afterwards, Nv was considered: As can be seen in figure 6.9, the value of Nv was
set to 20, 40, 50, 70, 100, and 200; where the profiles differ clearly from each other.
This was expected because the concentration gradient in z direction is stronger than
in x direction, therefore, more finite element are needed in z direction. In whole,
the values are set to Nv = 200, Nh = 100, and NT = 100 · Nv, which results in a
geometry of the finite elements with ∆x = 500µm and ∆z = 50µm.
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Table 6.1: Summary of the parameter values. The values of the parameters
used in the following sections, are summarized, where the standard settings are
plotted in bold print.
drug content in the wound covering
(fictive concentration) (c0)
section 6.3.4
2000 µmol/L
4500 µmol/L
9000 µmol/L
temperature (T)
section 6.3.5
20 oC
25 oC
45 oC
diffusion coefficient (D)
section 6.3.5
2.78· 10−11 m2/s
2.78· 10−10 m2/s
6.10· 10−10 m2/s
8.33· 10−10 m2/s
2.78· 10−9 m2/s
flow rate (f)
section 6.3.6
0.275 mL/h
0.550 mL/h
1.100 mL/h
2.200 mL/h
4.400 mL/h
height of the diffusion cell (H)
section 6.3.7
H c0
7 mm 800 µmol/L
7 mm 2000 µmol/L
10 mm 2000 µmol/L
15 mm 2000 µmol/L
15 mm 4000 µmol/L
thickness of the wound covering (HPU )
section 6.3.8
HPU H c0
2.5 mm 10 mm 4000 µmol/L
2.5 mm 10 mm 2000 µmol/L
5 mm 10 mm 2000 µmol/L
10 mm 15 mm 2000 µmol/L
10 mm 15 mm 1000 µmol/L
barrier (b)
(reduction by divisor b)
section 6.3.9
1
10
20
50
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Figure 6.9: Determination of the number of finite elements. With increasing
value of Nv, the difference between two succeeding release curves decreases, and the
curves resemble more and more the curve for Nv →∞. For the considered system,
Nv = 200 was chosen to approximates latter well enough.
6.3.2 Comparision with the Experiment
Different fitting functions were implemented, the resulting simulations of the diffu-
sion cell were compared with the experimental data. Nevertheless, the first equation
(iii = 1), namely
iii = 1 cwc(t) = c0 (6.48)
is that case, where the drug is assumed to be free in the foam; it is used for com-
parision with the controlled release, later. However, following fitting equations were
set, as described in the theoretical section 6.2.8, and were tested:
iii = 2 cwc(t) = c0 ·
(
1− 90 · e
−0.03125·t + 13 · e−25/3·t
103
)
(6.49)
iii = 3 cwc(t) = c0 ·
(
1− 72 · e
−0.025·t + 31 · e−25/6·t
103
)
(6.50)
iii = 4 cwc(t) = c0 ·
(
1− 70 · e
−0.025·t + 33 · e−25/3·t
103
)
(6.51)
iii = 5 cwc(t) = c0 ·
(
1− 43 · e
−8·t + 60 · e−0.03·t
103
)
(6.52)
iii = 6 cwc(t) = c0 ·
(
1− 2 · e
−0.2·t + 2 · e−4·t + 10 · e−0.025·t
14
)
(6.53)
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iii = 7 cwc(t) = c0 ·
(
1− 2 · e
−0.2·t + 100 · e−4·t + 220 · e−0.025·t
322
)
(6.54)
they are plotted in figure 6.10, it can be seen that they fit relatively well to the
experimental data.
The results of the simulation for above fitting functions are quite good, as can be
Figure 6.10: Exponential and biexponential fitting functions. Different fitting
functions, analoguoues to eq. 6.35, are presented; they fit relatively well to the
experimental data, which are plotted as cycles.
seen in figure 6.11, even so there are some small differences to the experimental data,
for all cases. In fact, in the very beginning, the release rate is lower than simulated
by finite element method, and after about two days, the simulated concentration is
higher than the experimental ones. The former difference could be originated by the
missing outlet of the diffusion cell, or by a barrier between the wound covering, and
the lower part of the diffusion cell, which is filled with a polymeric foam. Whereas,
the latter is probably caused by the fitting function, which has a too small slope at
this time point.
Prior to continue optimazation of the fitting function, the outlet is implemented,
as described in subsection 6.2.9, in order to test its effect. For this, the outlet
parameter, pictured in fig. 6.8, are set as follows: Hpyr = 8 mm, coutlet = 2.5 mm,
and Npyr = 200. The latter value is chosen in that way that the highest value for
∆xpyr is approximately as high as ∆x in the main part of the diffusion cell, in order
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Figure 6.11: Comparision of the simulated and the experimental data. In
general, the simulated curves resemble the experimental data well, despite some
small differences. In detail, the simulated peaks are too broad: the concentration
increases too early, and it decreases too slowly, after the maximum. Where the early
concentration increase is considered first; in fact, an outlet was implemented to find
out whether this is the origin of the difference.
to avoid problems due to the choice of Nt. Furthermore, Nh is chosen to be certainly
high enough with Nh = 100.
As already mentioned in subsection 6.2.9, for the convection steps, it is useful to
choose the number of finite elements of the outlet in a way that the volume of Nconv
elements of the pyramidal part matches the volume of all finite elements of the lower
part of the diffusion cell which are bordering the outlet (i.e. V = B ·(H−HPU)·∆x).
Using this requirement and above given values, the value for Nconv can be calculated
by
Nconv · VPyr
NPyr
!
= B · (H −HPU) ·∆x = B · (H −HPU) · L
Nh
(6.55)
⇔ Npyr
Nconv
=
Nh
25
(6.56)
⇔ Nconv = 200
100
· 25 = 50 (6.57)
Comparing the release profiles without (fig. 6.11), and with the outlet (fig. 6.12),
it can be seen that the implemented outlet has only little influence on the release
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Figure 6.12: Release profiles of the exponential and biexponential fitting
functions (iii = 27), with outlet implementation. The outlet was imple-
mented, and the obtained release profiles, for the fitting functions iii = 27 are
shown. There is only a slight difference to the release profiles, without outlet im-
plementation. But using another outlet implementation (further details are given in
the text), it can be seen that the outlet does have an influence, the starting of the
release is delayed, therefore, it fits the experimental data better, in the beginning.
profile. But, there is also an additional plot, named other implementation. In fact,
it is the case iii = 2, but distinguishing by the kind of the outlet implementation.
Actually, this was the first approach of the outlet implementation, when the exact
geometry of the diffusion cell was not available. Here, the pyramidal part was chosen
with a larger geometry. Due to this, it can be stated that the outlet does have an
influence on the release profile, mainly by retarding the release for some time.
Furthermore, in the experimental work, it was not possible to start without any
delay, because after filling the diffusion cell, at once, a syringe has to be refilled and
put into a syringe pump. It was not possible to arrange the syringe pump in that
way that the flow started directly, because it could not be adjusted exactly. Hence,
this `retards' the release in a similar manner as the outlet, in other words, both to-
gether could be simulated by an outlet, which is bigger than the real outlet. But this
was not done, because it is difficult to quantify the effect of the experimental delay.
However, this has to be kept in mind, for all the simulations in this subsection.
Comparing the simulated data (fig. 6.12) with the experiment, the values fit rela-
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tively well, but the `peaks' in the simulations are broader than in the experiment,
additionally, the concentration increases earlier, in the simulations, as already dis-
cussed. Furthermore, in the experiment, the concentration decreases faster, after
the maximum. The simulated curves for iii = 2  7 resemble each other, although,
the maximal concentration is too small for iii=2, and too high for iii=5, respectively.
In the following, the fitting function was further varied, under consideration of the
burst release, which was found in chapter 5. This was performed by the sum of a
constant and an equivalent function as used above. In detail, the following equations
were tested:
iii = 8 cwc(t) = c0 · 35
103
+ c0 · (1− 35
103
) ·
(
1− 2 · e
−4h−1·t + 5 · e−0.0275h−1·t
7
)
(6.58)
iii = 9 cwc(t) = c0 · 15
103
+ c0 · (1− 15
103
) ·
(
1− e
−0.21h−1·t + e−4h
−1·t + 5 · e−0.021h−1·t
7
)
(6.59)
iii = 10 cwc(t) = c0 · 40
103
+ c0 · (1− 40
103
) ·
(
1− 2 · e
−8h−1·t + 11 · e−0.017h−1·t
13
)
(6.60)
The fitting functions are plotted in figure 6.13(a) as well as their simulated release
profiles (fig. 6.13(b)); it can be seen that no improvement could be attained by the
fitting functions iii = 8  10. In fact, the simulated curves for iii = 9, 10 are too
broad and the maximum is too low; And the result for iii = 8 resembles the plots
of iii = 3, 4, 6, and 7, which are the best simulations, so far. In order to further
improve the fitting function, a different approach was chosen; in detail, the fitting
function was combined by several linear parts as given by following fitting equations
(where t is the time in hours, but in the following equations only the value without
the unit is used, for reasons of clarity and comprehensibility).
iii = 11 : cwc(t) =
{
c0 · (0.456 + 0.0063 · t) for t < 86.35 h
c0 for t ≥ 86.35 h
(6.61)
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iii = 12 : cwc(t) =

c0 · (0.456 + 0.0063 · t) for t < 48 h
c0 · (0.7584 + 0.0039 · (t− 48)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.62)
iii = 13 : cwc(t) =

c0 · (0.456 + 0.0063 · t) for t < 48 h
c0 · (0.7584 + 0.0039 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9456 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.63)
iii = 14 : cwc(t) =

c0 · (0.6072) for t < 24 h
c0 · (0.456 + 0.0063 · (t− 24)) for 24 h ≤ t < 48 h
c0 · (0.7584 + 0.0039 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9456 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.64)
iii = 15 : cwc(t) =

c0 · (0.50261 + 0.01784 · t) for t < 5 h
c0 · (0.59181 + 0.00081 · (t− 5)) for 5 h ≤ t < 24 h
c0 · (0.6072 + 0.0063 · (t− 24)) for 24 h ≤ t < 48 h
c0 · (0.7584 + 0.0039 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9456 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.65)
iii = 16 : cwc(t) =

c0 · (0.456 + 0.0063 · t) for t < 48 h
c0 · (0.7584 + 0.0035 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9264 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.66)
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iii = 17 : cwc(t) =

c0 · (0.59822 · t) for t < 1 h
c0 · (0.456 + 0.0063 · t) for 1 h ≤ t < 48 h
c0 · (0.7584 + 0.0035 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9264 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.67)
iii = 18 : cwc(t) =

c0 · (0.21008 · t) for t < 3 h
c0 · (0.456 + 0.0063 · t) for 3 h ≤ t < 48 h
c0 · (0.7584 + 0.0035 · (t− 48)) for 48 h ≤ t < 96 h
c0 · (0.9264 + 0.001 · (t− 96)) for t ≥ 96 h
c0 for c(t) ≥ c0
(6.68)
(6.69)
The fitting functions as well as the obtained release profiles are presented in fig. 6.14.
Altogether, the results are quite good, although the peaks are still somewhat too
broad, and the release starts too early, but latter difference to the experimental
data could be originated by experimental problems, as discussed earlier (page 183).
Furthermore, the simulated release profiles are somewhat wavy because these fitting
functions consist of several partial functions. Despite this, it was decided to proceed
with the fitting function iii=18. And in the following, fitting function 18 is used,
without the implemented outlet.
6.3.3 Investigation of the Spatial Drug Concentration Distri-
bution in the Wound and in the Wound Covering
In simulation, it is possible to determine any concentration profile, in the modelled
system. In fig. 6.15 and 6.16, time-dependent concentration profiles are plotted,
determined for different heights in the diffusion cell. In the top end of the wound
covering (fig. 6.16(b)), the concentration is relatively constant over all layers, con-
sidering any time point. Viewing the time-dependent progress of the concentration
of a layer, the profile resembles the release profile somewhat, but the concentration
is higher for every time point, and the peak' is smaller than in the release profile.
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(a) Fitting functions (iii = 8  10)
(b) Release profile of above fitting functions
Figure 6.13: Further multiexponential fitting functions, and their release
profiles. (a) Fitting functions iii = 810 are presented, which consider the burst
release, found in the experiment, therefore, the fitting functions do not start in the
origin. (b) Their release profiles do not fit better than the prior fitting functions.
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(a) Fitting functions (iii = 11  18)
(b) Release profile of above fitting functions
Figure 6.14: Linear fitting functions, and their release profiles. As another
approach for fitting, combined linear equations were used, they are plotted in (a).
(b) Their release profiles fit relatively well to the experimental data, indeed, fitting
function iii=18 was chosen for further investigations. Due the the combination of
different linear equations, the fitted release profiles are somewhat wavy.
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Looking at the uppermost layer of the lower part of the diffusion cell (fig. 6.16(a)),
the concentration profile for any time is less constant than for the top end of the
wound covering, as expected, because here the influence of the diffusion is stronger
than in the wound covering. Furthermore, the concentration is much smaller
than in the top end of the wound covering, for every time point. This was expected,
because the drug is release in the wound covering and diffuses downwards to the
lower part of the diffusion cell, therefore, the concentration in the wound decreases
with the distance to the wound covering.
It is interesting to compare the concentration profiles for controlled and non-controlled
release. In fig. 6.17 and 6.18, the concentration profiles of a wound covering with a
non-controlled drug release are presented, namely, this is case iii = 1. As expected,
there are two hugh differences. Firstly, the maximal drug concentration is much
higher, actually, it is about two times higher. Secondly, the concentration decreases
to values lower than 100 µmol/L much earlier.
Regarding the therapeutic window of L-arginine, the optimal concentration range
was set to 100 - 300 µmol/L, and the therapeutic window to 100 - 2000 µmol/L,
in chapter 3. Below 100 µmol/L, L-arginine is without any significant effect, and
by comparision of the time-dependent concentration profiles for controlled and non-
controlled release, it is clearly visible that controlled release is much better, because
the concentration is above 100 µmol/L, for a longer time.
From the physiological point of view, in case of L-arginine, the concentration en-
hancement from 100 µmol/L up to 3 mmol/L does not show a significant difference,
but for a concentration of 3 mmol/L or higher, L-arginine acts toxically. Hence,
the huge concentration difference for controlled and non-controlled release is not
sweeping, unless, the drug concentration in the wound covering is set higher. And
this might be desired, indeed, it is considered in the next section (section 6.3.4).
Altogether, it can be stated that it is very important to consider the concentration
profiles, since the concentrations differ from the release profile, obtained in practice,
because the release profile is an average over the whole wound. In case of other
drugs, the therapeutic window is usually much smaller, thus, the controlled release
is even more important for such drugs, in order to reach concentrations within the
therapeutic window, for a long time period, and for as much spatial points in the
wound, as possible.
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(a) Time-dependent concentration profile, 5 mm below the
wound covering, at the bottom of the diffusion cell
(b) Time-dependent concentration profile, 2.5 mm below the
wound covering, at middle height of the lower part of the
diffusion cell
Figure 6.15: Temporal progress of the concentration profiles, 5 mm or
2.5 mm below the wound covering. For every time point, the concentration
decreases from the first vertical layer to the last one, i.e. against the flow direction
in the diffusion cell. Furthermore, the shape of the temporal concentration progress
in every horizontal cross-section of the diffusion cell, resembles the release profile,
except for the height of the concentration. (a) At the bottom of the diffusion cell,
in the last 27 % of the layers, the concentration is always smaller than 100 µmol/L,
and the maximal concentration is 423 µmol/L, found in the first layers. Whereas,
the concentration is higher, for places nearer to the wound covering. (b) Here, only
in the last 12 % of the layers, the concentration is always smaller than 100 µmol/L,
and the maximal concentration is 450 µmol/L, found in the first layers.
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(a) Time-dependent concentration profile, directly below the
wound covering
(b) Time-dependent concentration profile, on the top of the
wound covering
Figure 6.16: Temporal progress of the concentration profiles, directly below
and at the upper surface of the wound covering. For every time point, there
is just a slight concentration decrease from the first vertical layer to the last one, i.e.
against the flow direction. Furthermore, the shape of the temporal concentration
progress in every horizontal cross-section of the diffusion cell resembles somewhat
the release profile. Directly below the wound covering (a), only in the last 2 % of the
layers, the concentration is always smaller than 100 µmol/L, and it is also smaller
than this, for all layers, after 100 h. The maximal concentration is 524 µmol/L,
found in the first layers. Whereas, at the top end of the wound covering (b), the
concentration is higher than 100 µmol/L, for all layers; after 108 h, the concentration
is smaller than 100 µmol/L, for all layers. The maximal concentration is 886 µmol/L.
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(a) Time-dependent concentration profile, 5 mm below the wound cov-
ering, at the bottom of the diffusion cell
(b) Time-dependent concentration profile, 2.5 mm below the wound
covering, at middle height/at medium level of the lower part of the
diffusion cell
Figure 6.17: Temporal progress of the concentration profiles, 5 mm or
2.5 mm below the wound covering, in case of non-controlled release. The
shape of this three-dimensional plot is very similar, as for the controlled release. But
the maximal concentration is much higher: (a) 834 µmol/L, and (b) 874 µmol/L.
Additionally, the concentration reaches values smaller than 100 µmol/L much earlier,
than in case of controlled release.
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Figure 6.18: Temporal progress of the concentration profiles, directly below
the wound covering, for non-controlled release. For every time point, the
concentration is almost constant, there is just a slight decrease from the first vertical
layer to the last one, i.e. against the flow direction. The maximal concentration
can be found in the beginning of the experiment, it is 990 µmol/L, afterwards,
it decreases relatively fast. After about 48 h, the concentration is smaller than
100 µmol/L, for all layers.
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6.3.4 Investigation of the Influence of the Wound Coverings'
Drug Loading
The influence of the drug amount loaded by the wound covering was investigated.
For this, it is assumed that the release kinetics out of the silicone microparticles,
and then out of the PU foam, is independent on the amount of loaded silicone
microparticles, i.e. on the whole amount of loaded drug. In reality, in the case of
very high drug loadings, the release out of the silicone microparticles is dependent
on the drug loading, because here, sink conditions are no longer fulfilled. For such
high drug loadings, a reduction of the release has to be implemented, but this is not
part of this work.
As can be seen in figure 6.19, the higher the amount of the loaded drug, the higher
is the concentration of the drug released out of the diffusion cell. Anyway, after
normalization of the concentration, by the fictive concentration c0 of the whole
amount of loaded drug in the volume of the wound covering (cnormalized(t) =
c(t)
c0
),
it can be seen (inlet of figure 6.19) that the wound covering's drug loading has
no qualitative effect on the release profile out of diffusion cell, for the considered
range of drug loading. This results in the possibility to easily estimate the optimal
concentration.
Plotting temporal progress of the concentration profiles (data not shown), maximal
concentrations of 950 µmol/L (layer 1: bottom of the 'wound'), 1010 µmol/L (layer
50: middle of the 'wound'), 1180 µmol/L (layer 100: top of the 'wound'), and
1780 µmol/L (layer 150: middle of the wound covering) for c0 =4500 µmol/L, and
1900 µmol/L (layer 1: bottom of the 'wound'), 2030 µmol/L (layer 50: middle of
the 'wound'), 2360 µmol/L (layer 100: top of the 'wound'), and 3560 µmol/L (layer
150: middle of the wound covering), for c0 =9000 µmol/L can be found. That
means that the highest concentration found in the lower part of the diffusion cell,
i.e. in the wound, is about 15 % higher than the highest value of the concentration
profile. This deviation might be even higher for different parameter like a higher
flow rate or a deeper wound. Therefore, the importance of this kind of plot have to
be emphasized, since for the drug loading of c0 =9000 µmol/L, the upper limit of
the therapeutic window is almost reached, which is not obvious in the plot of the
release profile (fig. 6.19).
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Figure 6.19: Influence of drug loading of the wound covering. In general, it
can be found that the higher the drug loading, the higher is the concentrations. (In-
let) After normalization of the concentration by dividing by the whole drug amount
(as described in the text), this results in identical release profiles for all considered
loadings, c0.
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6.3.5 Investigation of the Influence of the Diffusion Coeffi-
cient and of the Temperature
In wounds, the temperature is usually enhanced referred to usual body core tem-
perature of 37 oC, but wounds show a very indifferent behaviour, thus, there is a
wide temperature range, covered in different wounds. Therefore, the influence of the
temperature, in terms of changed diffusion coefficient, was investigated. However,
two aspects were neglected: Firstly, there is a temperature gradient between the
wound and the upper surface of the wound covering; secondly, the temperature also
influences the release kinetics in the wound covering (or more precisely, the release
out of the silicone microparticles).
The variation of the diffusion coefficient can also be originated by simply considering
another drug. In this case, the release in the wound covering (out of the particles)
is probably changed significantly.
In this chapter, the single influence of the drug's diffusion coefficient in the release
medium should be investigated, thus, a change in the release from the silicone par-
ticles in the wound covering, is neglected. Here, the diffusion coefficient is changed
within the limits of typical diffusion coefficients of drugs; in fact, small molecules
have a little smaller diffusion coefficient than water (D(H2O) = 2.3 ·10−9m2/s), it is
about D = 10−10m2/s, and polymeric drugs have much smaller diffusion coefficients.
Hence, values in the range of 2.77 · 10−9 m2/s to 2.77 · 10−11 m2/s were chosen for
the diffusion coefficients.
The results are shown in figure 6.20; it can be seen, that the higher the diffusion
coefficient, (i) the faster the maximal concentration is reached, (ii) the broader and
higher is the top end of the peak, and (iii) the stronger is the decay of concentration
after its maximum, resulting in smaller concentrations after about one or two days,
compared to smaller diffusion coefficients. Therefore, especially slow moving drugs
are very appropiate for receiving a relatively constant concentration in the wound,
over a long time period.
As mentioned above, the diffusion coefficient is dependent on the temperature, it
changes according to
D(T ) = D(298.15 K) · T
298.15 K
(6.70)
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this is based on Einstein-Stokes equation
D =
kBT
6pi η r
(6.71)
with the diffusion constant D, the Boltzmann's constant kB, the absolute tempera-
ture T , viscosity η, and the radius r of a spherical particle. Indeed, this equation was
Table 6.2: Diffusion coefficients of Arg in dependence of the temperature.
Diffusion coefficients are given in two different units: cm2/s is commonly used, and
mm2/h is used in FEM implementation. Diffusion coefficients are calculated from
D(25 oC), using equation 6.70.
Temperature Diffusion coefficient
oC K 10−6 cm2/s mm2/h
20 293,15 6,00 2,159
25 298,15 6,10 2,196
30 303,15 6,20 2,233
37 310,15 6,35 2,284
40 313,15 6,41 2,306
45 318,15 6,51 2,343
50 323,15 6,61 2,380
developed fot the diffusion of spherical particles through a liquid with low Reynolds
number, but it still can be used, as written in equation 6.70, to estimate the diffu-
sion coefficient for another temperature, from a given diffusion coefficient.
The diffusion coefficients of Arg for different temperatures, are listed in table 6.2.
And in figure 6.21, the temperature dependence of the release, using a diffusion cell,
is shown for Arg as drug. It was found that there is almost no influence of the tem-
perature on the release profile, which is very positive for the application as wound
covering.
6.3.6 Investigation of the Flow Rate
The lymph flow in wounds is dependent on the wound, the wound state, the pa-
tient, the kind of wound etc., thus, the influence of the flow rate was investigated.
Therefore, the rate of the lymph flow was varied strongly; the results for the typi-
cal flowrate of 1100 mm3/h (also used in the experiment), and for the flowrates of
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Figure 6.20: Influence of drug's diffusion coefficient. The higher the diffusion
coefficient, (1) the earlier the maximum is reached, (2) the broader is the top part of
the `peak' and (3) the stronger decays the concentration after reaching the maximum.
Figure 6.21: Influence of temperature. There is almost no influence of the
temperature, in the given temperature range. The inlet shows a magnification of
the peak's top, here, it can be seen that the influence of the temperature is negligible.
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(a) simulated data
(b) normalized data
Figure 6.22: Influence of the flowrate of the release medium. (a) The smaller
the flow rate, the broader is the release peak, furthermore, the maximal concentra-
tion gets much higher, and the maximal concentration is reached, later. (b) After
normalization of the time, regarding the flow rate, the maximal concentration is
reached, after the same normalized time (as further discussed, in the text).
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275 mm3/h, 550 mm3/h, 2200 mm3/h, and 4400 mm3/h, are shown in figure 6.22(a).
It was found that the smaller the flowrate, the longer the concentration has high
values (i.e. the broader the peak), and the higher is the maximal value. The decay
of the concentration after the maximum is almost equal in all three cases.
After normalization of the time by the flowrate, f : cnormalized(t) = c(t/f) (fig. 6.22(a)),
the maximal concentration is reached after almost the same normalized time. Since
here, the integral has to have the same value (because the initial drug loading in
the wound covering is equal), and the maximal concentration is smaller for higher
flowrates, the decay of concentration, after the maximum, is less for higher flowrates
than for smaller flowrates. This tendency is clearly visible, in the case of non-
controlled release (data not shown), whereas, in figure 6.22(b), a much longer time
period have to be considered. Anyway, it is a debatable point whether this plot
makes sense, because both, the effect of convection and of release, is normalized,
but release out of the wound covering need not to be normalized. However, for a
known flow rate, it is possible to calculate the time point of the maximal concentra-
tion, in that way.
As consequence of these results, it can be stated that the wound covering has to
be changed more frequently, in case of wounds with a high lymph flow rate. Fur-
thermore, for small lymph flow rates, the maximal concentration has to be kept in
mind, because it is much higher than for the standard lymph flow, and might be
above the therapeutic window.
6.3.7 Investigation of the Influence of the Diffusion Cell's
Height
The height of the diffusion cell was changed, because the wound covering may be
used for wounds having different depths. For that, two different cases were consid-
ered (figure 6.23): (a) Only the height of the diffusion cell, i.e. the depth of the
wound was changed (therefore, also the number of finite elements Nv in z direc-
tion has to be changed, in order to have the same volume for finite elements in the
wound covering as in the diffusion cell). (b) In the other case, in addition to the
latter change, the drug loading of the wound covering was adapted to the depth of
the wound, by means of keeping constant the quoting of the amount of the drug
substance divided by the volume of the lower part of the diffusion cell.
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(a) constant drug loading per volume unit
(b) drug loading adapted to the thickness of the diffusion cell
Figure 6.23: Influence of the height of the diffusion cell, simulating the
depth of the wound. The influence of the depth of the wound was investigated
for two different cases: (a) A defined wound covering is used for wounds having
different depths (indicated by the different heights of the diffusion cell). Here, the
concentration peak is broader and maximal concentration is smaller for enhanced
height of the diffusion cell. (b) Furthermore, the drug loading of the wound cov-
ering was adapted to the depth of the wound (as explained in the text). In this
case, concentration progress is equal in the beginning, but maximal concentration
is reached first for the less deepest wound, here, the maximal concentration is lower
than in the other cases considered. The concentration decrease after maximal con-
centration is similar in all three cases, but the deeper the wound, the broader is
the concentration peak, because maximal concentration is reached later, and the
maximal concentration is higher. Comparing both figures, it can be seen that the
time point of the maximal concentration depends on the thickness of the diffusion
cell, i.e. on the depth of the wound.
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As shown in figure 6.23(a), it was found for the former case (a), that the deeper
the wound, the lower is the maximal concentration, and the later is the maximal
concentration reached, furthermore, the concentration decrease, after the maximal
concentration, is less for deeper wounds.
For the latter case (b), i.e. a drug loading adapted to the depth, the results can
be seen in fig. 6.23(b); it was found that the concentrations are equal, in the very
beginning, but the deeper the wound, the later the concentration starts to decrease,
thus here, the maximal concentration is much higher, and the concentration peak is
much broader, as can be seen in figure 6.23(b).
Consequently, it can be stated that in the development of wound coverings, both,
flat and deep wounds, should be considered: Former is important with respect to
the upper limit of the therapeutic window, because here, the maximal concentra-
tion reached is much higher than for deeper wounds. Latter should be considered
regarding the lower limit of the therapeutic window, otherwise, the drug may be
concentrated too less for any physiological effects.
6.3.8 Investigation of the Influence of the Thickness of the
Wound Covering
The thickness of the wound covering was changed, the results are shown in fig-
ure 6.24. For the same drug loading per volume unit (figure 6.24(a)), it was found
that the concentration peak is much broader in case of a higher thickness; further-
more, the maximal concentration is higher because of the higher total drug loading.
Additionally, the influence of the wound covering's thickness, but with an equal to-
tal drug loading, was investigated, as shown in figure 6.24(b). Here, the maximal
concentration is reached at almost the same time, but the maximal concentration is
much higher for thinner wound coverings, furthermore, the concentration decrease,
after the maximal concentration, is much stronger for a thinner wound covering.
Thus, thicker wound coverings are preferable, because here are relatively high con-
centrations, over a longer time period. In order to find the optimal thickness, also
the detailed kind of application to the patient has to be taken into account.
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(a) constant drug loading per volume unit
(b) constant total drug loading
Figure 6.24: Influence of the height of the wound covering. The influence
of the height was investigated for two different cases: (a) Wound covering's drug
loading per volume unit is kept constant. Here, the concentration peak is higher
and much broader with increasing thickness. (b) Considering wound coverings with
the same total drug loading, maximal concentration is smaller and the peak is much
broader by increasing thickness.
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6.3.9 Investigation of the Influence of a Diffusion Barrier at
the Interface between the Wound Covering and the Re-
lease Volume
The influence of a diffusion barrier between the wound covering and the lower part of
the diffusion cell was investigated. For this, it was implemented that the diffusion
Figure 6.25: Chart of the diffusion barrier between wound covering and
release medium. A diffusion barrier was implementated, here, diffusion in z di-
rection is reduced by a divisor (B) for diffusion between two finite elements where
one belongs to the wound covering and the other not.
in z direction, is reduced between the wound covering and the release volume, as
demonstrated in figure 6.25; in detail, the calculated diffusion, according to Fick's
law, is divided by a divisor (b), but only between two elements where one belongs
to the wound covering, and the other not.
The introduction of such a diffusion barrier results in a reduced maximal concen-
tration, but the time point of the maximum is not influenced (see figure 6.26).
Furthermore, the concentration decay after the maximum is the slower, the higher
the barrier.
It was found that an introduction of an release barrier can flatten the concentration
profile, without changing the time, where the maximal concentration is reached.
Therefore, using a diffusion barrier can improve the release behaviour of a wound
covering.
In figure 6.27, it can be seen that the usage of a release barrier, delays and therefore
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Figure 6.26: Influence of a diffusion barrier between wound covering and
release medium. The time when the maximum is reached, is independent on a
barrier, whereas the height of the maximum is higher for smaller barriers and the
decay of the concentration afterwards is less.
Figure 6.27: Influence of a diffusion barrier between wound covering and
release medium, for non-controlled release; and comparision with con-
trolled release without any release barrier. The barrier effect, for a non-
controlled releasing wound covering, is analogues to the case of controlled release.
Furthermore, it can be seen that the controlled release without an additional barrier
is still much better than a non-controlled releasing wound covering with a strong
barrier. Consequently, a barrier does not replace a controlled release system, ade-
quately, especially under consideration of possible side effects of strong barriers like
reduced oxygen supply.
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improves the release profile, also in case of non-controlled release. But comparing
a controlled releasing wound covering without an additional release barrier with a
non-controlled releasing system with a strong barrier (reducing the diffusion by a
factor of 50), it can be stated that a barrier cannot replace a controlled drug deliv-
ery system. In particular, other effects of strong barriers have to be considered, like
reduction of the water diffusion from the wound to the wound covering, or maybe
reduction of the oxygen supply.
6.4 Conclusions
The finite element method is a great method to simulate the release out of a wound
covering, under wound conditions, basing only on the data of a common release
experiment. It could be shown that the experimental data could be fitted very well.
Moreover, it was possible to investigate the influence of plenty parameter.
In detail, it was found out that there is no influence of the initial amount of the
drug, loaded in the wound covering, on the normalized concentration, at least in a
concentration region, where sink conditions are fulfilled. Certainly, a higher drug
loading causes higher concentrations, but the progress of the curve is independent
on the initial amount of drug. For the optimisation of a wound covering follows the
possibility to adapt the amount of drug loading of the wound covering to the optimal
conditions, in a simple way. In fact, a concentration profile obtained in an initial
trial, can be multiplied by a factor by which this concentration profile is within the
therapeutic window of the considered drug, at least within certain concentration
regions. Moreover, it was found that the influence of the temperature is negligible,
therefore, this factor does not have to be considered much during development, al-
though, there are great temperature differences in different wounds.
In addition, it is preferably to use drugs with small diffusion coefficients, because
here, the concentration profile is flatter. Thus, if there are different kinds of the
drug (maybe a monomer and an oligomer) acting in the same way, the one with the
smaller diffusion coefficient should be preferred.
In wounds, the flow rate of the wound fluid is different, it was found that there is
a significant influence by the flowrate, which has to be considered. It results in the
necessity of more frequently changes of the wound covering, in case of high lymph
flow rates. Moreover, one can state that in the development of wound coverings,
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both, flat and deep wounds, should be considered: Former is important with respect
to the upper limit of the therapeutic window, because here, the maximal concentra-
tion reached is much higher than for deeper wounds. Latter should be considered
regarding the lower limit of the therapeutic window, otherwise, the drug may be
concentrated too low for any physiological effect.
Furthermore, the thickness of the wound covering influences the concentration pro-
file, indeed, a thick wound covering should be preferred because of the resulting
flattening of the concentration profile. But in order to find the optimal thickness,
also the application to the patient has to be taken into account.
Finally, it was found that an introduction of an release barrier can flatten the con-
centration profile without changing the time point, where the maximal concentration
is reached. Therefore, using a diffusion barrier can improve the release behaviour
of a wound covering. Although, a release barrier does not compensate a controlled
drug delivery system, in the wound covering.
6.5 Outlook
The results with changed parameters should be checked experimentally to further
confirm this model. After doing so, the FEM simulation developed in this chapter,
can be used during optimizing of wound covering development.
Here, it was assumed that the wound covering is used in a kind that there is no
water evaporation from wound covering. If this is true, depends on the application
of the wound covering to the patient. For a different application, this FEM model
should be adapted.
Further point would be the consideration of the wound fluid instead of buffer solution
or water, because body fluids, blood, and the like do not behave like water, which
is a Newtonian fluid. This study could be based on the results of an investigation
of the diffusion behaviour of L-arginine in non-Newtonian fluids[46, 47].
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Chapter 7
Polymersomes Consisting of a
Polyglycidol Based Amphiphilic
Block Copolymer as Drug Delivery
System for L-Arginine
Abstract
Polymersomes are promising systems in the area of drug delivery. For controlled
release, especially multilayered polymersomes are interesting because of their mul-
tiple release barriers. Here, it can be assumed that the release is more prolonged
than for single wall polymersomes. Such release systems with sustained release of a
specific drug could be benefitial in wound healing by applying them to the wound
prior to bandaging. This is advantageous, since the drug amount can be adapted to
the wound as required.
In this chapter, multilayered polymersomes consisting of a polyglycidol based am-
phiphilic block copolymer are investigated regarding their suitability as controlled
drug delivery system. They were prepared by self-assembling in water or hydrophilic
drug solutions, using the film hydration method. Where it has to be considered that
self-assembling processes are usually sensitive to relatively small changes of param-
eters like the ionic strenght of the medium. Indeed, it was found that (1) with
increasing temperature, an inverse order of the formed structures in comparision
to unloaded polymersomes was observed, when L-arginine hydrochloride (Arg-HCl)
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was added, i.e. with increasing temperature multilayered vesicles arise, with further
enhancement they are rebuilt to monolayered vesicles, and (2) the morphology was
changed by addition of fluorescent dyes. Additionally, the formation temperature,
and the fraction of multilayered vesicles compared to other morphologies obtained,
depends on the added substances.
In drug release experiments, a release of an L-arginine derivative over few hours was
found. However, this was not always reproducible. Thus, there is still a need to
improve the system and make it a robust approach, in order to develop controlled
drug delivery systems. Nevertheless, these vesicles might be appropiate for other
drugs, like hydrophobic or more voluminous drugs. For releasing Arg, small varia-
tions of the polymer structure might result in an appropiate drug delivery system,
if the hydrophobic layer thickness is increased or if a strong interaction between the
polymer and Arg can be achieved.
7.1 Introduction
As already described in chapter 2.6, polymersomes are vesicles made from block
copolymers. The term 'polymersomes' was coined in 1999[1]. Vesicles itself are three-
dimensional structures built up by amphiphilic molecules, which form a hydrophilic-
hydrophobic-hydrophilic bilayer surrounding a void.
Considered as a whole, vesicles are often shown in a spherical shape as in fig. 7.1(a).
But there are also other low energy shapes depending on the considered system,
for example, ellipsoidal vesicles[2], donut-like micells, which were first described in
1997[3], and many more morphologies. In fact, one way to control the morphology is
by changing the solvent composition[3]: It was found that the morphology changes
with increasing water content from spheres to a mixture of spheres and rods, further
to rods, and further to rods or open bilayer structures, or the latter, mixed with
vesicles, were found, depending on the polymer. And for some copolymers, for an
even higher water content, a mixture of open bilayer structures, vesicles and inverted
structures were reported[4].
Additionally, there are a few reports about onion-like or multilayered polymersomes
(illustrated in fig. 7.1(b)). Most of them were self-assembled in organic solvent
mixtures[57] or in a mixture of water and an organic solvent[811], whereas, self-
assembling in pure water was only published a few times[1215]. The preparation
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(a) Unilamellar vesicle (b) Multilayered vesicle
Figure 7.1: Sketch of an unilamellar, and of a multilamellar vesicle. (a) Vesi-
cles are usually spherical, where the `shell' consists of bilayer forming amphiphiles.
The inner hydrophobic layer is illustrated darker than the hydrophilic layers. The
void is filled with water, and optionally with hydrophilic drug molecules (illustrated
by the small balls). (b) Multilayered vesicles consist of multiple layers, either with
or without interlamellar space. In both cases, it can be expected that hydrophilic
drugs accumulates in the vesicle void, for strong interactions between the drug and
the vesicle forming molecules, the drug molecules accumulate next to the vesicle
wall. Whereas, amphiphilic drugs enter the bilayer, and hydrophobic drugs can be
found within the hydrophobic part of the vesicle wall.
in water is advantageous for medical applications, as intended in this work. Al-
ternatively, onion-like vesicles can be prepared by shear-induced formation[16, 17].
Due to the importance of this topic, preparation of multilayered vesicles has already
been reviewed[18], despite of the sparseness of publication to this topic regarding
polymeric multilayered vesicles, especially related to drug delivery.
The application of polymersomes, and vesicles in general, is versatile. For example,
polymersomes are promising for biomedical applications as 'artificial cells' or as 'cell
membrane mimics'. Furthermore, it is possible to create nanocapsules from spon-
taneously formed vesicles[19, 20]. Moreover, polymersomes can be used as nanore-
actors, which may contain active enzymes, and thus, the enzymes are protected.
Substrates can be provided to the enzymes by proteins incorporated in the polymer-
some membrane[21, 22].
Also, polymersomes can be used as controlled drug delivery systems[23]. In this
context, multilayered (also named onion-like) polymersomes can be assumed to be
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suitable, in particular: Here, the drug is distributed in several shells, surrounded
by multiple bilayers representing release barriers, therefore it can be assumed that
the release rate is prolonged compared to unilamellar vesicles, having one release
barrier. In this work, the aim was to develop such onion-like polymersomes, and to
investigate their suitability as controlled drug release system for a hydrophilic drug,
namely L-arginine (Arg).
In 2008, eleven therapeutic and diagnostic agents in liposomal dosage form were
approved[24], and the number has been increased until today[25]. Although, unil-
amellar as well as multilayered liposomes are well-known[25, 26], polymersomes are
hardly investigated, especially in the context of drug delivery.
The major problem of using uni- or multilamellar liposomes as drug delivery sys-
tems is their instability under physiological conditions. In 1981, the first approach
to solve this problem was to use polymers with a hydrophilic polyacrylamide back-
bone and dialkyl hydrophobic pendant groups separated from the polymer backbone
by hydrophilic oligo oxyethylene spacers[27]. In fact, this is a comb-like polymer.
Moreover, some other strategies are pursued to stabilise liposomes, they are sum-
marized elsewhere[28].
In general, polymersomes exhibit an increased stability and reduced permeability
compared to liposomes. Since polymers usually have a low entropy of mixing, the
disassembly of the bilayer, and thus of the whole vesicle, is hindered. This causes an
enhanced stability, and a higher selectivity for dissolution of hydrophobic molecules
because of the thicker bilayer, which plays an important role for polymersomes used
as drug delivery systems. Important differences of liposomes and polymersomes re-
garding their use as drug delivery systems are given in table 7.1.
Usually, block copolymers self-assemble to unilamellar instead of multilamellar
vesicles[27, 29]. Nevertheless, in a self-consistent field theory study, self-assembly
of a linear diblock copolymer in a poor solvent to onion-like vesicles was found[30].
Furthermore, in density functional theory calculations, it was found that comb-like
polymers can build multilayered polymersomes[31]; the morphology depends on the
chain length of the backbone as well as of the sidechains, the grafting intensity,
the number of the grafted points, and on the interaction strength between the hy-
drophobic part and the solvent. In fact, the multilayered structure was found for a
backbone consisting of 24 units with seven grafted sidechains with the length of ten
units; the interaction strength of the sidechains and the solvent was relatively poor
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Table 7.1: Important differences of liposomes and polymersomes regarding their use
as drug delivery systems.
liposomes polymersomes
• well-known systems • rarely investigated
• relatively instable • relatively stable
→ need of stabilization, e.g. by
PEGylation ('stealth vesicles')
• bilayer thickness of 3-5 nm • bilayer thickness of 5-20 nm
→ more efficient entrapment of
hydrophobic drugs
→ reduced membrane permeability,
followed by enhanced release duration
with χ = 1.8.
Therefore, in this chapter, the approach of comb-like polymers was traced in order
to build multilayered vesicles. In detail, the polymer structure is more remark-
able, it consists of a hydrophilic block and a relatively short comb-like block. Both
blocks of this block copolymer, named MHB326, are based on polyglycidol. In detail,
MHB326 consists of a hydrophilic polyglycidol block and of a comb-like polyglycidol-
based block with hydrophobic pendants. Thus, two aspects are involved, a comb-like
structure and a block copolymer. For such polymers, two assembling structures are
conceivable. Firstly, the comb-like block acts as hydrophobic part and the molecules
arrange themselves as other block copolymers. Secondly, the hydrophobic parts of
the comb-like blocks stick together and build the bilayer, the hydrophilic polyglyci-
dol block potrude from the vesicle bilayer. Latter arrangement might prefer to form
the desired multilayer polymersomes instead of unilamellar vesicles. And in fact, for
this polymer are self-assembling to multilayered vesicles was found.
For vesicles, there are two characteristic release types, namely triggered release and
diffusional release. In case of triggered release, the drug is released only under cer-
tain conditions; in fact, the drug is set free completely at once, due to an induced
sudden structural rearrangement. This can be achieved by either changes in the
local environment or by external stimuli[32]. Examples for a local influence are
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changes of the pH value[3338], or of the salt concentration[39]. Furthermore, there
are oxidation responsive vesicles[32, 4042], which can be used for targeted release
either intra- or extracellularly. Examples for an external stimulation are heat[4345]
or light[32, 46]. For example, the latter can be based on cis-trans isomerisation of
azobenzene-based block copolymers. Thermoresponsive vesicles are usually formed
by amphiphilic block copolymers with a hydrophilic poly(N-isopropylacrylamide)
block, because this polymer has a phase transition temperature close to body tem-
perature. In fact, such vesicles collapse and disassemble reversibly above the lower
critical solution temperature (LCST) (e.g. 32 oC[45]); they are often cross-linked to
avoid disassembling. More detailed information about these triggered release sys-
tems can be found in chapter 2.6.4 (page 41).
It can be imagined that polymersomes following the triggered release mechanism
are usually used for drug targeting, and thus, it is mostly desired that the whole
drug content is released at once, after arriving at their destination. This is the rea-
son why usually unilamellar polymersomes are prefered, in this case. In contrast,
multilayered polymersomes are attractive to achieve a slow release rate (based on
diffusion) because every bilayer represents a release barrier for the drug molecules,
distributed over all shells, as already mentioned above. However, to the knowledge
of the author, no study of drug release from polymeric multilayered vesicles has been
published, yet.
In fact, diffusional release is based on drug permeation through the bilayer, and this
mechanism follows Fick's law. Here, the release rate is dependent on the bilayer
thickness, and the permeation coefficient. This results in the possibility to influence
the release rate by modification of the vesicle size or of the membrane thickness,
where both are controlled by the block length of the polymer and the vesicle prepa-
ration method. Due to their thickness, permeation through a polymeric bilayer takes
longer than through a lipid bilayer. In fact, polymeric bilayers are about 5 - 20 nm
thick, whereas, lipid bilayers have a thickness of just 3 - 5 nm.
There are some model systems to investigate the suitability of vesicles as drug de-
livery system. On the one side, release systems for hydrophobic drugs like Rho-
damine B[19], and fluorescent zinc compounds[47] were tested, and on the other
side, both, hydrophobic Nile Red, and either hydrophilic calcein[48] or hydrophilic
fluoresceinamin[49], were embedded. All these systems are declared to be unilamellar
vesicles. Furthermore, for some vesicles with diffusional release, also an additional
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release mechanism was found. Here, the bilayer forming amphiphiles move according
to a so-called flip-flop mechanism; during this, also drug molecules are entrained[50].
In this work, a diffusional release is desired.
7.2 Experimental
7.2.1 Materials
The polymer MHB326 was was kindly provided by Marco Backes, who synthesised
and characterized the polymer[51]. A silicone kit, named Sylgard R© 184, and the
catalysator 'Syl-Off R© 4000' were purchased from Dow Corning, All other chemicals
were purchased from Sigma.
7.2.2 Instruments
The vesicles were visually investigated by a fluorescence microscope (Zeiss, Axio-
plan 2 imaging, Germany) in the reflective mode, in order to be able to use a
self-built temperature control. For vesicles prepared in the rotary evaporator (see
section 7.2.5), the vesicles were centrifuged by Biofuge Primo R (8500 rpm, 45 min,
15 oC).
Drug release experiments were carried out in an incubator 'Heidolph Inkubator 1000'
combined with 'Heidolph Unimax 1010'. Quantitative Arg analyses for the release
experiments were performed with high performance liquid chromatography (HPLC);
where HPLC 'Agilent 1100 Series' is equipped with an autosampler, and a fluores-
cence detector 'Agilent 1200 Series'; furthermore, an Eclipse Plus C18 column was
used.
In the case of experiments with radioactively labelled Arg derivative, the following
equipment was used: an Eppendorf Centrifuge 5415C (14000 U/min), a Heraeus
Labofuge 400 H (3500 U/min), and a Berthold Multi Crystal LB 2111 Gamma
Counter, equipped with a monitor Berthold LB 123 UMo.
7.2.3 HPLC
Quantitative analyses were performed using the HPLC method described in ap-
pendix A on page 275.
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7.2.4 Experimental Setup of the Microscopic Study of Poly-
mersome Self-Assembling
A silicon wafer was cut into pieces 1 cm2 big and cleaned in an ultrasonic bath
with acetone and isopropanol, each for 3 min. Thereafter, they were dried with
compressed air which is filtered through a 200 nm pore filter. Finally, organic
contaminations were removed by ozone treatment.
The first step of the microscopic study was the preparation of a polymer film on a
small part of a cleaned silicon wafer. This was done by depositing a drop of polymer
solution onto the silicone wafer. The polymer solution directly spread over the whole
surface of the silicon wafer. The silicone wafer was heated up, moderately, in order
to remove the solvent (CHCl3).
For the microscopic investigation, the challenge of the experimental assembly was
to seal the system, but to keep some free volume above the silicon wafer where the
polymer film was placed. This was needed so as to be able to hydrate the polymer
film, i.e. for letting the polymer self-assemble to form vesicles. For this, a silicone
film was prepared from a mixture of 4.3 g component A, 0.43 g component B of
Sylgard R© 184, and 0.15 g catalyst. This mixture was spread by a squeegee blade, on
a glass slab, and was vulcanised at 50 oC, for about 1 h. The thickness of this silicone
film was adjusted in a way that it was about 400 µm thicker than the silicone wafer.
Finally, the silicone film was cut to fit on a microscope slide. In order to incorporate
the silicon wafer in the silicone film, a hole about the size of the cover slip was cut
in the film. The silicon film set up was intended to be used several times, i.e. for
several pieces of the silicon wafer, therefore it was somewhat larger than the silicon
wafer. Such pieces have slightly different shapes and sizes. No problems arose due
to this extra free space. Finally, the silicone film was put onto the microscope slide;
due to the adhesive forces of the silicone, the film was fixed on the microscope slide.
The silicon wafer with the polymer film was arranged in the notch of the silicone film
on the microscope slide, as shown in fig. 7.2. Then, a small drop of water or of an
aqueous Arg derivative solution (namely, a few µL) was dropped onto the polymer
film. This assembly was covered by a cover slip, whose edges rested on the silicone
film so that the water drop, which was given onto the polymer film, spread over
the whole silicon wafer, without spreading aside the silicon wafer. Furthermore, the
water surface was flattened, due to the contact to the cover slip, which is important
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Figure 7.2: Experimental assembly of the microscope slide. A silicone film
is fixed onto a microscope slide, by its adhesive forces. In the middle, this film
has a notch, where the silicon wafer, coated with a thin polymeric film, is put in.
In order to investigate the polymersome self-assembling of the polymeric film, a
drop of water, or of an aqueous Arg derivative solution is put onto the polymer
film. After that, the notch with the silicon wafer is covered by a cover slip. Here,
it is noteworthy that the silicone film is somewhat thicker than the silicon wafer,
therefore, the water is spread over the whole silicon wafer, without overflowing. In
fact, on top of the polymeric film, there is a water layer of about 400 µm. This
enables the observation of the vesicle formation process, under the microscope.
for a clear view.
The microscope was used in reflection mode, thus, a temperature control could be
put beneath the microscope slide. The temperature was increased slowly, in order
to investigate the vesicle formation progress in dependence of the temperature.
7.2.5 Polymersome Preparation
The polymersomes were prepared by the film hydration method, using a rotary evap-
orator. In detail, a thin polymer film was prepared in a round-bottomed flask from a
polymer solution in chloroform, during solvent evaporation by decreased pressure in
the evaporator. When no solvent was visible anymore, the pressure was decreased as
much as possible, in order to obtain a solvent-free polymer film. The round-bottom
flask was covered with a filter and left overnight. In doing so, it could be ensured
that no solvent remained.
The vesicles were prepared by hydration of the polymer film for 5 hours at 45 oC,
under moderate rotation, but without decreasing the pressure, in the rotary evapo-
rator. Here, an aqueous L-arginine hydrochloride (Arg-HCl) solution was used, with
the aim to incorporate the drug Arg-HCl into the vesicles. Optionally, also dyes were
added to the Arg-HCl solution, furthermore, instead of Arg-HCl also ArgOEt was
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used. Non-embedded Arg-HCl had to be removed, after vesicle preparation. This
was done by different techniques, in order to find the most suitable one. In detail,
usage of a syringe filter, centrifugation as well as dialysis were tested. These meth-
ods are described and discussed in the following section.
Instead of aequeous Arg-HCl solution, also L-arginine ethylester (ArgOEt) solution
was used. Additionally, fluorescent dyes were added, when indicated.
In the case of investigating polymersomes using fluorescent dyes, the polymersomes
were prepared as previously described in this section, but dyes were added together
with the Arg-HCl solution. After vesicle formation, the residual solvent was removed
by centrifugation. The relatively solid filter cake was used for the investigation un-
der the fluorescence microscope. In fact, a small amount of the filter cake was put on
a silicon wafer, then, a small drop of water was added. The experimental assembly
of the microscope slide was the same as in section 7.2.4.
7.2.6 Drug Release Experiments
Drug release experiments were performed in an incubator at 37 oC, using a syringe
as release container, equipped with a syringe filter. At certain time points, samples
were taken to be measured quantitatively by HPLC. Two different methods were
chosen for sample taking, where in both cases, only a small volume of the release
medium (PBS), high enough for HPLC analysis, was pressed carefully through the
filter (the intension was, not to destroy the vesicles). Either, there was one syringe
for every sample taking, i.e. one single release curve was based on several syringes,
where the content of every syringe provided only one measured point. Or one release
container is used for a series of measured points, that means for one release curve.
7.2.7 Release Experiments Using a Radioactively Labelled
Drug
The first step of the radioactive experiment is the radioiodisation of the drug with
chloramin T. Here, instead of Arg-HCl, the RGD-peptide YRGDS was used. The
next two steps, the vesicle preparation and the drug release experiment, were per-
formed, as already described in sections 7.2.5 and 7.2.6. For the vesicle preparation
three different drug concentrations were used, namely 10 mg/mL, 20 mg/mL, and
50 mg/mL. Afterwards, the samples were analyzed using a gamma counter, where
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both, centrate and cake were measured.
7.3 Results and Discussion
The self-assembling process of vesicles is very sensitive to changes in the surrounding
medium. Therefore, the polymersome formation in pure water, and under addition
of Arg-HCl or ArgOEt was studied microscopically. Thereafter, vesicles containing
Arg-HCl or ArgOEt were prepared in a rotary evaporator; under the microscope,
it was verified that polymersome could be prepared by this method. Moreover, the
release behaviour of Arg derivatives out of polymersomes was investigated. In some
cases, fluorescent dyes were added, during preparation process of vesicles with Arg-
HCl inclusions. Although, every existing fluorescent dye is less hydrophilic than Arg
and therefore cannot simulate the release behaviour of Arg exactly, the aim was to
receive information regarding the drug release properties.
7.3.1 Microscopical Investigation of the Polymersome For-
mation
A film was prepared from a polyglycidol based amphiphilic block polymer, whose
structure is shown in fig. 7.3. When hydrated, such films show the formation of small
Figure 7.3: Structure of the polyglycidol-based amphiphilic block copoly-
mer, named MHB326. This polymer was used for the vesicle formation. Further
characterization can be found in literature[51].
monolayered polymersomes, with increasing temperature, multilayered vesicles were
observed, as has been described in previous work, done in our group[52].
In this thesis, an aqueous solution of Arg-HCl or of L-arginine-ethylether (ArgOEt)
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Figure 7.4: Microscopical image of an onion-like vesicle consisting of the
polymer MHB326, in the presence of Arg-HCl. At a temperature of about
43 oC, mainly multilayered vesicles arise. After further temperature increase by one
or two degrees, the morphology changes somewhat, i. e. the vesicles get worm-like
extensions or they move along worm-like polymeric vesicles. This is either caused
by the temperature increase, or more probably, by heat induced shear forces.
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was used instead of pure water, in order to load the polymersomes with Arg. Here,
the formation order is inverse, i.e. with increasing temperature large, partly mul-
tilayered vesicles arise (from the polymer film), at about 43 oC (see fig. 7.4). By
increasing the temperature by a few degrees, worm like structures can additionally
be found. Due to heat induced shearing forces, long filamentary extensions were
observed. These three morphologies are shown in fig. 7.5. At a temperature of
about 50 oC, small monolayered vesicles are formed. The reason for this inverse
formation is probably the enhanced ionic strength of the medium surrounding the
vesicles, such an effect has already been described in literature[53].
It was expected that Arg-HCl addition has an influence on the morphology, although,
is was not expected that the order of developed morphologies with increasing temper-
ature is inverse, as was found in this thesis. The reason for the significant influence
is probably also the enhanced ionic strength.
For the usage of L-arginine ethylester instead of Arg-HCl, at about 38 oC, mainly
wormlike vesicles arise, as can be seen in fig. 7.6. Furthermore, there are also a
few multilayered vesicles. After increasing the temperature to 45 oC, there is lit-
tle change in the morphology, but additionally polymeric filaments with spherical
unilamellar vesicles are observed. It was not expected that such a small variation
in the drug structure has an influence on the morphology. Thus the Arg counterion
influences the self-assembled structures.
In all cases, it is noticeable that the vesicles are only formed at places, where the
polymer film is not perfect. When contact to dust was avoided, such inhomogeneities
are still observable; therefore, these inhomogenities triggering the vesicle formation,
are probably simply polymer film inhomogenities. Up to now, there is no explana-
tion of this effect, even so it is already known for several years[54].
Regarding the desired application, it is interesting to investigate the behaviour of
the vesicles in cooling-heating cycles, because the temperature of the vesicle solu-
tion would be beneath body temperature, prior to medical application. On exposing
the vesicles to such temperature cycles, it was observed that they collapse, below
a certain temperature. This temperature is dependent on the composition of the
aqueous solution, but it is above room temperature, in all considered solutions. In
some cases, it was possible to observe a certain vesicle, during its collapsing and
reformation, during one, two or three cooling-reheating cycles. For other times, it
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(a) 43 oC: Multilayered vesicles and few worm-
like vesicles
(b) 45 oC: Multilayered vesicles, worm-like
vesicles, and filamentary extensions
Figure 7.5: Formation of vesicles. Under the microscope, the formation of vesicles
from MHB326 polymer was investigated. The vesicles are formed at the periphery of
polymeric inhomogeneities. At a temperature of about 43 oC, mainly multilayered
vesicles arise (a). Additionally, also few worm-like vesicles are formed (a). The
amount of latter increases with increasing temperature [picture not shown]. After
further temperature increase to 45 oC and some waiting time (b), polymeric filaments
arise, which are connected to vesicles. Tthis change in morphology is probably
caused by heat induced flow shear forces, and by the temperature increase.
Figure 7.6: Formation of vesicles in a solution of L-arginine ethylether
(ArgOEt). Under the microscope, the formation of vesicles from MHB326 was
investigated, in the presence of ArgOEt. The vesicles are formed at the periphery of
polymeric inhomogeneities. At a temperature of about 38 oC, mainly worm-like and
a few multilayered vesicles arise, after further temperature increase or shear forces
due to heat induced flow, there is little change.
226 www.bth.rwth-aachen.de
Polyglycidol Based Polymersomes as L-Arginine Drug Delivery System
was not possible because the vesicles drifted out of the field of view, or because
the sample dried out, and had to be refilled with water, again. However, there was
usually no difference in the vesicle morphology, after these cycles. Thus, the change
is reversible.
7.3.2 Drug Release Experiments
In presence of ArgOEt, vesicles could be prepared successfully using a rotary evap-
orator (as described in section 7.2.5), as verified under the microscope. The first
release experiment (as described in section 7.2.6) was promising, as can be seen in
fig. 7.7. In this figure, the ArgOEt release persists over about four or five hours. In
Figure 7.7: Cumulative release profile of ArgOEt out of MHB326 polymer-
somes. The result of two release experiments is presented. A release over about
four or five hours could be observed. For the timepoint t = 0, the total concen-
trations of the samples are plotted, therefore, it can be assumed that the release is
almost finished, after about four or five hours.
this case, the vesicle solution was just roughly purified from the surrounding ArgOEt
solution. For further experiments, it was desired to remove the outer Arg derivative
molecules, completely. Therefore, different purification methods were tested, namely
dialysis, filtering by syringe filters, and centrifugation.
Firstly, dialysis was performed. Since the release should not be started during dialy-
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sis, it was performed at room temperature with the idea that collapsed vesicles might
be non-permeable for hydrophilic substances, which would avoid drug release. Sec-
ondly, the volume of the vesicle solution was reduced with the help of a syringe filter.
This process may have destroyed a part of the vesicles, despite careful usage of the
syringe filter. Thirdly, centrifugation was performed. Here, the main problem was
the temperature elevation. Thus, it can be assumed that the release have already
started, during centrifugation. Therefore, the samples were centrifuged, at 15 oC,
using a centrifuge with a temperature control. Unfortunately, all the three purifi-
cation methods resulted in non-detectable concentrations of Arg-HCl as well as of
ArgOEt, after the purification procedure.
It was considered whether the Arg derivative solution used might have been too
diluted. Hence, as an alternative technique, a radioactively labelled drug was in-
vestigated, since here, the quantitative analysis is more sensitive than by HPLC
fluorescence detection. In fact, in gamma counter analysis, single molecules can be
detected, whereas in HPLC, the minimal detectable concentration with the used
method was about 5 µg/L.
For these experiments, the most similar and available molecule to Arg was used,
namely the radioactively labelled peptide RGD. As can be seen in fig 7.8, a release
over about two hours could be found, in these experiments. This is in contrast to the
former result of about four or five hours, this could be due to the different structures
of the used Arg derivative.
However, several aspects influence the release duration. First of all, release by dif-
fusion through the bilayer is more retarded than through holes in the vesicle walls.
For the considered polymersomes, no holes were visible under the microscope, fur-
thermore, the release of a large molecule (radioactively labelled Arg derivative) is
not prolonged regarding the release of a smaller molecule (ArgOEt). Therefore, it is
assumed that the permeation mechanism applies. This mechanism can be separated
into several steps: (1) drug molecules diffuse to the hydrophilic part of the bilayer,
(2) penetrate through the hydrophobic part of the bilayer to (3) the outer hydrophilic
part, and (4) are released. The first step is promoted by an attractive interaction
between the drug molecules and the hydrophilic part of the vesicle forming poly-
mer. But for a very strong interaction, the drug molecules might stay in the inner
part of the bilayer for a while, which prolongs the release process. The interaction
between the polymer and the two Arg derivatives was not investigated, but it was
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Figure 7.8: Cumulative release profile of a radioactively labelled L-arginine
derivative, out of MHB326 polymersomes. The result of three release experi-
ments of radioactively labelled RGD peptide, an Arg derivative, is plotted. For each
experiment, vesicles prepared in an aqueous Arg derivative solution of 20 mg/mL,
were dispersed in water, then, the resulting vesicle dispersion was separated into
six containers. The release was started, and after 1 min, 5 min, 15 min, 30 min,
2 h, 24 h, the content of one of these containers was analyzed in regards to the Arg
derivative concentration. A release over about two hours could be observed.
estimated that the interaction is comparable for both Arg derivatives. Nevertheless,
the penetration through the hydrophobic part is probably the step with the greatest
oppurtunity to retard the release. In case of very hydrophobic molecules, it can be
assumed that the drug molecules prefer to remain in the bilayer, thus, the release
is very slow. For very hydrophilic molecules, the hydrophobic part constitutes a
strong barrier, therefore, also for such molecules, the release rate is low, and the
thicker the hydrophobic layer, the stronger is the retarding effect. Moreover, the
steric hindrance plays an important role for the layer permeation. Considering the
two Arg derivatives, ArgOEt is more hydrophilic and smaller than the other deriva-
tive, thus, its release was estimated to be somewhat faster than for the radioactively
labelled Arg derivative, because the steric hindrance is much smaller, and the effect
of the hydrophobic barrier might be relatively small, since it is not that thick in the
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present system.
Another important possible reason for the difference is the formation of another
morphology due to the presence of the radioactively labelled Arg derivative. Where,
it was not possible to exclude this possibility because in the lab for radioactive ex-
periments, no microscope was available to check the evolved structures.
In detail, vesicles were prepared, using drug concentrations of 10, 20, and 50 mg/mL.
The release experiments were performed by using one container per experimental
series, at certain time points, samples were taken, afterwards the container was put
back until the next time point. Most of the resulting release profiles [figure not
shown] look analogously to the presented profile (see fig 7.8), but there are also a
few profiles, where the values fluctuate, and no release is visible. This could be
caused either by errors in practice, or by the high sensitivity of the self-assembling
process towards small parameter variations.
7.3.3 Microscopical Investigation of the Polymersomes Using
Dyes
Due to difficulties in the drug release experiments, fluorescent dyes were added dru-
ing the preparation process of Arg-HCl containing vesicles. The obtained vesicles
were investigated by using the fluorescence microscope, with the aim to gain infor-
mation about the release out of the vesicles.
Polymersomes prepared in the presence of fluorescent dyes in the rotary evaporator,
were investigated under the microscope. For that, four different dyes were used,
the structures of which are shown in fig. 7.9. Among these, two of the dyes, Rho-
damine B and Alexa Fluor, are derivatives of fluorescein. Where, fluorescein itself,
and its sodium salt 'fluorescein sodium' (German: Uranin) are very hydrophobic
dyes, the structure of Rhodamine B is slightly modified with respect to fluorescein.
These modifications render rhodamine B to be moderately lipophilic. It fluoresces
orange-red (with a maximum at 617 nm), after excitation with a wavelength of about
590 nm.
Alexa Fluor dyes are synthesized through sulfonation of coumarin, rhodamine, xan-
thene (such as fluorescein), and cyanine dyes. This sulfonation makes the class of
Alexa Fluor dyes negatively charged and more hydrophilic than the other dyes, pre-
sented in fig. 7.9. They are generally more stable, brighter, and less pH-sensitive
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(a) Rhodamine B (b) Alexa Fluor 594
(c) DiI
Figure 7.9: Structures of the used fluorescent dyes. The structures of the
used fluorescent dyes are presented. Rhodamine B (a) is hydrophobic, whereas, its
derivative `Alexa Fluor 594' (b) belongs to the class of Alexa Fluor dyes, one of the
most hydrophilic fluorescent dyes. Furthermore, DiI (c) is amphiphilic.
than common dyes of comparable excitation and emission[55], like fluorescein, or
rhodamine. Here, Alexa Fluor 594 was used, its excitation and emission maxima
have wavelengths of about 590 nm and 617 nm.
The third used fluorescent dye is called DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethyl-
indocarbocyanine iodide). In DMSO, its absorption maximum is at 549 nm, and it
fluoresces at a wavelenght of 565 nm. It is an amphiphilic fluorescent dye.
Rhodamine B (Moderate Lipophilic)
In order to load the vesicles with (Arg and) a fluorescent dye, Rhodamine B was
added, during vesicle preparation. The first hydration resulted in two different mor-
phologies: there are strings of vesicles, as depicted in figure 7.10(a), and a lot of
small unilamellar vesicles, which are connected to polymeric filaments, as can be
seen in fig. 7.10(b). The fluorescence images show, as expected, that Rhodamine B
is incorporated into the walls of the vesicles and also into the filaments, due to its
moderate lipophilicity.
After studying the structures thoroughly, the samples occasionally dried out and was
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(a) Strings of vesicles, next to a polymeric inhomogenity
(b) Small vesicles, connected by filaments
Figure 7.10: Morphology of MHB326, using Rhodamine B as fluorescent
dye. At 45 oC, (a) strings of vesicles, and (b) small unilamellar vesicles, which are
connected by filaments, are formed by MHB326, under addition of Rhodamine B and
Arg-HCl. The pictures, taken with a filter, are coloured and show the fluorescence
of Rhodamine B, it can be seen that the vesicle walls fluoresce very bright, but there
is also fluorescence within the vesicle void.
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rehydrated, on the next day (inbetween, it was stored at room temperature, in a
closed container), it was found that the morphology changed: For rehydration done
at about 43 oC, mainly multilayered structures arise, as can be seen in fig. 7.11(a).
Also many discrete multilayered vesicles are formed, which are shown in fig. 7.11(b).
During cooling, the structures collapse. However, there is a difference between col-
lapsing of complex, huge multilayered structures and smaller multilayered vesicles;
the former collapse at a temperature between 40 oC and 35 oC, whereas, the latter
collapse, at a temperature between 25 oC and 30 oC. After reheating, the collapsed
multilayered vesicular structures are reformed.
The difference between the structures of the first hydration and the rehydration may
be caused by transformation of the kinetically preferred structure to the thermody-
namically stable morphology. This still has to be investigated.
Alexa Fluoro (the Most Hydrophilic Fluorescent Dye Used in this Work)
In the presence of the relatively hydrophilic fluorescent dye `Alexa Fluoro 594',
the polymer MHB326 forms mainly multilayered vesicles in an Arg-HCl solution,
as shown in fig. 7.12(a), but there are also small vesicles, which are embedded
in filaments, as can be seen in fig. 7.12(b). In contrast to the other multilayered
structures, there are spaces inbetween all versicle layers. Additionally, it is worth to
mention, for both morphologies, that there is fluorescence within the interlamellar
spaces, and within the vesicle voids, which is consistent to the hydrophilicity of the
dye. With time, the fluorescence intensity decreases, but in the surrounding medium
no intensity increase was observed. There are two possible explanations: Firstly, the
usual fluorescence intensity reduction over time might be detected, i.e. bleaching;
or secondly, the dye might be released over time. However, the ratio of the vesicle
void volumes to the whole water volume is so small, that it would be very hard to
detect flourescence in the surrounding medium.
DiI (Amphiphilic)
DiI is an amphiphilic fluorescent dye, which is usually used for membrane staining.
Therefore, it is expected that the dye accumulates in the vesicle bilayer. As can be
seen in fig. 7.13, there are different morphologies, most of them very complex multi-
layered structures. These structures collapse during cooling down. After reheating
the sample, the fluorescence is less intensive and the rebuilt structures have mostly
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(a) Multilayered vesicles, next to a polymeric in-
homogenity
(b) A multilayered vesicle, and in the back-
ground other morphologies
Figure 7.11: Morphology of MHB326 with Rhodamine B as fluorescent
dye, after rehydration. After rehydration, and reheating to 43 oC, multilayered
structures arise, either (a) aggregated or (b) discrete. Possibly, the multilayered
vesicles are thermodynamically stable, whereas, former structure (fig. 7.10), prior to
rehydration, was kinetically stable.
(a) Multilayered vesicles (b) Small unilamellar vesicles and filaments
Figure 7.12: Morphology of MHB326 with Alexa Fluor 594 as fluorescent
dye. Under presence of Alexa Fluor 594 dye and Arg-HCl, the polymer MHB326
forms (a) multilayered vesicles, and (b) small unilamellar vesicles, which are some-
what connected to filaments. In contrast to previously described multilayered struc-
tures, here is a relatively large distance between the lamellae.
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(a) Complex multilayered structures
(b) Multilayered vesicles, partly connected to each other
Figure 7.13: Morphology of MHB326 with DiI as fluorescent dye. In the
presence of DiI and Arg-HCl, MHB326 forms mainly multilayered structures, which
are either (a) very complex, like partly coalesced multilayered vesicles, or (b) multi-
layered vesicles, where few are connected to each other. In case (b), the picture with
a fluorescence filter is also shown; here, additionally small vesicles and filaments can
be seen in the background. The fluorescence picture of (a) gives no further informa-
tion, and is not presented.
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the same structure as before cooling down, but there are slightly more worm-like
structures observable, after reformation. It is debatable whether the loss in fluores-
cence intensity is only caused by bleaching, or if the vesicles release a bit of their
content during collapsing.
7.4 Conclusions
Onion-like polymersomes are promising systems in the science of drug delivery. In
this chapter, it is shown that this kind of vesicle can be self-assembled from a
polyglycidol-based polymer, named MHB326, also under addition of the hydrophilic
drug L-arginine hydrochloride (Arg-HCl). Furthermore, also L-arginine ethylester
(ArgOEt), or fluorescent dyes combined with Arg-HCl were added during the prepa-
ration process. It could be shown that the vesicle morphology depends on the added
molecules in the aqueous environment, but it was possible to obtain multilayered
vesicles, in each case. In cooling-heating cycles of Arg-HCl containing vesicles, the
arised polymersomes collapse slightly above room temperature. By reheating, it
could be shown that the same kind of vesicle reforms, except in one case: Un-
der presence of Rhodamine B, the initial morphology varies from the morphology
obtained after rehydration of the sample. The reason might be that in the first
hydration, the kinetically preferred morphology was formed, whereas, the thermo-
dynamical equilibrium morphology was built, after rehydration. Additionally, it was
shown that the preparation is possible, under the microscope as well as using a ro-
tary evaporator, i.e. on a larger scale.
A further aim was to find out whether these vesicles are suitable as controlled drug
delivery systems. For this, drug release experiments were performed with ArgOEt
loaded vesicles. In a first trial, a release over four or five hours could be found.
Here, the surrounding medium was removed only roughly, after vesicle preparation.
For the next experiments (using Arg-HCl or ArgOEt), the aim was to purify the
samples completely from the surrounding drug solution. Due to non-detectable drug
concentrations in the following release experiments, the kind of purification process
was varied, namely, purification by syringe filters, dialysis, and centrifugation was
tested. Since the concentrations still remained non-detectable, the last step was to
use a radioactively labelled Arg derivative, since the detection by radioactivity is
more sensitive than by (HPLC) fluorescence. In these experiments, a release over
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about two hours was found. The difference to the longer release duration of the for-
mer experiment is probably caused by the effect that inclusion of the radioactively
labelled Arg derivative may cause a morphology change of the vesicles. Another pos-
sible reason is the greater hydrophilicity of ArgOEt, which could make the barrier
function of the hydrophobic bilayer part more efficient.
7.5 Outlook
It is possible to form onion-like vesicles from the polymer MHB326, also in the
presence of different molecules, but there are differences in the morphology. There-
fore, the dependence of the supramolecular polymer morphology has to be further
investigated, regarding different drugs or other additives. Furthermore, under the
addition of Rhodamine B, the morphology changed during cooling-heating cycles.
Here, it should be investigated, whether the rehydrated morphology is retained also
after many of such cycles, and whether this is also possible, after a longer storage at
the vesicle formation temperature. Depending on the desired application, also other
block copolymers might be investigated to improve the release properties. For ex-
ample, a polymer could be used which interacts strongly with L-arginine to prolong
the release time.
Moreover, the properties of multilayered vesicles have been investigated, for using
these vesicles as controlled drug delivery system. The first step is the purification
in order to remove any drug molecules which are not confined. In this work, there
were some problems with purification, with respect to retaining the confined drug
content. Hence, it has to be further investigated under which conditions the drug re-
mains within the vesicle, so that only the non-included drug molecules are removed.
However, there are promising results, therefore, it is probably possible to find a well-
working combination of an amphiphilic polymer, and a hydrophilic or hydrophobic
drug, after further investigation of the mentioned points. It also has to be consid-
ered that the structure of a hydrophilic drug seems to have a strong influence on the
polymer supramolecular morphology. However, this may also be a chance: Addition
of hydrophilic substances during the preparation process of drug loaded vesicles,
might have a positive influence on the morphology.
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Chapter 8
Pulsed-Field Gradient Diffusion
NMR Measurements:
Characterization of Vesicles
Abstract
Diffusion measurements by NMR offer great oppurtunities for different systems. In
the case of vesicles, the size of the vesicle and its void can be determined. Addition-
ally, for the most systems, it is possible to investigate the drug release process and
the permeability of the vesicle membrane for water or drug molecules. At this, it
is advantageous that the vesicles can be investigated in situ, without manipulating
the samples by freeze-drying, as it is necessary for other methods.
In this chapter, the theory of pulsed-field gradient (PFG) measurements is described
in detail, as well as its proficiency for the investigation of vesicles. Furthermore,
important experimental points to be considered, are particularised. In fact, most
problems arise from convection in the sample, where this can either lead to non-
evaluable measurements, due to oscillating signals, or to distorted results, which
may be not noticed.
8.1 Introduction
NMR diffusion measurements are based on pulsed-field gradients; these are addi-
tional magnetic fields with a gradient field strength in z-direction. Due to the ap-
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plication of such a gradient, the local position of spins can be marked by generating
different larmor frequencies depending on the local position of the spin. This process
is reversible, which is the reason for the possibility to study transport phenomena
with this technique. In fact, it is the spin displacement, which is measured. At this,
a great advantage of this method is, that in a mixture of substances, NMR measures
the component resolved displacement of the single components. Further advantages
are that this method is nondestructive, and no chemical or isotopic tracers have to
be involved.
Historically, in 1965, Stejskal and Tanner did the pioneering study, resulting in an
appropriate pulse sequence, called pulsed gradient spin echo (PGSE) or Stejskal
and Tanner sequence[1], which (apparent) diffusion coefficients can be determined
with[2]. This work was based on Woessner's observation[3] that the diffusion coef-
ficients he measured, were dependent on NMR experimental parameters, while he
used the spin echo methods of Hahn[4, 5], Carr and Purcell[6], and others[7].
In the following, PGSE measurements have been used for the determination of the
self-diffusion coefficients of fluids. Two years after PGSE development, the first mea-
surements of water diffusion in zeolites were published[8]. But several years later,
in 1971, this was studied again[9], obtaining different results, and it was stated that
in this previous publication, the water diffusion around and not within the zeolites
was measured. In 1978, theoretical calculations in the context of PFG NMR were
published about permeable barriers of any geometry[10]. Basing on these consider-
ations, measurements of porous materials were performed, and information about
their microscopic structure could be obtained[11, 12]; the topic of restricted diffusion
was reviewed[13], later.
Besides, PFG measurements became more common in the form of diffusion-ordered
spectroscopy (DOSY)[14]: DOSY generates pseudo-two-dimensional spectra, where
the diffusion coefficient is one of the dimensions. Furthermore, this technique can
be combined with two-dimensional experiments like NOESY, HMBC and the like,
resulting in diffusion-weighted spectra in the third dimension.
Actually, PFG NMR has been used, in many respects. For example, water dif-
fusion in unilamellar vesicle solutions was studied[1518]. Moreover, the perme-
ability of vesicle bilayers was investigated by PFG NMR in respect to different
hydrophobic-hydrophilic linkages, to different chain lengths, to saturation of the
surfactant chain, and also to the transition temperature[19]. Furthermore, in PFG
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NMR studies, it was found out that the permeability is dependent on the glass tran-
sition temperature[19, 20], and it increases with the temperature[21]. In detail, the
long-term diffusion coefficient reflects the membrane permeability and arrangement,
in case of permeable walls[10].
Also, a fluctuating system was investigated, in fact, it was the first simultaneous
diffusion measurement of the lipophilic drugs entrapped in the lipid bilayer, and of
the vesicle or micelle forming lipids[22]. With that, it was found that some molecules
interact with the lipids, and thus, have the same diffusion coefficient as the lipids;
whereas, other molecules have much higher diffusion coefficients, but smaller than
in water.
Possible applications are not limited to rocks, and vesicle solutions. For example,
also information about the release from poly(lactic-co-glycolic acid) microspheres
was received by PFG NMR; it was found that the release depends on the swelling
of the polymeric matrix[23].
Another interesting idea was to separate molecules by means of their hydrophobi-
city[24], in fact, this was done with the help of micelles. The concept is based on
following equation, which holds for long diffusion times, in case of fast exchange[24]
D = pDmic + (1− p)Dfree (8.1)
with the time averaged diffusion coefficient D, the degree of solubilization p, and the
diffusion coefficients Dfree of the free, and of the solubilized Dmic molecules. In case
of the occurence of micelles, the amount of molecules within a micelle is determined
by their hydrophobicity, under the aspect of a fast exchange. According to above
equation, the measured diffusion coefficient is determined by the diffusion coefficients
of the free molecules, and of the micelles, and it is determined by the fraction of the
molecule within the micelle. Latter is dependent on the hydrophobicity, hence, the
signals of molecules with different hydrophobicity can be separated by their averaged
diffusion coefficients, even so they have a similar molecular weight.
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8.2 Theoretical Background
8.2.1 Pulsed-Field Gradient NMR Measurements
Pulsed-field gradient (PFG) NMR is based on the possibility of encoding and de-
coding the local position of a spin, in order to measure the distance travelled along
the z-axis, due to molecular motion. This is done by a gradient pulse, i.e. by an
additional magnetic field with a gradient field strength in z-direction.
In fig. 8.1, the principle of this encoding and decoding process is shown. Here, a
NMR tube is considered as a system of several in z-direction superimposed partial
systems. Due to the application of a 90o pulse, the averaged magnetic momentum
Figure 8.1: Principle of local spin encoding using gradient pulses. With
kindly permission of Prof. Dr. Klaus Zangger, TU Graz[25]. On the left hand
side, spin systems in different z-levels are shown, after applying a 90o pulse, the
magnetic momentum, represented by the arrows, are parallel in all z-levels; this
is also elucidated by the bold arrow in the circle, where the cycle shows the view
along the z-axis. After applying a gradient pulse (+∆G), the magnetic momentum
arrows are dephased, resulting in a broader peak as with only applying a 90o pulse.
This process can be reversed by another gradient pulse (−∆G), as illustrated by
the double arrow. However, applying an additional gradient pulse with a certain
strength results in single magnetic momenta, whose net magnetization is zero. This
is why, there is no FID signal, for the third NMR tube.
vectors of the partial systems are flipped into the xy-plane, hence, all spins are in
phase to each other, as can be seen on the left hand side of fig. 8.1. The next step
is the encoding by a gradient pulse of the partial systems, referring to their local
position in z-direction. Due to the gradient-caused local different field strengths,
spins are dephased, regarding different z-levels, and they precess with different Lar-
mor frequencies (not demonstrated in the figure). Next, a stronger gradient pulse
is applied. This pulse is chosen in that way that a FID shows no signal, what is
clearly visible in the circle presentation: the sum of all magnetic momenta gives
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zero magnetization. Both of the steps can be reversed, as illustrated by the double
arrows in fig. 8.1. This reversibility is an essential point in diffusion measurements.
In PFG methods, the encoding process of the spin positions is followed by some
waiting time; in fact, this is the diffusion time (∆). Then, the position is decoded
by another gradient pulse. However, for spins, which move to another z-position,
the decoding process works only partially or not at all. Indeed, the signal becomes
smaller, the stronger the gradient pulse, and the larger the displacement along the
z-axis, during the time period between the gradient pulses. Due to this, it is possible
to determine the apparent or effective diffusion coefficient.
Actually, there are several pulse sequences which can be used for this purpose.
Pulsed gradient spin echo (PGSE) or Stejskal and Tanner sequence[1] is the basic
example for a PFG pulse sequence, it is shown in figure 8.2(a). PGSE consists of two
radio frequency (rf) pulses and two gradient pulses, where the latter are changed
stepwisely, resulting in a series of FIDs, or in a pseudo-two-dimensional spectrum.
The PGSE principle is illustrated in fig. 8.3; here, the average magnetic momentum
vector for three different z-positions is regarded. Applying the first pulse  namely
a pi/2 or 90o pulse in x-direction  causes a flip of the average magnetic momentum
vector from z-direction into the xy-plane (see fig. 8.3(a)) (more precisely, the vector
is flipped from the (+z)-axis onto the (-y)-axis); subsequently, a gradient pulse is
applied to mark the spin position (see fig. 8.3(b)). Because of local magnetic field
inhomogeneities (within one z-level), which are constant in time, some spins precess
somewhat faster or slower than the average magnetic momentum vector, resulting
in dephasing (slower spins precess 'behind' faster spins) (see fig. 8.3(c)); for the pur-
pose of nihilation of this effect caused by inhomogeneities, after some waiting time,
a pi or 180o pulse in y-direction is applied (see fig. 8.3(d)), resulting in a 180o flip
around the y-axis, thus, all spin coordinates change from (x,y) to (-x,y). One could
say that after this pi pulse, slower spins have overtaken the faster ones, but every
spin precess with the same velocity as before, hence, after the same waiting time,
the spins are rephased again (see fig. 8.3(e)). During this waiting time, a second
gradient pulse is applied to revers the encoding pulse depending on the spin position
(see fig. 8.3(f)).
However, the pulse sequence was varied, as shown in fig. 8.2(b), it is called stimu-
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(a) Pulsed gradient spin echo (PGSE) pulse sequence
(b) Stimulated echo (PFGSTE) pulse sequence with an optional spoil gradient
Figure 8.2: The two basic PFG diffusion pulse sequences: PGSE and PFG-
STE. In both sequences, a 90o pulse flips the magnetic momentum vector into xy-
plane, afterwards, a gradient pulse encodes the z-positions the spins. In PGSE (a),
this is followed by a 180o pulse, which flips the magnetization so that (x,y)→ (-x,y).
This causes a vanishing of inhomogeneity effects of the magnetic field. Whereas, in
PFGSTE (b), the encoding gradient pulse is followed by a second 90o pulse, flipping
the magnetization from the xy-plane into xz-plane. The homospoil gradient pulse
is optional, and serves to destroy any unwanted magnetization in the transverse
plane. Later, a third 90o pulse flips the magnetization from the xz-plane back into
the xy-plane causing a vanishing of inhomogeneity effects of the magnetic field. In
both sequences (a,b), by applying a second gradient pulse, the z-positions of the
spins are decoded. For spins which moved to another z-level, the decoding works
only partially or not at all. In fact, the encoding, and the decoding gradient pulses
are changed stepwisely, resulting in a series of spectra.
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Figure 8.3: The averaged magnetic momentum during PGSE, for non-
moving spins. Three planes in different z-positions are presented for each step. (a)
A 90o pulse flips the magnetic momentum vector into the xy-plane, afterwards, (b)
a gradient pulse, g, encodes the spins' z-positions. After some time, t, during which
(c) transverse relaxation occurs, (d) a 180o pulse flips the magnetization so that
(x,y) → (-x,y), which causes a vanishing of inhomogeneity effects of the magnetic
field. In fact, after some time, t (e), the spins are rephased, again. (f) Due to a
further gradient pulse, g, the local z-positions of the spins are decoded.
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lated PFG spin echo (PFGSTE)[26], and it is the second basic PFG pulse sequence.
This sequence is preferable against PGSE for viscous samples or for high diffusion
times[26]. In fact, PFGSTE contrasts favourably with PGSE, because there is T1
instead of T2 dependence, during the time between the second and the third 90o
pulse; this is particularly suitable for solids and other materials, which have much
higher T1 than T2 times.
However, the method has been improved and/or varied several times, up to now.
For example, a series of short gradient pulses was used to reduce the effect of an
inhomogeneous field caused by contrasts in the magnetic susceptibility[27], another
example is a pulse sequence, which preserves the magnetization, during the gradient
pulses, and stores it along the longitudinal direction, during the diffusion time[28].
Further sequences, and their advantages and disadvantages, can be looked up in the
literature[29].
Nevertheless, the following equations of this section hold for both pulse sequences,
because applying two 90o pulses have the same effect on the magnetization vector
as one 180o pulse. In case of the other PFG pulse sequences, similar equations hold.
Anyway, between the two gradient pulses, some spins diffuse to other z-levels so that
the experiment results in a decreasing signal. The intensity of such a remaining sig-
nal is depending on the gradient strength, because in case of stronger gradients, the
difference between the Larmor frequency of two spins, being in two certain z-levels,
is higher than after applying a weaker gradient.
As already mentioned, this is followed by the possibility to determine the length of
the way travelled by a spin, by PFG NMR. The length of this way is connected to
the (apparent) diffusion coefficient. And indeed, considering a series of such NMR
experiments with stepwisely increased gradient strength (starting with zero gradi-
ent), the (apparent) diffusion coefficient can be determined: The amplitude Ag of
such a single gradient step is given by[1]
Ag = A0 · exp
(−γ2g2Dδ2(∆− δ/3)) (8.2)
with the gyromagnetic ratio γ, the strength of the gradient g, and the duration of the
gradient δ. In order to get rid of the constant (A0), the ratio of the amplitudes Ag to
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the amplitude A(g=0), with zero gradient, is used, as given in following equations[30]
A(g=0) = A0 · exp (0) = A0 (8.3)
⇒ Ag/A0 = exp
(−γ2g2Dδ2(∆− δ/3)) (8.4)
⇒ ln(Ag/A0) = −γ2g2δ2(∆− δ/3) ·D (8.5)
Plotting − ln(Ag/A0) against γ2g2δ2(∆− δ/3) results in a linear curve with a slope
of the (apparent) diffusion coefficient D, as shown in fig. 8.4.
Figure 8.4: Determination of the (apparent) diffusion coefficient by the
ratio of the amplitudes, resulting from a PFG experiment. A series of
spectra is measured, where the gradient strength is changed stepwisely from zero to
the chosen maximal strenght. By plotting the natural logarithm of Ag/A0, against
the gradient strenght, g, or more precisely against (gγδ)2(∆ − δ/3), the diffusion
coefficient is given by the slope of the linear function. Where, Ag is the amplitude of
the gradient strength g, A0 is the amplitude for zero gradient, γ is the gyromagnetic
ratio, ∆ is the diffusion time, i.e. the time between the encoding and decoding pulse,
and δ is the duration of the gradient pulse.
8.2.2 Free, Obstructed, and Restricted Diffusion
Free, obstructed (or hindered), and restricted diffusion are the major modes of
diffusion[31, 32], which can be further divided into isotropic and anisotropic diffusion[33].
Free diffusion is connected to the self diffusion coefficient, which is originated by
Brownian motion. For example, the water self-diffusion coefficient is determined in
water without any additives.
Regarding an aqueous vesicle solution, the water molecules around the vesicles can
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diffuse freely, whereas the diffusion of the water molecules within the vesicle void
are restricted. But in case of a very concentrated vesicle solution, the diffusion of
the surrounding water molecules is not free, since the way of the diffusing molecules
is blocked by vesicles, thus, the diffusion of the water molecules is obstructed by col-
lision with the vesicles. Anisotropic diffusion can be found, when the steric barriers
are anisotropic.
Considering a series of PFG NMR measurements with varied diffusion times, it can
be differentiated between diffusion coefficients which are dependent or independent
on the diffusion time. In case of restricted diffusion, the diffusion coefficient is
dependent on the diffusion time, otherwise, it is constant over the diffusion time.
Furthermore, for obstructed and restricted diffusion, the diffusion coefficients are
smaller than for free diffusion.
The term `apparent' diffusion coefficient was introduced by Le Bihan for a diffusion
coefficient, which is smaller than the self-diffusion coefficient and independent on the
diffusion time[32]. However, in PFG NMR, it is often used for diffusion coefficients
which are dependent on the diffusion time.
8.2.3 Pore Size Determination
For the pore size determination in a restricted system, the apparent diffusion coeffi-
cient is dependent on the considered diffusion time. Extrapolating to zero diffusion
time (∆ = 0), the self-diffusion coefficient, D0, can be found.
The (apparent) diffusion coefficient can be calculated by the length of the macro-
scopic way, λp, and the velocity, v, of a molecule by the following equation[34]
D =
1
3
vλp. (8.6)
As shown in picture 8.5, the apparent diffusion coefficient is different for free and
restricted diffusion, respectively. In fact, it makes sense to consider three different
diffusion times: (1) For very short diffusion times (∆) (at the top of fig. 8.5), almost
all molecules in a restricted volume can diffuse, as if they were free, because λp is
much smaller than the pore diameter; thus, both diffusion coefficients are equal to
each other: Dfree(∆) = Drestricted(∆). (2) Whereas, for medial diffusion times (in
the center of fig. 8.5), the apparent diffusion coefficient in a restricted volume is
smaller than in the free volume: Drestricted(∆) < Dfree(∆), because in a restricted
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Figure 8.5: Free diffusion versus restricted diffusion in a spherical pore,
either with permeable or non-permeable walls. (according to [13], modified)
The zigzag arrows demonstrate a possible diffusion way of a molecule or particle,
during the diffusion time ∆. Whereas, the straight arrows indicate the length of the
way in z-direction (λp). (a) For a very short diffusion time, no difference between a
free and a restricted molecule (in a pore) can be seen. (b) But for middle diffusion
times, the molecule in the pore is restricted, thus, its travelled way (λp) is shorter
than in case of a free molecule. Here, also a slight difference between pores with
permeable and non-permeable walls can be seen: For permeable walls, the travelled
way, λp, is somewhat longer than for non-permeable walls, but significantly smaller
than for a free molecule. (c) And for very long diffusion times, it can be differentiated
clearly between the three showed kinds of diffusion. In fact, the travelled way
(λp) of the absolutely restricted molecule is negligible, regarding the way of a free
molecule. Furthermore, the diffusion coefficient for long diffusion times approximates
zero. For permeable walls, the diffusion coefficient remains at a certain value, which
is connected to the permeability of the walls or to the tortuosity. Whereas, the
diffusion coefficient of a free molecule does not change with the diffusion time, its
way prolongates with the diffusion time.
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volume some molecules can diffuse freely and some feel restricted by the pore walls,
depending on their starting position and their moving direction. For restricted
volumes, there is a small difference between permeable and non-permeable pore
walls: The lenght of the travelled way is somewhat larger for a molecule in a pore
with permeable walls. In both cases, Drestricted(∆) is dependent on the surface-to-
volume ratio of the pore and on ∆, as specified later. (3) For long diffusion times
(at the bottom of fig. 8.5), the length of the macroscopic way, λp, in an absolutely
restricted volume is constant (λp(∆) = const). Thus, the limit of the diffusion
coefficient as ∆ approaches infinity is zero:
lim
∆→∞
(Dres(∆)) =
v
3
lim
∆→∞
(λp(∆)) = 0 . (8.7)
In case of permeable walls, the limit is not zero but a constant, whose value is de-
termined by the tortuosity or by the permeability of the pore walls. In contrast, the
diffusion coefficient of a free molecule is independent on ∆, therefore, the travelled
way is much longer than for any restricted molecule.
For determination of the diffusion coefficient by PFG NMR, it has to be taken into
account that all spins are measured, within and outside the pores. Therefore, one has
to differentiate between systems, where all the spins are in pores (1), and systems,
where spins are within and outside the pores (2). A further necessary distinction is
between (a) non-permeable, and (b) permeable pore walls.
For example, a water-soaked PU foam is a system, where all water spins are in pores
with permeable walls (i.e. (1b)), whereas a vesicle solution is a system, where solvent
spins are within and outside the voids, which have permeable or non-permeable walls
on the NMR time scale, depending on the considered vesicles (i.e. (2a) or (2b)). For
the first example, an additional physical parameter can be determined by such PFG
NMR experiments: The tortuosity describes, how tortuous the way of a diffusing
molecule is. Where, the tortuosity can be calculated, using the remaining intensity
ratio Ag/A0 at long diffusion times[35].
As already mentioned, the limit of the diffusion coefficient is zero in restricted
volumes[3537]. Whereas, the diffusion coefficient approximates asymptotically a
finit limit, in connected porous materials[28, 35]. Thus, both can be differentiated
easily, by PFG NMR. Furthermore, for connected pores, following relation is given
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for long diffusion times[35, 38]
D(∆)
D0
=
1
τ
+
β1
∆
− β2
∆3/2
(8.8)
with the constants β1 and β2, whose values depend on the micro geometry. For
sufficient long diffusion times (∆→∞), the tortuosity can be determined according
to
τ =
D0
D(∆)
(8.9)
For all these considerations, it is important to know that the magnetization within
a pore is uniform, since the molecules diffuse many times through the whole pore,
prior to relaxation, caused by collision with the grain surface of the pore[39, 40]. In
very narrow channels, the passing spins relax directly, and cannot be detected any-
more. Therefore, PFG NMR is unable to tell the difference between a non-connected
porous material and a pore system connected by very narrow channels.
For the pore size determination, the initial slope of the apparent diffusion coeffi-
cient (plotted against
√
∆) is used. In fact, the pore size can be determined by
performing several diffusion experiments with different diffusion times (∆). In case
of a PU foam (for SEM picture, see fig. 5.4(a), page 143), fig. 8.6 shows a typi-
cal plot of D(∆) against
√
∆. There are two different regions: In the beginning,
D(∆) decreases linearly, in fact, it decreases by the factor 4
3
√
pi
· 1
r
(D0)
3/2; this part
is traceable to the pores. Extrapolating the linear part to zero diffusion time, the
self-diffusion coefficient, D0, can be found. Whereas, for high diffusion times, D(∆)
is constant, where the value of D(∆) is related to the tortuosity of the foam.
As already mentioned, the first part of the curve is used, for the pore size deter-
mination. Here, the apparent diffusion coefficient, for porous media with smooth
boundaries, is given by[28]
D(∆) = D0
(
1− 4
9
√
pi
· S
V
√
D0∆
)
(8.10)
which means that D is proportional to the surface-to-volume ratio ( S
V
) of the pore.
Considering spherical pores, the surface-to-volume ratio is given as
S
V
=
4pir2
4/3pir3
=
3
r
(8.11)
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Figure 8.6: Determination of the pore size and the tortuosity. The pore size
can be determined by measuring several PFG experiments with different diffusion
times ∆. Every single PFG experiment gives an apparent diffusion coefficient. These
diffusion coefficients are plotted against the square root of the diffusion time. The
slope of the first part of the curve is proportional to the radius in the case of a
spherical pore, whereas the other part of the curve might give information about
the tortuosity or wall permeability, depending on the considered system. Here, the
result for a polymeric foam is presented.
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which results in the proportionality of D
(√
∆
)
to 1
r
. More precisely, the apparent
diffusion coefficient depends on the spherical pore radius r, in following manner
D(∆) = D0 − 4
3
√
pi
· 1
r
(D0)
3/2 ·
√
∆ (8.12)
However, this is only the whole truth, if all the measured molecules are within pores
of the same size, like in a soaked foam. Whereas, in the case of a uniformly sized
vesicle solution with the vesicle concentration cV es, the function is
D(∆) =
npore
npore + nfree
·Dpore(∆) + nfree
npore + nfree
·Dfree(∆) (8.13)
=
nfree
npore + nfree
·D0 + npore
npore + nfree
·
(
D0 − 4
3
√
pi
· 1
r
(D0)
3/2 ·
√
∆
)
(8.14)
= D0 − npore
npore + nfree
· 4
3
√
pi
· 1
r
(D0)
3/2 ·
√
∆ (8.15)
= D0 − Vpore
V
· 4
3
√
pi
· 1
r
(D0)
3/2 ·
√
∆ (8.16)
= D0 − 4/3pir
3nV es
V
· 4
3
√
pi
· 1
r
(D0)
3/2 ·
√
∆ (8.17)
= D0 − 16
√
pi
9
· r2 · cV es(D0)3/2 ·
√
∆ (8.18)
with the volume of the sample, V , and the number of vesicles, nV es, the amounts of
measured molecules in the free volume, nfree, or in the pores, npore. However, this
equation only holds for vesicles, whose walls are non-permeable to the measured
spins, on the NMR time scale. Furthermore, for a concentrated vesicle solution,
obstructed diffusion is observed, i.e. Dpore < D0.
Using the equation
cV es =
mV es ·MV es
V
=
4pir2 ·mV es · δA
V
(8.19)
with the mass of the vesicles mV es, the molar mass of the vesicles MV es, and the
areal density δA, it results in
D(∆) = D0 − 64pi
3/2
9
· mV es
V
· δA(D0)3/2 ·
√
∆ (8.20)
(8.21)
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Thus, for a known mass of slightly or non-permeable vesicles, the areal density can
be calculated. And for a known vesicle concentration, the vesicle radius can be cal-
culated by the slope of the function D(∆).
8.2.4 Determination of the Vesicle Size
The size of spherical vesicles can be calculated by the diffusion coefficient, Dves,
of the molecules building the vesicle wall. Using the Stokes-Einstein equation, the
vesicle radius rves follows
rves =
kBT
6pi η Dves
(8.22)
with the Boltzmann's constant kB, the absolute temperature T, and the viscosity η.
However, one has to keep in mind that in case of phospholipid vesicles, a dependence
of T2 on tumbling rates of the vesicles was found. This results in a T2 dependence of
the measured vesicle size. That is why the contribution of smaller vesicles is higher
weighted than larger vesicles, and thus, the diffusion coefficient for the bilayer pro-
tons are found to be higher than for protons of entrapped molecules[41].
In order to determine the diffusion coefficient of the wall building molecules, it is
usually neccessary to use deuterated solvents, otherwise the solvent signal is too pre-
dominant. This can either be reached by freeze-dried vesicles, put into deuterated
solvents, or by multiple centrifugating, where the undeuterated solvent is removed,
and the deuterated solvent is added, or the solvent can be replaced by the deuterated
solvent by dialysis (but latter is time-consuming and expensive due to high amounts
of deuterated solvent). Another possibility is the usage of a solvent-suppressing
pulse sequence.
In case of unilamellar vesicles, there is almost no difference in determining the sizes
of vesicles and their voids. Considering the different diffusion coefficients determined
by PFG NMR for lipid bilayer protons and for entrapped protons[41], it is reason-
able to perform both experiments, even so the pore size determination is much more
time-consuming. That is because a series of PFG diffusion measurements is neces-
sary for pore size determination, in contrast to the vesicle size determination, where
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two or three experiments are sufficient. But for multilamellar vesicles, the compar-
ision of both experimental results gives further information about the thickness of
the layers. Additionally, it may be possible to differentiate between multilamellar
vesicles, whose vesicle layers are tightly packed (like in fig. 7.11(b), page 7.11(b)),
or have spaces inbetween (fig. 7.12(a), page 234).
The vesicle size in dependence of the solvent might also be interesting. Due to dif-
ferent viscosities of the solvents, it is better to compare the hydrodynamic radii,
in this case[10, 42]. Whereby, the hydrodynamic radius can be calculated by the
Stokes-Einstein equation (eq. 8.22).
8.2.5 Release Mechanism and Permeability
Considering a vesicle as possible drug release system or drug carrier, several points
concerning the permeability play an important role. For example, it is desired to
obtain information about the release mechanism[43]. Moreover, the volume fraction
of entrapped water[19, 43], and the role of water in supramolecular aggregates[44]
are of great interest[19, 43].
Volume Fraction of Entrapped Water
In order to determine the fraction of water, entrapped in the vesicles, the echo-decay,(
Ag
A0
)
, is fitted multiexponentially, in case of a size distribution of the vesicles[19, 43].
In contrast, it is sufficient to fit biexponential, for vesicles with the same size[19]:
Ag
A0
= pobst · e−γ2g2δ2(∆−δ/3)·Dobst + (1− pobst) · e−γ2g2δ2(∆−δ/3)·Drest (8.23)
with the fraction of obstructed diffusion pobst, and the diffusion coefficients Dobst and
Drest for obstructed and restricted diffusion. In detail, above fractions are apparent
volume fractions; the absolute volume fraction can be determined by extrapolation
(to zero time) of the plot of the apparent volume fraction versus the diffusion time,
furthermore, this plot represents how fast the molecules diffuse through the vesicle
membrane[43]. Comparing such plots for different vesicle building molecules, it can
be seen, which membrane is more permeable for the considered molecule[43], if the
vesicle size is equal. In fact, the volume fraction is constant over the time ∆, in case
of non-permeability[19]. This experiment might also be used for the drug signal, in
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case of triggered release, in order to study the release behaviour.
The echo-decay is the sum of echo-decays of the different compartiments, if there is
no exchange. Whereas, for exchanging molecules, the function of the echo-decay is
dependent on the ratio of the exchange rate to the experimental diffusion time ∆.
If the lifetime is smaller than ∆, the echo-decay is the weighted sum of the diffusion
coefficients: Dobs = p1D1 +p2D2. If the lifetime and ∆ have approximately the same
value, the echo-decay is very complicated and mostly not evaluable[43].
If the release out of a vesicle is sufficiently retarded, it is possible to determine the
release rate, equivalent to the determination of the entrapped water fraction. For
this, the signal of the drug molecule is regarded, and the volume fraction of interest is
that of the free drug molecules. Probably, it is not necessary to measure several echo-
decays per time-point, in order to extrapolate the real volume fractions, it might be
satisfactory to measure one PFG diffusion experiment with a small diffusion time,
in dependence of the release time, in order to get the release kinetics.
Role of Water in Supramolecular Aggregates
An additional approach is the usage of different pulse sequences. The diffusion
coefficients, determined by PGSE or PFGSTE, are different to those, obtained by
longitudinal eddy current delay sequence (LED) or bipolar longitudinal eddy current
delay sequence (BPLED)[44]. Using small values for the eddy-current delay in LED
or BPLED, the resulting diffusion coefficients are comparable to those of PGSE
and PFGSTE, but using higher eddy-current delay values, an additional diffusion
component can be observed[44]. This shows that there is an exchange between
two different water populations, which have very different diffusion coefficients[44].
Thus, by comparing the results of different pulse sequences, inferences about the
role of water in supramolecular aggregates can be drawn[44].
Solubility-Diffusion Mechanism and Pore Mechanism
There are two different release mechanisms for hydrophilic molecules: the solubility-
diffusion mechanism and the pore mechanism[20, 45, 46]. Where, the pore mecha-
nism means the diffusion through holes and dislocations in the vesicle wall, whereas,
the solubility-diffusion mechanism consists of several steps: Firstly, the molecules
have to dissolve in the hydrophobic layer, this is followed by diffusion through the
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layer, and finally, they redissolve into the outer hydrophilic phase[21]. However, it
was also found that different molecules can follow different mechanisms, in the same
system; for example, ions can diffuse through holes, whereas, all other molecules,
in this system, follow the solubility-diffusion mechanism[47]. Where, the release
mechanism, and with that the release rate, can be changed, due to changing the
surfactant chain with regards to length, branching and degree of unsaturation[19].
By determining the diffusion coefficient of small molecules like water, and of hugh
molecules like PEG, both entrapped in vesicles, it can be differentiated between
both mechanisms. It is based on the assumption that hugh molecules cannot pass
through the holes (if there are no microscopically visible holes), thus, comparing
both diffusion coefficients, it clarifies, whether both of them follow the solubility-
diffusion mechanism, or different mechanisms[43].
Furthermore, the permeability of a small and a huge molecule can be compared, by
calculating the volume fractions of the entrapped molecules (as already specified),
if both follow the same release mechanism[43]. In addition, measurements, using
different salt concentrations, can be performed. If the diffusion coefficient is inde-
pendent on the salt concentration, it can be assumed that there are holes in the
vesicle membrane, whereas, the diffusion coefficient decreases continuously with in-
creasing salt concentration, because of osmotically caused shrinking of vesicles with
an intact membrane[43].
8.3 Experimental
The major problems of PFG NMR diffusion measurements in practice, are convec-
tion, short relaxation times or a broad distribution of relaxation times, and addi-
tional field gradients, which are often connected to eddy currents. In the following,
these problems are specified, moreover, approaches to solve these problems are pre-
sented.
8.3.1 Convection
Convection is the most serious problem in diffusion measurements; it can be imag-
ined that there is hardly a possibility to divide the detected spin movements into
diffusion-, and convection-caused. Only in case of strong convection, the spin-echo
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decay of a PFG experiment is oscillating[48]. And for sparse convection, the detected
diffusion coefficient is larger than the real one[48, 49]. For free diffusing molecules,
it is possible to check the occurrence of convection by comparing the determined
diffusion coefficients for two different diffusion time. This results from the diffusion
time dependence of self-diffusion coefficients induced by convection[49]. Hence, con-
vection has to be avoided as effectively as possible.
The most frequent reason for convection is a temperature gradient. Therefore,
the most obvious approach to solution is to measure at room temperature, when
possible[48], and to let the sample well acclimatize to the probe's temperature. In
case of special diffusion probes, the gradient cooling system is sufficient to regulate
the temperature; and for other probes, the temperature regulating gas flow should
be set to a high gas flow rate[50].
However, the onset of convection in a fluid in a long non-rotating vertical cylindrical
tube is determined by the parameter γ[51]:
γ =
gα
νκ
· r4 · ∆T
d
(8.24)
with the acceleration of gravity g, the thermal volume expansion coefficient, α, of
the fluid, the kinematic viscosity ν (ν = η/ρ), which is dependent on the absolute
viscosity η, and the density ρ; the thermal diffusity κ, the inner radius of the tube
r, and the temperature gradient ∆T/d along the axis of the heigth d. Exceeding a
critical value of γ, convection starts. This critical value, γc, depends on the thermal
conductivity of the sidewalls of the NMR tube. It is possible to calculate the values
of γc for completely insulating or conducting walls, where, a higher temperature
gradient for conducting walls is determined.
Examining above equation, following aspects help to avoid convection: The NMR
tube is preferred to have a (1) radius as small as possible[49, 52], where also the
decreased signal-to-noise ratio has to be considered, and (2) it shall rather be tem-
perature conductive than isolating. Additionally, (3) the filling heigth shall be as
low as possible[53]. Regarding the used solvent, it shall have a (4) very low thermal
volume expansion coefficient, and a (5) high kinematic viscosity. Moreover, the tem-
perature shall be low (despite, there is also a temperature gradient, which causes
convection[49]), because ν has a higher value[48] for lower temperatures, and this is
followed by a smaller critical gradient[51].
264 www.bth.rwth-aachen.de
Pulsed-Field Gradient Diffusion NMR Measurements: Characterization of Vesicles
Figure 8.7: Shigemi NMR tube. Shigemi NMR tubes consist of special materials,
which are matched to the magnetic susceptibility of different solvents. Furthermore,
the volume for the sample is very small. After filling, an insert is introduced, which
covers the upper surface of the sample. With kindly permission of Shigemi, Inc.[61].
In case of a simple temperature control, sample rotation may suppress convection.
Since sample rotation is followed by Coriolis forces, which stabilize the conducting
state of the system, even using a slow rotation rate results in prevention of con-
vection, which could be proved by comparision of BPLED[54] measurements with
sample spinning, and measuring without spinning and usage of the compensated-
BPLED pulse sequences[51].
In fact, there are several PFG NMR diffusion pulse sequences, having different ad-
vantages and disadvantages, where some are developed in order to reduce the conse-
quences of convection; examples are the doneshot pulse sequence[23], a compensated
pulse sequence[5557], and specially designed pulse sequences[52, 55, 56, 58].
Additionally, also good results were achieved, using a plunger[59] or a coaxial insert[49].
In this context, special NMR tubes[60], called Shigemi NMR tubes, are worth to
mention, they consist of glass matched to the magnetic susceptibility of a solvent,
furthermore, they have a special shape, shown in fig. 8.7, whereby they are also
convenient for small sample amounts.
In addition, a spatially uniform B1 magnetic field is essential, especially, in case of
diffusion measurements, but also for all other high resolution NMR experiments.
For this, it is import to fill the NMR tube so that the height of the sample volume
covers the whole length of the rf coil but not more[62].
Furthermore, a vertical NMR spectrometer, preferably with a wide bore magnet, is
desirable[50], and special temperature controlling systems can reduce the convection
effects[63, 64], here, it has to be considered if it is better to regulate the tempera-
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ture with a gas flow up- or downwards. If the gas flows upwards, and the sample
is heated, the sample has a higher temperature, and therefore a slightly smaller
density, at the bottom of the NMR tube. This is preferable because less convection
can be found than in case of a smaller density in the top end of the sample. For
cooling, it is vice versa: A downward flowing gas stream is desirable.
8.3.2 Additional Field Gradients
Due to switching the additional magnetic field of the gradient pulses on or off, so-
called eddy currents arise in electrically conductive components, being next to the
gradient coils. These eddy currents lead to additional gradient fields, and disturb
NMR measurements.
Eddy currents can be reduced by using multi-pulse sequences, and they can be
avoided for the most part, by using a gradient pre-emphasis, which leads to a min-
imal dead-time between a gradient and the next rf pulse[65]. By using bipolar
gradient pulses, the effect of eddy currents can be further reduced.
Further problems arise due to background gradients. These are internal field gradi-
ents owing to differences in the magnetic susceptibility, especially in heterogeneous
samples; in fact, also the magnetic susceptibility difference between the pore wall
and the confined liquid, produces such field gradients[65]. These gradients couple
with the applied gradient pulses, and induce an additional dephasing of the spins,
in this way. Dephasing results in a stronger echo attenuation, thus, the diffusion
coefficient is determined, too high.
Further sources of errors are secondary stimulated spin echos, arised from the ad-
ditional 90o pulses in the PFGSTE sequence, they interfere with the acquisition of
the relevant stimulated echos.
A further important point is that the minimal diffusion time is dependent on the
minimal length of the gradient pulse, and on the subsequent recovery of the appa-
ratus from the eddy-current and magnetoacoustic effects[28].
8.3.3 Relaxation
The maximal value of the diffusion time depends on the longitudinal or transverse
relaxation[28, 35, 66], depending on the used pulse sequence. In porous materials,
the transverse relaxation time is usually short[65]. In fact, multiexponential decays
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of the relaxation times are found, for sedimentary rocks[35]. Due to this, signals of
one kind of molecules disappear, for high diffusion times, which explains that it is
not possible to determine the tortuosity of such samples, by PFG NMR[35]. In this
context, it is worth to mention that the magnetization for all spins of the diffusing
molecules within one pore is uniform, because the molecules diffuse many times
across the pore, before they relax due to collision with a grain pore surface[39, 40].
Summarising, short relaxation times or locally different relaxation times of molecules
in a different environment, result in a complex signal behaviour for long diffusions
times. More precisely, either a non-interpretable increase of the apparent diffusion
coefficient can be found, or the measured diffusion coefficient involves only a part of
the considered molecules.
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Appendix A
Quantitative L-Arginine Analysis
Using High Performance Liquid
Chromatography
Measurements were performed with high performance liquid chromatography (HPLC)
`Agilent 1100 Series', equipped with an autosampler and a fluorescence detector `Ag-
ilent 1200 Series'. `Eclipse Plus C18' from Agilent was used as HPLC column. The
HPLC method was adapted from literature[1].
L-arginine (Arg) concentration in aqueous solutions was quantified by a HPLC gra-
dient method with a flow rate of 2 mL/min, and a temperature of 40 oC; the general
parameter are summarised in table A.1. Two mobile phases were used: an aequeous
buffer solution (5 mM Na2HPO4, 10 mM Na2B4O7, 0.1 wt% NaN3; pH 8.2), and a
mixture of acetonitrile, methanol and water (45:45:10 in vol%). The standard ratio
was 98 % buffer solution and 2 % organic solvent; the gradient of the mobile phases
was set, as given in table A.2.
Due to very small Arg concentrations, it was necessary to derivate Arg with a flu-
Figure A.1: Arg derivatization with OPA. Arg as well as other molecules with a
primary amines, reacts with OPA in presence of a thiol. The product is a fluorescent
derivative of the amine. (according to [1])
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Table A.1: HPLC procedure: General parameter.
analysis parameter
Temperature 40 oC
Flow rate 2 mL/min
Fluorescence detector:
- Emission wavelenght 450 nm
- Excitation wavelenght 230 nm
- Photomultiplier tube 9
Table A.2: HPLC procedure: Gradient parameter. A mixture of two mobile
phases is used (a borate-phosphate buffer solution, and an organic phase of acetoni-
trile, methanol, and water). In the progress of each measurement, the mixture ratio
was varied, as given below.
time buffer solution
(min) (vol%)
0.0 98.0 %
1.0 98.0 %
5.5 54.8 %
5.6 0.0 %
6.9 0.0 %
7.1 98.0 %
7.2 (stop time) 98.0 %
Table A.3: HPLC procedure: Derivatization of Arg using OPA.
autosampler program
1 Draw borate buffer solution 2.5 µL
2 Wash needle 20 s
3 Draw sample 0.5 µL
4 Mix (5x) stroke of 3.0 µL
5 Wait 0.2 min
6 Draw OPA solution 0.5 µL
7 Mix (10x) stroke of 3.5 µL
8 Inject
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orescence label, and to detect the Arg derivative by a fluorescence detector. In
detail, derivatization process with ortho-phthaldehyde (OPA) was performed by the
autosampler, as given in table A.3. The reaction is shown in fig. A.1. In fact, the
derivatised Arg molecules were excitated with a wavelenght of 230 nm, the detected
wavelenght was 450 nm. Besides, OPA itself is nonfluorescent.
In this context, it is very important to mention that the derivatization process al-
ways took the same time duration, otherwise, it would not be possible to set different
chromatograms in quantitative relation to each other, because the fluorescence of
the Arg derivative changes much in time. Furthermore, the derivatization reagent,
OPA, is not very stable at room temperature, and under oxygen. It was observed
that the slope of the calibration line changes continuously over time, therefore, cal-
ibration solutions were frequently measured inbetween.
References
[1] C. Woodward, J.W. Henderson. High-Speed Amino Acid Analysis (AAA) on 1.8 µm Reversed-
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Appendix B
Finite Element Method:
Programming Code
In the following, the programming codes, developed in chapter 4 and 6, are shown.
B.1 Modeling Drug Release from Silicone Micropar-
ticles
unit UFiniteE1;
//----------------------------------------//
// iii = 0 konst. DiffKoeff //
// iii = 1 D[i] = f(n[i]/n0[i]) //
// iii = 2 D[i],D2[i] //
// n[i],nFrei[i]=f(n[i]/n0[i]) //
// iii = 3 D[i],D2[i] //
// n[i],nFrei[i]=f(n0[i]-n[i]) //
// iii = 4 D[i] = f(t) //
// iii = 5 D[i] = f(t) + D(PDMS) //
// iii = 6 D[i] = f(t,n[i]/n0{i]) //
//----------------------------------------//
interface
uses
Windows, Messages, SysUtils, Classes, Graphics, Controls, Forms, Dialogs,
StdCtrls, ExtCtrls, Spin;
type
TForm1 = class(TForm)
Memo1: TMemo;
Button1: TButton;
Edit1: TEdit;
PaintBox1: TPaintBox;
Memo2: TMemo;
279
Modeling Drug Release from Silicone Microparticles
Memo3: TMemo;
Memo4: TMemo;
Memo5: TMemo;
SpinEdit1: TSpinEdit;
procedure FormCreate(Sender: TObject);
procedure Button1Click(Sender: TObject);
private
{ Private-Deklarationen}
public
{ Public-Deklarationen}
end;
const NSchichten=1000; // bis N = 813 ist bei mitKonzGrad=1 nges = nges in memo5
var
Form1: TForm1;
t, nFreigesetzt:extended;
Gehalt, GehaltTHEO, DichteSP, MolareMasse, nges, radius, deltaX, DeltaXH2O, deltaT:double;
diffKoeff, DiffFaktorPDMS, DiffFaktorFrei:double;
h, qhours, hilfINT, mitSPKonzGradient, NH2O, DiffGrenze:integer;
hilf:extended;
hilfDOUBLE:double;
hilfINT:integer;
Volumen,:array[1..(NSchichten+1)] of extended;
Flaeche,StoffmengeFrei:array[1..NSchichten] of extended;
Stoffmenge, StoffmengeAlt, Stoffmenge0, Diff, Diff2, Diffundiere:array[1..(NSchichten+1)] of double;
implementation
{$R *.DFM}
procedure TForm1.FormCreate(Sender: TObject);
var i:integer;
begin
Gehalt := 0.104; // SP 15%-k haben einen Gehalt von etwa 10,4%
deltaT := 0.0001; // iii=0; DiffKoeff/100; N 200; R 300; DeltaT 0.35
radius := 0.0003; //Meter
diffKoeff := 6.1E-10; // 6.1E-10 m^2/s
DiffFaktorPDMS := 1.0E-7; // diffusion coefficient in the silicone: DiffFaktorPDMS*DiffKoeff
DiffFaktorFrei := 2.2E-6; // diffusion coefficient of "free" drug in the particle: DiffFaktorFrei*DiffKoeff
MolareMasse := 174.2; // g/mol
mitSPKonzGradient := 0;
GehaltTHEO := 0.15;
DichteSP := 1E06; // g/m^3
deltaX := radius/NSchichten;
nges := Gehalt * DichteSP/MolareMasse * 4/3 * pi * radius*radius*radius;
for i:=1 to NSchichten do Volumen[i] :=4/3*pi*deltaX*deltaX*deltaX*(i*i*i-(i-1)*(i-1)*(i-1));
for i:=1 to NSchichten do Flaeche[i] :=4*pi*deltaX*deltaX*(i*i);
for i:=1 to NSchichten do Stoffmenge0[i] :=Gehalt*DichteSP/MolareMasse*Volumen[i]; // mol
//mitSPKonzGradient=1: Stoffmenge0[i] wird später geändert
Volumen[NSchichten+1] :=10000;
h:=paintbox1.height;
end;
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procedure TForm1.Button1Click(Sender: TObject);
var i, grenze:LongInt;
ii,iii,j,tmp,x,y,weiter:integer;
begin
//****************************//
// Variablen-Initialisierung //
//****************************//
iii:=spinedit1.value;
grenze:=strToInt(edit1.text);
if (mitSPKonzGradient = 1) then
begin
for j:=1 to NSchichten do
begin
Stoffmenge0[j] := 0;
Stoffmenge0[j] := GehaltTHEO *( j*j*j*(1-j/NSchichten) - (j-1)*(j-1)*(j-1)*( 1 - (j-1)/NSchichten ) );
Stoffmenge0[j] := Stoffmenge0[j] + Gehalt * ( (4*j - 6)/NSchichten*j*j + (4*j -1)/NSchichten );
Stoffmenge0[j] := Stoffmenge0[j] * DichteSP*4/3*pi*radius*radius*radius/NSchichten/NSchichten/NSchichten;
Stoffmenge0[j] := Stoffmenge0[j] / MolareMasse;
end;
end
else
begin
for j:=1 to NSchichten do
Stoffmenge0[j] :=Gehalt*DichteSP/MolareMasse*Volumen[j];
end;
for j:=1 to NSchichten do StoffmengeAlt[j] :=Stoffmenge0[j];
for j:=1 to NSchichten do Stoffmenge[j] :=Stoffmenge0[j];
for j:=1 to NSchichten do StoffmengeFrei[j] :=0;
t:=0;
tmp :=0;
qhours:=1;
nFreigesetzt:=0;
StoffmengeAlt[NSchichten+1] :=0;
if (iii=2) then
begin
Diff[NSchichten+1] := DiffFaktorPDMS*DiffKoeff;
Diff2[NSchichten+1] := DiffFaktorFrei*DiffKoeff;
end
else
begin
Diff[NSchichten+1] := DiffFaktorFrei*DiffKoeff;
end;
for ii:=1 to NSchichten do
begin
Diff[ii] := 0;
Diff2[ii] := 0;
end;
with Paintbox1.canvas do
begin
brush.color:=clwhite;
rectangle(0,0,width,height);
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{ pen.color:=clmaroon;
brush.color:=clmaroon; }
end;
//************************//
// Bestimmung von DeltaT //
//************************//
if (iii<2) then
DeltaT := 0.5 *( radius*radius /( (DiffFaktorPDMS+DiffFaktorFrei)/2 *DiffKoeff ) /NSchichten/NSchichten )
else
DeltaT := 0.5/3 *( radius*radius /(DiffFaktorFrei*DiffKoeff) /NSchichten/NSchichten );
//**********************************//
// Textausgabe der einzelnen Memos //
//**********************************//
memo1.Clear;
memo2.Clear;
memo3.Clear;
memo4.Clear;
memo5.Clear;
memo1.lines.add('molar amount (outside):');
memo2.lines.add('time (in h)');
memo3.lines.add('profile:');
if (mitSPKonzGradient = 1) then
memo3.lines.add('concentration in the shell i')
else
memo3.lines.add('percental amount of molar amount in the shell i');
memo4.lines.add('profile:');
memo4.lines.add('timepoint (h): ');
memo5.lines.add('iii=' + IntToStr(iii) + ' is chosen:');
if (iii=0) then
begin
memo5.lines.add('D = D(PDMS)');
memo5.lines.add('D(PDMS): ' + FloatToStrF((DiffKoeff*DiffFaktorPDMS),ffExponent,3,4) + 'm^2/s');
end
else if (iii=1) then
begin
memo5.lines.add('D = D(PDMS)*(1-n[ii]/n0[ii])');
memo5.lines.add('D(PDMS): ' + FloatToStrF((DiffKoeff*DiffFaktorPDMS),ffExponent,3,4) + 'm^2/s');
end
else if (iii=2) then
begin
memo5.lines.add('D = D(PDMS)*(n0[ii]-n[ii])');
memo5.lines.add('D(PDMS): ' + FloatToStrF((DiffKoeff*DiffFaktorPDMS),ffExponent,3,4) + 'm^2/s');
end
else if (iii=4) then
begin
memo5.lines.add('D = D(Free) * delta(t)');
memo5.lines.add('D(Free): ' + FloatToStrF((DiffKoeff*DiffFaktorFrei),ffExponent,3,4) + 'm^2/s');
end
else if (iii=5) then
begin
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memo5.lines.add('D = D(Free) * f(t)');
memo5.lines.add('D(PDMS)');
memo5.lines.add('D(PDMS): ' + FloatToStrF((DiffKoeff*DiffFaktorPDMS),ffExponent,3,4) + 'm^2/s');
memo5.lines.add('D(Free): ' + FloatToStrF((DiffKoeff*DiffFaktorFrei),ffExponent,3,4) + 'm^2/s');
end
else if (iii=6) then
begin
memo5.lines.add('D = D(Free)*(1-n[ii]/n0[ii]) * f(t)');
memo5.lines.add('D = D(PDMS)*(1-n[ii]/n0[ii])');
memo5.lines.add('D(PDMS): ' + FloatToStrF((DiffKoeff*DiffFaktorPDMS),ffExponent,3,4) + 'm^2/s');
memo5.lines.add('D(Free): ' + FloatToStrF((DiffKoeff*DiffFaktorFrei),ffExponent,3,4) + 'm^2/s');
end;
if (mitSPKonzGradient = 1) then
memo5.lines.add('SP: with concentration gradient')
else
memo5.lines.add('SP: constant concentration');
memo5.lines.add('different parameter:') ;
memo5.lines.add('No. of Iterations ' + IntToStr(grenze)) ;
memo5.lines.add('Delta t (s)' + FloatToStrF(DeltaT,ffExponent,3,4)) ;
memo5.lines.add('PDMS PARTICLE:') ;
memo5.lines.add('radius (m) ' + FloatToStrF(radius,ffExponent,3,4)) ;
memo5.lines.add('matrix density (g/m3) ' + FloatToStrF(DichteSP,ffExponent,3,4)) ;
memo5.lines.add('No. of layers ' + IntToStr(NSchichten)) ;
memo5.lines.add('Delta x (m) ' + FloatToStrF(DeltaX,ffExponent,3,4)) ;
memo5.lines.add('drug content (wt%) ' + FloatToStrF(Gehalt,ffExponent,3,4)) ;
memo5.lines.add('DRUG:') ;
memo5.lines.add('molar mass (g/mol) ' + FloatToStrF(MolareMasse,ffExponent,3,4)) ;
memo5.lines.add('diffusion coefficient (m2/s) ' + FloatToStrF(DiffKoeff,ffExponent,3,4)) ;
memo5.lines.add('total molar amount (mol) ' + FloatToStrF(nges,ffExponent,3,4)) ;
nges := 0;
for ii:=1 to NSchichten do
nges := nges + Stoffmenge0[ii];
memo5.lines.add('total molar amount (mol) ' + FloatToStrF(nges,ffExponent,3,4)) ;
memo5.lines.add('total time interval (h) ' + FloatToStrF((DeltaT*grenze/3600),ffGeneral,5,6)) ;
// Ausgabe für t = 0 h
memo1.lines.add(FloatToStrF((Stoffmenge[NSchichten+1]),ffGeneral,3,1)) ;
memo2.lines.add(FloatToStrF((t/3600),ffGeneral,4,5)) ;
memo4.lines.add(FloatToStrF((t/3600),ffGeneral,4,5) + ' h') ;
if (mitSPKonzGradient = 1) then
begin
for ii:=1 to NSchichten do
begin
memo3.lines.add(FloatToStrF((Stoffmenge[ii]/Volumen[ii]*1E-3),ffGeneral,3,4)) ;
end;
end
else
begin
for ii:=1 to NSchichten do
begin
memo3.lines.add(FloatToStrF((Stoffmenge[ii]*100/Stoffmenge0[ii]),ffGeneral,3,4)) ;
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end;
end;
//*************************************//
// Initialisierung der Hilfsparameter //
//*************************************//
x := 0;
hilfInt := NSchichten; // 2 <= hilfInt <= NSchichten !!!
nH2O := NSchichten; // 2 <= nH2O <= NSchichten !!!
DiffGrenze := NSchichten-1; // 2 <= DiffGrenze <= (NSchichten-1) !!!
Diffundiere[NSchichten+1] := 1;
Diffundiere[NSchichten] := 1;
//******************************//
// vor der SCHLEIFE //
// Bestimmung des Diff.-koeff. //
// iii=0: DiffKoeff //
// sonst: Diff =0, Diff2 =0 //
//******************************//
if (iii=0) then
begin
Diffkoeff := DiffFaktorPDMS*Diffkoeff;
end;
if (iii=4) then // iii=4: keine Diff zwischen Schichten nH2O und nH2O-1
begin
Diffkoeff := DiffFaktorFrei*Diffkoeff;
end;
for ii:=1 to (NSchichten) do
begin
Diff[ii] := 0;
Diff2[ii] := 0;
end;
/////////////////////////////////////////////////////////////////////////////
// //
// Beginn der for-SCHLEIFE !!! //
/////////////////////////////////////////////////////////////////////////////
for i:=1 to grenze do
begin
t:=t+deltaT;
//**************************************//
// SCHLEIFE: //
// iii=0,1,5: Bestimmung von HilfInt //
// iii=4,5,6: Bestimmung von DeltaXH2O //
// iii=2,3: Bestimmung von DiffGrenze //
//**************************************//
// HilfINT ist die äußerste Schale, aus der noch nichts freigesetzt wurde
if (iii<2) or (iii=5) then
begin
weiter := 1;
for ii:=hilfInt downto 2 do // soll ja nur bis 2 runtergehen
begin
if (weiter=1) then
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begin
if (Stoffmenge[ii] = Stoffmenge0[ii]) then
begin
hilfInt := ii; //hilfInt := ii+1;
weiter := 0;
end;
end;
end;
if (weiter=1) then
hilfInt := 2;
end;
// -1E-05x4 + 0,0035x3 - 0,3723x2 + 19,888x - 24,815 (x=t, t in h, Rest in um)
// Schichtdicke in m: -5.95E-26*t^4 + 7.5E-20*t^3 - 2.87E-14*t^2 + 5.524E-09*t - 2.4815E-05 (t in s)
if (iii>3) then
begin
DeltaXH2O := -5.95E-26*t*t*t*t + 7.5E-20*t*t*t - 2.87E-14*t*t + 5.524E-09*t - 2.4815E-05;
if (DeltaXH2O < 0) then
DeltaXH2O := 0;
DeltaXH2O := DeltaXH2O / DeltaX;
nH2O := NSchichten - Trunc(DeltaXH2O);
if (nH2O <2) then
nH2O := 2;
end;
// iii=4: keine Diff zwischen Schichten nH2O und nH2O-1 (ANFANG)
if (iii=4) then
begin
hilfInt := nH2O;
end;
// iii=4: keine Diff zwischen Schichten nH2O und nH2O-1 (ENDE)
// Bestimmung von Diffgrenze (die äußerste Schicht, in welcher keine Diff2 stattfindet!
// 2 <= Diffgrenze <= NSchichten !!!
if (iii=2) or (iii=3) then
begin
weiter := 1;
for ii:=DiffGrenze downto 2 do
begin
if (weiter=1) then
begin
if ( ((Stoffmenge0[ii]-StoffmengeAlt[ii])/Volumen[ii]) < (StoffmengeAlt[ii+1]/Volumen[ii+1]) ) then
begin
DiffGrenze := ii;
weiter := 0;
end;
end;
end;
if (weiter = 1) then
DiffGrenze := 2;
end;
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//******************************//
// SCHLEIFE: //
// Bestimmung des Diff.-koeff. //
// iii<>0: Diff[ii] //
// iii=2,3: Diff2[ii] //
//******************************//
//-----------------------------------//
// iii = 1 //
// D[i] = f(n[i]/n0[i]) //
//-----------------------------------//
if (iii=1) then
begin
//for ii:=1 to (NSchichten) do
for ii:=hilfInt to NSchichten do
begin
Diff[ii]:= DiffFaktorPDMS * Diffkoeff * (1 - StoffmengeAlt[ii]/Stoffmenge0[ii]);
end;
Diff[1]:= DiffFaktorPDMS * Diffkoeff * (1 - StoffmengeAlt[1]/Stoffmenge0[1]);
end
//-----------------------------------//
// iii = 2 //
// D[i],D2[i] //
// n[i],nFrei[i]=f(n[i]/n0[i]) //
//-----------------------------------//
else if (iii=2) then
begin
StoffmengeFrei[NSchichten] := (1-StoffmengeAlt[NSchichten]/Stoffmenge0[NSchichten]) *StoffmengeAlt[NSchichten];
for ii:=(NSchichten-1) downto 1 do
begin
StoffmengeFrei[ii] := ( 1 - StoffmengeAlt[ii]/Stoffmenge0[ii] ) * StoffmengeAlt[ii];
hilf := StoffmengeFrei[ii+1] / Volumen[ii+1] * Volumen[ii] ;
if (StoffmengeFrei[ii] <= hilf) then
begin
StoffmengeFrei[ii] := hilf;
end;
end
//-----------------------------------//
// iii = 3 //
//-----------------------------------//
else if (iii=3) then
begin
exit;
end
//-----------------------------------//
// iii = 4 //
// D[i] = f(t) //
//-----------------------------------//
// iii=4: keine Diff zwischen Schichten nH2O und nH2O-1
//-----------------------------------//
// iii = 5 //
// D[i] = f(t) + D(PDMS) //
//-----------------------------------//
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else if (iii = 5) then
begin // begin(iii=5)
if (mitSPKonzGradient = 1) then
begin //begin(mitSPKonzGrad)
if ( (DeltaXH2O - (NSchichten-nH2O)) > 0.5 ) then
begin
Diff[nH2O] := DiffFaktorFrei * Diffkoeff;
end
else
begin
Diff[nH2O] := DiffFaktorPDMS * Diffkoeff;
end;
for ii:=1 to (nH2O-1) do
begin
Diff[ii] := DiffFaktorPDMS * Diffkoeff;
end;
for ii:=(nH2O+1) to NSchichten do
begin
Diff[ii] := DiffFaktorFrei * Diffkoeff;
end;
end //end(mitSPKonzGrad)
else
begin //begin(ohneSPKonzGrad)
if ( (DeltaXH2O - (NSchichten-nH2O)) > 0.5 ) then
begin
Diff[nH2O] := DiffFaktorFrei * Diffkoeff;
end
else
begin
if ( Stoffmenge[nH2O] = StoffmengeAlt[nH2O]) then
Diff[nH2O] := 0
else
Diff[nH2O] := DiffFaktorPDMS * Diffkoeff;
end;
for ii:=(nH2O+1) to NSchichten do
begin
Diff[ii] := DiffFaktorFrei * Diffkoeff;
end;
if (hilfInt < nH2O) then
begin
for ii:=hilfINT to (nH2O-1) do
begin
if (StoffmengeAlt[ii] = Stoffmenge0[ii]) then
Diff[ii] := 0
else
Diff[ii] := DiffFaktorPDMS * DiffKoeff;
end;
end;
if (hilfInt = 2) or (nH2O=2) then
begin
if (nH2O=2) and ( (NSchichten - DeltaXH2O) > 0.5) then
Diff[1] := DiffFaktorFrei * DiffKoeff
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else
begin
if (StoffmengeAlt[1] = Stoffmenge0[1]) then
Diff[1] := 0
else
Diff[1] := DiffFaktorPDMS * DiffKoeff;
end;
end;
end; //end(ohneSPKonzGrad)
end // end(iii=5)
//-----------------------------------//
// iii = 6 //
// D[i] = f(t,n[i]/n0{i]) //
//-----------------------------------//
else if (iii=6) then
begin
for ii:=NSchichten downto 1 do
begin
if ( (DeltaXH2O - (NSchichten-ii)) > 0.5 ) then
begin
Diff[ii] := DiffFaktorFrei * Diffkoeff * (1 - StoffmengeAlt[ii]/Stoffmenge0[ii]);
if ( Diff[ii] < (DiffFaktorPDMS * Diffkoeff) ) then
begin
Diff[ii] := DiffFaktorPDMS * Diffkoeff;
end;
end
else
begin
Diff[ii] := DiffFaktorPDMS * Diffkoeff;
end;
end;
//-----------------------------------//
// iii = 0 //
// konst. DiffKoeff //
//-----------------------------------//
end;
//************************************************//
//* SCHLEIFE: *//
//* Berechnung der Stoffmenge *//
//* iii=0: ( hilfInt -> N-1; 1; N ) *//
//* -> DiffKoeff *//
//* iii=1: ( HilfInt -> N-1; 1; N ) *//
//* -> (Diff[ii]+Diff[ii+1])/2 *//
//* iii=4: ( nH2O -> N-1; 1; N ) *//
//* -> (Diff[ii]+Diff[ii+1])/2 *//
//* iii=5: ( (nH2O OR hilfInt) -> N-1; 1; N ) *//
//* -> (Diff[ii]+Diff[ii+1])/2 *//
//* iii=2,3: ( hilfInt -> N-1; 1; N ) *//
//* -> (Diff[ii]+Diff[ii+1])/2 *//
//* -> (Diff2[ii]+Diff2[ii+1])/2 *//
//* iii=6: ( 1 -> N-1; 1; N ) *//
//* -> (Diff[ii]+Diff[ii+1])/2 *//
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//************************************************//
// ---
if (iii=0) then {iii=0: DiffKoeff constant}
begin
if (Stoffmenge[1] < Stoffmenge0[1]) then
Stoffmenge[1]:= StoffmengeAlt[1]
+ diffKoeff*deltaT/deltaX
*(-Flaeche[1]*(StoffmengeAlt[1]/Volumen[1]-StoffmengeAlt[2]/Volumen[2]));
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ diffKoeff*deltaT/deltaX
*( Flaeche[NSchichten-1] *( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- Flaeche[NSchichten] * StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
if (hilfInt = NSchichten) or (hilfInt = (NSchichten-1) ) then
begin
if (hilfInt = (NSchichten-1) ) then
Stoffmenge[NSchichten-1]
:= StoffmengeAlt[NSchichten-1] + diffKoeff*deltaT/deltaX
*( Flaeche[NSchichten-2]
*( StoffmengeAlt[NSchichten-2]/Volumen[NSchichten-2]
- StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1] )
- Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] ) );
end
else
begin
for ii:=hilfInt to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ diffKoeff*deltaT/deltaX
*( Flaeche[ii-1] * ( StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii] )
- Flaeche[ii] * ( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
end;
end;
end
// ---
else if (iii=1) then { (Diff[ii]+Diff[ii+1])/2; hilfINT}
begin //Diff dependent on shell i and time
if (Stoffmenge[1] < Stoffmenge0[1]) then
Stoffmenge[1]
:= StoffmengeAlt[1]
+ (Diff[1]+Diff[2])/2*deltaT/deltaX
*( -Flaeche[1] * (StoffmengeAlt[1]/Volumen[1]-StoffmengeAlt[2]/Volumen[2] ) );
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX
*( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
* ( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
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- Flaeche[NSchichten] * (Diff[NSchichten]+Diff[NSchichten+1])/2
* StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
if hilfInt < NSchichten then
begin
for ii:=hilfInt to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX
*( (Diff[ii-1]+Diff[ii])/2 * Flaeche[ii-1]
*( StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii] )
- ( Diff[ii]+Diff[ii+1] )/2 * Flaeche[ii]
*( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
end;
end;
end
// ---
else if (iii=4) then // (Diff[ii]+Diff[ii+1])/2; hilfINT
begin //Diff dependent on shell i and time // iii=4: keine Diff zwischen Schichten nH2O und nH2O-1
//--
if (nH2O = (NSchichten) ) then
begin
Stoffmenge[NSchichten] := StoffmengeAlt[NSchichten]
- deltaT/deltaX*DiffKoeff
* Flaeche[NSchichten] * StoffmengeAlt[NSchichten]/Volumen[NSchichten];
end
//--
else if (nH2O = (NSchichten-1) ) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX*DiffKoeff
*( Flaeche[NSchichten-1] *( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- Flaeche[NSchichten]*StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
Stoffmenge[nH2O]
:= StoffmengeAlt[nH2O]
- deltaT/deltaX*DiffKoeff * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1] );
end
//--
else if (nH2O < 3) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX*DiffKoeff
*( Flaeche[NSchichten-1] *( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten])
- Flaeche[NSchichten]*StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
for ii:=nH2O+1 to (NSchichten-1) do
begin
Stoffmenge[ii]
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:= StoffmengeAlt[ii]
+ deltaT/deltaX * DiffKoeff
*( Flaeche[ii-1] *(StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii])
- Flaeche[ii] *(StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1]) );
end;
if ( (NSchichten - DeltaXH2O) > 0.5) then
begin
nH2O := 2;
Stoffmenge[nH2O]
:= StoffmengeAlt[nH2O]
- deltaT/deltaX*DiffKoeff * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1] );
end
else
begin
Stoffmenge[2]
:= StoffmengeAlt[2]
+ deltaT/deltaX * DiffKoeff
*( Flaeche[1] * ( StoffmengeAlt[1]/Volumen[1]-StoffmengeAlt[2]/Volumen[2] )
- Flaeche[2] * ( StoffmengeAlt[2]/Volumen[2]-StoffmengeAlt[3]/Volumen[3] ) );
Stoffmenge[1]
:= StoffmengeAlt[1]
- deltaT/deltaX*DiffKoeff * Flaeche[1]
*( StoffmengeAlt[1]/Volumen[1] - StoffmengeAlt[2]/Volumen[2] );
end;
end
//--
else
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX*DiffKoeff
*( Flaeche[NSchichten-1] *( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten])
- Flaeche[NSchichten] * StoffmengeAlt[NSchichten]/Volumen[NSchichten]);
Stoffmenge[nH2O]
:= StoffmengeAlt[nH2O]
- deltaT/deltaX*DiffKoeff * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1] );
for ii:=nH2O+1 to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX * DiffKoeff
*( Flaeche[ii-1] *( StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii] )
- Flaeche[ii] *( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
end;
end
end
// ---
else if (iii=5) then { (Diff[ii]+Diff[ii+1])/2; hilfINT}
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begin //Diff dependent on shell i and time
if ( hilfINT < nH2O ) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX
*( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- (Diff[NSchichten]+Diff[NSchichten+1])/2 * Flaeche[NSchichten]
* StoffmengeAlt[NSchichten]/Volumen[NSchichten]);
for ii:=hilfInt to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX
*( (Diff[ii-1]+Diff[ii])/2 * Flaeche[ii-1]
*( StoffmengeAlt[ii-1]/Volumen[ii-1] - StoffmengeAlt[ii]/Volumen[ii] )
- (Diff[ii]+Diff[ii+1])/2 * Flaeche[ii]
*( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
if (hilfInt = 2) then
begin
Stoffmenge[1]
:= StoffmengeAlt[1]
- deltaT/deltaX
*( (Diff[1]+Diff[2])/2 * Flaeche[1]
*( StoffmengeAlt[1]/Volumen[1] - StoffmengeAlt[2]/Volumen[2] ) ) ;
end;
end;
end
else
begin
// ----
if (nH2O = (NSchichten) ) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
- deltaT/deltaX * Flaeche[NSchichten] * (Diff[NSchichten+1]+Diff[NSchichten])/2
* StoffmengeAlt[NSchichten]/Volumen[NSchichten];
end
//--
else if (nH2O = (NSchichten-1) ) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX
*( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- (Diff[NSchichten+1]+Diff[NSchichten])/2 * Flaeche[NSchichten]
* StoffmengeAlt[NSchichten]/Volumen[NSchichten]);
Stoffmenge[nH2O]
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:= StoffmengeAlt[nH2O]
- deltaT/deltaX * (Diff[nH2O+1]+Diff[nH2O])/2 * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1] );
end
//--
else if (nH2O < 3) then
begin
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX *( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- (Diff[NSchichten+1]+Diff[NSchichten])/2 * Flaeche[NSchichten]
* StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
for ii:=nH2O+1 to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX
*( (Diff[ii-1]+Diff[ii])/2 * Flaeche[ii-1]
*( StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii] )
- (Diff[ii+1]+Diff[ii])/2 * Flaeche[ii]
*( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
end;
if ( (NSchichten - DeltaXH2O) > 0.5) then
begin
nH2O := 2;
Stoffmenge[nH2O]
:= StoffmengeAlt[nH2O]
- deltaT/deltaX * (Diff[nH2O+1]+Diff[nH2O])/2 * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1] );
end
else
begin
Stoffmenge[2]
:= StoffmengeAlt[2]
+ deltaT/deltaX
*( (Diff[1]+Diff[2])/2 * Flaeche[1]
*( StoffmengeAlt[1]/Volumen[1]-StoffmengeAlt[2]/Volumen[2] )
- (Diff[3]+Diff[2])/2 * Flaeche[2]
*( StoffmengeAlt[2]/Volumen[2]-StoffmengeAlt[3]/Volumen[3] ) );
Stoffmenge[1]
:= StoffmengeAlt[1]
- deltaT/deltaX
*(Diff[1]+Diff[2])/2 * Flaeche[1]
*( StoffmengeAlt[1]/Volumen[1] - StoffmengeAlt[2]/Volumen[2] );
end;
end
//--
else
begin
Stoffmenge[NSchichten]
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:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX *( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- (Diff[NSchichten+1]+Diff[NSchichten])/2 * Flaeche[NSchichten]
* StoffmengeAlt[NSchichten]/Volumen[NSchichten]);
Stoffmenge[nH2O]
:= StoffmengeAlt[nH2O]
- deltaT/deltaX * (Diff[nH2O+1]+Diff[nH2O])/2 * Flaeche[nH2O]
*( StoffmengeAlt[nH2O]/Volumen[nH2O] - StoffmengeAlt[nH2O+1]/Volumen[nH2O+1]);
for ii:=nH2O+1 to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX *( (Diff[ii-1]+Diff[ii])/2 * Flaeche[ii-1]
*(StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii])
- (Diff[ii+1]+Diff[ii])/2 * Flaeche[ii]
*(StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1]) );
end;
end;
// ------
end;
end
// ---
else if (iii=6) then // (Diff[ii]+Diff[ii+1])/2 ; nH2O
begin
if (Stoffmenge[1] < Stoffmenge0[1]) then
Stoffmenge[1]
:= StoffmengeAlt[1]
+ (Diff[1]+Diff[2])/2 * deltaT/deltaX
*( -Flaeche[1] *( StoffmengeAlt[1]/Volumen[1]-StoffmengeAlt[2]/Volumen[2] ) );
Stoffmenge[NSchichten]
:= StoffmengeAlt[NSchichten]
+ deltaT/deltaX *( (Diff[NSchichten-1]+Diff[NSchichten])/2 * Flaeche[NSchichten-1]
*( StoffmengeAlt[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeAlt[NSchichten]/Volumen[NSchichten] )
- Flaeche[NSchichten] *(Diff[NSchichten]+Diff[NSchichten+1])/2
* StoffmengeAlt[NSchichten]/Volumen[NSchichten] );
for ii:=2 to (NSchichten-1) do
begin
Stoffmenge[ii]
:= StoffmengeAlt[ii]
+ deltaT/deltaX *( (Diff[ii-1]+Diff[ii])/2 * Flaeche[ii-1]
*( StoffmengeAlt[ii-1]/Volumen[ii-1]-StoffmengeAlt[ii]/Volumen[ii] )
- (Diff[ii]+Diff[ii+1])/2 * Flaeche[ii]
*( StoffmengeAlt[ii]/Volumen[ii]-StoffmengeAlt[ii+1]/Volumen[ii+1] ) );
end;
end
// ---
else // iii=2,3 // (Diff[ii]+Diff[ii+1])/2+(Diff2[ii]+Diff2[ii+1])/2 ; HilfINT
begin //two different diffusions
294 www.bth.rwth-aachen.de
Finite Element Method: Programming Code
Stoffmenge[1]
:= (-1) * DiffFaktorPDMS * Flaeche[1]
*( (StoffmengeAlt[1]-StoffmengeFrei[1])/Volumen[1]
- (StoffmengeAlt[1+1]-StoffmengeFrei[1+1])/Volumen[1+1] );
Stoffmenge[1]
:= Stoffmenge[1] - DiffFaktorFrei * Flaeche[1]
*( StoffmengeFrei[1]/Volumen[1] - StoffmengeFrei[1+1]/Volumen[1+1] );
Stoffmenge[1] := Stoffmenge[1] * deltaT/deltaX * DiffKoeff ;
Stoffmenge[1] := Stoffmenge[1] + StoffmengeAlt[1];
for ii:=(2) to (NSchichten-1) do
begin
Stoffmenge[ii]
:= DiffFaktorPDMS
*( Flaeche[ii-1] *( (StoffmengeAlt[ii-1]-StoffmengeFrei[ii-1])/Volumen[ii-1]
- (StoffmengeAlt[ii]-StoffmengeFrei[ii])/Volumen[ii] )
- Flaeche[ii] *( (StoffmengeAlt[ii]-StoffmengeFrei[ii])/Volumen[ii]
- (StoffmengeAlt[ii+1]-StoffmengeFrei[ii+1])/Volumen[ii+1] ) );
Stoffmenge[ii]
:= Stoffmenge[ii]
+ DiffFaktorFrei
*( Flaeche[ii-1] * (StoffmengeFrei[ii-1]/Volumen[ii-1]- StoffmengeFrei[ii]/Volumen[ii])
- Flaeche[ii] * (StoffmengeFrei[ii]/Volumen[ii]-StoffmengeFrei[ii+1]/Volumen[ii+1]) );
Stoffmenge[ii] := Stoffmenge[ii] * deltaT/deltaX * DiffKoeff ;
Stoffmenge[ii] := Stoffmenge[ii] + StoffmengeAlt[ii];
end;
Stoffmenge[NSchichten]
:= DiffFaktorPDMS * Flaeche[NSchichten-1]
*( (StoffmengeAlt[NSchichten-1]-StoffmengeFrei[NSchichten-1])/Volumen[NSchichten-1]
- (StoffmengeAlt[NSchichten]-StoffmengeFrei[NSchichten])/Volumen[NSchichten] );
Stoffmenge[NSchichten]
:= Stoffmenge[NSchichten]
+ DiffFaktorFrei * Flaeche[NSchichten-1] *( StoffmengeFrei[NSchichten-1]/Volumen[NSchichten-1]
- StoffmengeFrei[NSchichten]/Volumen[NSchichten] );
Stoffmenge[NSchichten]
:= Stoffmenge[NSchichten]
- DiffFaktorPDMS * Flaeche[NSchichten]
*(StoffmengeAlt[NSchichten]-StoffmengeFrei[NSchichten])/Volumen[NSchichten];
Stoffmenge[NSchichten]
:= Stoffmenge[NSchichten]
- DiffFaktorFrei * Flaeche[NSchichten] * StoffmengeFrei[NSchichten]/Volumen[NSchichten];
Stoffmenge[NSchichten] := Stoffmenge[NSchichten] * deltaT/deltaX * DiffKoeff;
Stoffmenge[NSchichten] := Stoffmenge[NSchichten] + StoffmengeAlt[NSchichten];
if Stoffmenge[NSchichten] < 0 then
memo3.lines.add( 'n[N]: ' + FloatToStrF( (Stoffmenge[NSchichten]),ffGeneral,3,1 ) );
end;
//************************************************//
//* SCHLEIFE: *//
//* Berechnung der Stoffmenge(außen:N+1) *//
//* iii=0,4: *//
//* -> DiffKoeff *//
//* iii=1,5,6: *//
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//* -> (Diff[N]+Diff[N+1])/2 *//
//* iii=2,3: *//
//* -> (Diff[N]+Diff[N+1])/2 *//
//* -> (Diff2[N]+Diff2[N+1])/2 *//
//************************************************//
if (iii=0) or (iii=4) then // DiffKoeff
Stoffmenge[NSchichten+1]
:= StoffmengeAlt[NSchichten+1]
+ deltaT/deltaX *Flaeche[NSchichten] *StoffmengeAlt[NSchichten]/Volumen[NSchichten] *diffKoeff
else if (iii=1) or (iii=5) or (iii=6) then // (Diff[ii]+Diff[ii+1])/2
Stoffmenge[NSchichten+1]
:= StoffmengeAlt[NSchichten+1]
+ deltaT/deltaX * Flaeche[NSchichten] * StoffmengeAlt[NSchichten]/Volumen[NSchichten]
* Diff[NSchichten]+Diff[NSchichten+1])/2
else // iii=2, iii=3, // (Diff[ii]+Diff[ii+1])/2 UND (Diff2[ii]+Diff2[ii+1])/2
begin
Stoffmenge[NSchichten+1]:= DiffFaktorPDMS * (StoffmengeAlt[NSchichten]-StoffmengeFrei[NSchichten]) ;
Stoffmenge[NSchichten+1]:= DiffFaktorFrei * StoffmengeFrei[NSchichten] ;
Stoffmenge[NSchichten+1]:= DiffFaktorPDMS * (StoffmengeAlt[NSchichten]-StoffmengeFrei[NSchichten])
+ DiffFaktorFrei * StoffmengeFrei[NSchichten] ;
Stoffmenge[NSchichten+1]:= Stoffmenge[NSchichten+1] *deltaT/deltaX
* Flaeche[NSchichten]/Volumen[NSchichten] * DiffKoeff ;
Stoffmenge[NSchichten+1]:= Stoffmenge[NSchichten+1] + StoffmengeAlt[NSchichten+1] ;
end;
//************************************************//
//* *//
//* AUSGABE *//
//* *//
//************************************************//
for ii:=1 to NSchichten do
begin
if (Stoffmenge[ii] < 0) then
begin
memo2.lines.add('Iteration: ' + IntToStr(i) + 'n[' + IntToStr(ii) + '] < 0');
end;
end;
if ( t >= (qhours*15*60) ) then {eine Ausgabe pro Viertelstunde}
begin
qhours := qhours + 1;
memo1.lines.add(FloatToStrF((Stoffmenge[NSchichten+1]),ffGeneral,3,1)) ;
memo2.lines.add(FloatToStrF((t/3600),ffGeneral,5,6)) ;
if ( (qhours-1) mod 4) = 0 then {eine Ausgabe pro Stunde }
begin
memo4.lines.add(FloatToStrF((t/3600),ffGeneral,4,5) + ' h') ;
if (mitSPKonzGradient = 1) then
begin
for ii:=1 to NSchichten do
begin
memo3.lines.add(FloatToStrF((Stoffmenge[ii]/Volumen[ii] * 1E-3 ),ffGeneral,3,4)) ;
// mol/m^3 * ( m / 10 dm )^3 = 1E-3 mol/L
end;
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end
else
begin
for ii:=1 to NSchichten do
begin
memo3.lines.add(FloatToStrF((Stoffmenge[ii]*100/Stoffmenge0[ii]),ffGeneral,3,4)) ;
end;
end;
end;
x:=x+1;
y:=round( (1-Stoffmenge[NSchichten+1]/(nges*1.05) )*h );
paintbox1.canvas.pixels[x,y]:=clblack;
if ( Stoffmenge[NSchichten+1] > nges * 0.9999 ) then
exit;
end;
//**************************************************//
//* ÜBERGABE: Stoffmenge -> StoffmengeAlt *//
//* iii=4: ( (nH2O-1) -> N+1 ) *//
//* iii=5: ( (nH2O-1 OR hilfInt-1) -> N+1 ) *//
//* iii=2,6: ( 1 -> N+1 ) *//
//* iii=0,1,3: ( hilfInt-1 -> N+1 ) *//
//**************************************************//
if (Stoffmenge[NSchichten+1] < StoffmengeAlt[NSchichten+1]) then
begin
memo5.lines.add('Iteration: ' + IntToStr(i) + ' n(N+1) sinkt ') ;
exit;
end;
//---
if (iii=4) then
begin
for ii:=(nH2O-1) to (NSchichten+1) do
begin
StoffmengeAlt[ii]:=Stoffmenge[ii];
end;
end
//---
else if (iii=5) then
begin
if (hilfInt < nH2O) then
begin
for ii:=(hilfINT-1) to (NSchichten+1) do
begin
StoffmengeAlt[ii]:=Stoffmenge[ii];
end;
end
else
begin
for ii:=(nH2O-1) to (NSchichten+1) do
begin
StoffmengeAlt[ii]:=Stoffmenge[ii];
end;
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end;
end
//---
else if (iii=2) or (iii=6) then
begin
for ii:=1 to (NSchichten+1) do
StoffmengeAlt[ii]:=Stoffmenge[ii];
end
//---
else // iii=0,1,3
begin
for ii:=(hilfInt-1) to (NSchichten+1) do
StoffmengeAlt[ii]:=Stoffmenge[ii];
end;
//************************************************//
//* ABBRUCH, falls Stoffmenge[ii] < 0 *//
//************************************************//
for ii:=1 to (NSchichten+1) do
begin
if (Stoffmenge[ii] < 0) then
begin
memo5.lines.add('Iteration: ' + IntToStr(i) + ' , ii: ' + IntToStr(ii)) ;
tmp := tmp +1;
if (tmp > 4) then
exit;
end;
end;
end;
end;
end.
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B.2 Modeling Drug Release in a Diffusion Cell
unit UFiniteE1;
interface
uses
Windows, Messages, SysUtils, Classes, Graphics, Controls, Forms, Dialogs,
StdCtrls, ExtCtrls, Spin;
type
TForm1 = class(TForm)
Memo1: TMemo;
Button1: TButton;
Edit1: TEdit;
PaintBox1: TPaintBox;
Memo2: TMemo;
Memo3: TMemo;
Memo4: TMemo;
Memo5: TMemo;
SpinEdit1: TSpinEdit;
procedure FormCreate(Sender: TObject);
procedure Button1Click(Sender: TObject);
private
{ Private-Deklarationen}
public
{ Public-Deklarationen}
end;
const Nhoriz = 100;
const NPU = 100; // NPU <! Nvert //AENDERN!!! // AENDERN!!! NPU := hPU/deltaZ
const Nvert = 200;
const Nb = 1; // Anzahl der FE in der Breite
const nT = 100 * Nvert; // mind. etwa 2.3 * Nvert^2/Nhoriz
const hPU = 5; // Einheit mm // muss mit NPU abgestimmt sein!!!
const hDiffzelle = 10; // Einheit mm // hDiffzelle / hPU = Nvert / NPU
const lDiffzelle = 50; // Einheit mm
const bDiffzelle = 50; // Einheit mm
const flowrate = 1100; // 1.10 mL/h = 1.10 cm^3/h = 1.10 * 1000 mm^3/h = 1100 mm^3/h
const diffKoeff = 2.196; // 6.1E-10 m^2/s = 6.1E-10 * 60^2 * 1E6 mm^2/h = 2.196 mm^2/h
const MolareMasse = 174.2; // ug/umol
const Gehalt = 0.1; // *100%
const DichtePU = 1E03; // g/mm^3
const c0 = 2000;
const barriere = 0;
const mitAuslass = 0;
const NPyr = 200; // Npyr finite elements in the pyramidal part
const NKonv = 50; // NPyr = 199 -> Nh = 100 und Nkonv = 50; Nh = 200 und Nkonv = 25
const CHilf = 2.5 ; // mm
const Hpyr = 8; // mm
const AAuslass = CHilf * CHilf; // Pyr unterteilt in NPyr Elemente/Scheiben
const NAuslass = 25;
const Vpyr = Hpyr/6 *( 2*AAuslass
+ cHilf * (HDiffzelle-HPU+BDiffzelle) + 2*(HDiffzelle-HPU)*BDiffzelle );
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var
Form1: TForm1;
t, cFS, cFSges, cFSAuslass, cPU0, cFreigesetzt, FSPU, nFreigesetzt, nges, nTest:extended;
Ax, Ay, Az, VWuerfel, WurzelT, SummeDiffZ,SummeDiffX:extended;
deltaX, deltaY, deltaZ, deltaXAuslass, deltaT:extended;
CardanoHilf, CardanoA, CardanoB, CardanoC,CardanoQ2, CardanoP3, CardanoWurzel, CardanoU, CardanoV:extended;
hilf1, hilf2, hilf0, hilfX, hilfZ, hilfXAuslass, hilfPyr, hilfTMP:extended;
h,hours:integer;
cWuerfel, cWuerfel0, cWuerfelAlt:array[1..Nvert,1..Nhoriz] of extended;
DiffX, DiffY, DiffZ:array[1..Nvert,1..Nhoriz] of extended;
cAuslass, cAuslassAlt:array[1..(Nvert-NPU),1..NAuslass] of extended;
DiffAuslass:array[1..NAuslass] of extended;
APyr, XPyr, cPyr, cPyrAlt, DiffPyr:array[1..NPyr] of extended;
DeltaXPyr:array[1..NPyr+1] of extended;
implementation
{$R *.DFM}
procedure TForm1.FormCreate(Sender: TObject);
var i:integer;
var j:integer;
begin
/////////////////////////////////////////////////////
// EINHEITEN: //
// mm, h,min, g, umol, ABER umol/L //
/////////////////////////////////////////////////////
VWuerfel := hDiffzelle*bDiffzelle*lDiffzelle / Nvert / Nhoriz / Nb; // Einheit mm^3
deltaX := lDiffzelle/Nhoriz; // mm
deltaZ := hDiffzelle/Nvert; // mm
deltaY := bDiffzelle/Nb; // mm
Ax := DeltaZ * DeltaY; // mm^2
Ay := DeltaZ * DeltaX; // mm^2
Az := DeltaX * DeltaY; // mm^2
deltaXAuslass := (hDiffzelle - hPU) * bDiffzelle * deltaX /AAuslass/NKonv;
deltaT := (hDiffzelle - hPU) * bDiffzelle * DeltaX / flowrate /nT; // h
hilfX := Diffkoeff*DeltaT / DeltaX / DeltaX;
hilfZ := Diffkoeff*DeltaT / DeltaZ / DeltaZ;
hilfXAuslass := Diffkoeff*DeltaT / DeltaXAuslass / DeltaXAuslass;
cPU0 := 4444.4;
nges := cPU0 * lDiffzelle*bDiffzelle*hPU;
cFS := 0.0; // umol/mm^3 = 1E6 umol/L
hours := 1; // h
t := 0.0;
WurzelT := 0.0;
h := paintbox1.height;
end;
procedure TForm1.Button1Click(Sender: TObject);
var NoIterationen, grenze:LongInt;
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ii,iii,j,k,x,y:integer;
hilf3:extended;
begin
iii:=spinedit1.value;
for k:=1 to NHoriz do
begin
for j:=(Nvert-NPU+1) to NVert do
begin
if (iii=1) then
begin
cWuerfel0[j,k] := c0;
end
else
begin
cWuerfel0[j,k] := 0.0;
end;
nTest := nTest + cWuerfel0[j,k]*VWuerfel/1E6;
end;
for j:=1 to (Nvert-NPU+1) do
cWuerfel0[j,k] := 0.0;
end;
cFSges := cWuerfel0[Nvert,Nhoriz];
// ------------------------------------------------------------------------------------------//
// For the calculation of the OUTLET's finite elements geometries, CARDANO's formula is used //
// ------------------------------------------------------------------------------------------//
if (mitAuslass = 1) then
begin
CardanoHilf := 3 * Hpyr /( HDiffzelle- HPU - cHilf) / (BDiffzelle - cHilf) ;
CardanoA := CardanoHilf * ( cHilf*(HDiffzelle - HPU + BDiffzelle)/2 - (HDiffzelle - HPU)*BDiffzelle ) ;
CardanoB := CardanoHilf * Hpyr * (HDiffzelle - HPU)*BDiffzelle ;
CardanoP3 := CardanoB - CardanoA*CardanoA/3;
CardanoP3 := CardanoP3 / 3;
CardanoQ2 := 2*CardanoA*CardanoA*CardanoA / 27 - CardanoA * CardanoB /3;
for j:=1 to (NPyr-1) do
begin
CardanoC := (-1) * CardanoHilf * Hpyr * Vpyr / Npyr * j;
//% ---------------------------
CardanoQ2 := 2*CardanoA*CardanoA*CardanoA / 27 - CardanoA * CardanoB /3;
CardanoQ2 := CardanoQ2 + CardanoC;
CardanoQ2 := CardanoQ2 / 2;
CardanoWurzel := CardanoQ2*CardanoQ2 + CardanoP3*CardanoP3*CardanoP3;
if (CardanoWurzel >= 0) then
begin
CardanoWurzel := sqrt(CardanoWurzel);
//Loesung:
CardanoU := CardanoWurzel - CardanoQ2;
CardanoV := (CardanoWurzel + CardanoQ2)*(-1);
if (CardanoU =0) then
begin
xPyr[j] := 0;
end
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else if (CardanoU >0) then
begin
xPyr[j] := exp( ln(CardanoU)/3 );
end
else
begin
xPyr[j] := (-1) * exp( ln( (-1)*CardanoU ) /3 );
end;
if (CardanoV =0) then
begin
xPyr[j] := xPyr[j];
end
else if (CardanoV >0) then
begin
xPyr[j] := xPyr[j] + exp( ln(CardanoV) /3 );
end
else
begin
xPyr[j] := xPyr[j] - exp( ln( (-1)*CardanoV ) /3 );
end;
xPyr[j] := xPyr[j] - CardanoA / 3;
end
else
begin
memo1.lines.add('The chosen parameter result in a special case of Cardano's formula,
which is not implemented');
exit;
end;
end;
xPyr[NPyr] := HPyr;
// Berechnung von DeltaXPyr
DeltaXPyr[1] := xPyr[1];
for j:=2 to NPyr do
begin
DeltaXPyr[j] := xPyr[j] - xPyr[j-1];
end;
HilfTMP := 0;
for j:=1 to Npyr do
HilfTMP := hilfTMP + DeltaXPyr[j];
// Berechnung von APyr
hilf0 := BDiffzelle * (HDiffzelle - HPU) ;
hilf1 := 2 * hilf0 - BDiffzelle * cHilf - (HDiffzelle - HPU) * cHilf;
hilf2 := hilf1 - hilf0 + cHilf*cHilf;
hilf1 := hilf1 /HPyr;
hilf2 := hilf2 /HPyr/HPyr;
for j:=1 to (NPyr-1) do
begin
APyr[j] := xPyr[j]*xPyr[j] * hilf2 - xPyr[j] * hilf1 + hilf0 ;
end;
APyr[NPyr] := AAuslass;
end; //% Ende von if (mitAuslass =1)
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// AUSLASS // AUSLASS // AUSLASS // AUSLASS // AUSLASS // AUSLASS // AUSLASS // AUSLASS //
for j:=1 to NVert do
begin
for k:= 1 to Nhoriz do
begin
cWuerfel[j,k] :=cWuerfel0[j,k]; // da am Anfang der Schleife cWuerfelAlt = cWuerfel
cWuerfelAlt[j,k] := 0.0;
end;
end;
t:=0.0;
nFreigesetzt:=0.0;
with Paintbox1.canvas do
begin
brush.color:=clwhite;
rectangle(0,0,width,height);
{ pen.color:=clmaroon;
brush.color:=clmaroon; }
end;
grenze:=strToInt(edit1.text);
x:=0;
// ----------------//
// AUSGABE //
// ----------------//
memo1.Clear;
memo2.Clear;
memo3.Clear;
memo4.Clear;
memo5.Clear;
memo1.lines.add('time (h)');
memo2.lines.add('released concentration (umol/L) ');
memo3.lines.add('concentration profiles at different timepoints for three different vertical cross sections');
memo4.lines.add('Paintbox-Hoehe h: '+InttoStr(h));
memo4.lines.add('10000 mod nT: ' + InttoStr(10000 mod nT));
if (mitAuslass=1) then
begin
memo4.lines.add('released concentration without the outlet');
end
else
begin
memo4.lines.add('total amount of substance released out of the wound covering');
memo4.lines.add('nFreigesetzt');
end;
memo5.lines.Add('chosen release profile from the PU foam:' );
memo5.lines.Add('iii =' + IntToStr(iii) );
memo5.lines.add(' ');
if barriere=1 then
memo5.Lines.add( 'with release barrier' )
else
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memo5.Lines.add( 'without release barrier' );
if mitAuslass=1 then
begin
memo5.lines.add(' ');
memo5.Lines.add( 'OUTLET' ) ;
memo5.Lines.add(' - Noutlet = ' + IntToStr(NAuslass) );
memo5.Lines.add(' - Npyr = ' + IntToStr(NPyr) );
memo5.Lines.add(' - Nconv = ' + IntToStr(NKonv) );
memo5.Lines.add(' - nT = ' + IntToStr(nT) );
memo5.Lines.add(' - lenght(outlet) = ' + FloatToStrF((NAuslass*DeltaXAuslass),ffGeneral,3,4) + ' mm') ;
end
else
memo5.Lines.add( 'without outlet' );
memo5.lines.add(' ');
memo5.lines.add('different parameter:') ;
memo5.lines.add('No. of Iterations ' + IntToStr(grenze)) ;
memo5.lines.add('Delta t (h)' + FloatToStrF(DeltaT,ffExponent,3,4)) ;
memo5.lines.add('flowrate (mL/h)' + FloatToStrF((flowrate/1000),ffGeneral,3,4)) ;
memo5.lines.add(' ');
memo5.lines.add('WOUND COVERING:') ;
memo5.lines.add('height (mm) ' + FloatToStrF(hPU,ffGeneral,2,2)) ;
memo5.lines.add('No. of vertical layers ' + IntToStr(Nhoriz)) ;
memo5.lines.add('No. of horizontal layers ' + IntToStr(Nvert)) ;
memo5.lines.add('No. of PU horizontal layers ' + IntToStr(NPU)) ;
memo5.lines.add('Delta x (m) ' + FloatToStrF(DeltaX,ffExponent,3,4)) ;
memo5.lines.add('drug content (wt%) ' + FloatToStrF(Gehalt,ffExponent,3,4)) ;
memo5.lines.add(' ');
memo5.lines.add('DIFFUSION CELL:') ;
memo5.lines.add('height (mm) ' + FloatToStrF(hDiffZelle,ffGeneral,2,2)) ;
memo5.lines.add('width (mm) ' + FloatToStrF(bDiffZelle,ffGeneral,2,2)) ;
memo5.lines.add('length (mm) ' + FloatToStrF(lDiffZelle,ffGeneral,2,2)) ;
memo5.lines.add('molar mass (g/mol) ' + FloatToStrF(MolareMasse,ffExponent,3,4)) ;
memo5.lines.add('diffusion coefficient (m2/s) ' + FloatToStrF((DiffKoeff/3600/1E6),ffExponent,3,4)) ;
memo5.lines.add(' ');
memo5.lines.add('c0 ' + FloatToStrF(c0,ffGeneral,2,2)) ;
memo5.lines.add('total molar amount (mol) ' + FloatToStrF(nges,ffExponent,3,4)) ;
memo5.lines.add('total time interval (h) ' + FloatToStrF((DeltaT*grenze),ffGeneral,5,6)) ;
memo5.lines.add(' ');
memo5.lines.add('total fictive concentration released out of the wound covering: ');
// Ausgabe für t = 0 h
memo1.lines.add('0') ;
memo2.lines.add(FloatToStrF((cFS),ffGeneral,4,5)) ;
memo4.lines.add(FloatToStrF((nFreigesetzt),ffGeneral,4,5) + ' mol') ;
memo4.lines.add(FloatToStrF((cFreigesetzt),ffGeneral,4,5) + ' mol/L') ;
memo5.lines.add(FloatToStrF((cFSges),ffGeneral,4,5) + ' umol/L') ;
//////////////////////////////////////////////////////
// SCHLEIFE: //
// grenze = Anzahl der Durchlaeufe //
// Index NoIterationen (deltaT) //
// Zeitparameter t //
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//////////////////////////////////////////////////////
for NoIterationen:=1 to grenze do
begin
t:=t+deltaT; // h
// fuer neuen Durchlauf: cWuerfel -> cWuerfelAlt
for j:=1 to NVert do
begin
for k:=1 to Nhoriz do
begin
if (cWuerfelAlt[j,k] < 0.0) then
begin
cWuerfelAlt[j,k] := 0.0;
end
else
begin
cWuerfelAlt[j,k] := cWuerfel[j,k];
end;
end;
end;
//% AUSLASS --- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ----
if (mitAuslass = 1) then
begin
// zwischen Diffzelle und Auslass
for j:=1 to NPyr do
cPyrAlt[j] := cPyr[j];
//Auslass
for k:=1 to NAuslass do
cAuslassAlt[1,k] := cAuslass[1,k];
end;
//% ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ----
//% Diffusion //% DiffX[j,k] -- (k-1) <-> k => DiffX[j,1] is different
for j:=1 to NVert do //% -- multiplied by Diffkoeff*DeltaT*Ax/VWuerfel/DeltaX
begin //% = Diffkoeff*DeltaT / DeltaX^2
for k:=2 to Nhoriz do
begin
DiffX[j,k] := cWuerfelAlt[j,k] - cWuerfelAlt[j,(k-1)];
end;
end;
//% AUSLASS --- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ----
if (mitAuslass = 1) then
begin
for j:=1 to (NVert-NPU) do
begin
DiffX[j,1] := cWuerfelAlt[j,1] - cPyrAlt[1];
DiffX[j,1] := DiffX[j,1] * 2 / ( 1 + DeltaXPyr[1] / DeltaX) ;
end;
end
//% ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ----
else
begin
for j:=1 to (NVert-NPU) do
begin
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DiffX[j,1] := 0.0;
end;
end;
//% DiffZ[j,k]: j <-> (j+1) => DiffZ[NVert,k] does not exist
for k:=1 to Nhoriz do //% DiffZ[j,k]: multiplied by Diffkoeff*DeltaT*Az/VWuerfel/DeltaZ
begin //% = Diffkoeff*DeltaT/DeltaZ^2
for j:=1 to (NVert-1) do
DiffZ[j,k] := cWuerfelAlt[j,k] - cWuerfelAlt[(j+1),k];
end;
//% Diffusionsbarriere
if (barriere=1) then
begin
for k:=1 to Nhoriz do
DiffZ[Nvert-NPU,k] := DiffZ[Nvert-NPU,k]/10;
end;
for j:=2 to (NVert-1) do
begin
for k:=2 to (Nhoriz-1) do
begin
cWuerfel[j,k] := cWuerfel[j,k]
- ( hilfX*(DiffX[j,k]-DiffX[j,k+1]) + hilfZ*(DiffZ[j,k]-DiffZ[j-1,k]) );
end;
end;
for j:=2 to (NVert-1) do
begin
cWuerfel[j,1] := cWuerfel[j,1] - ( hilfX *( DiffX[j,1] - DiffX[j,2] )
+ hilfZ*(DiffZ[j,1]-DiffZ[j-1,1]));
cWuerfel[j,Nhoriz] := cWuerfel[j,Nhoriz]
- ( hilfX*DiffX[j,Nhoriz] + hilfZ*(DiffZ[j,Nhoriz]-DiffZ[j-1,Nhoriz]) );
end;
for k:=2 to (Nhoriz-1) do
begin
cWuerfel[1,k] := cWuerfel[1,k] - ( hilfX*(DiffX[1,k]-DiffX[1,k+1]) + hilfZ*DiffZ[1,k] );
cWuerfel[Nvert,k] := cWuerfel[Nvert,k] - ( hilfX*(DiffX[Nvert,k]-DiffX[Nvert,k+1])
+ hilfZ *(DiffZ[Nvert,k]-DiffZ[Nvert-1,k]) );
end;
cWuerfel[1,1] := cWuerfel[1,1] - (hilfX*(DiffX[1,1]-DiffX[1,2]) + hilfZ*DiffZ[1,1]);
cWuerfel[1,Nhoriz] := cWuerfel[1,Nhoriz] - (hilfX*DiffX[1,Nhoriz] + hilfZ*DiffZ[1,Nhoriz]);
cWuerfel[Nvert,1] := cWuerfel[Nvert,1] - (hilfX*(DiffX[Nvert,1]-DiffX[Nvert,2])
+ hilfZ*(DiffZ[Nvert,1]-DiffZ[Nvert-1,1]));
cWuerfel[Nvert,Nhoriz] := cWuerfel[Nvert,Nhoriz] - (hilfX * DiffX[Nvert,Nhoriz]
+ hilfZ*(DiffZ[Nvert,Nhoriz]-DiffZ[Nvert-1,Nhoriz]));
for j:=1 to NVert do
begin
for k:=1 to Nhoriz do
begin
if (cWuerfel[j,k] < 0) then
begin
memo5.lines.add('Error: c <0 in iteration: ' + IntToStr(NoIterationen)) ;
exit;
end;
end;
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end;
//% Überprüfung von DiffX und DiffZ
SummeDiffX := 0.0;
SummeDiffZ := 0.0;
for j:=1 to (NVert) do
begin
for k:=1 to (Nhoriz) do
begin
SummeDiffX := SummeDiffX + cWuerfelAlt[j,k];
end;
end;
for j:=1 to (NVert) do
begin
for k:=1 to (Nhoriz) do
begin
SummeDiffX := SummeDiffX - cWuerfelAlt[j,k];
end;
end;
//% ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ----
//% DIFFUSION
if (mitAuslass = 1) then
begin //% Pyr (zwischen Diffzelle und Auslass)
hilfTMP := DiffKoeff * DeltaT * NKonv/DeltaX/bDiffzelle/(hDiffzelle-HPU);
for j:=1 to (NPyr-1) do
begin
if ((cPyrAlt[j] > 1E-20) or (cPyrAlt[j+1] > 1E-20)) then
begin
DiffPyr[j] := hilfTMP*APyr[j] *2/(DeltaXPyr[j]+DeltaXPyr[j+1]) * (cPyrAlt[j]-cPyrAlt[j+1]);
end
else
begin
DiffPyr[j] := 0;
if (j>1) then
DiffPyr[j-1] := DiffPyr[j-1] /2;
end;
end;
DiffPyr[NPyr] := hilfTMP*APyr[NPyr] *2/(DeltaXPyr[NPyr]+DeltaXAuslass)
* (cPyrAlt[NPyr]-cAuslassAlt[1,1]);
for j:=2 to NPyr do
begin
cPyr[j] := cPyrAlt[j] + (DiffPyr[j-1]-DiffPyr[j]);
end;
for j:=1 to (NVert-NPU) do
begin
DiffX[j,1] := DiffX[j,1] * DiffKoeff * DeltaT * NKonv/ DeltaX/DeltaX;
end;
cPyr[1] := cPyrAlt[1] - DiffPyr[1] ;
for j:=1 to (Nvert-NPU) do
cPyr[1] := cPyr[1] + DiffX[j,1] ;
//% Auslass
hilfTMP := Diffkoeff*DeltaT/DeltaXAuslass/DeltaXAuslass ;
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for j:=1 to (NAuslass-1) do
begin
DiffAuslass[j] := cAuslassAlt[1,j] - cAuslassAlt[1,j+1];
DiffAuslass[j] := hilfTMP * DiffAuslass[j];
end;
for k:=2 to (NAuslass-1) do
begin
cAuslass[1,k] := cAuslassAlt[1,k] - DiffAuslass[k] + DiffAuslass[k-1] ;
end;
cAuslass[1,1] := cAuslassAlt[1,1] - DiffAuslass[1] + DiffPyr[NPyr] ;
cAuslass[1,NAuslass] := cAuslassAlt[1,NAuslass] + DiffAuslass[NAuslass-1] ;
for j:= 1 to NPyr do
begin
if (cPyr[j] < 0) then
begin
memo3.lines.add('cPyr('+IntToStr(j)+') < 0; iteration: '+IntToStr(NoIterationen));
exit;
end;
end;
for j:= 1 to NAuslass do
begin
if (cAuslass[1,j] < 0) then
begin
memo3.lines.add('cAuslass('+IntToStr(j)+') < 0; iteration: '+IntToStr(NoIterationen));
exit;
end;
end;
end;
//% Ende Diffusion (Auslass)
//% ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ---- AUSLASS ----
//% ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ---- ENDE - AUSLASS ----
//-------------//
//% Konvektion //
//-------------//
if (NoIterationen mod nT) = 0 then
begin // START KONVEKTION
cFreigesetzt := 0.0;
for j:=1 to (NVert-NPU) do
begin //% aus Diffzelle freigesetzter Wirkstoff (kumulativ)
cFreigesetzt := cFreigesetzt + cWuerfel[j,1];
NFreigesetzt := NFreigesetzt + cWuerfel[j,1]*VWuerfel; //% mol
for k:=1 to (Nhoriz-1) do
begin
cWuerfel[j,k] := cWuerfel[j,k+1];
end;
cWuerfel[j,Nhoriz] := 0.0;
end;
cFreigesetzt := cFreigesetzt/(Nvert-NPU);
//% Auslass (Konvektion um NKonv FE)
if (mitAuslass=1) then
begin
cFSAuslass := 0;
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if (NAuslass >= NKonv) then // Falls NAuslass >= NKonv
begin
for j:=NAuslass downto (NAuslass-Nkonv+1) do
cFSAuslass := cFSAuslass + cAuslass[1,j];
cFSAuslass := cFSAuslass / Nkonv ;
for k:=NAuslass downto (Nkonv+1) do
begin
cAuslass[1,k] := cAuslass[1,k-Nkonv];
end;
for k:=1 to Nkonv do
begin
cAuslass[1,k] := cPyr[NPyr-Nkonv+k];
end;
for k:=NPyr downto (NKonv+1) do
begin
cPyr[k] := cPyr[k-NKonv];
end;
for k:=1 to NKonv do
begin
cPyr[k] := cFreigesetzt ;
end;
end // ENDE NAuslass >= NKonv
else
begin// NAuslass < NKonv
for j:=1 to NAuslass do
cFSAuslass := cFSAuslass + cAuslass[1,j];
for j:=(Npyr-NKonv+NAuslass+1) to Npyr do
cFSAuslass := cFSAuslass + cPyr[j];
cFSAuslass := cFSAuslass / Nkonv ;
for k:=1 to NAuslass do
begin
cAuslass[1,k] := cPyr[NPyr-Nkonv+k];
end;
for k:=NPyr downto (NKonv+1) do
begin
cPyr[k] := cPyr[k-NKonv];
end;
for k:=1 to NKonv do
begin
cPyr[k] := cFreigesetzt ;
end;
end; // ENDE NAuslass < NKonv
end; // ENDE mitAuslass
end; // ENDE KONVEKTION
//-----------------------------------------------------------------//
// concentration increase due to release within the wound covering //
//-----------------------------------------------------------------//
// Berechnung von cFS
if (iii=1) then
begin {für PU ohne SP}
cFS := 0;
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cFSges := cFSges + cFS;
end
else if (iii=2) then
begin {für PU mit SP, FS nur bei Konvektion}
if (NoIterationen mod nT) = 0 then
begin
cFS := c0 - c0/103*90 * EXP(-1*0.03125*t) + c0/103*13 * EXP(-1*25/3*t) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end
else if (iii=3) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := c0 - c0/103*72 * EXP(-1*0.025*t) + c0/103*31 * EXP((-1*25*t/6)) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=4) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := c0 - c0/103*70 * EXP((-1*0.025*t)) + c0/103*33 * EXP((-1*25*t/3)) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=5) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := c0 *( 1 - ( 43* EXP(-8*t) + 60*EXP(-0.021*t) ) / 103 ) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=6) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := c0 *( 1 - ( 2*EXP(-0.2*t) + 2*EXP(-4*t) + 10*EXP(-0.025*t) )/14 ) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=7) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := c0 *( 1 - ( 2*EXP(-0.2*t) + 100*EXP(-4*t) + 220*EXP(-0.025*t) )/322 ) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=8) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := 35*c0/103 + c0*(1-35/103) *( 1 - ( 2*EXP(-4*t) + 5*EXP(-0.0275*t) )/7 ) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=9) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := 15*c0/103 + c0*(1-15/103) *( 1 - ( EXP(-0.21*t) + EXP(-4*t) + 5*EXP(-0.021*t) )/7 ) - cFSges;
cFSges := cFSges + cFS;
end
else if (iii=10) then
begin {für PU mit SP -- andere Fitting-Funktion}
cFS := 40*c0/103 + c0*(1-40/103) *( 1 - ( 2*EXP(-8*t) + 11*EXP(-0.017*t) )/13 ) - cFSges;
cFSges := cFSges + cFS;
end
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// --- iii=11 ---
else if (iii=11) then // linear
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 5) then
begin
cFS := c0 * (0.50261 + 0.01784 * t) - cFSges;
cFSges := cFSges + cFS;
end
else if (hours >= 5) and (hours < 24) then
begin
cFS := c0 * ( 0.58776 + 0.00081 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5712 + 0.0039 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
begin
cFS := c0 * ( 0.8496 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end;
end
// --- iii=11 ---
// --- iii=12 ---
else if (iii=12) then // Linear
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
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begin
cFS := c0 * ( 0.5712 + 0.0039 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end
// --- iii=13 ---
else if (iii=13) then // Linear
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5712 + 0.0039 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
begin
cFS := c0 * ( 0.8496 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end
// --- iii=16 ---
else if (iii=16) then {Linear}
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5904 + 0.0035 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
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if (cFSges < c0) then
begin
cFS := c0 * ( 0.8304 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end
// --- iii=17 ---
else if (iii=17) then {Linear}
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 1) then
begin
cFS := c0 * 0.4623 - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5904 + 0.0035 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
begin
cFS := c0 * ( 0.8304 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end;
end
// --- iii=18 ---
else if (iii=18) then {Linear}
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 3) then
begin
cFS := c0 * 0.1583 - cFSges;
cFSges := cFSges + cFS;
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end
else
begin
if (hours < 48) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5904 + 0.0035 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
begin
cFS := c0 * ( 0.8304 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end;
end
// --- iii=14 ---
else if (iii=14) then {Linear}
begin {für PU mit SP -- andere Fitting-Funktion}
if (cFSges < c0) then
begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
cFS := 0;
end;
end
// --- iii=15 ---
else if (iii=15) then {Linear}
begin {für PU mit SP -- andere Fitting-Funktion}
if (hours < 24) then
begin
cFS := c0 * 0.6072 - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 48) then
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begin
cFS := c0 * ( 0.0063 * t + 0.456 ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (hours < 96) then
begin
cFS := c0 * ( 0.5712 + 0.0039 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
begin
if (cFSges < c0) then
begin
cFS := c0 * ( 0.8496 + 0.001 * t ) - cFSges;
cFSges := cFSges + cFS;
end
else
cFS := 0;
end;
end;
end;
end
// --- iii=0 ---
else {iii=0}
begin {für PU mit SP}
cFS := c0 - c0/103*90 * EXP((-1*0.03125*t)) - c0/103*13 * EXP((-1*25*t/3)) - cFSges;
cFSges := cFSges + cFS;
end;
// AUSGABE
if (NoIterationen mod nT) = 0 then
begin
memo5.lines.add( FloatToStrF((cFSges),ffExponent,3,4) ) ;
end;
// FS aus PU
for j:=(NVert-NPU+1) to NVert do
begin
for k:=1 to Nhoriz do
begin
cWuerfel[j,k] := cWuerfel[j,k] + cFS;
end;
end;
// AUSGABE pro Stunde (DeltaT in min)
if (t >= (hours)) then
begin
if (mitAuslass=1) then
begin
memo4.lines.add(FloatToStrF((cFreigesetzt),ffExponent,3,4)) ;
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memo2.lines.add(FloatToStrF((cFSAuslass),ffExponent,3,4)) ;
end
else
begin
memo2.lines.add(FloatToStrF((cFreigesetzt),ffExponent,3,4)) ;
memo4.lines.add(FloatToStrF((NFreigesetzt),ffExponent,3,4)) ;
end;
memo1.lines.add(IntToStr(hours)) ;
for j:= 1 to Nhoriz do
memo3.lines.add( IntToStr(j) + ' ' + FloatToStrF((cWuerfel[1,j]),ffExponent,3,4)
+ ' ' + IntToStr(hours) + ' 1' );
k := round((Nvert-NPU)/2);
for j:= 1 to Nhoriz do
memo3.lines.add( IntToStr(j) + ' ' + FloatToStrF((cWuerfel[k,j]),ffExponent,3,4)
+ ' ' + IntToStr(hours) + ' ' + IntToStr(k) );
k := round((Nvert-NPU)*3/4);
for j:= 1 to Nhoriz do
memo3.lines.add( IntToStr(j) + ' ' + FloatToStrF((cWuerfel[k,j]),ffExponent,3,4)
+ ' ' + IntToStr(hours) + ' ' + IntToStr(k) );
k := round(Nvert-NPU);
for j:= 1 to Nhoriz do
memo3.lines.add( IntToStr(j) + ' ' + FloatToStrF((cWuerfel[k,j]),ffExponent,3,4)
+ ' ' + IntToStr(hours) + ' ' + IntToStr(k) );
k := round((Nvert-NPU) + NPU/2);
for j:= 1 to Nhoriz do
memo3.lines.add( IntToStr(j) + ' ' + FloatToStrF((cWuerfel[k,j]),ffExponent,3,4)
+ ' ' + IntToStr(hours) + ' ' + IntToStr(k) );
hours := hours + 1;
x:=x+1;
if (mitAuslass=1) then
begin
y:=round( ( 1 - cFSAuslass/c0 )*h );
end
else
begin
y:=round( ( 1 - cFreigesetzt/c0*2 )*h );
end;
paintbox1.canvas.pixels[x,y]:=clblack;
end;
// Ende: grenze = Anzahl der Durchlaeufe
end;
end;
end.
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